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Abstract 
 The ring-opening process of cyclopropane derivatives is prominent in biological 
processes and synthetic methodology. The reactivity of bifunctional three-membered 
rings is attributed to the ring-strain and the attached functional groups which can 
stabilise their ring-opened counterparts. This thesis reports the use of cyclopropane 
derivatives in synthetic methodology and syntheses of prodrugs – an overview of the 
thesis is provided in Chapter 1. 
Chapter 2 reports the development of tumour selective prodrug Q-PAC, which 
liberates a 2-phenylcyclopropylamine moiety (2-PCPA, LSD1 inhibitor) and quinone 
methide (antioxidant scavenger) upon activation in GBM where ROS is abundant. As 
expected, prodrug Q-PAC selectively inhibited cell growth of GBM cells while healthy 
astrocytes remained unaffected.  
Chapter 3 reports the preparation of metallocene derivatives for 2-PCPA. While 
the ferrocenyl derivatives unexpectedly underwent facile ring-opening to form β-
hydroxyamides, the ruthenocenyl derivative was stable and displayed superior LSD1 
inhibitory activity (IC50 = 1.43 μM) compared to its parent compound (IC50 = 23.0 μM).  
The cyclopenta[b]indoline scaffold is featured in many bioactive compounds. 
Although many methods have been reported to prepare this scaffold, the resulting 
cyclopenta[b]indoline lacks of functional groups to allow further derivatisation. Chapter 
4 reports the study of palladium-catalysed dearomative [3 + 2] cycloaddition of 3-
nitroindoles with vinylcyclopropanes (VCPs). Using this method that we developed, 
densely functionalised cyclopenta[b]indolines were synthesised in good yield and 
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Utilising cyclopropane scaffolds in synthetic methodology and syntheses of prodrugs: 
Thesis overview 
1.1 Thesis overview 
Bifunctional three-membered rings, such as cyclopropylamines and 
vinylcyclopropanes (VCP), are useful scaffolds in synthetic methodologies and 
medicinal chemistry. Apart from the intrinsic ring-strain in cyclopropane (strain energy 
= 27.5 kcal/mol)1 that acts as a thermodynamic driving force, their reactivities are 
greatly influenced by the functional groups present on the ring. These spring-loaded 
scaffolds can participate in reactions upon chemical activation, or biological processes 
when interacting with cellular enzymes.  
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer 
with poor survival rate,2 unfortunately current available treatments either have difficulty 
in administration or undesired side effects after treatment. Various cancers, including 
GBM, express elevated level of lysine-specific demethylase 1 (LSD1) which causes 
abnormal demethylation of histone proteins and subsequently suppression of tumour 
suppressor genes.3 Therefore, 2-phenylcyclopropylamine (2-PCPA)-based LSD1 
inhibitors were studied and they demonstrated promising outcome in cancer treatment 
studies. The FAD cofactor in the active site of LSD1 carries out the single electron 
oxidation of amine nitrogen on 2-PCPA which leads to the ring-opening of 
cyclopropane. As a result, the ring-opened distonic radical cation fuses with FAD and 
irreversibly inhibits LSD1 (Scheme 1). Meanwhile, boronate-containing compounds 
also recently emerged as a new class of prodrug which selectively target cancer cells 
2 
with release of toxic quinone methides. In Chapter 2, inspired by the potency and 
selectivity of these motifs towards cancer cells, we designed and created a prodrug 
hybrid of these two motifs to harness the reactive distonic radical cation and quinone 
methide, which was subjected to in vitro evaluation on GBM cells and healthy 
astrocytes (Scheme 1).  
Scheme 1: Thesis overview. 
3 
Incorporation of redox active metallocenes into existing drugs has been reported 
to enhance drug potency and provide a secondary mechanism to induce cytotoxicity, for 
example, the ferrocene derivatives of the breast cancer drug tamoxifen (namely 
ferrocifen) demonstrated remarkable antiproliferative effect on hormone-independent 
breast cancer cell line MDA-MB-231 while hydroxytamoxifen (the active metabolite of 
tamoxifen) was inactive.4 Syntheses of metallocene derivatives of 2-PCPA will be 
discussed in Chapter 3 (Scheme 1). It was revealed that ferrocene-derivatives of 2-
PCPA were susceptible to spontaneous oxidative ring-opening in air to form β-
hydroxyamides, where the reaction mechanism was similar to that of 2-PCPA with 
FAD/LSD1 except molecular oxygen was the oxidant in this case. Chapter 3 discusses 
the substrate scope of this ring-opening process that proceeds via proposed distonic 
radical cation, and also the preparation and in vitro evaluation of air-stable ruthenocene 
derivative of 2-PCPA (Scheme 1). 
The cyclopenta[b]indoline scaffold is featured in many bioactive compounds, 
such as diazepinoindoline (treatment and prevention of central nervous system 
disorders)5 and polyveoline (antitrypanosomal alkaloid)6. Although many methods have 
been reported to prepare this scaffold in high yield, the resulting cyclopenta[b]indoline 
lacks functional groups to allow further derivatisation, which poses a challenge to 
access structures with higher complexity. A solution to this problem is found in the 
cycloaddition of 3-nitroindoles with vinylcyclopropanes (VCPs) that affords densely 
functionalised cyclopenta[b]indolines. Pd(0) catalyses the formation of zwitterionic 1,3-
dipoles from VCPs, which then react with 3-nitroindoles in a [3 + 2] cycloaddition 
fashion to yield the cyclopenta[b]indolines (Scheme 1). Chapter 4 reports the study of 
Pd-catalysed dearomative and diastereoselective [3 + 2] cycloaddition of 3-nitroindoles 
with VCPs, which details the reaction optimisation, substrate scope and proposed 
4 
reaction mechanism. This chapter also demonstrates the utility of these densely 
functionalised cyclopenta[b]indoline in further chemical transformations. 
1.2 References 
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Design and synthesis of a novel dual-action prodrug to target glioblastoma multiforme 
via lysine-specific demethylase 1 (LSD1) inhibition and glutathione depletion 
2.1 Introduction 
2.1.1 Glioblastoma multiforme (GBM) 
 Glial cells are a broad class of non-neuronal cells that provide physical support 
and protection to neurons in the central and peripheral nervous systems. The name was 
derived from the ancient Greek word “glía” which means glue. This class of cells are 
regarded as the “glue” to hold neurons together, they also supply oxygen and nutrients to 
neurons while removing neurotoxic substances. Half of the brain volume is comprised of 
different glial cells, such as astrocytes, oligodendrocytes and microglia.1 The star-shaped 
cells, astrocytes, are the most abundant cell types in the human brain. They are mainly 
responsible for the distribution of neurotransmitters around synapses, maintenance of ion 
balance and detoxification of xenobiotics.2 Oligodendrocytes produce the myelin sheath, 
which is a fatty substance that wraps around axons – this myelin sheath acts as insulation 
to the axon so that electrical messages can be delivered faster. As the main immune 
defence in the central nervous system (CNS), microglia are macrophages that protect the 
CNS from pathogens, toxins and remove dead or damaged cells from the CNS. 
 Glioblastoma multiforme (GBM) is the most aggressive and fatal form of brain 
cancer. GBM patients have a median survival of 12 to 15 months after diagnosis, while 
the five-year survival rate is merely 5%.3-5 The life expectancy is significantly reduced to 
3 months if left untreated.6 This glioma was observed to grow rapidly and invade 
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neighbouring tissue easily, hence it is notorious for its highly malignant character and 
frequent reoccurrence in patients even after treatment.  
Higher incidence of GBM is recorded in senior citizens, Caucasians and males.7 
The aetiology and cause for this disease remain unclear. Although the cell of origin for 
glioblastoma remains inconclusive, recent studies suggested that astrocytes and 
oligodendrocyte progenitor cells could serve as the cell of origin.8,9  
Although treatment options for GBM are available, these options possess 
difficulty in execution and often cause undesirable side effects. First lines of defence are 
surgery, radiation therapy, anti-angiogenic agents and chemotherapy. In surgical removal, 
the tumour is often surrounded by sensitive brain cells which have low capacity in self-
repair, therefore it is challenging to access the tumour and remove it completely without 
damaging the surrounding tissue. Also, metastasis to other parts of the brain means that 
surgery alone is often unsuccessful. In terms of challenges in chemotherapy, the intrinsic 
defence of the brain, the blood brain barrier (BBB), hinders some drug molecules from 
entering the target site, therefore reducing the efficacy of chemotherapy. Therefore 
chemotherapeutic drugs need to be designed to cross the BBB or other strategies 
employed to deliver them directly to the brain. Temozolomide is an FDA approved oral 
chemotherapy drug that alkylates DNA and triggers apoptosis. Moreover, administration 
of temozolomide was observed to sensitise tumours for radiotherapy.10 However, 
significant toxicities and side effects are associated with administration of temozolomide, 
such as thrombocytopenia, lymphopenia, neutropenia and myelodysplastic syndrome.11 
In a treatment trial combining radiotherapy and temozolomide, 15 to 20% of all patients 
in this regimen were affected by at least one of the side effects stated above, which 
resulted in premature discontinuance in treatment in some cases.12 Nevertheless, it is still 
less toxic than other alkylator-based chemotherapies, such as nitrosoureas.11 
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In addition to the challenges and side effects in GBM treatments, the prognosis 
for GBM is notoriously poor even with therapies. Furthermore, despite innovative 
therapies being introduced for the treatment of GBM (such as molecularly targeted agents, 
immunotherapy and gene therapy),13 there has been a lack of significant improvement on 
extending patient survival over the last few decades. From 2009 to 2013, Australians 
diagnosed with brain and other CNS cancer had an average of 25% chance of surviving 
for 5 years compared with others in the general population, and this rate has remained 
steady over the last 30 years.14 In order to improve patient survival rate, there is a pressing 
need to develop novel and efficient treatment options that can either prevent or minimise 
undesired side effects. 
 
2.1.2 Reactive oxygen species (ROS), glutathione (GSH) and the antioxidant system 
in cancers, such as GBM 
 Reactive oxygen species (ROS) is a broad term covering reactive chemical species 
that are oxygen-containing, such as the superoxide anion radical (O2●-), the hydroxyl 
radical (HO●) and hydrogen peroxide (H2O2). ROS in living organisms can be derived 
from exogenous sources, such as tobacco15, pollutants16 and radiation17, or from 
endogenous sources, as a by-product of the electron transport chain during mitochondrial 
respiration. During the synthesis of ATP by the electron transport chain, electrons are 
transferred between proteins in a process that ultimately reduces oxygen to water. A small 
proportion of the electrons can leak from the chain and partially reduce oxygen molecules 
to superoxide. It has been estimated that around 0.2 – 2% of the molecular oxygen 
consumed by mitochondria is converted to superoxide.18 Subsequently, superoxide 
dismutase (SOD) can carry out the dismutation of superoxide into oxygen and hydrogen 
peroxide. Other biological processes can also give rise to ROS as by-products, for 
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example during β-oxidation in peroxisomes, synthesis of prostaglandin or metabolism 
reactions by cytochrome P450.19 
 Excessive amounts of ROS can exert oxidative damage to cellular contents such 
as DNA, proteins and lipids. Although ROS can be harmful in organisms due to their high 
reactivity, a moderate amount of ROS is essential for biological functions. ROS is 
involved in signalling and regulation of cellular functions, such as cell proliferation, 
differentiation, metabolism and the DNA damage response.20 
Intrinsic antioxidant or ROS-scavenging systems are in place to prevent oxidative 
cellular damage. SOD, glutathione peroxidase and catalase are examples of enzymes that 
detoxify ROS in cells. Furthermore, the tripeptide antioxidant, glutathione (GSH, 
consisting glutamate, cysteine and glycine, Figure 1) is one of the main antioxidants, in 
which the cysteine thiol group acts as the reducing agent. GSH is oxidised to glutathione 
disulfide (GSSG) upon reducing superoxide and hydroxyl radicals.21 The conversion of 
GSH to GSSG also occurs when GSH peroxidases reduce hydrogen peroxide and organic 
peroxides. GSSG reductase converts GSSG back to GSH in order to counteract further 
ROS.  
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Figure 1: Antioxidant glutathione (GSH) is converted to glutathione disulfide (GSSG) 
while reducing ROS (such as H2O2, O2- and OH●). GSSG is then reduced to GSH in order 
to counteract further oxidative stress. 
 When the ROS balance within the cells is disrupted by elevated level of ROS 
and/or reduced capacity in antioxidant, the cells are said to be under oxidative stress. 
Growing evidence has shown that various types of cancers have increased level of ROS.22-
24 The intracellular concentration of H2O2 in normal cells ranges between 1 – 700 nM, 
where 1 μM is considered toxic.25 On the other hand, cancer cells can withstand a higher 
H2O2 concentration of 10 – 100 μM, which is more than 10 fold higher than in normal 
cells.26 These highly reactive ROS damage nucleic acids, proteins and lipids, therefore 
they can lead to DNA mutations, cancer cell proliferation, metastasis and angiogenesis.27  
 It has been postulated that while cancer cells generate higher ROS levels they also 
upregulate antioxidant systems to maintain the redox homeostasis.19 This adaptive 
mechanism is vital for cancer cells to survive under the high oxidative stress conditions 
by regulating ROS levels within the range where severe oxidative damage and apoptosis 
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can be avoided. For instance, H-Ras-transformed ovarian epithelial T29H cells with high 
concentrations of ROS were found to have elevated levels of the antioxidants 
peroxiredoxin-3 and thioredoxin peroxidase, compared to their non-tumorigenic 
equivalents.28 Ras-transformed cells were also found to be prone to cell death upon 
glutathione depletion, implying the vital role of GSH to maintain their survival.29 As such, 
interfering with the redox balance by suppression of the antioxidant system could be a 
feasible avenue for cancer treatment. 
 Due to the significant role GSH plays in cancer cell survival, several studies have 
been focussing on scavenging GSH or inhibiting its production to allow ROS 
accumulation and hence induce apoptosis. β-Phenylethyl isothiocyanate (PEITC, Figure 
2) conjugates with GSH, therefore depleting the GSH pool. Trachootham et al. showed 
that when Ras-transformed ovarian epithelial cells T72 (T72Ras) were treated with 
PEITC, substantial increase in ROS and concomitant cell death were observed.29 An in 
vivo study also showed that PEITC treatment extends animal survival.29 Without 
treatment, mice inoculated with T72Ras cells have a median survival time of 25 days. 
The median survival time was significantly improved to 48 days when mice were treated 
with PEITC by i.p. injection (50 mg/kg, five times per week). 
γ-Glutamylcysteine synthetase is another attractive target for impairing cancer 
cells antioxidant system as it ligates glutamate and cysteine and is the rate-limiting 
enzyme in the production of GSH. As buthionine sulfoximine (BSO, Figure 2) inhibits γ-
glutamylcysteine synthetase, Maeda et al. investigated the synergistic effect of BSO and 
arsenic trioxide (As2O3, ROS generator) on 11 cancer cell lines and it was observed that 
the growth inhibition effect was enhanced by 1.2 to 52.5-fold compared to administration 
of As2O3 alone.30  
11 
 
Figure 2: Inhibitors of the antioxidant system (PEITC and BSO). 
 
2.1.3 Utilisation of reactive oxygen species (ROS) in cancer therapeutic strategies 
  The presence of elevated ROS associated with cancer cells has been harnessed to 
develop selective anti-cancer treatments. Several research groups have exploited the high 
ROS content of cancer cells to develop cancer-specific prodrugs. These prodrugs usually 
consist of a “trigger” moiety and an “effector”/“drug” moiety. The trigger moiety is 
initiated only upon exposure to H2O2, which subsequently leads to activation of the 
effector unit to induce cytotoxicity in cancer cells.27 Aryl boronates have been commonly 
utilised as a trigger unit in these cases because they are readily available and can be 
oxidatively cleaved selectively by H2O2, which is abundant in cancer cells. As the 
activation of an aryl boronate prodrug relies on the concentration of H2O2, cytotoxicity 
should be lower in healthy cells that maintain reduced levels of ROS, compared to cancer 
cells. 
Peng and co-workers developed a series of ROS-initiated DNA cross-linking 
agents (nitrogen mustards) that selectively induced apoptosis in chronic lymphocytic 
leukemia (CLL) over normal lymphocytes (Scheme 2).31 Once the carbon-boron bond of 
these aryl boronate prodrugs 1 is oxidised by H2O2 and transformed into alcohol 2, the 
electron density on the aromatic ring is increased – inducing the formation of a highly 
electrophilic aziridinium ring 3, which is susceptible to cross-linking with DNA. Without 
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exposure to H2O2, the lone pair on the nitrogen mustard is unavailable for aziridinium 
formation as it is delocalised into the benzene ring, due to the presence of an electron-
withdrawing boronate group attached to the ring, therefore these prodrugs will not affect 
normal cells. As a result, the most potent analogue in this study had an IC50 value of 5 – 
6 µM in CLL, while normal lymphocytes remained unaffected. 
Scheme 2: Mechanism of DNA cross-linking by ROS-induced nitrogen mustards.31,32 
Recent interest in aryl boronate prodrugs has been focussing on dual action to 
induce cytotoxicity. Mokhir and co-workers reported several studies on dual-action 
prodrugs (4), which give rise to catalysts for ROS generation and antioxidant scavengers 
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upon activation (Scheme 3).26,33-35 Upon entering cancer cells and exposure to H2O2, the 
aryl boronate group of 4 is converted into a phenol, which is in equilibrium with the 
corresponding phenolate. The phenolate can then undergo 1,6-elimination to give 
compound 5 and p-quinone methide (QM). Compound 5 is unstable and undergoes 
decarboxylation to yield compound 6, followed by oxidation of the ferrocene moiety to 
yield ferrocinium ion 7 that can serve as a catalyst for ROS production. Furthermore, 7 
eventually decomposes in water to give Fe2+/Fe3+, which can also generate ROS 
catalytically. Meanwhile, GSH is quenched through the nucleophilic addition to QM, the 
antioxidant scavenger. The high electrophilicity of QM is attributed to the activated 
conjugated system, which aromatises upon nucleophilic attack, therefore making it 
susceptible to nucleophilic addition of GSH. As a result, the death of cancer cells is 
accelerated as the antioxidant level is decreasing, while the ROS concentration is 
increasing. The most potent prodrug 4 in these studies is toxic towards several cancer cell 
lines (IC50 = 1.5 – 27 µM), and non-toxic towards non-malignant cells such as fibroblasts 
and mononuclear cells (MNC) (Table 1).26,33,35 In vivo experiments also revealed that 
prodrug 4 (6 daily doses of 26 μg/kg) extended the survival of BDF1 hybrid mice 
(DBA/2,♀ × C57Bl/6,♂) implanted with L1210 leukemia from 13.7 ± 0.6 days to 17.5 ± 
0.7 days.34  
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Scheme 3: Activation mechanism of aminoferrocene-based prodrugs in cancer cells with 
higher concentration of ROS. Upon activation, electrophilic QM will be generated to 
scavenge GSH, therefore leaving oxidative stress unsuppressed. At the same time 
ferrocinium 7 and inorganic iron species will be generated to generate ROS and hence 
amplifying oxidative stress. 
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Table 1: Cytotoxicities and selectivities of aminoferrocene-based prodrug 4 in cancer 
cells.26,33,35 
Malignant/Normal Cells Cell Lines IC50 (µM) 
Malignant HL-60 (Human promyelocytic leukemia) 9 
U373 (Human glioblastoma-astrocytoma) 25 
CLL (Chronic lymphocytic leukemia) 1.5 
DU145 (Prostate cancer) 18 - 27 
LNCaP (Prostate cancer) 11 - 17 
Normal Fibroblasts > 100 
MNC (Mononuclear cells) > 10 
 
 Noh et al. recently reported the dual stimuli-responsive hybrid anticancer drug 
QCA (Scheme 4).36 The prodrug relied on not only ROS, but also acidic pH for activation, 
which is a property displayed in the extracellular microenvironment of cancer cells due 
to rapid glycolysis and lactic acid production.37 Similar to the work from Mokhir and co-
workers, upon prodrug activation, QM will be liberated from QCA as the antioxidant 
scavenger but with cinnamaldehyde as the ROS generator. Cinnamaldehyde induces ROS 
production in mitochondria and inhibits growth of cancer cells. More importantly, it 
possesses minimal cytotoxicity to normal cells. However the use of cinnamaldehyde in 
clinical applications has been limited by its poor bioavailability due to the aldehyde group 
being prone to rapid oxidation. Therefore, masking cinnamaldehyde in the form of acetal 
in prodrug QCA extends its bioavailability, due to the stability of this moiety under non-
acidic aqueous conditions. The prodrug activation mechanism is similar to the above 
study from Mokhir and co-workers – after 1,6-elimination and decarboxylation, QM and 
an acetal-protected cinnamaldehyde are released. The acetal-protected cinnamaldehyde 
can then be unmasked under aqueous acidic conditions to release the ROS-generating 
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cinnamaldehyde. The acetal-deprotection selectively occurs in cancer cells as the 
extracellular pH of cancer cells ranges from 6.2 – 6.9 whereas the value of that in normal 
cells is usually 7.3 – 7.4.38  
In the studied cell lines, human prostate cancer DU145 was found to have the 
highest level of H2O2 and GSH, while normal mouse fibroblast NIH3T3 had the least 
amount of these species.36 As a result, a remarkable decrease in GSH level was observed 
in DU145 cells following treatment with QCA. QCA induced cytotoxicity in DU145 (IC50 
= 48 µM) and colon cancer SW620 (IC50 = 76 µM) cells, while minimal cytotoxicity was 
found in normal NIH3T3 cells (IC50 = 182 µM). Even though the selectivity towards 
human cancer cell lines was promising, perhaps normal human cells should be used as 
comparison, rather than using mouse fibroblast NIH3T3. 
In the in vivo study, mice were subcutaneously injected with SW620 or DU145 
cells and treated with QCA at a physiologically relevant dose of 2 mg/kg every 3 days for 
22 days. Mice treated with QCA had a significantly smaller tumour mass compared to 
mice treated with cinnamaldehyde and/or quinone methide-generator. Furthermore, no 
observable damages or lesions were found in the heart or liver, therefore suggesting that 
QCA can exhibit anticancer effects without inducing off-target cytotoxicity.  
In order to create a safety profile for QCA, normal mice were administered with 
QCA at the same dosage of 2 mg/kg every other day for 10 days. A biomarker for liver 
health (alanine transaminase) was monitored and there was no difference in treated and 
untreated normal mice. There was also no histological evidence indicating toxicity in the 
heart, indicating that QCA had limited toxicity in normal mice. 
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Scheme 4: Activation mechanism of dual stimuli-responsive prodrug QCA.36 
Redox-active anticancer prodrugs have just recently been investigated but are 
clearly showing promising results in cellular and mouse models, due to their ability to 
target cancer cells over healthy cells. 
 
2.1.4 Function of lysine-specific demethylase 1 (LSD1) and its role in cancers 
Lysine-specific demethylase 1 (LSD1) can alter chromatin compactness and gene 
expression. As such, LSD1 plays an important role in cancer progression. Chromatin is 
made up of DNA and histone proteins. Histones are octamers consisting two H2A-H2B 
dimers and one H3-H4 tetramer.39 Approximately 146 base pairs of DNA surround this 
histone protein to form a nucleosome.40 The polynucleosome string is composed of a 
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series of nucleosomes linked with a short segment of linker DNA (10 to 80 base pairs)41, 
which undergoes a few rounds of folding to compress the chromatin structure. 
Importantly, the compactness of chromatin is associated with gene repression.41 
The structure of the chromatin and gene expression are influenced by post-
translational modifications on histone tails, which protrude from the nucleosome surface. 
For example, methylated lysine 4 at histone 3 (H3K4), H3K36 and H3K79 is generally 
associated to transcriptional activation; whereas methylated H3K9, H3K27 and H4K20 
is mostly related with transcriptional repression.42  
The methylation status of these histone lysines can be modified by enzymes, and 
hence gene expression will be altered as well. Histone lysine methyltransferases install 
methyl groups on histone lysine residues, and while several enzymes of this class had 
been identified by 2003,43 it was only in 2004 that the lysine-specific demethylase 1 
(LSD1) was reported by Shi et al.44 LSD1 was the first reported histone demethylase 
which carries out the demethylation of mono- and dimethylated lysine 4 of histone 3 
(H3K4me1/2). The demethylation process involves flavin adenine dinucleotide (FAD) 
dependent enzymatic oxidation (Scheme 5).44 Firstly, FAD oxidises H3K4me1/2 to form 
an iminium cation, while itself converts into FADH2. The unstable iminium cation then 
undergoes hydrolysis and deformylation to yield the demethylated lysine. Meanwhile, 
FAD can be regenerated through oxidation of FADH2 with molecular oxygen, hence 
repeating the demethylation process.45 A lone pair of electrons on the substrate’s nitrogen 
atom is required during the flavin-dependent amine oxidation, therefore LSD1 can only 
demethylate H3K4me1/2, but not H3K4me3.45 
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Scheme 5: Mechanism of H3K4me1/2 demethylation catalysed by LSD1. 
Corepressor protein CoREST was found to bind with LSD1 and it was essential 
in H3K4 demethylation.46 The crystal structure of LSD1-CoREST-H3 revealed that H3 
adopts three consecutive γ-turns and fits nicely inside the LSD1 active site, therefore 
generating many sequence-specific interactions with LSD1.47 Furthermore, this creates 
an ideal side chain spacing, which orientates the H3 N-terminus into an anionic pocket, 
while placing H3K4me1/2 towards FAD for catalysis. The catalytic site of LSD1 is 
incapable to accommodate more than three residues on the methylated lysine N-terminal, 
therefore providing specificity towards H3K4. 
In a prostate cell line, when LSD1 complexes with the androgen receptor, it carries 
out the demethylation of H3K9me1/2 instead.48 Different from the demethylation of 
H3K4me1/2 (where LSD1 is bound to CoREST), demethylation of H3K9me1/2 promotes 
gene activation.48 Therefore when binding to different partners, LSD1 can have different 
target of demethylation and hence different transcription outcome. Apart from histone 
protein demethylation, LSD1 can also carry out the demethylation of non-histone proteins 
to regulate cellular functions. For instance, LSD1 can demethylate p53 on K370me1/2 to 
inhibit its roles as a transcriptional activator and tumour suppressor.49 Moreover, LSD1 
catalysed the demethylation of DNA methyltransferase 1 to stabilise it for the regulation 
of global DNA methylation.50 
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Overexpression of LSD1 was observed in various cancers, such as GBM,51 acute 
myeloid leukemia (AML),52 neuroblastoma,53 prostate cancer,48,54 breast cancer,55 lung 
cancer,56 and bladder cancer cells.56 As a result of LSD1 overexpression, abnormal 
demethylation of H3K4me1/2 leads to inhibition of tumour suppressor genes.57 LSD1 is 
also responsible for tumorigenesis by suppressing p53-mediated apoptosis.56,58 
Fortunately, elevated H3K4 methylation and suppression of cancer cell growth were 
observed in studies involving inhibition or RNAi-mediated knockdown of LSD1.53,59,60 
Due to the fact that LSD1 inhibition leads to the suppression of carcinogenesis, inhibiting 
LSD1 could be a potential option for cancer therapy.61,62 
 
2.1.5 Inhibition of LSD1 using trans-2-phenylcyclopropylamine (2-PCPA) analogues 
Due to the potential role of LSD1 in cancer highlighted in the previous section, 
several classes of LSD1 inhibitors have been studied. Similar to LSD1, monoamine 
oxidases (MAOs) A and B are also flavin-dependent enzymes. MAOs are involved in 
degradation of important neurotransmitters, and their inhibition has been widely 
investigated for treatment in neurological disorders, such as Parkinson’s disease and 
depression.63 As the active site in LSD1 shares partial homology with MAOs,64 a few 
classes of MAO inhibitors were shown to inhibit LSD1 as well. These include trans-2-




Figure 3: Examples of MAO inhibitors that also inhibit LSD1.43,66 
2-PCPA and its derivatives are the most studied LSD1 inhibitors.43 Even though 
2-PCPA is a potent MAO inhibitor and antidepressant drug,63 its clinical use is restricted 
due to several undesirable side effects, including headaches, dizziness, orthostatic 
hypotension, and sexual dysfunction.63,67 Despite these unfavourable side effects, 2-
PCPA demonstrated promising results in LSD1 inhibition, therefore it could be useful in 
cancer treatment. For instance, 2-PCPA was reported to suppress androgen receptor-
dependent transcription and growth of bladder cancer cells.68 Furthermore, 2-PCPA 
induced global H3K4 methylation and growth inhibition in neuroblastoma cells.53 
Inhibition of xenograft growth was observed in a mouse neuroblastoma model, after 
administering i.p. injection of 2-PCPA (2 mg/kg) daily for 21 days.53 
Schmidt et al. conducted kinetic studies and mass spectrometry (MS) analyses, 
the study indicated that 2-PCPA is a time-dependent, mechanism-based irreversible 
LSD1 inhibitor.64 It was postulated that through single-electron transfer (SET) 
mechanism, 2-PCPA forms a covalent C−C bond with FAD at C(4a) in the catalytic site 
of LSD1, follow by concomitant ring-opening of the cyclopropyl ring (Figure 4).64 Two 
possible adducts of 2-PCPA (atropaldehyde or cinnamaldehyde adducts) can be formed 
depends on which C−C bond in the cyclopropyl ring is cleaved (Figure 4).64 Structural 
and MS analyses performed by Yang et al. revealed that the proposed cinnamaldehyde 
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adduct can then transformed into a five-membered ring structure, which is the major 2-
PCPA-FAD adduct obtained in LSD1 inhibition (Figure 4).69 Based on the crystal 
structure analysis reported by Mimasu et al., the five-membered ring adduct is not the 
sole adduct formed during LSD1 inhibition and an intermediate N(5) adduct A was 
proposed.70 Subsequently, Binda et al. demonstrated that (1R,2S)-2-PCPA provides the 
N(5) adduct A, while (1S,2R)-2-PCPA provides N(5) adduct B (Figure 4).71 In summary, 
no matter which 2-PCPA-FAD adduct is formed, covalent alteration of FAD decreases 
the availability of FAD to oxidise H3K4me1/2. Importantly, demethylation of 
H3K4me1/2 by LSD1 is obstructed due to the depletion of functional FAD. 
Despite 2-PCPA exhibited promising results in LSD1 inhibition and the 
mechanism being known, its use for LSD1 inhibition suffers from poor inhibitory activity 
(Ki = 243 µM).64 In addition, 2-PCPA is more selective towards MAO than LSD1.64 To 
overcome this selectivity issue, there is an urgent need to alter the 2-PCPA structure to 
improve its inhibitory activity and selectivity against LSD1. Towards this goal, many 
studies reported 2-PCPA derivatives with enhanced inhibitory activity and selectivity 
towards LSD1 compared to the parent compound (Figure 5).71-80 The active sites in MAO 
A and MAO B are less spacious than LSD1, and hence their active sites are less likely to 
accommodate large substituents on the phenyl moiety of 2-PCPA.60,81 Therefore 
substitution on the phenyl ring of 2-PCPA is one of the common modifications reported 
to achieve LSD1 selectivity by size exclusion. Furthermore, alkylation on the 2-PCPA 
amine nitrogen was also found to improve selectivity and potency in LSD1 inhibition. 
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Figure 4: LSD1 inhibition by 2-PCPA through irreversible covalent modification of FAD. 
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Figure 5: Selected examples of reported 2-PCPA derivatives as LSD1 inhibitors.71-80 
 Very few LSD1-based prodrugs have been reported, but recently in seminal work 
Suzuki and co-workers reported novel prodrugs 10 that consisted of 2-PCPA and 4-
hydroxytamoxifen (4OHT) moieties covalently linked together (Scheme 6).66 Once the 
2-PCPA moiety of this prodrug interacts with the LSD1 active site, activation to liberate 
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4OHT – an anti-estrogen agent for the treatment of breast cancer – occurs. Therefore, in 
breast cancer cells where LSD1 is overexpressed, the anticancer effect is achieved 
through inhibition of LSD1 and estrogen receptor α (ERα) synergistically. Prodrug 10 
also serves as a selective treatment due to the difference in LSD1 expression in cancer 
and normal cells. In ERα-positive breast cancer MCF7 cells, prodrugs 10 exerted 
cytotoxicity and significantly reduced cell growth at 0.1 µM. When non-cancerous human 
mammary epithelial cells (HMEC) were treated with 10, the viability of the cells was not 
affected at concentrations up to 2.5 µM, therefore suggesting that prodrug 10 is selective 
towards breast cancer cells. To date, prodrug 10 remained as the first and only reported 
prodrug based on the LSD1 inhibitor 2-PCPA. 
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Scheme 6: Activation mechanism of prodrug 10 to exert dual action on ERα-positive 
breast cancer cells.66 
 
2.1.6 Clinical trials involving 2-PCPA-based LSD1 Inhibitors 
Since the discovery of LSD1 in 2004 and multiple studies on its inhibitors, there 
are currently several on-going clinical trials targeting LSD1 inhibition by 2-PCPA based 
derivatives. The combination of 2-PCPA and retinoid all-trans-retinoic acid (ATRA) is 
currently in a Phase I study to investigate a new treatment paradigm in AML 
(ClinicalTrials.gov Identifier: NCT02273102). Notably, it was proposed that LSD1 
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inhibition sensitises non-acute promyelocytic leukemia AML towards ATRA treatment, 
which was a challenge due to drug resistance.82 Oryzon developed the N-alkylated 2-
PCPA analogue ORY-1001 (Figure 6), which is currently in Phase I/IIa study in patients 
with relapsed acute leukemia (EudraCT Number: 2013-002447-29). ORY-1001 
displayed excellent selectivity, LSD1 inhibitory activity and oral bioavailability in 
rodents.83 Furthermore, no off-target toxicity was observed in 28 days rat toxicology 
studies. Subsequently, GlaxoSmithKline also enrolled an N-alkylated 2-PCPA analogue 
GSK2879552 (Figure 6) into Phase I study for AML treatment (ClinicalTrials.gov 
Identifier: NCT02177812). 
 
Figure 6: 2-PCPA derivatives that are currently in clinical trials (as of 28th December 
2017).83-85  
 
2.1.7 Other classes of LSD1 inhibitors 
 Other than investigating derivatisation of 2-PCPA, another strategy to identify 
potential LSD1 inhibitors is to shift away from the 2-PCPA template and search for other 
core structures that may interact with LSD1. Hence in recent years, structural diversity 
was observed in the literature on LSD1 inhibitors.86 Non-2-PCPA based LSD1 inhibitors 
may have a different mode of action in LSD1 inhibition, therefore providing an alternative 
avenue for cancer treatment. 
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Figure 7: Selected examples of other classes of LSD1 inhibitors.87-90 
 Similar to 2-PCPA, phenelzine 9 is also a mechanism-based LSD1 inhibitor which 
can covalently fused to FAD in the active site, however in this case the key initiating step 
involves hydrazine rather than cyclopropylamine oxidation.91 The use of the MAO 
inhibitor phenelzine 9 in LSD1 inhibition is underexplored, however, Cole and co-
workers reported bizine, an analogue of phenelzine 9, as a superior LSD1 inhibitor 
compared to its parent compound (Figure 7).89 Bizine was found to be selective and potent 
towards LSD1 compared to MAO, and it demonstrated antiproliferative effects in lung 
cancer H460 (IC50 = 14 µM) and prostate cancer LNCaP (IC50 = 16 µM) cell lines. 
Furthermore, LSD1 inhibition by bizine provided neuroprotection to neurons under 
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oxidative stress. Neurons were treated with homocysteic acid to induce oxidative stress 
(via GSH depletion) and then treated with bizine. As a result, significantly enhanced 
survival of neurons was observed with 0.5 µM of bizine. 
 Zheng et al. reported the triazole–dithiocarbamate based molecule 11, which was 
potent and selective against LSD1 (Figure 7).90 Unlike 2-PCPA, it was proposed that 11 
is a reversible LSD1 inhibitor and it inhibited LSD1 by causing FAD ejection. Compound 
11 demonstrated excellent LSD1 inhibitory activity in gastric cancer cell lines MGC-803 
(IC50 = 0.89 µM) and HGC-27 (IC50 = 1.13 µM). It was also demonstrated that 11 induced 
apoptosis and inhibited cell migration in MGC-803 cells. Due to lower LSD1 expression 
in gastric cancer cell line SGC-7901, the LSD1 inhibitory effect of 11 was significantly 
lower than the previous cell lines (IC50 = 89.5 µM). As expected, 11 did not show marked 
effects on normal gastric epithelial cell line GES-1. When treating MGC-803-implantated 
mice (xenograft model) with 11 at a dose of 20 mg/kg, tumour weight was reduced by 
68.5%, while no apparent body weight was lost during treatment, suggesting that 11 is 
efficient in suppressing tumour growth without inducing global toxicity. 
 By virtual screening of the Maybridge Hitfnder 5 compound library for the 
identification of LSD1 inhibitors, Woster and co-workers reported the triazole-based 
molecule 12 as a potent and reversible LSD1 inhibitor (Figure 7). Molecular modelling 
studies reveal that 12 forms several key interactions with the LSD1 active site through 
hydrogen bonding and FAD through π-stacking, therefore effectively hindering substrate 
binding. Compound 12 was potent and selective towards LSD1 (IC50 = 1.19 µM), and it 
induced cytotoxicity in several cancer cell lines (IC50 ranges from 12 µM – 74 µM). 
  Woster and co-workers also reported amidoxime 13 as LSD1 inhibitor in a 
separate study identified through virtual screening (Figure 7).87 In silico analysis 
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suggested that 13 binds to precisely the same region as H3K4 of the histone tails. 
Furthermore, a combination of both hydrophobic and hydrophilic interactions stabilises 
the LSD1/CoREST complex with 13 such that the latter is placed directly in front of FAD, 
preventing it from accessing other substrates. Compound 13 significantly increased the 
methylation level of H3K4me2 in the human lung carcinoma cell line Calu-6. 
Furthermore, through quantitative PCR significant upregulation in the expression level of 
aberrantly silenced tumour suppressor genes (SFRP2, HCAD and GATA4) was observed 
in the Calu-6 cell treated with 13. 
 
2.2 Aim and research plan 
The survival rate of GBM patients has not been improved in the past few decades 
and current available treatment options have their limitations and undesired side-effects. 
Therefore, there is a pressing need to develop new treatment options for GBM to 
overcome these issues.  
In the literature, the difference in ROS concentration between cancer and normal 
cells has been utilised to develop cancer-selective prodrugs. Upon activation by the high 
concentration of ROS in cancer cells, these prodrugs mainly induce cytotoxicity in these 
cells by suppression of antioxidant systems (e.g. inhibition of GSH by QM) and 
amplification of ROS. Under these synergistic effects, cancer cells will be more 
susceptible to further ROS insults therefore leading to cell death. On the other hand, 2-
PCPA based LSD1 inhibitors have demonstrated promising outcomes in cancer 
treatment, notably there are two N-alkylated 2-PCPA analogues currently in active 
clinical trials. 
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Given that prodrugs based on LSD1 inhibitor have been scarcely reported, in this 
study, we aim to develop a GBM-selective prodrug which will liberate QM (antioxidant 
scavenger) and 2-PCPA (LSD1 inhibitor) upon activation by ROS. The prodrug we have 
designed consists of an aryl boronate trigger and 2-PCPA joined by a carbamate linker as 
is named Q-PAC (quinone-methide-phenylaminocyclopropane) (Scheme 7). It is 
anticipated that upon entering cancer cells, activation of Q-PAC would occur by excess 
H2O2, converting the aryl boronate moiety into a phenol - the phenolate counterpart 14 
then undergoes 1,6-elimination to give QM and intermediate 15. Ultimately, 2-PCPA 
would be obtained after decarboxylation of 15. While the formation of phenolate 14 
depends on its equilibrium with phenol, the decarboxylation of intermediate 15 will 
promote the equilibrium shifting towards the phenolate. As discussed above QM is highly 
electrophilic and is anticipated to quench the antioxidant GSH, therefore further 
obstructing the cancer cells’ ability to counteract oxidative stress which subsequently 
allows the accumulation of ROS. Concurrently, we would expect 2-PCPA to inhibit LSD1 
which is overexpressed in GBM, thus reducing the suppression of tumour suppressor 
genes and limiting cancer cell proliferation and survival. In summary, the novel prodrug 
is expected to have a dual-action of antioxidant scavenging and LSD1 inhibition. 
The research plan will involve testing the cytotoxicity of Q-PAC on the 
immortalised GBM cell line U87. Furthermore, in order to demonstrate clinical 
significance of Q-PAC, testing on three different primary GBMs of different GBM 
subtypes (RN1: classical, JK2: proneural, SJH1: neural) is necessary. The selectivity of 
Q-PAC against GBM is also important to ascertain, so healthy astrocytes will also treated 
with Q-PAC to determine this. Several analogues and individual components of Q-PAC 
will be prepared and assessed in parallel to gain an understanding of what portions of the 
molecule are important for activity (Table 2). 
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Scheme 7: Proposed activation mechanism of Q-PAC to release QM and 2-PCPA. 
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To study the effect of having a halogen 
substituent at the para position on 




To study the effect of solely QM in the 
absence of LSD1 inhibitor (2-PCPA). 
Upon activation by ROS, QAC will 
generate QM and cyclopropylamine, 
instead of 2-PCPA. Cyclopropylamine 
is not an LSD1 inhibitor. 
 
PBE 
(Phenyl boronate ester) 
To study the effect of solely QM in the 
absence of LSD1 inhibitor (2-PCPA). 
Upon activation by ROS, PBE can 
potentially generate QM solely. 
 
2-PCPA 
To study the effect of solely LSD1 
inhibitor in the absence of antioxidant 
scavenger (QM). Racemic mixture of 2-
PCPA was used. 
 
2.3 Results and discussion 
2.3.1 Syntheses of prodrugs Q-PAC, Q-BrAC and QAC 
The preparation of prodrugs Q-PAC and Q-BrAC were initiated with Corey–
Chaykovsky cyclopropanation of commercially available ethyl cinnamates (Scheme 8). 
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The reaction proceeded through the deprotonation of Me3S(O)I with NaH to generate 
sulfoxonium ylide, followed by methylene transfer from the ylide to the ethyl cinnamate 
substrates (reaction mechanism and trans diastereoselectivity will be discussed in Chapter 
3 Section 3.3.1). In the 1H NMR spectrum of cyclopropane 16a, the cyclopropanation of 
ethyl cinnamates was indicated by the absence of olefin protons (doublets at 7.67 and 
6.43 ppm) and the presence of cyclopropane protons (2.53 – 2.50, 1.90, 1.59, 1.33 – 1.26 
ppm). Similarly in the 13C NMR spectrum of 16a, absence of olefin carbon signals (144.5 
and 118.4 ppm) and presence of cyclopropane carbon signals (26.2, 24.2 and 17.1 ppm) 
indicated that the cyclopropanation was successful. 
The resulting cyclopropyl esters 16a-b were then subjected to basic hydrolysis to 
yield carboxylic acids 17a-b in excellent-quantitative yields. In the 13C NMR spectrum 
of carboxylic acid 17a, the absence of OCH2CH3 signals (60.7 and 14.3 ppm) indicated 
that the basic hydrolysis was successful. 
The carboxylic acids 17a-b were then subjected to Curtius rearrangement with 
PBE, which furnished the proposed prodrugs Q-PAC and Q-BrAC. Mechanistically, the 
Curtius rearrangement involves formation of an acyl azides upon treatment of carboxylic 
acids with diphenylphosphoryl azide (DPPA). At elevated temperature, acyl azides 
underwent thermal decomposition, rearrangement and liberation of nitrogen gas to form 
the isocyanate intermediates. Lastly, nucleophilic attack of hydroxyl group from PBE to 
the isocyanates created the carbamate linker between two substrates. 
In the 1H NMR spectrum of Q-PAC, the OCH2 proton signal was shifted down-
field from 4.66 ppm (PBE)92 to 5.12 ppm. Meanwhile in the 13C NMR spectrum of Q-
PAC, the carbonyl signal (156.6 ppm) from the carbamate linker supported that the 
linking of two building blocks was successful. It should be noted that prodrug Q-PAC 
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was obtained as a racemic mixture, therefore two enantiomers of 2-PCPA will be liberated 
upon oxidative activation of Q-PAC, namely (1S,2R)-2-PCPA and (1R,2S)-2-PCPA. The 
fact that two enantiomers of 2-PCPA will be generated should not pose difficulty in the 
interpretation of biological evaluation results because Benelkebir et al. showed that the 
two trans enantiomers possess similar LSD1 inhibition activity: Ki = 28.1 μM for (1S,2R)-
2-PCPA and Ki = 26.6 μM for (1R,2S)-2-2-PCPA.93 
 
Scheme 8: Synthetic route to prepare prodrugs Q-PAC, Q-BrAC and QAC. 
Similar to the preparation of Q-PAC and Q-BrAC, prodrug QAC was synthesised 
by Curtius rearrangement using commercially available cyclopropanecarboxylic acid and 
PBE in 35% yield. Some key features in the NMR spectra of QAC was similar to that of 
Q-PAC, the down-field chemical shift of OCH2 (from 4.66 to 5.11 ppm) in 1H NMR and 
36 
the presence of carbonyl signal (157.0 ppm) in 13C NMR indicated that the Curtius 
rearrangement had proceeded smoothly. 
 
2.3.2 Utilisation of mass spectrometry for the detection of Q-PAC active components 
upon activation 
 As a proof of concept for prodrug activation, Q-PAC was treated with hydrogen 
peroxide and the generated active species were detected using electrospray ionisation 
mass spectrometry (ESI-MS). It was envisaged that prodrug Q-PAC activation via 
hydrogen peroxide would yield QM and 2-PCPA (Scheme 9). In the absence of GSH, 
QM can react with 2-PCPA to yield adduct QMA1, which can then further react with 
another QM to form adduct QMA2. 
 
Scheme 9: Activation of Q-PAC by H2O2 to liberate QM and 2-PCPA. In the absence of 
other nucleophilic species (such as GSH), subsequent formation of QMA1 and QMA2 
adducts was detected. Exact mass/charge (m/z) values and corresponding MS accuracy 
(Δppm) of detected species are stated above. 
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Positive-mode ESI-MS was utilised to examine this activation process. Prior to 
H2O2 addition to an Q-PAC solution a signal detected at m/z 416 is assigned to [Q-PAC 
+ Na]+ (Figure 8a). Under identical instrument conditions the appearance of m/z 107 and 
134 following 5 minutes treatment with hydrogen peroxide indicates the presence of 
initial products QM and 2-PCPA, respectively (Figure 8b). Analysis following longer 
reaction times results in Figure 8 spectra (c) and (d) which indicate: (1) further relative 
increase in QM and 2-PCPA; (2) production of QMA1 and QMA2 adducts evidenced by 
m/z 240 and 346 signals, respectively. These results are consistent to the activation 
mechanism and adduct formation illustrated in Scheme 9. In a separate Q-PAC solution 
where hydrogen peroxide was not added, the sample was analysed with ESI-MS three 
days after preparation. Q-PAC was detected intact while QM, 2-PCPA, QMA1 and 
QMA2 were not detected, suggesting that hydrogen peroxide is required for the activation 
of prodrug. 
Experiments were repeated on a LTQ XL Orbitrap for high resolution mass 
analysis to further support assignment (spectra not shown). Experimental errors from 
those theoretical m/z values shown in Scheme 9 are included for each putative elemental 
ionic composition where all fall within 2 ppm. 
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Figure 8: Low resolution (+)ESI-MS data collected at increasing times after Q-PAC 
treatment with H2O2. The sodiated Q-PAC m/z 416 is labelled in the spectrum resulting 
from analysis of the untreated prodrug. Mass spectra were collected after 5, 10 and 25 
minutes of Q-PAC treatment time. Signals corresponding to activation products and 
adducts (as shown in Scheme 9) are labelled in the spectra; all other peaks have been 
accounted for as background with the exception of m/z 306, which could be the sodiated 
phenol intermediate after the oxidative hydrolysis of Q-PAC and prior to 1,6-elimination. 
In this mass spectrometry assay, prodrug Q-PAC was treated with 9 mM of 
hydrogen peroxide, which was consistent to the condition employed by Hagen et al.26 
While this oxidant concentration was higher than physiological level, it was necessary in 
order to observe the activation process in a practical timeframe. In experiments using 
physiological level of hydrogen peroxide (100 μM and 1 mM), the activation occurred in 
a significantly slower rate where prodrug was still present even after a day. It should also 
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be pointed out that the level of hydrogen peroxide in this assay declined as time 
progressed due to reaction with the prodrug or decomposition; while the ROS level in 
cancer cells would elevate due to the ROS production in mitochondria and the 
antioxidant-scavenging action of QM.  
While this mass spectrometry study was not a kinetic assay, it was confirmed that 
prodrug Q-PAC was able to undergo H2O2 induced oxidative cleavage of its boronate 
trigger and 1,6-elimination to release QM, 2-PCPA and QM-derived adducts (QMA1 and 
QMA2). This was critical given the desired dual action of the drug that required QM to 
reduce the antioxidant inhibitor GSH while 2-PCPA simultaneously inhibits LSD1. The 
obtained result is consistent with the report of Mokhir and co-workers, who demonstrated 
a similar breakdown of aminoferrocene-based prodrugs with H2O2.26 Unlike Mokhir and 
co-workers however, we were able to directly detect QM. Given the concentration of 
GSH in cells is higher than the effective concentration of Q-PAC,94 the desired reaction 
between GSH and QM would negate the formation of QM-derived adducts 
QMA1/QMA2 and therefore reduce the antioxidant ability of the cell.  
 
2.3.3 Evaluation of prodrugs on viability and migration in U87 glioblastoma cells 
With the synthesis of the prodrugs in hand and mechanistic information obtained, 
attention was turned towards biological testing. Much of this work was carried out 
experimentally by collaborators Dr M. Engel and D. Cross (Illawarra Health & Medical 
Research Institute).  
The immortalised GBM cell line U87 is commonly used to assess novel GBM 
treatments and it was employed for the preliminary screening of the prodrug prepared in 
this study. Interestingly, Q-PAC reduced U87 confluence and hence proliferation in a 
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dose-dependent manner within 24 h (F(7, 42)=73.94, P<0.0001; Figure 9A). Cell viability 
was quantified through a Resazurin-based fluorometric assay, and it was found that U87 
cell viability was also reduced dose-dependently after 24 h (F(6,35)=51.34, P<0.0001) 
and 48 h (F(6,28)=9.47, P<0.0001) (Figure 9D). In scratch-wound assay where an area of 
the U87 cells was removed to create a gap for cells to migrate, Q-PAC was found to dose-
dependently inhibit the migration of U87 cells (F(6, 13)=16.93, P<0.0001; Figure 9B). 
3D Cell invasion through matrigel after Q-PAC treatment was measured by electrical 
impedance, and it was discovered that the migration and invasion were suppressed (F(4, 
14)=5.324, P = 0.0081; Figure 9C). Consistent to the observed results, the cell 
morphology displayed distinct change after Q-PAC treatment of 10 µM and 100 µM, 
where treated cells were clearly shrinking compared to cells that were only treated with 
ethanol vehicle (Figure 9E-G). In summary, Q-PAC dose-dependently reduced the cell 





Figure 9: Q-PAC impairs viability and mobility of U87 glioblastoma cells. (A) 
Confluence of U87 cultures treated with Q-PAC. Algorithm-based confluence analysis of 
phase-contrast microscope images at 10x magnification every 2 h over a 24 h period 
following Q-PAC treatment (n=6 per concentration), normalised to culture confluence 
prior treatment. (B) 2D migration of U87 cells treated with Q-PAC. Algorithm-based 
scratch wound analysis of phase-contrast microscope images at 10x magnification every 
2 h over a 24 h period following scratch wound and Q-PAC treatment (n=4 per 
concentration), normalised to wound width prior treatment. (C) 3D invasion of U87 cells 
treated with Q-PAC. Invasion through matrigel was measured via electrical impedance 
every 30 min over a 24 h period following Q-PAC treatment (n=4 per concentration). (D) 
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Viability of U87 cultures treated for either 24 h (grey circles) or 48 h (black triangles) 
with Q-PAC (0 to 300 µM). Cell viability was quantified via a Resazurin-based 
fluorometric assay (n = 5), with readings normalised to media-only cultures. Data 
represent mean ± SEM, * P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 compared to 
vehicle control. (E-G) Representative images of U87 cultures treated with Q-PAC. 
Cultures treated with vehicle (E, EtOH), 10 µM (F) and 100 µM (G) were captured in 
phase-contrast images 4 h and 24 h after treatment at 10x magnification (scale bar = 50 
µm). In vitro assays were performed by Dr M. Engel and D. Cross (Illawarra Health & 
Medical Research Institute). 
Analogues and fragments of Q-PAC were then examined on U87 cell line. 
Interestingly, Q-BrAC (brominated version of Q-PAC) did not affect U87 confluence (F 
(6, 14)=5.220, P = 0.0052) and viability (F (6, 14)=2.634,  P = 0.0635). Upon hydrogen 
peroxide-induced activation, Q-BrAC was hypothesised to liberate QM and a brominated 
version of 2-PCPA (Br-PCPA). Since both Q-PAC and Q-BrAC generate QM upon 
activation, the difference in cell proliferative inhibition could be due to the difference in 
LSD1 inhibition by 2-PCPA and Br-PCPA. In a report from Binda et al. and Benelkebir 
et al., Br-PCPA was found to be more potent than 2-PCPA by having a lower Ki (4.6 – 
9.6 fold difference).71,93 However Gooden et al. reported that 2-PCPA was slightly more 
potent in LSD1 inhibition than Br-PCPA (1.2 fold difference). The discrepancies in 
results between each study could be due to differences in assays and experimental 
condition. Results from our examination of Q-BrAC implied that Br-PCPA may be a 
weaker LSD1 inhibitor compare to 2-PCPA, consistent to the findings from Gooden et 
al.81 
Results from several studies indicated that para-substituted 2-PCPA analogues 
were more potent in LSD1 inhibition than the mother compound, as shown in Figure 
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5.71,72,75 These reported para-substituents were larger and bulkier than bromine atom, 
which may suggest that the decrease in LSD1 inhibitory action of Br-PCPA may not be 
due to steric clash with LSD1 active site, however the actual reason for inactivity 
remained unclear. 
Since Q-PAC demonstrated promising results in the preliminary evaluation on 
U87 cell line, individual fragments of Q-PAC as listed in Table 2 were then evaluated on 
U87 to investigate the importance of each components. These include 2-PCPA (LSD1 
inhibitor), CPA (phenyl-free version of 2-PCPA), PBE (weak QM generator) and QAC 
(generates QM and CPA upon activation by H2O2). None of these four fragments affected 
the confluence, viability or migration ability of U87 cells for up to 300 µM (Appendix 1, 
Figure A1). This data suggests that by inhibiting LSD1 or GSH alone could not achieve 
the same anticancer effect Q-PAC demonstrated. Moreover, co-treatment of 2-PCPA and 
PBE did not affect the confluence and viability for U87 cultures (Appendix 1, Figure A1), 
which implies that the delivery of these two fragments in the form of Q-PAC is essential 
for the suppression of U87 cell growth. As a suggestion for future work, co-treatment of 
QAC (QM source) and 2-PCPA (LSD1 inhibitor) is advised to investigate the importance 
of linking the two active components with carbamate linker. Even if the same cytotoxicity 
can be achieved, it is unlikely to deliver these two compounds to patients due to the 
undesired effect of 2-PCPA. 
In this study, the 2-PCPA-based prodrug Q-PAC impaired several cancer 
properties of U87 cells at concentration as low as 10 µM, while even 300 µM of 2-PCPA 
was ineffective against the immortalised GBM cells. Even though the use of 2-PCPA in 
cancer treatment was reported in several studies,53,55 a high concentration was usually 
required, with up to 20-fold higher than the IC50. Moreover, 2-PCPA was shown to be 
ineffective against immortalised GBM cultures even at a high concentration of 1 mM, 
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despite high expression of LSD1 in these cells.51 Not only Q-PAC performed better than 
2-PCPA in reducing viability in U87 cells, it also suppressed the migration and invasion 
phenotype of U87 cells, which are the most notorious cancerous features of GBM.95 
 
2.3.4 Higher selectivity of Q-PAC for GBM over healthy astrocytes 
 Inspired by the promising results of Q-PAC in U87 cell lines, the investigation 
was further extended to primary GBM cultures. The primary GBM cultures were grown 
from untreated human biopsy samples of three different subtypes (RN1: classical; JK2: 
proneural; SJH1: neural), which were previously characterised.96 Consistent to the results 
observed in U87 cell line, Q-PAC dose-dependently reduced confluence in primary 
GBMs (P<0.001 for each cell line, Figure 10A-C), and suppressed migration in the 
scratch-wound assay (P<0.001 for each cell line, Figure 10E-G). Even though the three 
tested primary GBMs displayed different proliferation and migration rates, Q-PAC 
inhibited both tumour properties at concentrations above 10 µM. GBM culture viability 
reduced within 48 h of Q-PAC treatment at concentrations of 30 µM and above (Figure 
11). On the other hand, Q-BrAC did not reduce the confluence or viability of RN1 cells 
(Figure 12), consistent to the results from U87 cultures. 
 Next, primary cerebral astrocyte cultures (human and mouse) were treated with 
Q-PAC to probe for the prodrug selectivity against GBMs. In contrast to the GBM 
cultures, healthy astrocytes treated with Q-PAC at concentrations up to 300 µM for 48 h 
did not show reduction in cell viability (human astrocytes: F(6, 53)=0.56, P=0.76; mouse 
astrocytes: F(6, 36)=0.91, P=0.49; Figure 11A), nor a change in their migratory behaviour 
(F(6, 12)=0.47, P = 0.82; Figure 10H). Although the confluence of primary astrocyte 
cultures differed after Q-PAC treatment (F(6, 38)=15.3, P<0.0001; Figure 10D), only 30 
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µM Q-PAC resulted in cell confluence reduction (80.1 % of vehicle after 48 h, P<0.001; 
Figure 10D), it was a smaller reduction than for any of the GBM cultures at the same 
concentration (RN1: 32.7%, JK2: 64.6% and SJH1: 62.7% of vehicle; Figure 10A-C). 
These data show that primary GBM cells are more vulnerable to Q-PAC treatment than 




Figure 10: Q-PAC impairs proliferation and mobility of primary glioblastoma (GBM) 
cells but not healthy astrocytes. Confluence of primary human GBM (A-C) and astrocyte 
(D) cultures treated with Q-PAC was quantified via algorithm-based analysis of phase-
contrast microscope images at 10x magnification over a 48 h period (n=3 per 
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concentration & culture), normalised to culture confluence prior treatment. 2D migration 
of human GBM (E-G) and astrocyte (H) cultures treated with Q-PAC. Scratch wound 
width was quantified through algorithm-based analysis of phase-contrast microscope 
images at 10x magnification following scratch wound and Q-PAC treatment (n=3 per 
concentration and culture), normalised to wound width prior treatment. Data represent 
mean ± SEM, * P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 compared to vehicle 
control. 
 
Figure 11: (A) Viability of primary cultures treated with Q-PAC for 48 h. Cell viability 
was quantified via a Resazurin-based fluorometric assay in cultures treated for 48 h (n = 
4). Readings were normalised to media-only cultures. Data represent mean ± SEM, * 
P<0.05, ** P<0.01, ***P<0.001, ****P<0.0001 compared to vehicle control. (B-D) 
Representative images of human SJH1 primary glioblastoma (B), RN1 primary 
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glioblastoma (C) and healthy astrocyte (D) cultures treated Q-PAC. Cells treated with 
vehicle (EtOH), or 100 µM Q-PAC were captured in phase-contrast 24 h after treatment 
at 10x magnification (scale bar = 50 µm). 
 
Figure 12: (A) Confluence of primary human GBM RN1 cultures treated with Q-BrAC 
was quantified via algorithm-based analysis of phase-contrast microscope images at 10x 
magnification over a 72 h period (n = 2 per concentration & culture), normalised to 
culture confluence prior treatment. (B) Viability of primary GBM RN1 culture treated 
with Q-BrAC for 48 h. Cell viability was quantified via a Resazurin-based fluorometric 
assay in cultures treated for 48 h (n = 2). Readings were normalised to media-only 
cultures. Data represent mean ± SEM. 
 
2.3.5 Effect of Q-PAC on histone modifications 
 Intrigued by the promising results as observed in the U87 cell line and primary 
GBMs, the underlying mechanisms of Q-PAC treatment were then investigated. Firstly, 
the epigenetic profile of histones was studied as LSD1 demethylates H3K4me1/2. 
 The histone demethylase LSD1 was reported to overexpress in GBM,51,97 
therefore the expression of LSD1 in GBM cultures of this study was quantified by western 
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blot analysis. As expected, primary GBMs RN1 and SJH1 expressed higher levels of 
LSD1 compared to healthy astrocytes (Figure 13A). Interestingly, the LSD1 expression 
in U87 and JK2 did not differ compared to healthy astrocytes (Figure 13A).  
 
Figure 13: (A) LSD1 protein levels in human astrocytes and glioblastoma cells 
(established cell line: U87MG; primary patient samples: RN1, SJH1, JK2) were 
quantified via immunoblotting (n=3 per cell type), normalised to total protein content of 
each sample. (B) Representative immunoblot for LSD1 (detected at 110 kDa) and total 
protein for each cell type (healthy astrocytes, U87, RN1, SJH1 and JK2). 
 As a proxy to measure the degree of LSD1 inhibition induced by Q-PAC, the 
expression of H3K4me1/2 in U87 (basal LSD1 level) and RN1 (overexpressed LSD1 
level) were quantified by western blot analysis 4 h after Q-PAC treatment. The duration 
of 4 h was chosen because changes in confluence and migration were observed within 4 
h in response to Q-PAC treatment. In treated U87 cells, no effect was observed in the 
levels of H3K4me1 (F(5, 18)=1.024, P=0.43) and H3K4me2 (F(5, 12)=0.25, P=0.93) 
(Figure 14A). On the other hand in RN1 culture, the levels of H3K4me1 (F(5,12)=3.18, 
P=0.05) and H3K4me2 (F(5,12)=2.74, P=0.07) increased and peaked at 10 µM of Q-
PAC, while not differing to control level at lower or higher concentrations (Figure 14B). 
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Lastly, 10 µM of Q-PAC did not affect the level of H3K4me2 (t=0.26, df=6, P=0.814; 
data not shown) in healthy astrocytes (H3K4me1 was not detected in the human 
astrocytes). 
 
Figure 14: (A-B) H3K4 monomethylation (me1), dimethylation (me2) and H4 acetylation 
(ace) levels quantified via immunoblotting in U87MG (A, n=4) and RN1 cells (B, n=3) 
cells after 4 h treatment with Q-PAC (0 to 100 µM). Immunoblot intensities were adjusted 
to total loaded protein and normalised to vehicle control cultures. Data represent mean 
± SEM, * P<0.05 compared to vehicle control. (C) Representative immunoblot for RN1 
cell samples, blotted for H3K4me1 (detected at 15 kDa), H3K4me2 (detected at 16 kDa), 
and total protein (segment depicking 8 to 20 kDa) for each Q-PAC concentration (0 to 
100 µM). 
 Apart from H3K4me1/2, H4 pan acetylation in treated U87 and RN1 cultures was 
also quantified by western blot, as this histone modification has been reported to control 
chromosome assembly and transcription.98 However no changes in H4 acetylation was 
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observed in U87 (F(5, 17)=1.13, P=0.38; Figure 14A) and RN1 (F(5, 12)=1.51, P=0.26; 
Figure 14B). 
 The 2-PCPA-based prodrug Q-PAC displayed better treatment response in U87 
cells compared to 2-PCPA, therefore this attracts the question whether Q-PAC retained 
its LSD1 inhibitor function. While an inverted U-shaped concentration-dependent effect 
on H3K4me1/2 was observed in primary GBM cells, with the peak difference at 10 µM; 
the H3K4me1/2 levels were surprisingly unaffected by Q-PAC treatment in immortalised 
U87 cells. The unchanged H3K4me1/2 levels in U87 cells were unexpected as both U87 
and primary GBM cultures demonstrated decrease in cell confluence after Q-PAC 
treatment. This finding may suggest that Q-PAC only cause minor global methylation 
changes, or gene-specific methylation changes are likely.82,99 
 
2.3.6 Reduction of GSH levels in GBM cells after Q-PAC treatment 
  Q-PAC was designed to not only inhibit LSD1 but also suppress antioxidant 
system by quenching GSH. Therefore, the GSH and ROS levels in GBM cultures were 
quantified 4 h after Q-PAC treatment, where onset of treatment effects on confluence and 
migration were observed. Through a fluorometric assay, it was discovered that Q-PAC 
dose-dependently reduced GSH concentration in U87 and RN1 cells, but not in healthy 
astrocytes (Figure 15A). Similarly, ROS level elevated dose-dependently with Q-PAC 
concentration in U87 (F(7, 33)=5.03, P<0.001) and RN1 (F(6, 28)=5.76, P<0.001) cells 
within the same treatment timeframe (Figure 15B). In summary, suppression of 
antioxidant system to increase ROS was observed in Q-PAC treated GBM cells but not 
in healthy astrocytes. 
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Figure 15: Q-PAC increases oxidative stress and reduces GSH in GBM cells but not 
healthy astrocytes. (A) Intracellular GSH concentration was quantified via fluorometric 
assay 4 h after Q-PAC treatment (0 to 300 µM) in human established GBM cells 
(U87MG), primary GBM cells (RN1) and primary astrocytes (n=3 per concentration and 
cell type). (B) Oxidative stress levels were quantified via a cell-permeant fluorogenic 
probe 4 h after Q-PAC treatment (0 to 300 µM) in human established GBM cells 
(U87MG) and primary GBM cells (RN1), normalized to vehicle treated cultures (n=3 per 
concentration and cell type). Data represent mean ± SEM, ****P<0.0001 compared to 
vehicle control; $$P<0.01 compared vehicle control (RN1); ##P<0.01 compared to 
vehicle control (U87MG). 
 
2.3.7 Q-PAC induced apoptosis in GBM by increasing caspase 3/7 activity  
 In order to gain further insight into the underlying mechanism of Q-PAC reducing 
confluence and cell viability in GBM, we next investigated if Q-PAC induced cell cycle 
arrest, since LSD1 inhibitors have been reported to induce cell cycle arrest in breast 
cancer cells.100 Minichromosome maintenance 2 (MCM2) is part of the DNA replication 
machinery which is only expressed in proliferating cells.101 48 h of Q-PAC treatment did 
not affect the proportion of MCM2-positive U87 or primary GBM cultures (Figure 16), 
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suggesting that the reduction in viable cells may not be due to cancer cells driving out of 
the cell cycle. 
 
Figure 16: Reduction in GBMs cell viability was not due to cell cycle arrest. Cells 
positive for minichromosome maintenance 2 expression (MCM2, part of the DNA 
replication machinery that is only expressed in proliferating cells), were counted in 
cultures treated with Q-PAC (0 to 300 µM) for 48 h (n=4 per concentration and type). 
MCM2-positive cells were quantified via antibody-based immunofluorescence labelling 
in microscope images at 20x magnification and presented as % of total cell number. 
 Caspase 3/7 play essential roles in executing cell apoptosis.102 It is well 
documented that apoptosis is closely related to ROS concentration, and GSH depletion 
induced activation of caspase 3.103,104 Furthermore, LSD1 inhibition was also reported to 
induce caspase-dependent apoptosis in AML,52 Ewing sarcoma105 and endometrial 
carcinoma,106 therefore caspase 3/7 activity was monitored in GBM cells and healthy 
astrocytes after Q-PAC treatment. Q-PAC does-dependently increased caspase 3/7 
activity in U87 (F(6, 11)=24.30, P < 0.0001; Figure 17A), RN1 (F(5, 22)=6.2, P=0.001; 
Figure 17B), JK2 (F(5, 6)=5.7, P = 0.027; Figure 17C) and SJH1 (F(6, 7)=4.83, P=0.028; 
Figure 17D) cultures, without affecting caspase 3/7 activity in healthy astrocytes (F(5, 
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12)=2.67, P=0.08; Figure 17E). The increase in caspase 3/7 activity suggest that the 
reduction in GBMs cell viability was due to caspase-mediated apoptosis induced by Q-
PAC, while the basal caspase activity in healthy astrocytes was consistent to the observed 
unaffected viability. 
 
Figure 17: Q-PAC triggers caspase-dependent apoptosis in primary GBM cells but not 
in healthy astrocytes. Caspase activity of established U87 GBM cells (A), primary human 
GBM cultures (B-D) and primary human astrocytes cultures (E) after treatment with Q-
PAC. Apoptosis was quantified through counting of green-fluorescent caspase 3/7 
substrates per mm2 in microscope images at 20x magnification over time (n=3 per 
concentration & culture). Data represent mean ± SEM, * P<0.05, ** P<0.01, 
***P<0.001, ****P<0.0001 compared to vehicle control. 
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2.3.8 Proposed mechanism for the Q-PAC induced caspase-dependent apoptosis 
 Due to the difference in cellular ROS concentration, prodrug Q-PAC selectively 
targeted GBM cells over healthy astrocytes (Section 2.3.4). Upon activation by hydrogen 
peroxide, Q-PAC liberated 2-PCPA (LSD1 inhibitor) and QM (GSH scavenger) which 
reduced viability in GBM cells. In this study, Q-PAC inhibited LSD1 in primary GBM 
RN1 as shown from the increased H3K4me1/2 levels at 10 μM (Section 2.3.5), GSH 
depletion and oxidative stress elevation were also observed in GBM cells upon Q-PAC 
treatment (Section 2.3.6). As a result, the synergistic effect of LSD1 inhibition and GSH 
depletion likely induced caspase 3/7-mediated apoptosis in GBM cells (Section 2.3.7). 
 Due to the fact that the cytochrome c-initiated pathway is the main caspase 
activation pathway in mammalian cells, we proposed that cytochrome c plays a major 
role in the apoptosis of GBM cells through activation of caspase 9 and subsequently 
caspase 3/7 (Figure 18).107 The release of cytochrome c from mitochondria is normally 
suppressed by Bcl-2 to prevent apoptosis.107,108 Since reduced expression of Bcl-2 was 
reported in LSD1 inhibition,109,110 this led us to believe that the release of cytochrome c 
is favoured and hence inducing caspase-dependent apoptosis in GBM cells treated with 
Q-PAC. Furthermore, release of cytochrome c is promoted under elevated oxidative stress 
caused by GSH depletion.104 Therefore, we proposed that the dual-action prodrug Q-PAC 
promotes the liberation of cytochrome c from mitochondria by simultaneously increasing 
oxidative stress (via QM-induced GSH depletion) and suppressing the expression of Bcl-
2 (via LSD1 inhibition). To verify this hypothesis, the expression of Bcl-2 can be 
quantified by Western blot analysis while the release of cytochrome c can be measured 
by immunodetection in the future.110,111 
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Figure 18: Proposed mechanism of caspase-dependent apoptosis induced by 2-PCPA 
and QM (generated from Q-PAC). 
 
2.3.9 Preparation and biological evaluation of iodinated prodrugs 
 The capability to pass through BBB is an essential criterion for drugs targeting 
GBM, and this is reflected by the log BB parameter.112,113 The calculated log BB value 
for Q-PAC is 0.10, which is above the −0.3 cut-off for BBB permeability,114 suggesting 
that Q-PAC will pass through the blood brain barrier. Inspired by the promising and 
selective treatment effect demonstrated by Q-PAC in GBMs, and to gain insight into the 
biodistribution and metabolic stability, we aimed to radiolabel Q-PAC with 124I in order 
to proceed forward with mice model. Isotope 124I was chosen because this isotope has a 
relatively long half-life (4.2 days), which is feasible for prolonged in vivo studies.115 
 Prior to radiolabelling, three non-radioactive iodo-derivatives of prodrug Q-PAC 
were synthesised and tested in vitro to observe if the anticancer properties can still be 
retained with the presence of iodine atom, especially since Q-BrAC (the bromo-analogue 
of Q-PAC) did not show the same anticancer effect as observed with Q-PAC. Iodine atom 
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was located on the 2-PCPA phenyl moiety at different position in these three derivatives 
(namely Q-2IAC, Q-3IAC and Q-4IAC). 
Scheme 10: Preparation for the iodo-analogues of prodrug Q-PAC. 
Ethyl cinnamates with iodine on the phenyl ring are not commercially available, 
therefore the syntheses of Q-2IAC and Q-3IAC started from Horner–Wadsworth–
Emmons reaction of iodobenzaldehydes to yield the corresponding ethyl cinnamates 
(Scheme 10). NaH deprotonated triethyl phosphonoacetate to form the phosphonate 
carbanion, which then attacked the carbonyl in iodobenzaldehydes to yield the 
oxaphosphetane intermediate, followed by elimination of diethoxyphosphate salt to yield 
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the desired ethyl cinnamates. During the formation of oxaphosphetane intermediate, the 
ester group was placed anti to the aromatic ring to minimise steric hindrance. As a result, 
(E) olefin isomer was obtained solely as the product – indicated by the 1H NMR analysis 
discussed below. 
For the 2-iodo ethyl cinnamate, its formation was indicated by the absence of 
singlet at 9.97 ppm (R-CHO) in 1H NMR spectrum, while the signals at 7.91 – 7.88 and 
6.31 ppm were assigned as the olefin protons. The doublet at 6.31 ppm had a coupling 
constant of 15.5 Hz, which corresponded to an (E) alkene – consistent to the mechanism 
of Horner–Wadsworth–Emmons reaction. 
Similar to the preparation of Q-PAC and Q-BrAC, the obtained iodo ethyl 
cinnamates were subjected to Corey–Chayvosky cyclopropanation, basic hydrolysis and 
ultimately Curtius rearrangement with PBE to yield the prodrugs Q-2IAC and Q-3IAC 
(Scheme 10). Among all the synthetic steps, low yields of 16 – 19% were obtained during 
the Corey–Chayvosky cyclopropanation. As the ethyl cinnamate substrates were not 
detected after the reaction, it was proposed that decomposition of reaction intermediates 
might have occurred – possibly a result of lower electrophilicity of the esters compare to 
the more commonly used aldehyde substrates. 
On the other hand, Q-4IAC can be easily prepared from the iodination of trans-2-
phenylcyclopropane-1-carboxylic acid 17a follow by Curtius rearrangement with PBE 
(Scheme 10). Under acidic conditions, the triiodine cation (I3+) was formed upon 
treatment of I2 with IO3-, the I3+ then acted as an iodinating agent for the phenyl ring in 
17a to yield 17c.116 In the 1H NMR spectrum of 17c, two distinct doublets with total 
integration of four protons were observed at 7.60 and 6.86 ppm (J = 8.0 Hz for both 
doublets), which is a feature of para disubstituted phenyl ring. The success in iodination 
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was also indicated in the 13C NMR spectrum of 17c, where an up-field shift was observed 
for the iodinated carbon (from 128.6 – 126.3 ppm in 17a to 91.7 ppm in 17c). 
Immortal U87 cultures were then treated with these three iodo-prodrugs and cell 
confluence was assessed. Q-4IAC reduced cell confluence at concentrations of 100 µM 
or higher (Figure 19C). Although Q-2IAC also reduced U87 cell confluence at 100 µM 
in the first two hours after treatment, the cell confluence was observed to recover after 
four hours of treatment (Figure 19A). Meanwhile, Q-3IAC only reduced U87 cell 
confluence at a higher concentration of 300 µM (Figure 19B). The migratory ability of 
U87 cells was also assessed through a scratch-assay. The results of scratch-assay for the 
three iodo-prodrugs are consistent to the cell confluence, except Q-2IAC was able to 
reduce migration of U87 cells at a lower concentration of 30 µM rather than 100 µM 
(Figure 19D-F). In summary, cell proliferation and migratory ability of U87 cells were 
impaired by Q-4IAC and Q-2IAC, but at higher concentrations compared to Q-PAC.  
Interestingly, although Q-4IAC displayed a reduced anticancer effect compared 
to Q-PAC, Q-4IAC was still more potent than Q-BrAC in the inhibition of U87 cell 
proliferation, and they are only differed in the halogen atoms on the 2-PCPA phenyl 
moiety. Since iodine atom is larger than bromine atom in size, this further supports the 
hypothesis that the lack of anticancer activity shown in Q-BrAC was not due to the steric 
clash of brominated 2-PCPA in the LSD1 active site. 
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Figure 19: (A-C) Confluence of primary human GBM RN1 cultures treated with Q-2IAC 
(A), Q-3IAC (B) and Q-4IAC (C) were quantified via algorithm-based analysis of phase-
contrast microscope images at 10x magnification over a 28 h period (n=3 per 
concentration & culture), normalised to culture confluence prior treatment. (D-F) 2D 
migration of human GBM RN1 cultures treated with Q-2IAC (D), Q-3IAC (E) and Q-
4IAC (F). Scratch wound width was quantified through algorithm-based analysis of 
phase-contrast microscope images at 10x magnification following scratch wound and Q-
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PAC treatment (n=3 per concentration and culture), normalised to wound width prior 
treatment. Data represent mean ± SEM. 
In order to access radiolabelled prodrugs, the stannylated derivatives of prodrugs 
needed to be prepared as precursors for radioiodination. The understanding of the 
prodrug’s stability is vital to decide if preparation of stannylated derivatives should 
commence. As the prodrugs in this study were novel and their stability under 
radioiodination was unknown, Q-4IAC was subjected to radioiodination conditions to 
understand its molecular stability under these conditions. Experiments were conducted 
by Dr I. Greguric (Australian Nuclear Science and Technology Organisation). Prodrug 
Q-4IAC was subjected to two different radioiodination conditions: (i) Chloramine-T (100 
µg/100 µL in H2O) + 1.0 M HCl + 1 crystal of NaI; (ii) 2% peracetic acid/acetic acid + 1 
crystal of NaI. The integrity of prodrug Q-4IAC was monitored via HPLC after treatments 
with radioiodination conditions. Based on the HPLC chromatograms after treatment, less 
than 3% of prodrug Q-4IAC remained while more than two decomposed species were 
present in each condition. The decomposed species were not identical in each condition 
as shown from the difference in retention time. Although it is possible that hydrolysis of 
the boronic ester to the acid took place, hydrolysis of the carbamate linkage could also be 
possible. 
 In summary, while prodrug Q-4IAC moderately decreased U87 cell confluence 
and migration, radiolabelling of Q-4IAC under these conditions is unlikely to be possible, 
with the degradation perhaps due to the oxidative aqueous acidic conditions used during 
radioiodination, which might cause both oxidation and/or hydrolysis of the boronate 
functionality. Therefore alternative milder radiolabelling approaches should be attempted 
in the future.117  
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2.3.10 Biological evaluation of reported LSD1 inhibitors on GBM cells 
 Since the discovery of LSD1 in 2004, 2-PCPA derivatives have been studied 
extensively in LSD1 inhibition, especially two of these derivatives are currently in 
clinical trials (Section 2.1.6). At the same time, potent and selective non-2-PCPA-based 
LSD1 inhibitors (11-13, bizine) have also been reported in literature (Section 2.1.7). Even 
though these non-2-PCPA-based LSD1 inhibitors demonstrated promising in vitro results 
in their respective studies, these inhibitors have not been assessed on GBM cell lines. In 
parallel to the GBM prodrug study, we investigated these reported non-2-PCPA-based 
LSD1 inhibitors in the treatment of GBM cells. Promising hits from this investigation 
could be incorporated into our prodrug platform to replace the 2-PCPA moiety in hope of 
improving LSD1 inhibitory activity. 
Non-2-PCPA-based LSD1 inhibitors 11-13 and bizine were prepared based on 
their original reported literature (Scheme 11).87-90 During the course of preparing these 
inhibitors, it was discovered that several characterisation data for the reported inhibitors 
and their intermediates (such as 13C NMR, IR, HRMS and melting point) was missing 
from the literature. Therefore, these characterisation data were collected and reported in 
the experimental section of this chapter. 
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Scheme 11: Preparation of reported non-2-PCPA-based LSD1 inhibitors. 
Inhibitor 11 was prepared in two steps (Scheme 11a). Firstly, intermediate 19 was 
prepared in one-pot from tert-butyl piperazine-1-carboxylate 18, carbon disulfide and 
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propargyl bromide in the presence of Na3PO4•12H2O. Subsequently, a Huisgen 1,3-
dipolar cycloaddition between the alkyne in 19 and 4-methylbenzyl azide yielded the 
desired inhibitor 11 in an overall yield of 73% over two steps. The 1H NMR data of 11 
was consistent with the literature.90 
Inhibitor 12 was prepared in four steps (Scheme 11b). After coupling phenol with 
2-fluoro-6-chlorobenzonitrile 20 to form intermediate 21, the nitrile group in 21 was 
reduced to amine 22 using LiAlH4. Subsequent reaction with N-
cyanodithioiminocarbonate then hydrazine hydrate furnished the desired inhibitor 12. The 
1H NMR data of 12 was consistent with the literature.88 In the IR spectrum obtained from 
this study, the signals at 3352 and 3266 cm-1 were assigned as the N-H bonds in 12. 
Moreover, the HRMS of 12 was acquired in this study with good accuracy (∆ppm = 4.1). 
Inhibitor 13 was prepared in two steps (Scheme 11c). Intermediate 23 was 
obtained from the coupling of 2-aminophenol with cyanoacetic acid in the presence of 
phosphorus pentachloride. Subsequently, reaction of 23 with hydroxylamine 
hydrochloride and potassium carbonate provided the amidoxime inhibitor 13. A low 
isolated yield of 12% was obtained in the final step, this could be due to the loss of 
material during recrystallisation. The 1H NMR data of 13 was consistent with the 
literature.87 While the 13C NMR data was not reported, the 13C NMR spectrum obtained 
in this study was consistent with the proposed structure. Due to the introduction of amine 
to nitrile via hydroxylamine hydrochloride, the H2N-C=N carbon signal shifted down-
field from 115.8 ppm to 148.7 ppm. Similarly, the CH2 signal shifted down-field from 
27.2 ppm to 39.7 ppm due to the introduction of amine group to the adjacent carbon. 
Furthermore, the HRMS of 13 obtained in this study matched the proposed structure with 
great accuracy (∆ppm = 1.0).  
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Bizine was prepared in four steps (Scheme 11d). Firstly, 4-phenylbutyric acid was 
treated with thionyl chloride to form the acyl chloride intermediate 24. This was followed 
by the nucleophilic addition of 2-(4-aminophenyl)ethanol to link the two fragments with 
an amide linkage. The resulting 25 intermediate was subjected to an Appel reaction with 
triphenylphosphine and tetrabromomethane, in order to convert the hydroxyl group to 
bromine. Eventually, the bromine atom was substituted by hydrazine to yield bizine. The 
1H NMR data of bizine was consistent with the literature.89 While the IR data was not 
reported, the IR spectrum for bizine obtained in this study displayed signals at 3303 and 
1684 cm-1, corresponding to the N-H and C=O bonds in the molecule. 
These LSD1 inhibitors and 2-PCPA were then subjected to treatment on primary 
GBM cell line RN1 which was found to overexpress LSD1 (Figure 13). Among the tested 
LSD1 inhibitors, only inhibitor 11 was found to affect RN1 cell confluency over a 48 h 
treatment period (Concentration: F(5, 30)=25.80, P<0.001; Time: F(24, 720) = 568.3, 
P<0.001), with concentrations of 10 µM and higher significantly lowering culture 
confluence (10 µM: P=0.0005, 30 µM: P=0.0029, 100 µM: P<0.0001) (Figure 20). 
Moreover, treatment of inhibitor 11 also impaired the migration of RN1 cells 
(Concentration: F(5, 30)=34.36, P<0.001; Time: F(22, 660)=104.3, P<0.0001) at 
concentrations of 10 µM and higher (P<0.0001 vs vehicle) (Figure 21). No effect on cell 
confluence or migration was observed when RN1 cells were treated with inhibitors 12, 
13, bizine and 2-PCPA (Figure 20, Figure 21). Consistent to the reduction in RN1 cell 
confluence and migration, inhibitor 11 treatment dose-dependently reduced RN1 viability 
at concentration of 10 µM and higher (10 µM: P=0.0168, 30 µM: P<0.0001, 100 µM: 
P<0.001 vs vehicle) after 48 h of treatment (Figure 22). 
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Figure 20: Confluence of RN1 cultures treated with different reported LSD1 inhibitors. 
Algorithm-based confluence analysis of phase-contrast microscope images at 10x 
magnification every 2 h over a 48 h period following LSD1 inhibitor treatment (n=3 per 
concentration). Data represent mean ± SEM. 
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Figure 21: 2D migration of RN1 cells treated with reported LSD1 inhibitors. Algorithm-
based scratch wound analysis of phase-contrast microscope images at 10x magnification 
every 2 h over a 48 h period following scratch wound and LSD1 inhibitor treatment (n=3 
per concentration). Data represent mean ± SEM. 
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Figure 22: After treatment of reported LSD1 inhibitors, cell viability of RN1 culture was 
quantified via a Resazurin-based fluorometric assay (n = 4), with readings normalised to 
vehicle treated cultures. Data represent mean ± SEM. 
 Since our 2-PCPA-based prodrug Q-PAC was found to induce caspase-mediated 
apoptosis in GBM cells, the caspase 3/7 activity was also monitored after RN1 cells were 
treated with these reported LSD1 inhibitors. Consistent to the observed reduction in RN1 
cell viability, inhibitor 11 dose-dependently increased caspase 3/7 activity in RN1 cells 
(Concentration: F(5, 30)=38.67, P<0.0001; Time: F(24, 720)=1157, P<0.0001) at 
concentration of 10 µM or higher (10 µM: P=0.0016, 30 µM: P<0.0001, 100 µM: 
P<0.0001) (Figure 23). This result may suggest that the observed reduction in cell 
confluence and migration were caused by caspase-dependent apoptosis triggered by 
LSD1 inhibition and subsequently Bcl-2 suppression and cytochrome c release.108-110 
Similarly, no effect on caspase 3/7 activity was observed when RN1 cells were treated 
with inhibitors 12, 13, bizine and 2-PCPA (Figure 23). 
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Figure 23: Apoptosis of primary GBM RN1 cultures treated with reported LSD1 
inhibitors. Apoptosis was quantified through counting of green-fluorescent caspase 3/7 
substrates per mm2 in microscope images at 20x magnification over time (n=3 per 
concentration). 
Among the tested LSD1 inhibitors, only inhibitor 11 displayed anticancer effect 
on primary GBM RN1 cells by inducing caspase-dependent apoptosis triggered by LSD1 
inhibition. This demonstrated the potential of this inhibitor as a lead for further 
development and incorporation into the concept of dual-action prodrug described in this 
chapter. 
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2.4 Conclusions and future work 
 The dual-action prodrug Q-PAC described in this chapter utilised the high ROS 
concentration in tumour cells as an activation method to selectively target GBM cells over 
healthy astrocytes. Upon activation by hydrogen peroxide, Q-PAC releases 2-PCPA 
(LSD1 inhibitor) and QM (antioxidant scavenger), as verified from mass spectrometry 
experiments. LSD1 inhibition may lead to the suppression of Bcl-2 which allows the 
release of cytochrome c from mitochondria. At the same time, the liberation of 
cytochrome c is promoted when cells are under oxidative stress induced by GSH 
depletion. The release of cytochrome c from mitochondria is crucial in the caspase-
dependent apoptosis pathway where caspase 9 is activated follow by caspase 3/7. As a 
result of caspase-dependent apoptosis induced by Q-PAC, the confluence, migration and 
cell viability of GBM cells were found to be reduced dose-dependently, while healthy 
astrocytes remained unaffected. 
 The selectivity of Q-PAC towards GBM cells over healthy astrocytes is mainly 
attributed to the aryl boronate functionality. Despite boronic esters having been described 
to have low hydrolytic stability in biological media,118,119 our results demonstrated that 
the boronic ester-containing Q-PAC was able to induce apoptosis in GBM selectively at 
micromolar range. In fact, the hydrolysed aryl boronic acid can also be oxidised to the 
phenol intermediate in the presence of H2O2.120 Furthermore, Mokhir and co-workers 
have also reported promising results on aryl boronate-containing prodrugs.26,33,35 In the 
future, a more hydrolytic stable analogue of Q-PAC can be prepared in order to 
investigate if hydrolytic stability plays a role in the prodrug activity or its 
pharmacokinetics. Bernardini et al. reported that introducing steric hindrance to the diol 
moiety of boronic ester can slow down the hydrolysis rate (Figure 24a), presumably by 
blocking the attack of water molecule towards the boron p-orbital.118 Based on this 
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reported observation, we proposed the preparation of a hydrolytic stable analogue of Q-
PAC with fused-cyclohexanes at the diol moiety (26, Figure 24b). Prodrugs Q-PAC and 
26 can then be subjected to GBM treatment to observe if there is any difference in drug 
activity, as such the role of hydrolytic stability can be understood. 
Figure 24: (a) Introduction of steric hindrance around the diol moiety in boronic esters 
was found to minimise hydrolysis.118 (b) Proposed preparation of hydrolytic stable 
analogue of Q-PAC (26). 
 Since Q-PAC demonstrated promising results in primary GBM cultures, the study 
should be preceded with in vitro studies. Radioiodination of the prodrug enable the study 
of biodistribution and metabolic stability in animal models. However preliminary results 
from this chapter suggest that the prodrug was unstable in the radioiodination conditions, 
therefore other radiolabelling methods should be considered. For example, tritium is 
another commonly used radioisotope in drug discovery.121 The tritium labelling of Q-
PAC can be completed in two steps: Pd-catalysed iodine exchange of carboxylic acid 
precursor 17c follow by the Curtius rearrangement with PBE (Scheme 12). The boronate 
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functionality is unlikely to be affected from the radiolabelling by introducing the tritium 
label before the aryl boronate. Moreover, due to the similar size of hydrogen atom and 
tritium, the tritium-labelled Q-PAC 27 is expected to have similar anticancer effect 
compared to Q-PAC but better than Q-4IAC. 
 
Scheme 12: Proposed preparation of tritium-labelled Q-PAC. 
 In parallel to the prodrug study, reported LSD1 inhibitor 11 was found to induce 
caspase-dependent apoptosis in primary GBM RN1 cells, therefore reducing cell 
confluence, migration and viability. Encouraged by the promising results exhibited by 
LSD1 inhibitor 11, and to enhance the LSD1 inhibitory action of prodrug, we proposed 
to replace the 2-PCPA moiety of Q-PAC with 11. The designated prodrug 28 can be easily 
prepared from the coupling of 11 and PBE in one-pot (Scheme 13).122 In cancer cells 
where higher ROS concentration is present, prodrug 28 is proposed to release QM and a 
Boc-free analogue of inhibitor 11. According to the literature, the Boc-free analogue of 
11 was still able to inhibit LSD1, however its inhibitory activity was poorer than 11 (IC50 
for 11: 2.1 µM; IC50 for Boc-free 11: 28.9 µM).90 Nevertheless, based on available SAR 
information from the literature, the functionalisation of carbamate moiety in 11 is the 
most practical approach to prepare dual-action prodrug without completely diminishing 
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the LSD1 inhibitor property.90 Furthermore, due to the structural homology between 11 
and its Boc-free counterpart, the selectivity towards LSD1 over MAOs could be retained 
in the latter. Besides, the presence of GSH-scavenging QM might be able to compensate 
the reduction in LSD1 inhibitory activity. 
 
Scheme 13: Proposed preparation of prodrug 28 which will liberate QM and a Boc-free 
analogue of 11 in cancer cells. 
 
2.5 Experimental 
All organic syntheses and molecule characterisation were performed by Y. S. Gee. 
Mass spectrometry experiments were conducted by Y. S. Gee and Dr A. Maccarone 
(University of Wollongong). In vitro assays were performed by Dr M. Engel and D. Cross 
(Illawarra Health & Medical Research Institute). The log BB value of prodrug Q-PAC 
was calculated by Dr H. Yu (University of Wollongong). Radioiodination and HPLC 
analysis of prodrug Q-4IAC were conducted by Dr I. Greguric (Australian Nuclear 
Science and Technology Organisation). 
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2.5.1 General experimental details for organic syntheses 
Unless stated specifically, all chemicals were purchased from commercial 
suppliers and used without purification. All reactions were conducted in oven-dried 
glassware under nitrogen atmosphere. Reaction solvents were dried by passing through a 
column of activated alumina and then stored over 4Å molecular sieves. Progress of 
reactions was tracked by TLC and was performed on aluminium backed silica gel sheets 
(Grace Davison, UV254). TLC plates were visualised under UV lamp at 254 nm and/or 
by treatment with one of the following TLC stains: Phosphomolybdic acid (PMA) stain: 
PMA (10 g), absolute EtOH (100 mL); Potassium permanganate stain: KMnO4 (1.5 g), 
10% NaOH (1.25 mL), water (200 mL); Vanillin stain: Vanillin (15 g), concentrated 
H2SO4 (2.5 mL), EtOH (250 mL). For NMR spectroscopy analytes were dissolved in 
deuterated chloroform or stated otherwise. NMR spectra for each compound were 
collected from one of the following instrument: Mercury 2000 spectrometer operates at 
500 and 125 MHz for 1H and 13C NMR respectively; Bruker spectrometer operates at 400, 
100 and 470 MHz for 1H, 13C and 19F NMR respectively; Varian spectrometer operates 
at 300 and 75 MHz for 1H and 13C NMR respectively. NMR data are expressed in parts 
per million (ppm) and referenced to the solvent (7.26 ppm for 1H NMR and 77.16 ppm 
for 13C NMR). The following abbreviations are used to assign the multiplicity of the 1H 
NMR signal: s = singlet; bs = broad singlet; d = doublet; t = triplet; q = quartet; quin = 
quintet; dd = doublet of doublets; m = multiplet. NMR assignments were made on the 
basis of HMBC, HSQC, COSY and DEPT experiments. For mass spectrometry analytes 
were dissolved in HPLC grade methanol or dichloromethane. High-resolution mass 
spectra were collected from a Waters Xevo G1 QTOF mass spectrophotometer (ESI or 
ASAP) or Thermo Scientific LTQ Orbitrap XL (ESI). Infrared spectra were obtained from 
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a Shimadzu IRAffinity-1 Fourier transform infrared spectrophotometer with ATR 
attachment. Melting point measurements were taken on a Buchi M-560. 
 
2.5.2 Preparation of Q-PAC and its precursors 
Ethyl 2-phenylcyclopropane-1-carboxylate (16a) 
 
A suspension of trimethylsulfoxonium iodide (3.75 g, 17.0 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 685 mg, 17.1 mmol, 1.2 equiv) in anhydrous DMSO (14 
mL) were stirred for 1 h before the addition of ethyl cinnamate (2.40 mL, 2.52 g, 14.3 
mmol, 1 equiv). After the reaction was heated at 60 °C overnight, the reaction solution 
was poured into brine solution (50 mL) and extracted with ethyl acetate (4 × 30 mL). The 
combined organic extracts were washed with water (50 mL) and brine solution (50 mL). 
After drying the solution with magnesium sulfate, the solution was concentrated under 
reduced pressure to give a pale yellow oil crude which was later subjected to column 
chromatography (10% ethyl acetate/hexane). The title compound was collected as a pale 
yellow oil (1.01 g, 5.30 mmol) in 37% yield. 1H NMR (500 MHz, CDCl3): δ 7.29 – 7.26 
(m, 2H, CHAr), 7.21 – 7.18 (m, 1H, CHAr), 7.10 (d, J = 7 Hz, 2H, CHAr), 4.17 (q, J = 7 
Hz, 2H, OCH2), 2.53 – 2.50 (m, 1H, CH-Ar), 1.90 (ddd, J = 8.7, 4.5, 4.5 Hz, 1H, CH-
COOEt), 1.59 (ddd, J = 9.4, 4.8, 5.0 Hz, 1H, CH2-CH-Ar), 1.33 – 1.26 (m, 4H, CH2-CH-
Ar and OCH2CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 173.4 (C=O), 140.1 (CAr), 128.5 
(CHAr), 126.5 (CHAr), 126.2 (CHAr), 60.7 (OCH2), 26.2 (CH-Ar), 24.2 (CH-COOEt), 17.1 
(CH2-CH-Ar), 14.3 (CH3) ppm. NMR data consistent with literature.123,124 
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2-Phenylcyclopropane-1-carboxylic acid (17a) 
 
1 M Sodium hydroxide solution (3.2 mL, 3.2 mmol, 2 equiv) was added to a solution of 
16a (304 mg, 1.60 mmol, 1 equiv) in ethanol (6 mL). The reaction was left stirring at 
room temperature for 24 h and then quenched with 2 M hydrochloric acid (2.4 mL, 4.8 
mmol, 3 equiv) and water (5.43 mL) at 0 °C. The solution was stirred for 5 min before 
extraction with ethyl acetate (4 × 15 mL). Combined organic fractions were washed with 
water (10 mL) then brine (10 mL). The organic extracts were dried with magnesium 
sulfate and the solvent evaporated under reduced pressure to yield the product as a white 
solid that required no further purification (251 mg, 1.55 mmol) in 97% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.30 – 7.27 (m, 2H, CHAr), 7.23 – 7.20 (m, 1H, CHAr), 7.11 (d, J = 
8 Hz, 2H, CHAr), 2.62 – 2.58 (m, 1H, CH-Ar), 1.91 (ddd, J = 8.4, 4.5, 4.5 Hz, 1H, CH-
COOH), 1.66 (ddd, J = 9.2, 4.8, 5.0 Hz, 1H, CH2), 1.43 – 1.39 (m, 1H, CH2) ppm. 13C 
NMR (125 MHz, CDCl3): δ 179.8 (C=O), 139.5 (CAr), 128.6 (CHAr), 126.7 (CHAr), 126.3 
(CHAr), 27.1 (CH-Ar), 24.0 (CH-COOH), 17.5 (CH2) ppm. Melting point: 82.9 – 84.9 






Triethylamine (0.400 mL, 0.290 g, 2.87 mmol, 1.2 equiv) and diphenylphosphoryl azide 
(0.580 mL, 742 mg, 2.70 mmol, 1.1 equiv) were added to a solution of 17a (0.400 g, 2.46 
mmol, 1 equiv) and 4-(hydroxymethyl)phenylboronic acid pinacol ester (638 mg, 2.72 
mmol, 1.1 equiv) in dry dioxane (5 mL). The reaction solution was heated at 105 °C for 
4 h then cooled to room temperature. Solvent was evaporated under reduced pressure and 
the compound was purified by column chromatography (25% ethyl acetate/hexane). The 
title compound was obtained as a colourless oil (514 mg, 1.31 mmol) in 53% yield. 1H 
NMR (500 MHz, CDCl3): δ 7.79 (d, J = 7.5 Hz, 2H, CHAr-B(OR)2), 7.33 (d, J = 7.5 Hz, 
2H, CHAr-B(OR)2), 7.25 – 7.23 (m, 2H, CHAr), 7.17 – 7.09 (m, 3H, CHAr), 5.23 (bs, 1H, 
NH), 5.12 (s, 2H, OCH2), 2.75 (bs, 1H, CH-NH), 2.06 (bs, 1H, CH-Ar), 1.33 (s, 12H, 
CH3), 1.18 (bs, 2H, CH2-CHNH) ppm. 13C NMR (75 MHz, CDCl3)a: δ 156.8 (C=O), 
140.5 (CAr), 139.5 (CAr-B(OR)2), 135.1 (CHAr-B(OR)2), 128.4 (CHAr), 127.2 (CHAr-B(OR)2), 
126.6 (CHAr), 126.2 (CHAr), 83.9 (C-Me2), 66.7 (OCH2), 32.7 (CH-NH), 24.9 (CH3 and 
CH-Ar), 16.2 (CH2-CHNH) ppm. IR (Neat): 3318, 2977, 1706 cm-1. HRMS (ESI) m/z: 
[M]+ Calcd for C23H28BNO4 393.2111; Found 393.2102. 




2.5.3 Preparation of Q-BrAC and its precursors 
Ethyl 2-(p-bromophenyl)cyclopropane-1-carboxylate (16b) 
 
A suspension of trimethylsulfoxonium iodide (3.61 g, 16.4 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 664 mg, 16.6 mmol, 1.2 equiv) in anhydrous DMSO (12 
mL) were stirred for 1 h before the addition of ethyl (E)-3-(p-bromophenyl)-2-propenoate 
(3.48 g, 13.6 mmol, 1 equiv) in anhydrous DMSO (12 mL). After the reaction was heated 
at 60 °C for 36 h, the reaction solution was poured into brine solution (50 mL) and 
extracted with ethyl acetate (4 × 30 mL). The combined organic extracts were washed 
with water (50 mL) and brine solution (50 mL). After drying the solution with magnesium 
sulfate, the solution was concentrated under reduced pressure to give a brown oil crude 
which was later subjected to column chromatography (10% ethyl acetate/hexane). The 
title compound was collected as a colourless oil (1.52 g, 5.64 mmol) in 41% yield. 1H 
NMR (500 MHz, CDCl3): δ 7.39 (d, J = 8 Hz, 2H, CHAr), 6.97 (d, J = 8 Hz, 2H, CHAr), 
4.17 (q, J = 7 Hz, 2H, OCH2), 2.49 – 2.45 (m, 1H, CH-Ar), 1.86 (ddd, J = 8.4, 4.5, 4.5 
Hz, 1H, CH-COOEt), 1.60 (ddd, J = 9.3, 4.8, 5 Hz, 1H, CH2-CH-Ar), 1.29 – 1.25 (m, 4H, 
CH2-CH-Ar and CH3) ppm. HRMS (ASAP) m/z: [M + H]+ Calcd for C12H14O2Br 
269.0177; Found 269.0164. 1H NMR data are consistent with literature.127 
 
2-(p-Bromophenyl)cyclopropane-1-carboxylic acid (17b) 
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Sodium hydroxide solution (1 M, 6.9 mL, 6.9 mmol, 2 equiv) was added to a solution of 
16b (922 mg, 3.43 mmol, 1 equiv) in ethanol (12 mL). After the solution was left stirring 
overnight at room temperature, hydrochloric acid solution (2 M, 5.20 mL, 10.4 mmol, 3 
equiv) and water (5 mL) were added to the reaction solution at 0 °C. The solution was 
extracted with ethyl acetate (3 × 30 mL) and washed with brine solution (2 × 30 mL). 
After drying the solution with magnesium sulfate, the solution was concentrated under 
reduced pressure to give the title compound as a white solid (823 mg, 3.41 mmol) in 100% 
yield. 1H NMR (500 MHz, CDCl3): δ 7.41 (d, J = 8.5 Hz, 2H, CHAr), 6.98 (d, J = 8 Hz, 
2H, CHAr), 2.57 – 2.53 (m, 1H, CH-Ar), 1.88 (ddd, J = 8.2, 4.2, 4.0 Hz, 1H, CH-COOH), 
1.66 (ddd, J = 9.2, 4.8, 5.0 Hz, 1H, CH2), 1.39 – 1.35 (m, 1H, CH2) ppm. 13C NMR (75 
MHz, CDCl3): δ 179.3 (C=O), 138.8 (CAr), 131.7 (CHAr), 128.2 (CHAr), 120.5 (CAr), 26.5 
(CH-Ar), 24.2 (CH-COOH), 17.5 (CH2) ppm. IR (Neat): 2923, 1681 cm-1. HRMS 
(ASAP) m/z: [M + H]+ Calcd for C10H10O2Br 240.9864; Found 240.9865. Melting point 





Triethylamine (0.380 mL, 276 mg, 2.73 mmol, 1.1 equiv) and diphenylphosphoryl azide 
(0.590 mL, 755 mg, 2.74 mmol, 1.1 equiv) were added to a solution of 17b (0.600 g, 2.49 
mmol, 1 equiv) and 4-(hydroxymethyl)phenylboronic acid pinacol ester (641 mg, 2.74 
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mmol, 1.1 equiv) in anhydrous dioxane (5 mL). The reaction solution was heated at 105 
°C for 2.5 h before it was concentrated under reduced pressure. After purification using 
column chromatography (25% ethyl acetate/hexane), the title compound was obtained as 
white powder (498 mg, 1.05 mmol) in 42% yield. 1H NMR (500 MHz, CDCl3): δ 7.79 
(d, J = 7.5 Hz, 2H, CHAr-B(OR)2), 7.33 (d, J = 7.5 Hz, 4H, CHAr-B(OR)2 and CHAr), 7.02 – 
6.84 (m, 2H, CHAr), 5.12 (bs, 3H, OCH2 and NH), 2.70 (bs, 1H, CH-NH), 2.04 (bs, 1H, 
CH-Ar), 1.34 (s, 12H, CH3), 1.16 (bs, 2H, CH2-CH-NH) ppm. 13C NMR (125 MHz, 
CDCl3)a: δ 156.6 (C=O), 139.4 (CAr), 139.3 (CAr), 135.0 (CHAr-B(OR)2), 131.3 (CHAr), 
128.4 (CHAr), 127.2 (CHAr-B(OR)2), 119.8 (CAr), 83.9 (C-Me2), 66.6 (OCH2), 32.6 (CH-
NH), 24.8 (CH3 and CH-Ar), 15.9 (CH2-CH-NH) ppm. IR (Neat): 3314, 2978, 1710 cm-
1. HRMS (ESI) m/z: [M + Na]+ Calcd for C23H27BBrNO4Na 494.11142; Found 
494.11037. Melting point: 117.3 – 122.9 °C. 
a The carbon directly attached to boron was not detected, this is probably due to 
quadropolar relaxation.126 
 
2.5.4 Preparation of QAC 
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl cyclopropylcarbamate (QAC) 
 
Cyclopropanecarboxylic acid (0.190 mL, 205 mg, 2.39 mmol, 1 equiv), triethylamine 
(0.360 mL, 261 mg, 2.58 mmol, 1.1 equiv) and diphenylphosphoryl azide (0.550 mL, 702 
mg, 2.55 mmol, 1.1 equiv) were added to a solution of 4-(hydroxymethyl)phenylboronic 
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acid pinacol ester (599 mg, 2.56 mmol, 1.1 equiv) in anhydrous dioxane (4.5 mL). After 
the solution was left stirring at 105 °C overnight, it was concentrated under reduced 
pressure and the crude mixture was subjected to column chromatography (30% ethyl 
acetate in petroleum spirit). The title compound was obtained as a white solid (266 mg, 
0.838 mmol) in 35% yield. 1H NMR (500 MHz, CDCl3): δ 7.79 (d, J = 7.5 Hz, 2H, CHAr), 
7.34 (d, J = 7 Hz, 2H, CHAr), 5.11 (s, 2H, OCH2), 4.99 (bs, 1H, NH), 2.60 (bs, 1H, CH-
NH), 1.34 (s, 12H, CH3), 0.71 (d, J = 6 Hz, 2H, CH2), 0.52 (bs, 2H, CH2) ppm. 13C NMR 
(125 MHz, CDCl3)a: δ 157.0 (C=O), 139.6 (CAr), 135.0 (CHAr), 127.1 (CHAr), 83.8 (C-
Me2), 66.5 (OCH2), 24.9 (CH3), 23.2 (CH-NH), 6.9 (CH2-CH-NH) ppm. IR (Neat): 3362, 
2980, 1726 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C17H24NO4BNa 340.16961; 
Found 340.16915. Melting point: 96.7 – 97.2 °C. 
a The carbon directly attached to boron was not detected, this is probably due to 
quadropolar relaxation.126 
 
2.5.5 Preparation of Q-2IAC and its precursors 
Ethyl (E)-3-(2-iodophenyl)acrylate 
 
Triethyl phosphonoacetate (0.750 mL, 848 mg, 3.78 mmol, 1.1 equiv) was slowly added 
to a suspension of NaH (60% in mineral oil, 217 mg, 5.42 mmol, 1.6 equiv) in anhydrous 
THF (34 mL). The suspension was stirred for 10 mins before the addition of 2-
iodobenzaldehyde (802 mg, 3.46 mmol, 1 equiv). After the reaction solution was stirred 
overnight at room temperature, the reaction was quenched with solid ammonium chloride 
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and 1 M HCl (10 mL) then diluted with ethyl acetate (10 mL) and water (10 mL). The 
aqueous fraction was isolated and extracted with ethyl acetate (2 × 10 mL) and the 
combined organic fractions were washed with saturated NaHCO3 solution (20 mL) then 
brine (20 mL). The solution was then dried with magnesium sulfate and concentrated 
under reduced pressure. The crude product was purified with column chromatography 
(5% ethyl acetate/hexane) to give the title compound as a pale yellow oil (653 mg, 2.16 
mmol) in 63% yield. 1H NMR (500 MHz, CDCl3): δ 7.91 – 7.88 (m, 2H, HC=CH-COOEt 
and CHAr), 7.56 (d, J = 7.5 Hz, 1H, CHAr), 7.36 (t, J = 7.5 Hz, 1H, CHAr), 7.05 (t, J = 7.5 
Hz, 1H, CHAr), 6.31 (d, J = 15.5 Hz, 1H, HC=CH-COOEt), 4.29 (q, J = 7 Hz, 2H, OCH2), 
1.35 (t, J = 7.5 Hz, 3H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 166.3 (C=O), 147.7 
(HC=CH-COOEt), 140.0 (CHAr), 137.9 (CAr), 131.1 (CHAr), 128.5 (CHAr), 127.4 (CHAr), 
121.3 (HC=CH-COOEt), 101.1 (CAr), 60.7 (OCH2), 14.3 (CH3) ppm. IR (Neat): 1707 cm-




A suspension of trimethylsulfoxonium iodide (610 mg, 2.77 mmol, 1.4 equiv) and sodium 
hydride (60% in mineral oil, 115 mg, 2.88 mmol, 1.5 equiv) in anhydrous DMSO (3 mL) 
were stirred for 30 mins before the addition of ethyl (E)-3-(2-iodophenyl)acrylate (597 
mg, 1.97 mmol, 1 equiv) in anhydrous DMSO (2 mL). After the reaction was heated at 
60 °C overnight, the reaction solution was poured into brine solution (25 mL) and 
extracted with ethyl acetate (3 × 15 mL). The combined organic extracts were washed 
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with water (50 mL) and brine solution (50 mL). After drying the solution with magnesium 
sulfate, the solution was concentrated under reduced pressure to give a brown oil crude 
which was later subjected to column chromatography (5% ethyl acetate/hexane). The title 
compound was collected as a colourless oil (116 mg, 368 µmol) in 19% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.85 (d, J = 8 Hz, 1H, CHAr), 7.26 (t, J = 9 Hz, 1H, CHAr), 7.00 (d, 
J = 7.5 Hz, 1H, CHAr), 6.93 (t, J = 7.5 Hz, 1H, CHAr), 4.27 – 4.17 (m, 2H, OCH2), 2.62 – 
2.58 (m, 1H, CH-Ar), 1.78 – 1.73 (m, 1H, CH-COOEt), 1.63 (ddd, J = 9.2, 4.8, 5.0 Hz, 
1H, CH2-CH-Ar), 1.34 – 1.29 (m, 4H, CH2-CH-Ar and CH3) ppm. 13C NMR (125 MHz, 
CDCl3): δ 173.2 (C=O), 142.2 (CAr), 139.2 (CHAr), 128.4 (CHAr), 128.2 (CHAr), 127.4 
(CHAr), 102.6 (CAr), 60.7 (OCH2), 31.8 (CH-Ar), 23.7 (CH-COOEt), 16.2 (CH2-CH-Ar), 
14.4 (CH3) ppm. IR (Neat): 1719 cm-1. HRMS (ASAP) m/z: [M + H]+ Calcd for 




Sodium hydroxide solution (1 M, 0.64 mL, 0.64 mmol, 2 equiv) was added to a solution 
of ethyl 2-(2-iodophenyl)cyclopropane-1-carboxylate (101 mg, 0.320 mmol, 1 equiv) in 
ethanol (5 mL). After the solution was left stirring overnight at room temperature, 
hydrochloric acid solution (2 M, 0.48 mL, 0.96 mmol, 3 equiv) and water (10 mL) were 
added to the reaction solution at 0 °C. The solution was extracted with diethyl ether (3 × 
20 mL) and washed with brine solution (30 mL). After drying the solution with 
magnesium sulfate, the solution was concentrated under reduced pressure to give the title 
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compound as a white solid (81.0 mg, 0.280 mmol) in 88% yield. 1H NMR (500 MHz, 
CDCl3): δ 7.84 (d, J = 8 Hz, 1H, CHAr), 7.27 (d, J = 7.5 Hz, 1H, CHAr), 7.01 (d, J = 7.5 
Hz, 1H, CHAr), 6.94 (td, J = 7.5, 1.0 Hz, 1H, CHAr), 2.71 – 2.67 (m, 1H, CH-Ar), 1.78 – 
1.77 (m, 1H, CH-COOH), 1.71 (ddd, J = 9.2, 4.7, 5.0 Hz, 1H, CH2), 1.43 – 1.39 (m, 1H, 
CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 179.9 (C=O), 141.8 (CAr), 139.3 (CHAr), 
128.7 (CHAr), 128.3 (CHAr), 127.7 (CHAr), 102.8 (CAr), 32.7 (CH-Ar), 23.7 (CH-COOH), 
17.2 (CH2) ppm. IR (Neat): 1685 cm-1. HRMS (ESI) m/z: [M - H]- Calcd for C10H8IO2 





Triethylamine (0.100 mL, 72.6 mg, 0.717 mmol, 2.8 equiv) and diphenylphosphoryl azide 
(0.100 mL, 128 mg, 0.464 mmol, 1.8 equiv) were added to a solution of 2-(2-
iodophenyl)cyclopropane-1-carboxylic acid (74.0 mg, 0.257 mmol, 1 equiv) and 4-
(hydroxymethyl)phenylboronic acid pinacol ester (69.3 mg, 0.296 mmol, 1.2 equiv) in 
dry dioxane (1 mL). The reaction solution was heated at 105 °C for 2 h 15 mins then 
cooled to room temperature. Solvent was evaporated under reduced pressure and the 
compound was purified by column chromatography (25% ethyl acetate/hexane). The title 
compound was obtained as a colourless oil (36.2 mg, 69.7 µmol) in 27% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.81 (app t, J = 7.5 Hz, 3H, CHAr), 7.36 (d, J = 8.0 Hz, 2H, CHAr), 
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7.26 (bs, 1H, CHAr), 7.08 (bs, 1H, CHAr), 6.91 (t, J = 7.5 Hz, 1H, CHAr), 5.36 (bs, 1H, 
NH), 5.14 (s, 2H, OCH2), 2.71 (d, J = 2.5 Hz, 1H, CHNH), 2.13 – 2.09 (m, 1H, CH-Ar), 
1.34 (s, 12H, CH3), 1.26 – 1.21 (m, 2H, CH2-CH-NH) ppm. 13C NMR (125 MHz, CDCl3): 
δ 156.7 (C=O), 142.3 (CAr), 139.3 (CAr), 138.9 (CHAr), 135.0 (CHAr), 128.3 (CHAr), 128.2 
(CHAr), 128.0 (CHAr), 127.2 (CHAr), 102.5 (CAr), 83.8 (C-Me2), 66.7 (OCH2), 32.5 (CH-
NH), 30.5 (CH-Ar), 24.8 (CH3), 16.4 (CH2-CH-NH) ppm. IR (Neat): 3317, 2976, 2923, 
1700 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C23H27BINO4Na 542.09755; Found 
542.09612. 
 
2.5.6 Preparation of Q-3IAC and its precursors 
Ethyl (E)-3-(3-iodophenyl)acrylate 
 
Triethyl phosphonoacetate (0.580 mL, 655 mg, 2.92 mmol, 0.8 equiv) was slowly added 
to a suspension of NaH (60% in mineral oil, 163 mg, 4.07 mmol, 1.2 equiv) in anhydrous 
THF (26 mL). The suspension was stirred for 10 mins before the addition of 3-
iodobenzaldehyde (804 mg, 3.46 mmol, 1 equiv). After the reaction solution was stirred 
for 1 h at room temperature, the reaction was quenched with solid ammonium chloride 
then 1 M HCl (10 mL) and water (10 mL). The aqueous fraction was isolated and 
extracted with ethyl acetate (2 × 10 mL) and the combined organic fractions were washed 
with saturated NaHCO3 solution (20 mL) then brine (20 mL). The solution was then dried 
with magnesium sulfate and concentrated under reduced pressure to give a crude yellow 
oil. 1H NMR spectrum of the crude yellow oil indicated that starting material was still 
present therefore it was further treated with a solution of triethyl phosphonoacetate (0.230 
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mL, 260 mg, 1.16 mmol, 0.3 equiv) and NaH (60% in mineral oil, 79.5 mg, 1.99 mmol, 
0.6 equiv) in THF following the procedure above. The crude product was purified with 
column chromatography (5% ethyl acetate/hexane) to give the title compound as a pale 
yellow oil (666 mg, 2.20 mmol) in 64% yield. 1H NMR (500 MHz, CDCl3): δ 7.88 (d, J 
= 1.5 Hz, 1H, CHAr), 7.70 (d, J = 7.5 Hz, 1H, CHAr), 7.57 (d, J = 16 Hz, 1H, HC=CH-
COOEt), 7.47 (d, J = 7.5 Hz, 1H, CHAr), 7.12 (t, J = 7.5 Hz, 1H, CHAr), 6.42 (d, J = 16 
Hz, 1H, HC=CH-COOEt), 4.27 (q, J = 7 Hz, 2H, OCH2), 1.34 (t, J = 7.5 Hz, 3H, CH3) 
ppm. 13C NMR (125 MHz, CDCl3): δ 166.5 (C=O), 142.7 (HC=CH-COOEt), 138.9 
(CHAr), 136.7 (CHAr), 136.6 (CAr), 130.5 (CHAr), 127.2 (CHAr), 119.6 (HC=CH-COOEt), 
94.7 (CAr), 60.7 (OCH2), 14.3 (CH3) ppm. IR (Neat): 3059, 1707 cm-1. HRMS (ASAP) 




A suspension of trimethylsulfoxonium iodide (577 mg, 2.62 mmol, 1.4 equiv) and sodium 
hydride (60% in mineral oil, 0.110 g, 2.76 mmol, 1.5 equiv) in anhydrous DMSO (4 mL) 
were stirred for 45 mins before the addition of ethyl (E)-3-(3-iodophenyl)acrylate (559 
mg, 1.85 mmol, 1 equiv). After the reaction was heated at 60 °C overnight, the reaction 
solution was poured into brine solution (20 mL) and extracted with ethyl acetate (3 × 15 
mL). The combined organic extracts were washed with water (50 mL) and brine solution 
(50 mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give a light brown film crude which was later subjected to 
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column chromatography (5% ethyl acetate/hexane). The title compound was collected as 
a colourless oil (91.9 mg, 291 µmol) in 16% yield. 1H NMR (500 MHz, CDCl3): δ 7.53 
(d, J = 7.5 Hz, 1H, CHAr), 7.45 (s, 1H, CHAr), 7.06 (d, J = 7.5 Hz, 1H, CHAr), 7.00 (t, J = 
8 Hz, 1H, CHAr), 4.17 (q, J = 7 Hz, 2H, OCH2), 2.47 – 2.43 (m, 1H, CH-Ar), 1.88 (ddd, 
J = 8.3, 4.2, 4.5 Hz, 1H, CH-COOEt), 1.61 – 1.57 (m, 1H, CH2-CH-Ar), 1.28 (t, J = 7 Hz, 
4H, CH2-CH-Ar and CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 173.0 (C=O), 142.6 
(CAr), 135.6 (CHAr), 135.3 (CHAr), 130.1 (CHAr), 125.6 (CHAr), 94.4 (CAr), 60.8 (OCH2), 
25.4 (CH-Ar), 24.1 (CH-COOEt), 16.9 (CH2-CH-Ar), 14.3 (CH3) ppm. IR (Neat): 1718 




Sodium hydroxide solution (1 M, 0.48 mL, 0.48 mmol, 2 equiv) was added to a solution 
of ethyl 2-(3-iodophenyl)cyclopropane-1-carboxylate (75.5 mg, 0.240 mmol, 1 equiv) in 
ethanol (4 mL). After the solution was left stirring overnight at room temperature, 
hydrochloric acid solution (2 M, 0.36 mL, 0.72 mmol, 3 equiv) and water (10 mL) were 
added to the reaction solution at 0 °C. The solution was extracted with diethyl ether (3 × 
20 mL) and washed with brine solution (30 mL). After drying the solution with 
magnesium sulfate, the solution was concentrated under reduced pressure to give the title 
compound as a white solid (66.6 mg, 0.231 mmol) in 96% yield. 1H NMR (500 MHz, 
CDCl3): δ 7.54 (d, J = 8 Hz, 1H, CHAr), 7.46 (s, 1H, CHAr), 7.06 (d, J = 7.5 Hz, 1H, CHAr), 
7.01 (t, J = 7.5 Hz, 1H, CHAr), 2.53 (bs, 1H, CH-Ar), 1.89 (bs, 1H, CH-COOH), 1.65 – 
1.65 (m, 1H, CH2), 1.37 (bs, 1H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 179.5 
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(C=O), 141.9 (CAr), 135.8 (CHAr), 135.4 (CHAr), 130.1 (CHAr), 125.6 (CHAr), 94.5 (CAr), 
26.3 (CH-Ar), 24.1 (CH-COOH), 17.3 (CH2) ppm. IR (Neat): 1685 cm-1. HRMS (ESI) 






Triethylamine (0.100 mL, 72.6 mg, 0.717 mmol, 2.5 equiv) and diphenylphosphoryl azide 
(0.100 mL, 128 mg, 0.465 mmol, 1.6 equiv) were added to a solution of 2-(3-
iodophenyl)cyclopropane-1-carboxylic acid (83.1 mg, 0.288 mmol, 1 equiv) and 4-
(hydroxymethyl)phenylboronic acid pinacol ester (74.2 mg, 0.317 mmol, 1.1 equiv) in 
dry dioxane (1 mL). The reaction solution was heated at 105 °C for 2 h then cooled to 
room temperature. Solvent was evaporated under reduced pressure and the compound 
was purified by column chromatography (25% ethyl acetate/hexane). The title compound 
was obtained as a colourless oil (36.9 mg, 71.1 µmol) in 25% yield. 1H NMR (400 MHz, 
CDCl3): δ 7.79 (d, J = 8.4 Hz, 2H, CHAr), 7.51 – 7.47 (m, 2H, CHAr), 7.34 (d, J = 8.0 Hz, 
2H, CHAr), 7.12 – 7.10 (m, 1H, CHAr), 7.01 – 6.95 (m, 1H, CHAr), 5.12 (bs, 2H, OCH2), 
2.74 (bs, 1H, CHNH), 2.01 (bs, 1H, CH-Ar), 1.34 (s, 12H, CH3), 1.19 – 1.15 (m, 2H, 
CH2-CH-NH) ppm. 13C NMR (100 MHz, CDCl3): δ 156.7 (C=O), 142.8 (CAr), 139.3 
(CAr), 135.6 (CHAr), 135.2 (CHAr), 135.0 (CHAr), 130.0 (CHAr), 127.2 (CHAr), 126.0 
89 
(CHAr), 94.4 (CAr), 83.8 (C-Me2), 66.7 (OCH2), 32.7 (CH-NH), 24.9 (CH3 and CH-Ar), 
16.1 (CH2-CH-NH) ppm. IR (Neat): 3316, 2979, 1710 cm-1. HRMS (ESI) m/z: [M + Na]+ 
Calcd for C23H27BINO4Na 542.09755; Found 542.09676. 
 
2.5.7 Preparation of Q-4IAC and its precursor 
2-(4-Iodophenyl)cyclopropane-1-carboxylic acid (17c) 
 
2-Phenylcyclopropanecarboxylic acid 17a (151 mg, 930 µmol, 1 equiv), iodine (150 mg, 
592 µmol, 0.64 equiv), potassium iodate (49.1 mg, 229 µmol, 0.25 equiv) were added to 
a solution of concentrated sulfuric acid (0.2 mL) in water (1 mL) and glacial acetic acid 
(4 mL). The solution was heated to reflux and glacial acetic acid (6 mL) was added 
portion-wise over 4 h to rinse down iodine from the condenser. The reaction was 
quenched with 1 M Na2S2O4 solution (1 mL) and water (24 mL). The solution was 
extracted with ethyl acetate (4 × 15 mL) then the extracts were washed with brine (2 × 30 
mL) and dried over sodium sulfate. After recrystallization of the crude product, the title 
compound was collected as a white solid (98.5 mg, 342 µmol) in 37% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.60 (d, J = 8 Hz, 2H, CHAr), 6.86 (d, J = 8 Hz, 2H, CHAr), 2.54 
(bs, 1H, CH-Ar), 1.87 (bs, 1H, CH-COOH), 1.67 – 1.65 (m, 1H, CH2), 1.38 – 1.36 (m, 
1H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 179.4 (C=O), 139.2 (CAr), 137.5 (CHAr), 
128.3 (CHAr), 91.7 (CAr), 26.6 (CH-Ar), 24.0 (CH-COOH), 17.4 (CH2) ppm. IR (Neat): 
1685 cm-1. HRMS (ESI) m/z: [M - H]- Calcd for C10H8IO2 286.9569; Found 286.9565. 






Triethylamine (0.100 mL, 72.6 mg, 0.717 mmol, 2.2 equiv) and diphenylphosphoryl azide 
(0.100 mL, 128 mg, 0.465 mmol, 1.4 equiv) were added to a solution of 17c (95.2 mg, 
0.330 mmol, 1 equiv) and 4-(hydroxymethyl)phenylboronic acid pinacol ester (87.0 mg, 
0.372 mmol, 1.1 equiv) in dry dioxane (1 mL). The reaction solution was heated at 105 
°C for 24 h then cooled to room temperature. Solvent was evaporated under reduced 
pressure and the compound was purified by column chromatography (25% ethyl 
acetate/hexane). The title compound was obtained as a colourless oil (58.0 mg, 0.112 
mmol) in 34% yield. 1H NMR (500 MHz, CDCl3): δ 7.79 (d, J = 8.0 Hz, 2H, CHAr), 7.55 
(bs, 2H, CHAr), 7.33 (d, J = 7.5 Hz, 2H, CHAr), 6.89 – 6.71 (m, 2H, CHAr), 5.20 (bs, 1H, 
NH), 5.11 (s, 2H, OCH2), 2.70 (bs, 1H, CHNH), 2.01 (bs, 1H, CH-Ar), 1.34 (s, 12H, 
CH3), 1.15 (bs, 2H, CH2-CH-NH) ppm. 13C NMR (125 MHz, CDCl3): δ 156.6 (C=O), 
140.1 (CAr), 139.3 (CAr), 137.3 (CHAr), 135.0 (CHAr), 128.7 (CHAr), 127.2 (CHAr), 91.0 
(CAr), 83.8 (C-Me2), 66.6 (OCH2), 32.6 (CH-NH), 24.8 (CH3 and CH-Ar), 15.9 (CH2-CH-
NH) ppm. IR (Neat): 3261, 2978, 1704 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 
C23H27BINO4Na 542.09755; Found 542.09673. Melting point: 138.7 – 140.6 °C. 
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2.5.8 Preparation of 11 and its precursors 
tert-Butyl 4-((prop-2-yn-1-ylthio)carbonothioyl)piperazine-1-carboxylate (19) 
 
Carbon disulfide (0.200 mL, 253 mg, 3.33 mmol, 3 equiv) was added dropwise to a 
solution of tert-butyl piperazine-1-carboxylate (209 mg, 1.12 mmol, 1 equiv) and Na3PO4 
· 12 H2O (247 mg, 0.650 mmol, 0.6 equiv) in dry acetone (4.3 mL). After stirring for 30 
mins at room temperature, propargyl bromide (80 wt. % in toluene, 0.140 mL, 0.150 g, 
1.26 mmol, 1.1 equiv) was added dropwise to the solution. After the reaction was left 
stirring at room temperature for 30 mins, it was filtered and the filtrate was concentrated 
in vacuo. The residue was dissolved in ethyl acetate (10 mL) and washed with water (10 
mL) then brine (10 mL). The organic solution was dried over magnesium sulfate and 
concentrated under reduced pressure to yield the title compound as a milky white solid 
(284 mg, 0.944 mmol) in 84% yield. 1H NMR (300 MHz, CDCl3): δ 4.12 (d, J = 2.4 Hz, 
2H, CH2-S), 3.56 (t, J = 5.4 Hz, 4H, CH2-CH2), 2.26 (t, J = 2.4 Hz, 1H, C≡CH), 1.48 (s, 






A solution of 19 (99.1 mg, 0.330 mmol, 1 equiv), 4-methylbenzyl azide (61.4 mg, 0.417 
mmol, 1.3 equiv), copper(II) sulfate (5.70 mg, 35.7 μmol, 0.1 equiv) and sodium 
ascorbate (8.80 mg, 44.4 μol, 0.1 equiv) in a mixture of THF and water (1:1 ratio), was 
stirred for 2 h at room temperature. Water (1.4 mL) was added to the reaction and the 
mixture was extracted with ethyl acetate (3 × 5 mL). The combined organic fractions were 
washed with brine solution (10 mL), dried over magnesium sulfate and concentrated 
under reduced pressure to give the title compound as a yellow solid (129 mg, 0.288 mmol) 
in 87% yield. 1H NMR (300 MHz, CDCl3): δ 7.55 (s, 1H, C=CH-N), 7.17 (s, 4H, CHAr), 
5.44 (s, 2H, CH2), 4.67 (s, 2H, CH2), 4.29 (bs, 2H, CH2), 3.92 (bs, 2H, CH2), 3.52 (t, J = 
5.1 Hz, 4H, CH2-CH2), 2.35 (s, 3H, Tosyl CH3), 1.47 (s, 9H, CH3) ppm. Melting point: 
168.2 – 172.2 °C. 
 
2.5.9 Preparation of 12 and its precursors 
2-Chloro-6-phenoxybenzonitrile (21) 
 
A solution of 2-fluoro-6-chlorobenzonitrile (775 mg, 4.98 mmol, 1 equiv), potassium 
carbonate (831 mg, 6.01 mmol, 1.2 equiv) and phenol (469 mg, 4.99 mmol, 1 equiv) in 
DMF (10.6 mL) was heated overnight at 100 °C. The reaction solution was diluted with 
ethyl acetate (30 mL) and water (20 mL). The organic fraction was isolated then washed 
with brine (20 mL) and dried over magnesium sulfate. The solution was concentrated 
under reduced pressure to give the title compound as an orange solid (1.08 g, 4.69 mmol) 
in 94% yield. 1H NMR (500 MHz, CDCl3): δ 7.42 (t, J = 7.5 Hz, 2H, CHAr), 7.36 (t, J = 
8.5 Hz, 1H, CHAr), 7.26 – 7.24 (m, 1H, CHAr), 7.17 (d, J = 8 Hz, 1H, CHAr), 7.10 (d, J = 
93 
8 Hz, 2H, CHAr), 6.73 (d, J = 8.5 Hz, 1H, CHAr) ppm. 13C NMR (125 MHz, CDCl3): δ 
161.4 (CAr), 154.5 (CAr), 138.1 (CAr), 134.1 (CHAr), 130.3 (CHAr), 125.6 (CHAr), 123.4 
(CHAr), 120.3 (CHAr), 114.6 (CHAr), 113.1 (C≡N), 104.9 (CAr) ppm. IR (Neat): 3089, 
1569, 1488, 1448, 1256 cm-1. HRMS (ASAP) m/z: [M + H]+ Calcd for C13H9ClNO 




At 0 °C, a solution of 2-chloro-6-phenoxybenzonitrile 21 (1.00 g, 4.35 mmol) in 
anhydrous diethyl ether (45 mL) was degassed by using nitrogen gas for 10 mins. LiAlH4 
(1 M in THF, 13.2 mL, 13.2 mmol, 3 equiv) was added dropwise to the solution over 10 
mins at 0 °C and the reaction was left stirring at the same temperature for 2 h. The reaction 
was then gradually warmed to room temperature and left stirring overnight. At 0 °C, the 
reaction was quenched by the addition of Na2SO4 · 10 H2O until no gas evolution was 
observed. The solution was left stirring for 30 mins before filtration through a plug of 
Celite. The filtrate was concentrated under reduced pressure to give a residue which was 
then purified using column chromatography (50% ethyl acetate/hexane). The title 
compound was obtained as a yellow oil (482 mg, 2.06 mmol) in 47% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.34 (t, J = 7.5 Hz, 2H, CHAr), 7.18 – 7.10 (m, 3H, CHAr), 6.96 (d, 
J = 8.5 Hz, 2H, CHAr), 6.80 (d, J = 7.5 Hz, 1H, CHAr), 4.01 (s, 2H, CH2) ppm. 13C NMR 
(125 MHz, CDCl3)a: δ 157.2 (CAr), 155.7 (CAr), 135.0 (CAr), 129.9 (CHAr), 128.5 (CHAr), 
124.9 (CHAr), 123.5 (CHAr), 118.2 (CHAr), 117.7 (CHAr), 38.5 (CH2) ppm. IR (Neat): 
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1587, 1569, 1488, 1447, 1256 cm-1. HRMS (ASAP) m/z: [M + H]+ Calcd for 
C13H13ClNO 234.0686; Found 234.0686. 
a One of the aromatic quaternary carbon could not be accounted for, it could be overlapped 




A solution of dimethyl N-cyanodithioiminocarbonate (348 mg, 2.38 mmol, 1.2 equiv) and 
(2-chloro-6-phenoxyphenyl)methanamine 22 (452 mg, 1.93 mmol, 1 equiv) in dry 
methanol (6 mL) was heated to reflux for 3 h. The reaction solution was concentrated 
under reduced pressure before the addition of dry ethanol (6 mL) and hydrazine hydrate 
(50 – 60%, 0.350 mL, 198 mg, 3.96 mmol). The reaction solution was heated to reflux 
for 1.5 h before concentrated under reduced pressure. After purifying the crude mixture 
with column chromatography (5% methanol in dichloromethane), the title compound was 
obtained as a white solid (426 mg, 1.35 mmol) in 70% yield. 1H NMR (500 MHz, 
DMSO): δ 7.39 (t, J = 8 Hz, 2H, CHAr), 7.31 – 7.24 (m, 2H, CHAr), 7.16 (t, J = 7.5 Hz, 
1H, CHAr), 7.04 (d, J = 8 Hz, 2H, CHAr), 6.77 (d, J = 7.5 Hz, 1H, CHAr), 4.36 (d, J = 5 
Hz, 2H, CH2) ppm. 13C NMR (100 MHz, DMSO)a: δ 156.6 (CAr), 156.6 (CAr), 135.2 
(CAr), 130.0 (CHAr), 129.7 (CHAr), 128.0 (CAr), 124.4 (CHAr), 123.8 (CHAr), 118.8 (CHAr), 
117.1 (CHAr), 39.5 (CH2) ppm. IR (Neat): 3352, 3266, 1658, 1489, 1448 cm-1. HRMS 
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(ESI) m/z: [M + H]+ Calcd for C15H15ClN5O 316.0965; Found 316.0978. Melting point: 
192.9 – 200.4 °C. 
a Two of the aromatic quaternary carbons could not be accounted for, they could be 
overlapped with one/two of the observed aromatic quaternary carbon signals. 
 
2.5.10 Preparation of 13 and its precursor 
2-Cyano-N-(2-hydroxyphenyl)acetamide (23) 
 
Cyanoacetic acid (0.400 g, 4.70 mmol, 1 equiv) was added to a suspension of phosphorus 
pentachloride (958 mg, 4.60 mmol, 1 equiv) in dry dichloromethane (84 mL). The 
suspension was heated to reflux for 45 mins then cooled down to room temperature and 
2-aminophenol (504 mg, 4.60 mmol, 1 equiv) was added. The suspension was heated to 
reflux for 3.5 h before cooling down and solvent evaporation under reduced pressure. 
Water (20 mL) was added to the purplish white solid and the mixture was stirred for 10 
mins. After filtration, the solid was washed with saturated sodium bicarbonate solution 
(10 mL) and water (2 × 10 mL). The title compound was collected as a purplish white 
solid (525 mg, 3.00 mmol) in 65% yield after drying. 1H NMR (400 MHz, (CD3)2CO): δ 
9.07 (bs, 1H, OH or NH), 7.91 (d, J = 8 Hz, 1H, CHAr), 7.00 (td, J = 8.0, 1.2 Hz, 1H, 
CHAr), 6.92 (dd, J = 7.8, 0.8 Hz, 1H, CHAr), 6.84 (td, J = 8.0, 1.2 Hz, 1H, CHAr), 3.97 (s, 
2H, CH2) ppm. 13C NMR (100 MHz, (CD3)2CO): δ 162.1 (C=O), 148.1 (CAr), 127.0 
(CAr), 126.1 (CHAr), 122.4 (CHAr), 120.7 (CHAr), 116.7 (CHAr), 115.8 (C≡N), 27.2 (CH2) 
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ppm. IR (Neat): 3314, 3268, 1670 cm-1. HRMS (ASAP) m/z: [M + H]+ Calcd for 




Hydroxylamine hydrochloride (93.8 mg, 1.35 mmol, 1.6 equiv) was added to a solution 
of potassium carbonate (148 mg, 1.07 mmol, 1.3 equiv) in water (0.45 mL). After the 
solution was diluted with methanol (4.5 mL), 23 (0.150 g, 0.850 mmol, 1 equiv) was 
added and the reaction solution was heated to reflux. After 2 h, the reaction solution was 
concentrated under reduced pressure and the resulting residue was added to a hot mixture 
of ethyl acetate and methanol (3:1 ratio). The mixture was filtered and the filtrate was 
concentrated under reduced pressure to give the crude product. The crude product was 
first purified using column chromatography (0 - 5% methanol in ethyl acetate), then 
recrystallisation (methanol/ethyl acetate). The title compound was obtained as a white 
solid (21.2 mg, 0.101 mmol) in 12% yield. 1H NMR (500 MHz, DMSO): δ 9.82 (bs, 1H, 
NH), 9.28 (s, 1H, OH), 9.10 (s, 1H, OH), 7.87 (d, J = 8 Hz, 1H, CHAr), 6.93 – 6.90 (m, 
1H, CHAr), 6.86 – 6.84 (m, 1H, CHAr), 6.75 (t, J = 7.5 Hz, 1H, CHAr), 5.58 (s, 2H, NH2), 
3.13 (s, 2H, CH2) ppm. 13C NMR (125 MHz, DMSO): δ 166.8 (C=O), 148.7 (C=N), 
147.3 (CAr), 126.3 (CAr), 124.3 (CHAr), 121.2 (CHAr), 118.9 (CHAr), 115.2 (CHAr), 39.7 
(CH2) ppm. IR (Neat): 3420, 3329, 1653, 1550, 1454, 1281 cm-1. HRMS (ASAP) m/z: 




2.5.11 Preparation of bizine and its precursors 
N-(4-(2-Hydroxyethyl)phenyl)-4-phenylbutanamide (25) 
 
A solution of 4-phenylbutyric acid (2.00 g, 12.2 mmol, 1 equiv) in dichloromethane (3 
mL) was cooled to 0 °C for 5 mins before the dropwise addition of thionyl chloride (4.50 
mL, 7.34 g, 61.7 mmol, 5.1 equiv). The solution was stirred at 0 °C for 10 mins then 
heated to 55 °C. After 20 h, the reaction progress was monitored via TLC (2% MeOH in 
DCM with a few drops of glacial acetic acid) and small amount of starting material was 
still present, hence the temperature was raised to 65 °C. After 3 h, the reaction was 
monitored by TLC and small amount of starting material was still present. Solvent and 
remaining thionyl chloride were removed by distillation, then the residue was dried under 
reduced pressure. The acid chloride intermediate was collected as a brown liquid (2.06 g, 
11.3 mmol). 1H NMR (500 MHz, CDCl3): δ 7.16 – 7.32 (m, 5H, CHAr), 2.89 (t, J = 7 Hz, 
2H, CH2-CH2), 2.68 (t, J = 7 Hz, 2H, CH2-CH2), 2.04 (quin, J = 7.5 Hz, 2H, CH2-CH2-
CH2) ppm. NMR data consistent with literature.128 
To a cold solution of 2-(4-aminophenyl)ethanol (1.55 g, 11.3 mmol, 1 equiv) in dry 
dichloromethane (15.5 mL), N,N-diisopropylethylamine (13.8 mL, 10.2 g, 79.2 mmol, 7 
equiv) was added dropwise, follow by the acid chloride intermediate (2.06 g, 11.3 mmol, 
1 equiv). After 5 mins, the solution was left stirring at room temperature for 22 h. The 
solution was diluted by adding dichloromethane (75 mL) then washed with 2 N HCl (40 
mL), saturated NaHCO3 solution (75 mL) and brine (75 mL). After the solvent 
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evaporation under reduced pressure, the brown solid residue was dissolved in methanol 
(75 mL) and 1 M NaOH (35 mL) was added dropwise to the solution. The solution was 
left stirring under nitrogen atmosphere for 12 h. The reaction solution was concentrated 
in vacuo then diluted with ethyl acetate (100 mL). After washing the solution with 1 N 
HCl (80 mL), saturated NaHCO3 solution (2 × 80 mL) and brine (80 mL), the solution 
was dried with magnesium sulfate and concentrated under reduced pressure. The title 
compound was collected as a brown solid (2.30 g, 8.11 mmol) in 66% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.43 (d, J = 8 Hz, 2H, CHAr), 7.31 – 7.28 (m, 2H, CHAr), 7.21 – 
7.17 (m, 5H, CHAr), 7.04 (bs, 1H, NH), 3.84 (t, J = 6 Hz, 2H, CH2-OH), 2.83 (t, J = 6 Hz, 
2H, CH2-CH2), 2.72 (t, J = 7 Hz, 2H, CH2-CH2), 2.34 (t, J = 7.5 Hz, 2H, CH2-CH2), 2.08 
(quin, J = 7 Hz, 2H, CH2-CH2-CH2) ppm. 13C NMR (500 MHz, CDCl3): δ 171.3 (C=O), 
141.4 (CAr), 136.3 (CAr), 134.5 (CAr), 129.4 (CHAr), 128.5 (CHAr), 128.4 (CHAr), 126.0 
(CHAr), 120.3 (CHAr), 63.5 (CH2OH), 38.6 (CH2), 36.6 (CH2), 35.1 (CH2), 26.9 (CH2) 
ppm. IR (Neat): 3326, 1654 cm-1. HRMS (ASAP) m/z: [M + H]+ Calcd for C18H22NO2 




Triphenylphosphine (1.85 g, 7.06 mmol, 2 equiv) and tetrabromomethane (2.34 g, 7.07 
mmol, 2 equiv) were added to a solution of 25 (1.01 g, 3.56 mmol, 1 equiv) in dry 
dichloromethane (48 mL). After leaving the reaction stirring overnight at room 
temperature, the reaction was concentrated under reduced pressure and subjected to 
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column chromatography (40% ethyl acetate/hexane). The title compound was obtained 
as a pale yellow solid (687 mg, 1.98 mmol) in 56% yield. 1H NMR (300 MHz, CDCl3): 
δ 7.45 (d, J = 8.4 Hz, 2H, CHAr), 7.33 – 7.28 (m, 3H, CHAr), 7.23 – 7.15 (m, 4H, CHAr), 
7.03 (bs, 1H, NH), 3.54 (t, J = 7.5 Hz, 2H, CH2-Br), 3.12 (t, J = 7.8 Hz, 2H, CH2-CH2), 
2.72 (t, J = 7.5 Hz, 2H, CH2-CH2), 2.34 (t, J = 7.2 Hz, 2H, CH2-CH2), 2.07 (quin, J = 7.8 
Hz, 2H, CH2-CH2-CH2) ppm. IR (Neat): 3298, 1654, 1604, 1535, 1514, 1411 cm-1. 




Hydrazine hydrate (50 – 60%, 2.05 mL, 1.16 g, 23.2 mmol, 20 equiv) was added dropwise 
to a solution of N-(4-(2-bromoethyl)phenyl)-4-phenylbutanamide (401 mg, 1.16 mmol, 1 
equiv) in ethanol (4 mL). The solution was heated to reflux for 1 h before concentrated 
under reduced pressure. After sodium hydroxide solution (1 M, 80 mL, 80 mmol, excess) 
was added to the residue, it was extracted with dichloromethane (3 × 80 mL) and 
concentrated in vacuo. The resulting yellow oil was dissolved in methanol (10 mL) and 
treated with hydrochloric acid (6 M, 2.0 mL, 12 mmol, excess) at 0 °C. After stirring for 
10 mins at 0 °C, diethyl ether (5 mL) was added to the solution before it was concentrated 
under reduced pressure to yield a precipitate that was filtered and washed with cold 
diethyl ether. After drying the precipitate in a vacuum desiccator overnight, the title 
compound was obtained as a pale yellow solid (79.1 mg, 0.237 mmol) in 20% yield. 1H 
NMR (500 MHz, DMSO): δ 9.88 (s, 1H, NH), 7.53 (d, J = 8 Hz, 2H, CHAr), 7.30 – 7.27 
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(m, 2H, CHAr), 7.21 – 7.17 (m, 3H, CHAr), 7.14 (d, J = 8 Hz, 2H, CHAr), 3.09 – 3.06 (m, 
2H, CH2-NH), 2.78 (bs, 2H, CH2), 2.61 (t, J = 8 Hz, 2H, CH2-CH2), 2.31 (t, J = 7.5 Hz, 
2H, CH2-CH2), 1.88 (quin, J = 7.5 Hz, 2H, CH2-CH2-CH2) ppm. IR (Neat): 3303, 1684 
cm-1. Melting point: 173.4 – 177.1 °C. 
 
2.5.12 ESI-MS experiment for prodrug activation 
Following the procedure of Hagen et al.26 a solvent system of 9:1 
acetonitrile:water (v:v) was used to prepare a solution of Q-PAC and triethylamine (both 
0.9 mM) for activation with hydrogen peroxide (9 mM). At 5 minute intervals out to 30 
minutes aliquots were diluted 90-fold in solvent for analysis via electrospray ionization 
mass spectrometry on either a Thermo LTQ ion-trap or LTQ Orbitrap XL. Both utilized 
an Ion Max ESI source operated in positive mode with nitrogen as the desolvation gas. 
The following conditions were employed on the single-trap instrument: 5 µL/min infusion 
rate, 3.5 kV source voltage; sheath, auxillary and sweep gases set to 12, 0 and 0 (arbitrary 
flow), respectively; capillary temperature 200 °C and voltage 46 V; tube lens 130 volts. 
Settings for Orbitrap analysis: 10 µL/min infusion rate, 4.2 kV source voltage; sheath, 
auxillary and sweep gases set to 10, 0 and 0 (arbitrary flow), respectively; capillary held 
at 275 °C and 50 volts; tube lens 150 volts. The infusion syringe, tubing and ESI probe 
were rinsed with solvent until the ionized Q-PAC signal was reduced to background levels 
prior to analysis of a particular sample. Spectra reported here constitute the average 
between 50 and 100 scans and were analysed to monitor reaction species relative to Q-
PAC as a function of reaction time. 
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2.5.13 Culture details for cell culture assays 
U87MG cells (ECACC, Acc Nr.: 89081402, obtained in 2014, Female 
astrocytoma, identity confirmed via short tandem repeat profiling by Garvan Institute 
(Sydney, AU) in 2015) were maintained in Dulbecco’s Modified Eagle Medium with F12 
supplement (Life Technologies, #10565-018), 10% foetal bovine serum (Bovogen, 
#SFBS-F), and seeded at 20,000 cells/cm2. Cells were used between passage 8 and 15, 
absence of mycoplasma confirmed every three month (MycoAlert, Lonza, AU). 
Primary glioblastoma cultures provided by the Brain Cancer Research Unit of the 
QIMR Berghofer Medical Research Institute (2015) were established from untreated 
biopsy samples of different glioblastoma subtypes3,96 (SJH1: 72 years male, neural; RN1: 
56 years male, classical; JK2: 75 years male, proneural). Approval for this study was 
obtained from the Human Research Ethics Committee of The University of Wollongong 
(HE16/324). Cells were maintained in Knockout-DMEM/F12 (Life Technologies, 
#12660-012) with StemPro supplement (Life Technologies, #A10508-01), human EGF 
(20 ng/ml) (Life Technologies, #PHG0314) and human FGF2 (10 ng/ml) (Life 
Technologies, #PHG0024), and seeded at 35,000 cells/cm2 on matrigel (Corning, 
#354277, 1/100 dilution). Cells were used between passage 5 and 13 in 2015 and 2016, 
absence of mycoplasma confirmed every three month (MycoAlert, Lonza, AU). 
Human astrocyte cultures were generated from human foetal brain tissue, which 
was obtained from 17 to 20-week-old foetuses collected after therapeutic termination 
following informed consent. Approval for this study was obtained from the Human 
Research Ethics Committee of Macquarie University (#5201200411). Written informed 
consent was obtained from the participants. Astrocytes were prepared using a protocol 
adapted from previously described methods129 with slight modification. 1 g of brain was 
washed thrice with PBS containing 1% antibiotic/antimycotic to remove contaminating 
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blood. Visible blood vessels were removed with sterile scissors. Next, the tissue was 
placed in RPMI medium (Sigma-Aldrich, Australia) supplemented with 10% FBS and 
2% antibiotic/antimycotic and dissociated mechanically by pipetting with a serological 
pipette. After one week in culture, the medium was removed and the culture was washed 
with PBS to remove unattached tissue fragments followed by addition of fresh medium. 
Once confluent, the culture was subjected to successive passage with trypsin-EDTA 
(0.25%) (Life Technologies) to remove contaminating cells and seeded at 20,000 
cells/cm2 for experiments. Cells were used between passage 2 and 5 in 2016, absence of 
mycoplasma confirmed every three month (MycoAlert, Lonza, AU). 
 
2.5.14 Confluence assay 
Culture confluence was monitored in 96 well plates (Greiner Bio-One 
CELLSTAR®) imaged every 2 h using an IncuCyte Zoom (Essen Bioscience) at 10x 
magnification (1.22 µm/pixel resolution) with three images per well. Pre- and post-
treatment confluence was quantified through the inbuilt basic analyser algorithm (Essen 
Bioscience) adjusted to the individual morphology of each culture type. 
 
2.5.15 Migration assay 
For migration assays, cells were seeded into ImageLock 96-well Plates (Essen 
Biosciences) and maintained until 70% confluent. The 700-800 µm scratch wounds were 
made in each well using the 96 well WoundMaker (Essen Biosciences) directly prior to 
drug treatment. Plates were imaged every 2 h and migration into the wound area was 
quantified using the inbuilt Scratch Wound algorithm (Essen Biosciences), adjusted to 
the individual morphology of each culture type. 
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2.5.16 Invasion assay 
Cell invasion was examined in real time using the xCELLigence RTCA DP 
System (Roche Applied Science). The xCELLigence system allows continuous 
quantitative monitoring of cellular behaviour including invasion by measuring electrical 
impedance at a porous membrane (pore size 8 μm). U87 cells were seeded at 22,500 
cells/well into specialised two-layer Cell Invasion and Migration (CIM) plates coated 
with 20 µl matrigel (Corning, 1:30 dilution) and cultured without FBS for 24 in the 
presence or absence of Q-PAC. Lower layer wells were filled with DMEM/F12 with 10% 
FBS as chemoattractant. Invasion was continuously monitored in real time over a period 
of 24 h. Data analysis was carried out using RTCA Software 1.2.1 supplied with the 
instrument. 
 
2.5.17 Cell viability assay 
Culture viability was assessed with the resazurin-based Presto Blue cell viability 
reagent (Life Technologies, #A13261) according to the manufacturer’s instructions (2 h 
incubation) and quantified on a FLUOstar Optima (BMG labtech, excitation/emission 
540 nm/580 nm). 
 
2.5.18 Apoptosis assay 
For apoptosis assays, the culture media was supplemented with caspase 3/7 
NucView 488 enzyme substrate (2.5 µM final concentration, Biotium, #10402) 2 h prior 
to drug treatment. Phase contrast and fluorescent images were captured using an IncuCyte 
Zoom (green emission/excitation at 460 nm/524 nm) at 2 h intervals and 10x 
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magnification. Caspase substrates were quantified using the in-built basic analyser 
algorithm (Table 1) from a minimum of three images per well and time point. 
 
2.5.19 Immunocytochemistry 
Cultures were fixed (4% paraformaldehyde, 15 min) and blocked (5% goat serum, 
1 h), before incubation with MCM2 polyclonal rabbit antibody (Cell Signalling 
Technologies, #4007, 1/500 in 5% BSA) overnight at 4 °C. This was followed by 
incubation with goat anti-rabbit IgG conjugated to Alexa 488 (Life Technologies, # 
A11008, 1/1000, 1%BSA) for 1 hr at room temperature and reddot2 (Biotium, #40061-1, 
1/200) as a nuclear counterstain. Images were captured on an Incucyte Zoom in phase-
contrast, green and red (emission/excitation 585 nm/635 nm) at 20x magnification with 
three images per well. The fraction of MCM2-positive cells was determined through 
automatic counting of reddot2 and MCM2 positive cells per image (see Table 1 for mask 
parameters). 
 
2.5.20 Western blot 
For histone modification quantification, cultures were lysed in triton extraction 
buffer (PBS containing 0.5% Triton X 100 (v/v), 1% protease inhibitor cocktail (P8340-
1ML, Sigma-Aldrich) and 0.02% (w/v) NaN3) and histones extracted in 0.2 M HCl at 4°C 
over 16 h. Reduced samples were separated on 15% polyacrylamide gels and transferred 
onto PVDF membranes (Millipore). Membranes were immunoblotted at 4 °C over 16 h 
for monomethylated H3K4 (5% milk block, Abcam #ab8895, 1:10,000 in 1% BSA), 
dimethylated H3K4 (5% milk block, Abcam #ab7766, 1:10,000 in 1%BSA) and 
acetylated H4 (3% milk block, Millipore #06-866, 1:4000 in 3% milk) followed by goat 
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anti-rabbit IgG-HRP (Millipore, #AP307P, 1:2500 in 1% milk) and detected by 
chemiluminescence. LSD1 expression was quantified in whole-cell lysates, separated on 
Criterion TGX Stain-Free Precast Gels (4-20%, Biorad #567-8095) and transferred onto 
PVDF membranes. Total protein loading was quantified by UV-imaging of trihalo 
transferred from the gels. Membranes were immunoblotted at 4 °C over 16 h for LSD1 
(5% milk block, Cell Signalling #C69G12, 1:1,500 in 5% milk), followed by goat anti-
rabbit IgG-HRP (Sigma, #A0545, 1:3,000 in 2.5% milk) and detected by 
chemiluminescence. 
 
2.5.21 GSH assay 
Reduced glutathione (GSH) of cell lysates was measured with a fluorometric kit, 
according to the manufacturer’s instructions (Abcam, #ab138881) and fluorescence 
intensity monitored on a FLUOstar Optima (excitation/emission 490 nm/520 nm). 
Sample GSH concentration was determined through a serial-diluted GSH calibration 
curve (150 nM to 20 µM). 
 
2.5.22 Reactive oxygen species (ROS) quantification 
Oxidative stress in live cultures was assessed with CellROX Green (Life 
Technologies, #C10444), which remains non-fluorescent until oxidized by intracellular 
reactive oxygen species (ROS). The fluorescent signal intensity is proportional to the 
levels of intracellular free radicals. Cultures were plated in black optical bottom plates 
(Thermo Fisher, #NUN165305) and incubated in CellROX Green for 30 min after 
treatment, followed by 2x PBS washes prior to imaging. Images were captured on an 
Incucyte Zoom in phase-contrast and green at 20x magnification (0.61 µm/pixel 
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resolution) with three images per well. Mean Green Intensity was normalised to culture 
confluence for each image. 
 
2.5.23 Statistical analysis 
Analyses were performed using Graphpad Prism (Graphpad Software Inc.). 
Treatment effects were assessed using one-way or two-way analysis of variance 
(ANOVA) as relevant, followed by Bonferroni’s multiple comparisons test where 
appropriate. All cell culture experiments were conducted with at least three independent 
biological replicates and at least two technical replicates each. Significance was accepted 
at p<0.05 and data presented as mean ± standard error of mean (SEM) for biological 
replicates. 
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Synthesis and biological evaluation of metallocene derivatives of cyclopropylamines 
3.1 Introduction 
3.1.1 Oxidative ring-opening of cyclopropylamines 
 Cyclopropylamines are found in a broad variety of biologically active compounds, 
such as the broad-spectrum antibiotics Ciprofloxacin, Moxifloxacin and Trovafloxacin. 
As mentioned in the previous chapter, trans-2-phenylcyclopropylamine (2-PCPA) and its 
derivatives were reported to be LSD1 inhibitors, and they displayed potential as 
anticancer agents since two active clinical trials are currently in place. Over 200 patented 
pharmaceutically relevant molecules contain a cyclopropylamine moiety,1 therefore 
much attention was drawn to the synthesis and reactivity of these moieties in recent 
years.2,3  
Cyclopropylamines also display interesting reactivity as they can undergo 
irreversible ring-opening reactions via a single-electron transfer mechanism to yield a β-
carbon radical iminium ion 29 (Scheme 14). This ring-opening process is important in 
biological systems; for example, 2-PCPA inhibits LSD1 by oxidation of the 
cyclopropylamine nitrogen by FAD in the active site, subsequent ring-opening to 29 and 
covalent attachment to FAD (Scheme 14). In these systems it has been postulated that the 
ring-opened 29 reacts irreversibly with FAD in the active site to inactivate the enzyme.4 
Their ability to undergo this ring-opening process has also seen them used as tools for 
studying biological amine-oxidation.5,6 However, to date, these oxidative ring-opening 
processes have not been greatly utilised as a tool in synthetic chemistry, but the process 
has been studied by several groups. 
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Scheme 14: An example of LSD1 inhibition through chemical modification of FAD by 2-
PCPA. FAD induced single-electron oxidation on 2-PCPA nitrogen, and hence ring-
opening of 2-PCPA occurs and the resulting benzylic radical covalently fused to FAD. 
 The single-electron oxidation of cyclopropylamine nitrogen can be achieved 
enzymatically (as seen in LSD1), chemically, photochemically and electrochemically.7 
Wimalasena et al. reported the autocatalytic radical ring-opening of N-cyclopropyl-N-
phenylamines 30 under aerobic conditions in the presence of (phen)3Fe(PF6)3 (single-
electron oxidant), benzoyl peroxide (hydrogen-abstracting reagent) or t-butyl 
peroxide/UV light (Scheme 15a).8 As a result of the oxidative ring-opening, 1,2-
dioxolanes 31 were formed in all three conditions in high conversion, however isolated 
yields could not be accurately determined due to their instability during purification. 
When a methyl substituent was placed on a different carbon atom from the amine nitrogen 
(32a or 32b), a mixture of dioxolane diastereomers 33a and 33b in a 55:45 (trans:cis) 
ratio was obtained, regardless of the substrate’s stereochemistry (Scheme 15b). 
 The reaction was proposed to be initiated by a single-electron oxidation on the 
amine nitrogen facilitated by one of the three conditions (Scheme 15c). The formation of 
radical cation on the nitrogen induces ring-opening to the cyclopropane ring, followed by 
reaction with molecular oxygen to form the 1,2-dioxolane ring. The final step is an 
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extraction of electron from the N-cyclopropyl-N-phenylamine substrate in order to 
propagate the cycle. 
 
Scheme 15: (a) Autocatalytic radical ring-opening of N-cyclopropyl-N-phenylamines 
under aerobic conditions using different oxidants.8 Isolated yields of 1,2-dioxolanes could 
not be accurately determined due to instability during purification process. (b) When a 
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1,2-disubstituted cyclopropylamine was treated with the reaction condition, a mixture of 
diastereomers were obtained with a dr of 55:45 (trans:cis), regardless of the 
stereochemistry of the substrate. (c) Mechanism of oxidative ring-opening of N-
cyclopropyl-N-phenylamines. 
 Interestingly, the 1,2-dioxolane product 31 underwent ring-opening and formed 
β-hydroxyamide 34 when excess benzoyl peroxide was used (Scheme 16). The excess 
benzoyl peroxide was proposed to extract the α-hydrogen from 1,2-dioxolane 31, which 
led to the formation of a carbonyl bond and homolytic cleavage of the O–O bond. 
Subsequently, an extraction of proton from the solvent furnished the β-hydroxyamide 34. 
 
Scheme 16: Presence of excess (BzO)2 led to ring-opening of 1,2-dioxolane 31 and 
formation of β-hydroxyamide 34.8 
 In a separate study conducted by Blackburn et al., the formation of β-
hydroxyamides 36 was also observed even when neat N-cyclopropylanilines 35 were left 
in open air for prolong period (2 – 90 days) without any chemical treatment (Scheme 17).9 
The reaction was also proposed to proceed via an 1,2-dioxolane intermediate, however in 
this case, a small amount of the acetamide 37 was also formed. A control experiment was 
conducted where a mixture of β-hydroxyamide and N-cyclopropylaniline with different 
substituents on each phenyl ring was left in open air. As a result, the β-hydroxyamide 
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substrate remained intact, while the N-cyclopropylaniline gave rise to its corresponding 
β-hydroxyamide and acetamide. The outcome of this control experiment suggests that the 
formation of acetamide is derived from the reaction intermediate, rather than the 
deformylation of the β-hydroxyamide product. While this study possessed limited 
synthetic practicality due to the prolonged time needed in the absence of accelerants, it 
provided insight into the stability of these N-cyclopropylanilines and their susceptibility 
towards oxidation in open air.  
Scheme 17: Oxidative ring-opening of N-cyclopropylanilines occurred slowly in open air 
without any chemical treatment.9 Three conditions were attempted and they all gave 36 
and 37 in varied amount: (i) rt, 150 W lamp (ii) 50 °C, lab lighting (iii) rt, lab lighting. 
 Aiming to gain further insight into the reaction and to develop a more 
environmentally friendly method, Six and co-workers reported the electrochemical 
oxidative ring-opening of cyclopropylamines 38a/38b to form 1,2-dioxolanes 39 
(Scheme 18).10,11 In order to facilitate the single-electron oxidation of the amine nitrogen, 
the electrolyses were conducted in divided cells at constant potential values. The 
generated aminium cation radicals could then react with oxygen introduced by bubbling 
air through the anodic compartment. The electrolyses were followed by in situ cyclic 
voltammetry to ensure the consumption of cyclopropylamine substrates and formation of 
1,2-dioxolane products 39. In this study, several analogues of 1,2-dioxolane were found 
to be highly unstable and prone to decompose swiftly. Similar issues were encountered 
by Wimalasena et al. mentioned earlier, in which isolation yields could not be determined 
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accurately due to decomposition during purification.8 Even though pure samples could be 
obtained in this case, significant loss of material was observed after flash chromatography 
(on silica gel or neutral alumina gel) or HPLC, therefore posing a challenge to synthetic 
utility. Nevertheless, the obtained 1,2-dioxolanes demonstrated moderate antimalarial 
activities against chloroquine-resistant FcB1 strains of Plasmodium falciparum (IC50 = 1 
– 13 µM). 
 
Scheme 18: Electrochemical approach to oxidatively ring-open cyclopropylamines and 
form 1,2-dioxolanes.10,11 
Itoh et al. reported one of the earliest works on the oxidative ring-opening of 
cyclopropylamines (Scheme 19).12 The treatment of fused-cycloalkyl-cyclopropylamine 
40 with CuCl2 and oxygen led to the ring-opening and expansion of the cycloalkyl ring 
followed by subsequent oxidation to yield the epoxy ketone 43 in modest yield. Other 
copper halides and cobalt halides were also compatible with the reaction, however the 
reaction did not proceed when iron(III) chloride was used. After the single-electron 
oxidation of amine nitrogen, two possible bonds of intermediate 41 may undergo cleavage 
to give the ring-expanded 42 or branched-cycloalkane 44. As epoxy ketone 43 was 
obtained as the sole product, it was postulated that the formation of intermediate 44 did 
not proceed. This data may suggest that radical intermediate 42 is more stable than 44 as 
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the extra adjacent alkyl chain provides further stabilisation to the carbon radical. Note 
that even though this reaction has 1,2-dioxolane as intermediate, epoxy ketone 43 was 
formed instead of a β-hydroxyamide or acetamide as observed from other studies. This 
could be due to the fact that the amine carbon in cyclopropane is tertiary instead of 
secondary, and hence no acidic proton to be liberated at the α position of 1,2-dioxolane. 
As a result, carbonyl formation and elimination of pyrrolidine occurred after the O–O 
bond cleavage in the 1,2-dioxolane. 
 
Scheme 19: CuCl2-catalysed.oxidative ring-opening of fused-cycloalkyl-
cyclopropylamine 40, follow by ring-expansion and subsequent oxidation to yield epoxy 
ketone 43.12 
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Cyclopropylamines are susceptible to oxidative ring-opening which leads to the 
formation of distonic radical cation species, for instance 29 in Scheme 14 and 42 in 
Scheme 19. The examples demonstrated so far show that these distonic ion species can 
react with molecular oxygen to yield 1,2-dioxolanes, subsequently forming β-
hydroxyamides, acetamides or epoxy ketones. Instead of allowing the distonic radical 
cation to react with molecular oxygen, Zheng and co-workers have demonstrated that this 
distonic ion species can be generated through photocatalysis, then trapped with a terminal 
olefin in a [3 + 2] cycloaddition to form five-membered carbocycles 47 or 49 (Scheme 
20).13 In this study, the photocatalyst [Ru(bpz)3](PF6)2 acts as the single-electron oxidant 
for amine nitrogen upon irradiation with visible light. During the optimisation of reaction 
conditions, it was discovered that degassing solvent is crucial for obtaining high reaction 
yield as molecular oxygen may intercept the distonic radical cation to form 1,2-dioxolane. 
The use of a 13W fluorescent light source was also found to be crucial to achieve high 
reaction yield. Zheng and co-workers also pointed out that the phenyl ring on 
cyclopropylamine nitrogen is necessary for the single-electron oxidation, as it lowers the 
redox potential of the amine nitrogen. 
Initially, the reaction was conducted using monocyclic cyclopropylamines 46 with 
different substituted phenyl rings to give the product in good yields (71 – 87%) but poor 
diastereoselectivity (1:1 to 3:2) (Scheme 20a). The reaction conditions were then applied 
to bicyclic cyclopropylamines 48, which were expected to exert steric hindrance during 
cycloaddition and hence increase the diastereoselectivity. The diastereoselectivity was 
indeed improved (3:1 to 25:1), however the reaction yield was slightly decreased (58 – 
77% yield) (Scheme 20a). Notably, when R1 on the cyclopropane was a t-Bu group 
instead of methyl group, an excellent diastereoselectivity of 25:1 was obtained, but with 
a poor yield of 28% (64% yield based on recovered cyclopropylamine substrate). This 
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result highlights the need to introduce steric hindrance in order to provide good 
diastereoselectivity in this reaction. Instead of using styrene-based substrates, the study 
also demonstrated that the photocatalytic condition can be extended to terminal olefins 
substituted with electron-withdrawing groups (52% yield, 1:1 dr) and conjugated dienes 
(40% yield, 2:1 dr). However, the reaction did not proceed using tertiary 
cyclopropylamines or internal olefins. 
Mechanistically, upon irradiating the Ru(II) photocatalyst with 13W fluorescent 
light, the excited Ru(II)* species extracts an electron from the cyclopropylamine nitrogen 
and is concomitantly reduced to Ru(I). This results in the formation of a radical cation on 
the amine nitrogen 50 and hence subsequent ring-opening of the cyclopropane. The 
generated distonic cation radical 51 can then be added to an olefin substrate in a Giese 
reaction fashion. After the ring-formation is completed, the resulting nitrogen radical 




Scheme 20: (a) [3 + 2] Cycloaddition of monocyclic and bicyclic cyclopropylamines with 
olefins under visible-light photocatalysis.13 (b) Proposed catalytic cycle.  
 In a separate study, Zheng and co-workers have demonstrated that the 
photocatalytic cycloaddition of cyclopropylamines can be extended to terminal alkynes 
(which have a lower reactivity), however a stronger light source of 18W LED was 
required to obtain higher yields (Scheme 21a).7 Terminal alkynes with various aromatic 
rings, heterocycles and electron-withdrawing groups were tolerated, while alkyl-
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substituted terminal alkynes and internal alkynes were inert under the optimised 
conditions.  
In order to further explore the substrate scope in this photocatalytic cycloaddition, 
Zheng and co-workers extended the scope to conjugated alkyne substrates, such as diynes 
and enynes (Scheme 21b-c).14 Moderate yields were obtained using symmetrical or 
asymmetrical diynes (Scheme 21b). In the case of asymmetrical diynes where one alkyne 
terminal was occupied with phenyl ring, the cycloaddition with cyclopropylamines 
occurred on the adjacent alkyne regioselectively. In the case of enynes, moderate yields 
were also obtained, but an issue of chemoselectivity became apparent (Scheme 21c). 
Generally within an enyne, the cycloaddition occurred on the olefin moiety provided 
minimal steric hindrance was present around the olefin. In the examples where sterically 
hindered olefins were employed, the cycloaddition with cyclopropylamines would then 
occur on the alkyne moiety. Lastly, substituted cyclopropylamines were also investigated 
as part of the substrate scope (Scheme 21d). Consistent with previous findings, tertiary 
cyclopropylamines failed to participate in cycloaddition with terminal alkynes. 
Substitution of a methyl group on any cyclopropane carbon was tolerated – giving the 
products in moderate yields. 
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Scheme 21: Photocatalytic [3 + 2] cycloaddition of N-arylcyclopropylamines with (a) 
terminal alkynes;7 (b) asymmetric and symmetric diynes;14 (c) enynes;14 (d) 
Photocatalytic [3 + 2] cycloaddition of substituted N-arylcyclopropylamines with 
terminal alkynes.14  
 Based on literature record, addition of external oxidants or an electrochemical 
approach was required to oxidatively ring-open cyclopropylamines in a facile manner. To 
date, cyclopropylamines with redox active organometallic moieties have been scarcely 
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studied, therefore we were intrigued to investigate the stability, reactivity and also the 
medical application of these derivatives.  
 
3.1.2 Application of ferrocene in medicinal chemistry 
Traditionally, organometallic complexes were perceived as toxic, unstable, and 
incompatible with aqueous or atmospheric environments. While this may be true in many 
cases, organometallic complexes that are non-toxic and stable in air or water do 
commonly exist. In fact, these stable organometallic complexes have gained attention in 
the field of medicinal chemistry, as they can enhance existing drug activity in different 
ways. In general, organometallic complexes are relatively lipophilic, therefore they can 
assist in drug delivery across cell membrane or blood brain barrier (BBB).15 
Organometallic complexes also exhibit structural diversity that is not observed in 
hydrocarbon molecules, such as square planar, trigonal bipyramidal and octahedral 
geometry. This provides extra scope for SAR studies. Furthermore, the charge of the 
metal species can also vary depending on the cellular environment, and this may provide 
some control over drug activity or selectivity.16 The pharmacokinetic properties and 
cytotoxicities of the drugs can also be regulated through ligand hydrolysis rate by rational 
ligand design.17  
Ferrocene is a redox-active metallocene composed of an Fe(II) core sandwiched 
between two cyclopentadienes, and its derivatives have been reported in different medical 
applications, such as a kinase inhibitor,18 a HDAC inhibitor,19 an antimalarial agent,20 and 
an anticancer agent.21 Ferrocene is characterised by its capability to undergo single-
electron oxidation, forming a ferrocenium cation − the redox reaction (Fe2+ ↔ Fe3+) is 
reversible for most ferrocene derivatives.21 This unique reversible redox activity of 
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ferrocene could be harnessed to improve existing drug activity – an example of such an 
approach is now discussed. 
In two-thirds of breast cancer patients, the tumorigenesis is attributed to the 
binding of estrogen (predominantly estradiol) with the alpha form of estrogen receptor 
(ERα). This population of patients are classified as ER(+) as they are hormone-dependent, 
while those patients who are hormone-independent are described as ER(−). Tamoxifen 
(Figure 25a), which is a selective estrogen receptor modulator (SERM), has been 
clinically administered to ER(+) breast cancer patients. Tamoxifen itself is a prodrug 
which releases hydroxytamoxifen (Figure 25a) to competitively bind to ERα. 
Unfortunately, tamoxifen is not effective for ER(−) due to the lack of ERα for binding. 
Even in the treatment for ER(+) patients, expression of ERα may be progressively 
downregulated under treatment which renders the drug ineffective eventually. 
Ferrocifens is an organometallic derivative of hydroxytamoxifen in which the β-
phenyl ring is replaced with ferrocene (Figure 25a). With the introduction of the 
ferrocenyl moiety, ferrocifen was found to have a higher value of log Po/w (4.3 – 4.5) 
compared to hydroxytamoxifen (3.2 – 3.4) and estradiol (3.5), indicating that it has 
superior cell permeability compared to hydroxytamoxifen and estradiol.22 In MCF7 cells 
which are ER(+), the antiproliferative effect of ferrocifen was approximately 1.7-fold 
stronger than hydroxytamoxifen while ferrocene alone did not display any activity.22  
Interestingly, ferrocifen also displayed an antiproliferative effect on ER(−) cell 
line MDA-MBA-231 which is immune to tamoxifen due to the lack of ERα.22 This 
implies that ferrocifen possesses a secondary action other than being an antiestrogen. 
Through electrochemical experiments, Jaouen and co-workers proposed that the 
secondary action is attributed to the redox nature of ferrocenyl moiety and the conjugated 
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system.23 These factors convert ferrocifen into a highly electrophilic quinone methide, 
which is susceptible to nucleophilic addition of glutathione (GSH) and nucleobases 
(Figure 25b), hence inducing cytotoxicity. 
Figure 25: (a) SERMs: Tamoxifen, hydroxytamoxifen, ferrocifen and ruthenocene 
derivatives of hydroxytamoxifen 53. (b) In ferrocifen, the redox active ferrocenyl moiety 
and conjugated system give rise to quinone methide intermediate which is prone to 
nucleophilic addition at positions indicated by arrows. 
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Since ruthenium is placed below iron in the periodic table, it was hypothesised 
that the ruthenocene derivatives of tamoxifen (53, Figure 25) could be easily oxidised 
therefore increasing antiproliferative effect on breast cancer cells. Jaouen and co-workers 
showed that the ruthenocene derivatives 53 indeed exhibited improved antiproliferative 
effect on ER(+) MCF7 cells compared to hydroxytamoxifen.24 However unlike 
ferrocifen, the ruthenocene derivatives 53 did not display an antiproliferative effect on 
ER(−) MDA-MBA-231 cells, suggesting that the 53 may possess the antiestrogen nature 
of tamoxifen but not the cytotoxicity of ferrocifen. While ferrocene undergoes reversible 
redox reaction, electrochemical experiments revealed that the ruthenocenyl moiety was 
oxidised irreversibly and the resulting ruthenocenium species was unstable. Even though 
53 only inhibits proliferation in ER(+) cells, it could still useful in radioimaging for these 
cells due to the availability of γ-emitting isotopes 97Ru and 103Ru.24 
While organometallic derivatives of many structures are known, none (or few) are 
known for cyclopropylamine-based compounds. Since organometallics such as ferrocene 
has demonstrated redox activity, we were intrigued of the possibility for the catalytic ring-
opening of cyclopropylamine in such derivatives.  
 
3.2 Aim and research plan 
 As mentioned in the previous chapter sections 2.1.5 and 2.1.6, LSD1 inhibition 
using 2-PCPA analogues has attracted attention in the field of cancer research, especially 
two of the N-alkylated 2-PCPA derivatives are currently in clinical trials. Inspired by the 
potential of 2-PCPA in cancer treatment, and the utility of ferrocene in drug discovery, 
we originally aimed to prepare ferrocene derivatives of 2-PCPA. As a precursor to this 
comprehensive study, ferrocenecarboxaldehyde 54 and 2-PCPA were subjected to several 
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reductive amination conditions, however a ring-opened β-hydroxyamide 57 was obtained 
instead of the desired N-ferrocenylmethylcyclopropylamine 56 (Scheme 22).25 
Nevertheless, the formation of amine 56 was proposed as an intermediate because the 
C=N double bond in imine 55 was found to be reduced in amide 57. Although the 
formation of β-hydroxyamide was similar to that in the study from Wimalasena et al.,8 
this observation was unexpected due to the absence of external oxidant for the single-
electron oxidation of amine nitrogen. Therefore, it was proposed that the ferrocene moiety 
acted as an internal oxidant to remove single electron from amine nitrogen, similar to that 
in ferrocifen. Furthermore, a study on dehydrogenative Heck reaction conducted by Pi et 
al. demonstrated that in the absence of external oxidant, the ferrocene substrates can 
oxidise the reduced Pd(0) catalyst back to Pd(II) and hence promote the catalytic cycle.26 
 In this study, we aim to couple 2-PCPA derivatives with redox active 
metallocenes (such as ferrocene and ruthenocene) to both create medicinally relevant 
compounds and investigate the fundamental activity of these systems. This investigation 
should lead to a better understanding of the catalytic ring-opening process and the impact 
on bioactivity or organometallic cyclopropylamines. Firstly, the use of ferrocene as 
internal oxidant will be extended to other 2-PCPA derivatives with different substituents 
on the aromatic ring at various positions. In order to investigate the role of stable radical 
intermediate in the reaction, the reaction condition will be applied to cyclopropylamine 
which lacks of an aryl ring to stabilise the ring-opened radical cation intermediate. Lastly, 
ruthenocene derivative of 2-PCPA will be synthesised and subjected to LSD1 and MAOs 
inhibition assay to determine its potency and selectivity. 
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Scheme 22: Preliminary observation of ferrocenyl 2-PCPA ring-opening. Conditions: (a) 
(i) MgSO4, CH2Cl2; (ii) NaBH4, MeOH; (b) Bu3SnH, SiO2; (c) (i) NaBH(OAc)3, 1,2-
dichloroethane; (ii) LiBH4, EtOH. NaBH3CN was attempted as reducing agent however 
neither amine 56 nor amide 57 was obtained.25 
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3.3 Results and discussion 
3.3.1 Preparation of 2-PCPA derivatives 
 
Scheme 23: Stepwise preparation of 2-PCPA derivatives with different substituents on 
phenyl ring. 
 While 2-PCPA is commercially available, 2-PCPA analogues with different 
substituents were prepared in a multi-step sequence (Scheme 23). Firstly, cinnamic acids 
58b-g underwent acid-catalysed esterification to yield ethyl cinnamates 59b-g in 
excellent yields. In the 1H NMR of ethyl cinnamates 59b-g, the signals for OCH2CH3 can 
be clearly observed at approximately 4.27 (q, 2H) and 1.34 (t, 3H) ppm. The cyclopropyl 
131 
ring of 60b-g was then constructed on the olefin of 59b-g through Corey–Chaykovsky 
cyclopropanation. Sulfur ylide was generated through the deprotonation of 
trimethylsulfoxonium iodide with NaH, it was then added to the olefin moiety of 59b-g 
and DMSO was eliminated during ring-closure. As a result of the cyclopropanation, the 
olefin proton signals in 1H NMR disappeared (doublets at approximately 7.60 and 6.40 
ppm), while cyclopropane proton signals were observed as multiplets in the aliphatic 
region (approximately 2.52 – 2.48, 1.92 – 1.88, 1.63 – 1.59 and 1.28 ppm, 1H for each 
multiplet).  
Based on the mechanism of Corey–Chaykovsky cyclopropanation (Scheme 23), 
the use of an (E)-olefin substrate moulds the trans diastereoselectivity in the cyclopropane 
product. After the nucleophilic attack of the sulfur ylide to the olefin substrate, bond 
rotation to place the ester group syn to the aromatic ring is energetically undesirable due 
to steric hindrance, therefore cis-diastereomers of the cyclopropanes were not obtained. 
Furthermore, the 1H NMR spectra of cyclopropanes 60b-g were consistent with the 
literature where the trans-cyclopropanes were reported (except 60d which was not 
reported in the literature).27,28 
This was followed by basic hydrolysis of 60b-g to yield carboxylic acids 61b-g 
(Scheme 23). Apart from the apparent change in physical appearance (from liquid to 
solid), the 1H NMR spectra of 61b-g lacked of signals for the OCH2CH3 moiety from the 
substrate (quartet at around 4.17 ppm and triplet at around 1.28 ppm), therefore indicating 
that the ester moiety was successfully hydrolysed.  
The hydrochloride salts of 2-PCPA derivatives 62b-g were obtained after Curtius 
rearrangement of 61b-g with t-BuOH, acidic deprotection of the N-Boc-group and acidic 
salt precipitation (Scheme 23). Treatment of carboxylic acids 61b-g led to the formation 
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of their corresponding acyl azides. The acyl azides then underwent decomposition, which 
involved evolution of nitrogen gas and rearrangement to form the isocyanate 
intermediate. Nucleophilic attack of t-BuOH to this isocyanate intermediate yielded the 
N-Boc carbamate product, where the presence of Boc group was evidenced by the singlet 
(9H) at around 1.45 ppm in 1H NMR. After Boc-deprotection using TFA, the obtained 
amines were acidified using ethereal HCl to precipitate out the amine salts 62b-g. In the 
1H NMR spectra of 62b-g, singlet with 9H integration was not observed at around 1.45 
ppm, indicating the Boc group was successfully removed. In samples where deuterated 
DMSO was used during NMR analysis, a broad singlet was observed at around 8.70 ppm, 
which was assigned as NH3+ in 62b-g. 
In the Curtius rearrangement of 61b-g, instead of directly hydrolysing the 
isocyanate intermediates to amines, t-Bu carbamates were prepared and deprotected in 
order to access the amines 62b-g as solid hydrochloride salts which were easier to 
handle/weigh out in the laboratory. 
 Although some of these 2-PCPA derivatives and their precursors were reported in 
literature and patents, not all of their characterisation data (such as NMR, IR, HRMS and 
melting point) were documented, and hence these data were collected and listed in the 
experimental section of this chapter. 
 
3.3.2 Oxidative ring-opening of ferrocenylmethylcyclopropylamines 
 All 2-PCPA substrates 62a-g were subjected to condensation with 
ferrocenecarboxaldehyde 54 to yield the corresponding imines 63a-g (Scheme 24), which 
were then treated with sodium borohydride to form the corresponding β-hydroxyamides 
65a-g in moderate yields (22 – 58% over two steps from amine salt). This demonstrated 
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that the reaction is compatible with a range of electron-donating and electron-
withdrawing substituents, at different positions of the aromatic rings. 
 
Scheme 24: Oxidative ring-opening of 2-PCPA derivatives, two-steps yields (from 2-
PCPA salts) were reported for β-hydroxyamides 65. 
 From the 1H NMR spectrum of β-hydroxyamide 65d the absence of cyclopropane 
C-H signals (typically range from 1.30 – 1.90 ppm) indicated that the ring-opening had 
occurred. The β-hydroxyl carbon had originated from the cyclopropane (Ph-CH-CH2), 
and the proton signal shifted downfield to 5.11 ppm due to the attachment of the hydroxyl 
group. The presence of an amide carbonyl was verified from the peak at 171.0 ppm in 13C 
NMR and 1650 cm-1 in the IR. Furthermore, the X-ray analysis of 65d confirmed its 
assigned structure (Figure 26). 
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Figure 26: Crystal structure of β-hydroxyamide 65d, collected by Dr M. Gardiner 
(University of Tasmania). 
 
3.3.3 Proposed mechanism for the formation of β-hydroxyamides derived from 
oxidative ring-opening of ferrocenylmethylcyclopropylamines 
 The reactivity of the ring-opening was attributed to the redox activity of the 
ferrocenyl moiety, especially as the corresponding benzyl-derivative has been reported to 
be air stable and subjected to biological studies.29 The redox activity of ferrocene was not 
only observed in drugs like ferrocifen, it has been reported that air generated ferrocinium 




Scheme 25: The redox capability of ferrocene was utilised as an internal oxidant to 
recover Pd(II) from Pd(0) in a dehydrogenative Heck reaction.26 
 Based on the proton NMR analysis of the obtained products, we proposed that the 
ferrocenylmethylcyclopropylamine 64 is formed in the first place due to the 
disappearance of imine N=CH-Fc signal at 8.25 ppm and presence of N-CH2-Fc signal 
between 4.10 – 4.15 ppm. Note that the reaction was conducted under nitrogen 
atmosphere and there was no positive supply of oxygen gas to the system, thus the 
oxidation of ferrocenyl moiety in amine 64 may occur during workup where the amines 
are exposed to air (Scheme 26). As a result, the ferrocenium counterpart 66 is formed 
which led to the formation of radical cation 67 through single-electron oxidation of the 
amine nitrogen. The amine radical cation 67 prompts the ring-opening of cyclopropane 
by exclusively cleaving the C1-C2 bond, so that the more stable benzylic radical 68 can 
be formed. This is consistent with Wimalasena et al. who suggested the carbon-centered 
radical is a discrete intermediate in radical ring-opening of cyclopropylamines and 
therefore, ring-opening and molecular oxygen insertion are not concerted.8 The distonic 
radical cation 68 can then be trapped with molecular oxygen to yield adduct 69 and 
subsequently undergo 5-exo-trig cyclisation to radical cation 70. The catalytic cycle is 
propagated by abstraction of an electron from amine 64 by radical cation 70, which yields 
dioxolane 71 as an intermediate.  
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Dioxolane 71 was not observed in our current study, as it is likely undergoing 
isomerisation by concomitant O–O bond cleavage to yield N-ferrocenylmethyl β-
hydroxyamide 65, which is a facile process under basic conditions. This isomerisation 
step to the hydroxyamide could occur via several pathways. While it has been reported 
that 1,2-dioxolanes can undergo conversion to β-keto alcohols in the presence of silica 
gel,30,31 in our case this is unlikely as signals corresponding to the hydroxyamide were 
observed in the 1H NMR of the crude reaction material prior to contact with silica gel. 
Therefore, it is more likely that the isomerisation occurs via base-mediated32 or radical 
abstraction8 of hydrogen. Of these two possibilities the base-mediated mechanism would 
appear more likely as no clear mechanism for generation of RO• is apparent and our 
conditions are intrinsically basic due to the presence of NaBH4. 
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Scheme 26: Proposed mechanism of oxidative ring-opening of cyclopropylamines 64 to 
form β-hydroxyamides 65. 
 
3.3.4 Role of stable radical intermediate in the oxidative ring-opening of 
ferrocenylmethylcyclopropylamines 
Apart from the redox capability of ferrocene, the reactivity of the ring-opening 
process could also be promoted by the release of ring-strain in cyclopropylamine 
intermediate 67 and subsequently the formation of radical intermediate 68 where the 
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radical is stabilised by the aromatic ring. This process is similar to the ring-opening 
process of 2-PCPA in LSD1 inhibition, where bond cleavage occurs exclusively between 
C1 and C2 to yield a stable benzylic radical 29 prior to covalent fusing with FAD (Scheme 
14). Conversely, bond cleavage between C1 and C3 was not observed as the resulting 
methylene radical intermediate is less stable than benzylic radical 29. In the work of Itoh 
et al. (Scheme 19), bond cleavage also occurred specifically between C1 and C2 in 
cyclopropylamine intermediate 41 as the resulting radical can be stabilised by two alkyl 
groups rather than one.12 The stability of the radical intermediate seems to manipulate the 
ring-opening of cyclopropylamine.  
To investigate the role of stable radical intermediate in this ring-opening process, 
cyclopropylamine which lacks of a stabilising phenyl ring, were subjected to 
condensation with ferrocenecarboxaldehyde 54 and formed cyclopropylimine 72 
(Scheme 27). As such, it was anticipated that ferrocenylmethylcyclopropylamine 73 
could form without subsequent ring-opening, due to the lack of phenyl ring to stabilise 
the radical intermediate if ring-opening occurs. 
 
Scheme 27: Oxidative ring-opening was not observed during the preparation of 
ferrocenylmethylcyclopropylamine 73 from the reduction of of cyclopropylimine 72. 
As expected, ring-opening was not observed after reducing cyclopropylimine 72 
with sodium borohydride, and ferrocenylmethylcyclopropylamine 73 was obtained 
successfully. In the 1H NMR spectrum of 73, the cyclopropane proton signals were 
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located at 2.18 – 2.17 (1H, CH-NH), 0.44 – 0.43 (2H, CH2-CH-NH) and 0.362 – 0.358 
(2H, CH2-CH-NH) ppm. Furthermore, an amide signal was not detected based on the 
absence of signals at around 171.0 ppm in 13C NMR and 1650 cm-1 in IR, which further 
supports that oxidative ring-opening did not occur. Even though spectroscopic evidence 
support that ferrocenylmethylcyclopropylamine 73 was formed, the molecule slowly 
decomposed after column chromatography and leaving aside for a few days. The 
decomposition might not be solely due to ring-opening of cyclopropylamine because 
many unidentifiable peaks were observed within the aliphatic region in 1H NMR 
spectrum. 
Due to the lack of phenyl group to stabilise the radical intermediate, it was 
observed that ferrocenylmethylcyclopropylamine 73 was more resistant to ring-opening 
compared to 64, suggesting that the stability of ring-opened radical intermediate plays a 
role in the stability and reactivity of ferrocenylmethylcyclopropylamines. 
 
3.3.5 Trapping benzylic radical intermediate 68 in [3 + 2] cycloaddition 
 Based on literature reports of cyclopropylamine ring-opening, together with the 
observed formation of β-hydroxyamides 65 derived from 
ferrocenylmethylcyclopropylamine 64, we proposed that the benzylic radical 68 formed 
is a crucial reaction intermediate. Inspired by Zheng and co-workers’ work in [3 + 2] 
cycloadditions of cyclopropylamines and olefins,33 we attempted to trap benzylic radical 
68 (generated through the reduction of cyclopropylimine 63a with NaBH4) using 4-
methylstyrene, however the desired cycloaddition did not occur while β-hydroxyamides 
65a was obtained (Scheme 28).  
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 Commercially sourced 4-methylstyrene was supplemented with 3,5-di-tert-
butylcatechol as radical inhibitor to prevent polymerisation of 4-methylstyrene. It was 
assumed that this inhibitor may hinder the cycloaddition, therefore commercially sourced 
4-methylstyrene was passed through an alumina plug to remove the inhibitor. Despite the 
removal of the inhibitor, the desired cycloaddition still did not occur while β-
hydroxyamide 65a was obtained again.  
 The cycloaddition was proven to be challenging, as the reaction required trace 
amount of oxygen to oxidise ferrocene to ferrocinium, while the generated benzylic 
radical 68 may have a higher affinity with molecular oxygen compared to 4-
methylstyrene, which was added in abundance (5 equivalent). In summary, the trace 
amount of molecular oxygen required to initiate the oxidation could also be the 
interference for the cycloaddition to occur. 
Scheme 28: Attempt to subject benzylic radical 68 to [3 + 2] cycloaddition with 4-
methylstyrene. However, β-hydroxyamide 65a was obtained, with or without removing 
3,5-di-tert-butylcatechol (radical inhibitor) from 4-methylstyrene. 
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3.3.6 Preparation of ruthenocene derivatives of 2-PCPA 
 As ferrocenylmethylcyclopropylamines were intrinsically unstable and prone to 
ring-opening, ruthenocene analogues of 2-PCPA were the next focus of the project. In the 
study conducted by Jaouen and co-workers, ruthenocene analogues of ferrocifen (53, 
Figure 25) were found to retain the antiestrogen nature of hydroxytamoxifen but not the 
cytotoxicity exhibited by ferrocenyl group.24 It was further pointed out that ruthenocene 
undergoes an irreversible oxidation, in contrast to the reversible redox activity observed 
in ferrocene. Therefore, we proposed that the ruthenocenylmethylcyclopropylamine 76 
(Scheme 29) might be more stable in air than the ferrocenyl-counterpart – the latter 
transforming to a β-hydroxyamide via reversible Fe(II) oxidation. Despite this, it is 
possible that the redox active ruthenocene may enhance the FAD-mediated N-oxidation 
of 76 vs. 2-PCPA during LSD1 inhibition. Furthermore, the lipophilicity of ruthenocene 
moiety could facilitate the transport of 76 across the cell membrane.  
LSD1 possesses a more spacious active site compared to MAOs based on the 
comparison of X-ray crystal structures,34-36 therefore 76, which is larger than 2-PCPA in 
size, may be able to inhibit LSD1 selectively due to size exclusion by MAOs. Consistent 
to this hypothesis, N-alkylated 2-PCPA derivatives have demonstrated superior 
selectivity towards LSD1 compared to MAOs in literature and clinical trials.37-40 
 The synthesis of ruthenocenylmethylcyclopropylamine 76 requires the 
condensation of ruthenocenecarboxaldehyde 75 and 2-PCPA, follow by reduction of 
imine with sodium borohydride (Scheme 29). Unlike ferrocenecarboxaldehyde 54, 
ruthenocenecarboxaldehyde 75 was not commercially available. The literature method to 
synthesise 75 from ruthenocene usually involved the use of t-BuLi/t-BuOK “super base” 
pair at low temperature (−75 °C),41-43 which posed a moderate to high risk in the 
laboratory. In order to access 75 more safely, ruthenocene was subjected to Vilsmeier–
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Haack reaction with N-methylformanilide in a moderate yield of 60% (Scheme 29). N-
Methylformanilide reacted with phosphorus oxychloride to generate a chloroiminium ion 
(Vilsmeier reagent), which then underwent electrophilic aromatic substitution with the 
electron rich ruthenocene, followed by hydrolysis to furnish the aldehyde moiety. 
 
Scheme 29: Preparation of ruthenocenecarboxaldehyde 75 and 
ruthenocenylmethylcyclopropylamine 76. 
 Upon using NaBH4 to reduce the imine resulting from the condensation of 
ruthenocenecarboxaldehyde 75 and 2-PCPA, the desired 
ruthenocenylmethylcyclopropylamine 76 was obtained in a moderate yield of 41% (two 
steps yield from 75), with no sign of ring-opening (Scheme 29). The obtained 76 was 
much more stable than ferrocenylmethylcyclopropylamine 73 (Scheme 27), in which the 
former passed through column chromatography without sign of decomposition or ring-
opening. In the 1H NMR of 76, no aldehyde signal was detected at 9.73 ppm, indicating 
the complete consumption of substrate 75. On the other hand, cyclopropane proton signals 
of 76 were observed at 2.44 (CH-NH), 1.91 (CH-Ar), 1.11 – 1.07 (CH2-CH-NH) and 0.97 
(CH2-CH-NH) ppm. In terms of the Cp signals for ruthenocene in 76, although the 
chemical shifts were slightly different from substrate 75, the total proton integration 
matched the proposed structure of 76. Moreover, the absence of carbonyl signals in 13C 




3.3.7 Selectivity and potency of ruthenocenyl-2-PCPA 76 in LSD1 inhibition 
 Despite the fact that there are many literature examples of 2-PCPA derivatives in 
the studies of LSD1 inhibition, there is no reported precedent for organometallic 
analogues of 2-PCPA. Therefore, it was important to evaluate the LSD1 inhibitory 
activity and selectivity of ruthenocenyl-2-PCPA 76, with 2-PCPA as a comparison 
control. This work was carried out by our collaborators at the Kyoto Prefectural 
University of Medicine (group of Prof T. Suzuki). 
 Using an LSD1 fluorometric drug discovery kit (BML-AK544-0001, Enzo), the 
IC50 of 76 in LSD1 inhibition was determined as 1.4 µM, which is 16.4 times more potent 
than 2-PCPA (LSD1 IC50 = 23.0 µM) (Table 3). Furthermore, 76 was determined to be 
inactive in MAO A and MAO B. These data demonstrated that ruthenocenyl-2-PCPA 76 
is a potent and selective LSD1 inhibitor. 
 
Table 3: Inhibitory activity of 2-PCPA and ruthenocene derivative 76 in LSD1 and 
MAOs. 
 IC50 (µM)a 
  LSD1 MAO A MAO B 
2-PCPA 23.0 ± 3.4 6.00 ± 1.38 6.54 ± 0.51 
Inhibitor 76 1.43 ± 0.07 > 10 > 10 
a Values are means ± SD of at least three experiments. 
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 Inhibitor 76 demonstrated superior LSD1 inhibitory activity compared to its 
mother compound 2-PCPA. This could be due to the introduction of the bulky 
ruthenocene group on the cyclopropylamine nitrogen, as the two clinical trial candidates 
have bulky alkyl group on amine nitrogen as well (Section 2.1.6). Since the X-ray crystal 
structure of LSD1 revealed that this enzyme has a more capacious active site than MAOs, 
34-36 the selectivity towards LSD1 can be justified as the result of size exclusion from 
MAOs. 
Ruthenocene derivatives of hydroxytamoxifen were found to have higher log Po/w 
values compared to hydroxytamoxifen, therefore assisting the drug to cross the cell 
membrane.24 While the assay performed in this study was not a cellular assay, the 
ruthenocene in inhibitor 76 would be expected to aid the drug crossing cell membrane 
and hence achieve great potency in cancer cell lines. Due to the availability of γ-emitting 
isotopes 97Ru and 103Ru, ruthenocene derivative 76 can also be useful in the radioimaging 
of cancer cells, which will eliminate the challenge of radiolabelling.24 
This highly promising result lays the foundation for investigation of other 
analogues containing ruthenocene, which should be carried out in future studies.  
 
3.4 Conclusion and future work 
 In conclusion, ferrocenylmethylcyclopropylamines 64 derived from 2-PCPA and 
ferrocenecarboxaldehyde 54 were prone to oxidative ring-opening and yield β-
hydroxyamides 65. This observation was consistent with different variation of 
substituents on the phenyl ring, so as different positions on the ring. β-Hydroxyamide 
moiety features in bioactive compounds, such as Cruentaren A (antifungal)44 and 
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Octreotide (growth hormone inhibitor)45, organometallic analogues of this moiety can be 
potential interest to medicinal chemists. Further, this is the first study of an organometallic 
derivative of the biologically important cyclopropylamine moiety and will provide 
fundamental reactivity information to future workers in the medicinal organometallic 
field. 
By replacing 2-PCPA with cyclopropylamine, in the Fc derivatives oxidative ring-
opening did not occur due to the lack of phenyl ring to stabilise radical intermediate. 
However, the obtained ferrocenylmethylcyclopropylamine 73 slowly decomposed after 
purification and storage for a few days. Lastly, ruthenocene analogue of 2-PCPA 76 was 
successfully synthesised and subjected to in vitro assay. It was determined as a potent and 
selective LSD1 inhibitor (IC50 = 1.4 µM). The different fate of ferrocene and ruthenocene 
2-PCPA analogues highlights the importance of metallocene redox potential, in which 
crucial to determine the ring-opening propensity. As such, the incorporation of 
ruthenocene to 2-PCPA created a LSD1 inhibitor that is air stable yet potent. 
 Preliminary results of 76 in the in vitro assay was promising and should be follow 
up with a cellular assay. The presence of ruthenocene increases the lipophilicity of the 2-
PCPA analogue and hence an increase in cellular uptake is anticipated. Similar to 2-
PCPA, it was assumed that 76 inhibits LSD1 by covalently fused to FAD in the active 
site. To verify this hypothesis, the 76-FAD adduct generated during LSD1 inhibition can 
be detected using mass spectrometry.37,46 Furthermore, the H3K4me1/2 levels can be 
quantified by western blot. An increase in H3K4me1/2 levels is expected to occur if 76 
successfully inhibits LSD1, due to the possible enhanced reactivity of ruthenocene 
towards the FAD-mediated ring-opening of 76. 
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Although clinical trial candidates ORY-1001, GSK2879552 and 76 are all N-
alkylated 2-PCPA derivatives with no substituent on the phenyl ring, it was not clear why 
the N-alkyl group increases potency in LSD1 inhibition. In silico docking study may shed 
a light on how these N-alkyl groups interact with the LSD1 active site and hence increase 
their inhibitory activities. Using this information with SAR analysis, a second generation 
of ruthenocene analogues can be developed, with derivatisation on ruthenocene and/or 
the phenyl ring. 
A modified version of 76 without the phenyl ring can also be synthesised (77, 
Scheme 30), since ring-opening is unlikely to occur in this case. With such, we were 
intrigued to observe if ruthenocenylmethylcyclopropylamine 77 will still be able to 
inhibit LSD1 and induce cytotoxicity in cancer cells. This information can provide us 
some insight into the role of the ruthenocenyl moiety in LSD1 inhibition. 
 
Scheme 30: Proposed preparation of ruthenocenylmethylcyclopropylamine 77 from the 




All organic syntheses and molecule characterisation listed below were performed 
by Y. S. Gee. The preparation of 62f, 65f, data acquisition of IR and HRMS for 65g, were 
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assisted by an undergraduate student N. Goertz (University of Wollongong). X-ray 
crystallography was performed by Dr M. Gardiner (University of Tasmania). In vitro 
assay of ruthenocenyl-2-PCPA 76 was performed by Professor T. Suzuki and co-workers 
(Kyoto Prefectural University of Medicine). 
General experimental details for organic syntheses and molecule characterisation 
are stated in Chapter 2 Section 2.5.1. 
 
3.5.1 Esterification of cinnamic acids 
Ethyl (E)-3-(o-tolyl)-2-propenoate (59b) 
 
Concentrated sulfuric acid (~ 1 mL) was added to a solution of 2-methylcinnamic acid 
(2.01 g, 12.4 mmol) in ethanol (40 mL). After heating to reflux for 24 h, the reaction 
solution was concentrated in vacuo and diluted with ethyl acetate (40 mL). The solution 
was washed with 5% by mass NaHCO3 aqueous solution (3 × 30 mL) and water (3 × 30 
mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give the title compound as a pale yellow oil (2.12 g, 11.1 mmol) 
in 90% yield. 1H NMR (500 MHz, CDCl3): δ 7.98 (d, J = 16 Hz, 1H, Ar-CH=CH), 7.55 
(d, J = 7.5 Hz, 1H, CHAr), 7.29 – 7.26 (m, 1H, CHAr), 7.21 (t, J = 6.5 Hz, 2H, CHAr), 6.36 
(d, J = 16 Hz, 1H, Ar-CH=CH), 4.27 (q, J = 7 Hz, 2H, OCH2), 2.44 (s, 3H, Ar-CH3), 1.34 
(t, J = 7 Hz, 3H, CH2CH3) ppm. 1H NMR data consistent with literature and the material 
is commercially available.47,48 
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Ethyl (E)-3-(m-methoxyphenyl)-2-propenoate (59c) 
 
Concentrated sulfuric acid (~ 1 mL) was added to a solution of 3-methoxycinnamic acid 
(2.00 g, 11.2 mmol) in ethanol (38 mL). After heating to reflux for 24 h, the reaction 
solution was concentrated in vacuo and diluted with ethyl acetate (38 mL). The solution 
was washed with 5% by mass NaHCO3 aqueous solution (3 × 30 mL) and water (3 × 35 
mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give the title compound as a pale yellow oil (2.09 g, 10.1 mmol) 
in 90% yield. 1H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 16 Hz, 1H, Ar-CH=CH), 7.30 
(t, J = 8 Hz, 1H, CHAr), 7.12 (d, J = 7.5 Hz, 1H, CHAr), 7.05 (s, 1H, CHAr), 6.93 (d, J = 
8.5 Hz, 1H, CHAr), 6.43 (d, J = 16 Hz, 1H, Ar-CH=CH), 4.27 (q, J = 7 Hz, 2H, OCH2), 
3.83 (s, 3H, OCH3), 1.34 (t, J = 7 Hz, 3H, CH2CH3) ppm. 1H NMR data consistent with 
literature and the compound is commercially available.49 
 
Ethyl (E)-3-(m-fluorophenyl)-2-propenoate (59d) 
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Concentrated sulfuric acid (~ 1 mL) was added to a solution of 3-fluorocinnamic acid 
(1.51 g, 9.07 mmol) in ethanol (30 mL). After the solution was heated to reflux for 24 h, 
the reaction solution was concentrated in vacuo and diluted with ethyl acetate (30 mL). 
The solution was washed with 5% by mass NaHCO3 aqueous solution (3 × 30 mL) and 
water (3 × 30 mL). After drying the solution with magnesium sulfate, the solution was 
concentrated under reduced pressure to give the title compound as a pale yellow oil (1.42 
g, 7.29 mmol) in 80% yield. 1H NMR (500 MHz, CDCl3): δ 7.64 (d, J = 15 Hz, 1H, Ar-
CH=CH), 7.40 – 7.20 (m, 3H, CHAr), 7.08 (t, J = 11.5 Hz, 1H, CHAr), 6.43 (d, J = 18 Hz, 
1H, Ar-CH=CH), 4.27 (q, J = 11.5 Hz, 2H, OCH2), 1.34 (t, J = 12 Hz, 3H, CH2CH3) ppm. 
13C NMR (75 MHz, CDCl3): δ 166.6 (C=O), 163.0 (d, J = 247.5 Hz, CAr), 143.2 (d, J = 
2.25 Hz, Ar-CH=CH), 136.7 (d, J = 0.75 Hz, CAr), 130.4 (d, J = 8.25 Hz, CHAr), 124.0 
(d, J = 1.5 Hz, CHAr), 119.7 (Ar-CH=CH), 117.1 (d, J = 21 Hz, CHAr), 114.3 (d, J = 21.8 
Hz, CHAr), 60.7 (OCH2), 14.3 (CH3) ppm. IR (Neat): 1708 cm-1. HRMS (ASAP) m/z: [M 
+ H]+ Calcd for C11H12O2F 195.0821; Found 195.0821. 1H NMR data consistent with 
literature and the compound is commercially available.50 
 
Ethyl (E)-3-(p-tolyl)-2-propenoate (59e) 
 
Concentrated sulfuric acid (~ 1 mL) was added to a solution of 4-methylcinnamic acid 
(1.50 g, 9.26 mmol) in ethanol (31 mL). After heating to reflux for 24 h, the reaction 
solution was concentrated in vacuo and diluted with ethyl acetate (30 mL). The solution 
was washed with 5% by mass NaHCO3 aqueous solution (3 × 30 mL) and water (3 × 30 
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mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give the title compound as a colourless oil (1.50 g, 7.86 mmol) 
in 85% yield. 1H NMR (500 MHz, CDCl3): δ 7.66 (d, J = 16 Hz, 1H, Ar-CH=CH), 7.43 
(d, J = 8 Hz, 2H, CHAr), 7.19 (d, J = 8 Hz, 2H, CHAr), 6.39 (d, J = 16 Hz, 1H, Ar-CH=CH), 
4.26 (q, J = 7 Hz, 2H, OCH2), 2.37 (s, 3H, Ar-CH3), 1.34 (t, J = 10 Hz, 3H, CH2CH3) 
ppm. 1H NMR data consistent with literature.51 
 
Ethyl (E)-3-(p-methoxyphenyl)-2-propenoate (59f) 
 
Concentrated sulfuric acid (~ 1 mL) was added to a solution of 4-methoxycinnamic acid 
(2.01 g, 11.3 mmol) in ethanol (35 mL). After heating to reflux for 24 h, the reaction 
solution was concentrated in vacuo and diluted with ethyl acetate (35 mL). The solution 
was washed with 5% by mass NaHCO3 aqueous solution (3 × 30 mL) and water (3 × 30 
mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give the title compound as a colourless oil (2.20 g, 10.7 mmol) 
in 95% yield. 1H NMR (500 MHz, CDCl3): δ 7.64 (d, J = 16 Hz, 1H, Ar-CH=CH), 7.48 
(d, J = 8.5 Hz, 2H, CHAr), 6.90 (d, J = 8.5 Hz, 2H, CHAr), 6.31 (d, J = 16 Hz, 1H, Ar-
CH=CH), 4.25 (q, J = 7.5 Hz, 2H, OCH2), 3.84 (s, 3H, OCH3), 1.33 (t, J = 7 Hz, 3H, 
CH2CH3) ppm. 1H NMR data are consistent with literature.52 
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Ethyl (E)-3-(p-bromophenyl)-2-propenoate (59g) 
 
Concentrated sulfuric acid (~ 1 mL) was added to a solution of 4-bromocinnamic acid 
(3.40 g, 15.0 mmol) in ethanol (50 mL). After heating to reflux for 24 h, the reaction 
solution was concentrated in vacuo and diluted with ethyl acetate (50 mL). The solution 
was washed with 5% by mass NaHCO3 aqueous solution (3 × 30 mL) and water (3 × 30 
mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give a mixture of colourless oil and white precipitate. After 
hexane was added to the mixture, the colourless oil was dissolved in the solvent while the 
precipitate remained insoluble. After filtering the suspension, the filtrate was 
concentrated in vacuo to give the title compound as a pale yellow oil (3.48 g, 13.6 mmol) 
in 91% yield. 1H NMR (300 MHz, CDCl3): δ 7.61 (d, J = 15.9 Hz, 1H, Ar-CH=CH), 7.52 
(d, J = 8.4 Hz, 2H, CHAr), 7.38 (d, J = 8.4 Hz, 2H, CHAr), 6.42 (d, J = 16.2 Hz, 1H, Ar-
CH=CH), 4.27 (q, J = 7.2 Hz, 2H, OCH2), 1.34 (t, J = 7.2 Hz, 3H, CH2CH3) ppm. 1H 
NMR data are consistent with literature.53 
 
3.5.2 Corey–Chaykovsky cyclopropanation of ethyl cinnamates 
Ethyl 2-(o-tolyl)cyclopropane-1-carboxylate (60b) 
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A suspension of trimethylsulfoxonium iodide (2.94 g, 13.4 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 544 mg, 13.6 mmol, 1.2 equiv) in anhydrous DMSO (10 
mL) were stirred for 1 h before the addition of 59b (2.12 g, 11.1 mmol, 1 equiv) in 
anhydrous DMSO (10 mL). After the reaction was heated at 55 °C for 24 h, another 
suspension of trimethylsulfoxonium iodide (0.750 g, 3.41 mmol, 0.3 equiv) and sodium 
hydride (60% in mineral oil, 137 mg, 3.43 mmol, 0.3 equiv) in anhydrous DMSO (2.5 
mL) was stirred for 1 h and added to the reaction solution. The reaction was then heated 
at 65 °C overnight before it was poured into brine solution (50 mL) and extracted with 
ethyl acetate (4 × 30 mL). The combined organic extracts were washed with water (50 
mL) and brine solution (50 mL). After drying with magnesium sulfate, the solution was 
concentrated under reduced pressure to give a mixture of yellow oil and brown precipitate 
which was later subjected to column chromatography twice (5% ethyl acetate/hexane). 
The title compound was collected as a pale yellow oil (1.39 g, 6.78 mmol) in 61% yield. 
1H NMR (500 MHz, CDCl3): δ 7.15 – 7.11 (m, 3H, CHAr), 7.00 (d, J = 6 Hz, 1H, CHAr), 
4.25 – 4.15 (m, 2H, OCH2), 2.53 – 2.49 (m, 1H, CH-Ar), 2.38 (s, 3H, Ar-CH3), 1.78 (ddd, 
J = 8.6, 4.5, 4.5 Hz, 1H, CH-COOEt), 1.59 – 1.56 (m, 1H, CH2-CHCOOEt), 1.32 – 1.28 
(m, 4H, CH2-CHCOOEt and CH2CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 174.0 (C=O), 
138.1 (CAr), 138.0 (CAr), 130.0 (CHAr), 126.8 (CHAr), 126.0 (CHAr), 126.0 (CHAr), 60.8 
(OCH2), 24.8 (CH-Ar), 22.5 (CH-COOEt), 19.7 (Ar-CH3), 15.5 (CH2-CHCOOEt), 14.5 
(CH2CH3) ppm. IR (Neat): 2923, 1724 cm-1. HRMS (ASAP) m/z: [M + H]+ Calcd for 




Ethyl 2-(m-methoxyphenyl)cyclopropane-1-carboxylate (60c) 
 
A suspension of trimethylsulfoxonium iodide (2.69 g, 12.2 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 498 mg, 12.4 mmol, 1.2 equiv) in anhydrous DMSO (10 
mL) were stirred for 1 h before the addition of 59c (2.08 g, 10.1 mmol, 1 equiv) in 
anhydrous DMSO (10 mL). After the reaction was heated at 55 °C for 24 h, the reaction 
solution was poured into brine solution (50 mL) and extracted with ethyl acetate (3 × 30 
mL). The combined organic extracts were washed with water (2 × 20 mL) and brine 
solution (2 × 20 mL). After drying with magnesium sulfate, the solution was concentrated 
under reduced pressure to give a yellow oil crude which was later subjected to column 
chromatography (10% ethyl acetate/hexane). The title compound was collected as a 
colourless oil (809 mg, 3.67 mmol) in 36% yield. 1H NMR (500 MHz, CDCl3): δ 7.19 (t, 
J = 8 Hz, 1H, CHAr), 6.74 (d, J = 8 Hz, 1H, CHAr), 6.69 (d, J = 7.5 Hz, 1H, CHAr), 6.65 
(s, 1H, CHAr), 4.17 (q, J = 7 Hz, 2H, OCH2), 3.79 (s, 3H, OCH3), 2.51 – 2.47 (m, 1H, 
CH-Ar), 1.90 (ddd, J = 8.4, 4.5, 4.5 Hz, 1H, CH-COOEt), 1.60 – 1.57 (m, 1H, CH2-
CHCOOEt), 1.32 – 1.26 (m, 4H, CH2-CHCOOEt and CH2CH3) ppm. 1H NMR data are 
consistent with literature.28  
 
Ethyl 2-(m-fluorophenyl)cyclopropane-1-carboxylate (60d) 
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A suspension of trimethylsulfoxonium iodide (1.93 g, 8.78 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 355 mg, 8.87 mmol, 1.2 equiv) in anhydrous DMSO (7.5 
mL) were stirred for 1 h before the addition of 59d (1.42 g, 7.29 mmol, 1 equiv) in 
anhydrous DMSO (7.5 mL). After heating at 55 °C for 24 h, the reaction solution was 
poured into brine solution (45 mL) and extracted with ethyl acetate (3 × 30 mL). The 
combined organic extracts were washed with water (4 × 20 mL) and brine solution (2 × 
20 mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give a yellow oil crude which was later subjected to column 
chromatography (5% ethyl acetate/hexane). The title compound was collected as a 
colourless oil (650 mg, 3.12 mmol) in 43% yield. 1H NMR (500 MHz, CDCl3): δ 7.26 – 
7.21 (m, 1H, CHAr), 6.91 – 6.87 (m, 2H, CHAr), 6.78 (d, J = 10 Hz, 1H, CHAr), 4.17 (q, J 
= 7 Hz, 2H, OCH2), 2.52 – 2.48 (m, 1H, CH-Ar), 1.92 – 1.88 (m, 1H, CH-COOEt), 1.63 
– 1.59 (m, 1H, CH2-CHCOOEt), 1.28 (t, J = 7 Hz, 4H, CH2-CHCOOEt and CH2CH3) 
ppm. 13C NMR (125 MHz, CDCl3): δ 172.7 (C=O), 162.8 (d, J = 245 Hz, CAr), 142.8 (d, 
J = 7.5 Hz, CAr), 129.7 (d, J = 8.8 Hz, CHAr), 121.8 (d, J = 2.5 Hz, CHAr), 113.1 (d, J = 
21.3 Hz, CHAr), 112.7 (d, J = 22.5 Hz, CHAr), 60.5 (OCH2), 25.5 (d, J = 1.3 Hz, CH-Ar), 
24.1 (CH-COOEt), 16.9 (CH2-CHCOOEt), 14.0 (CH2CH3) ppm. IR (Neat): 1718 cm-1. 
HRMS (ESI) m/z: [M + H]+ Calcd for C12H14FO2 209.09778; Found 209.09770.  
 
Ethyl 2-(p-tolyl)cyclopropane-1-carboxylate (60e) 
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A suspension of trimethylsulfoxonium iodide (1.30 g, 5.89 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 243 mg, 6.07 mmol, 1.2 equiv) in anhydrous DMSO (5 mL) 
were stirred for 1 h before the addition of 59e (932 mg, 4.90 mmol, 1 equiv) in anhydrous 
DMSO (5 mL). After the reaction was heated at 55 °C for 5 h, the reaction solution was 
poured into brine solution (30 mL) and extracted with ethyl acetate (3 × 20 mL). The 
combined organic extracts were washed with water (2 × 30 mL) and brine solution (30 
mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give a yellow oil crude which was later subjected to column 
chromatography (5% ethyl acetate/hexane). The title compound was collected as a 
colourless oil (481 mg, 2.35 mmol) in 48% yield. 1H NMR (300 MHz, CDCl3): δ 7.09 
(d, J = 7.8 Hz, 2H, CHAr), 6.99 (d, J = 8.1 Hz, 2H, CHAr), 4.16 (q, J = 7.2 Hz, 2H, OCH2), 
2.52 – 2.45 (m, 1H, CH-Ar), 2.31 (s, 3H, Ar-CH3), 1.86 (ddd, J = 8.7, 4.7, 4.2 Hz, 1H, 
CH-COOEt), 1.60 – 1.53 (m, 1H, CH2-CHCOOEt), 1.27 (t, J = 7.2 Hz, 4H, CH2-
CHCOOEt and CH2CH3) ppm. HRMS (ASAP) m/z: [M + H]+ Calcd for C13H17O2 
205.1229; Found 205.1228. 1H NMR data are consistent with literature.28 
 
Ethyl 2-(p-methoxyphenyl)cyclopropane-1-carboxylate (60f) 
 
A suspension of trimethylsulfoxonium iodide (2.83 g, 12.8 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 537 mg, 13.4 mmol, 1.3 equiv) in anhydrous DMSO (10 
mL) were stirred for 1 h before the addition of 59f (2.21 g, 10.7 mmol, 1 equiv) in 
anhydrous DMSO (10 mL). After the reaction was heated at 55 °C for 24 h, another 
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suspension of trimethylsulfoxonium iodide (0.750 g, 3.41 mmol, 0.3 equiv) and sodium 
hydride (60% in mineral oil, 137 mg, 3.43 mmol, 0.3 equiv) in anhydrous DMSO (2.5 
mL) was stirred for 1 h and added to the reaction solution. The reaction was then heated 
at 65 °C for 84 h before it was poured into brine solution (60 mL) and extracted with ethyl 
acetate (4 × 30 mL). The combined organic extracts were washed with water (50 mL) and 
brine solution (50 mL). After drying the solution with magnesium sulfate, the solution 
was concentrated under reduced pressure to give an orange-yellow solid crude which was 
later subjected to column chromatography (10% ethyl acetate/hexane). The title 
compound was collected as a white solid (919 mg, 4.17 mmol) in 39% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.03 (d, J = 8.5 Hz, 2H, CHAr), 6.82 (d, J = 9 Hz, 2H, CHAr), 4.16 
(q, J = 7 Hz, 2H, OCH2), 3.78 (s, 3H, OCH3), 2.50 – 2.46 (m, 1H, CH-Ar), 1.82 (ddd, J 
= 8.5, 4.8, 5 Hz, 1H, CH-COOEt), 1.57 – 1.53 (m, 1H, CH2-CHCOOEt), 1.29 – 1.23 (m, 
4H, CH2-CHCOOEt and CH2CH3) ppm. HRMS (ASAP) m/z: [M + H]+ Calcd for 
C13H17O3 221.1178; Found 221.1179. 1H NMR data are consistent with literature.28 
 
Ethyl 2-(p-bromophenyl)cyclopropane-1-carboxylate (60g) 
 
A suspension of trimethylsulfoxonium iodide (3.61 g, 16.4 mmol, 1.2 equiv) and sodium 
hydride (60% in mineral oil, 664 mg, 16.6 mmol, 1.2 equiv) in anhydrous DMSO (12 
mL) were stirred for 1 h before the addition of 59g (3.48 g, 13.6 mmol, 1 equiv) in 
anhydrous DMSO (12 mL). After the reaction was heated at 60 °C for 36 h, the reaction 
solution was poured into brine solution (50 mL) and extracted with ethyl acetate (4 × 30 
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mL). The combined organic extracts were washed with water (50 mL) and brine solution 
(50 mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give a brown oil crude which was later subjected to column 
chromatography (10% ethyl acetate/hexane). The title compound was collected as a 
colourless oil (1.52 g, 5.64 mmol) in 41% yield. 1H NMR (500 MHz, CDCl3): δ 7.39 (d, 
J = 8 Hz, 2H, CHAr), 6.97 (d, J = 8 Hz, 2H, CHAr), 4.17 (q, J = 7 Hz, 2H, OCH2), 2.49 – 
2.45 (m, 1H, CH-Ar), 1.86 (ddd, J = 8.4, 4.5, 4.5 Hz, 1H, CH-COOEt), 1.60 (ddd, J = 
9.3, 4.8, 5 Hz, 1H, CH2-CHCOOEt), 1.29 – 1.25 (m, 4H, CH2-CHCOOEt and CH2CH3) 
ppm. HRMS (ASAP) m/z: [M + H]+ Calcd for C12H14O2Br 269.0177; Found 269.0164. 
1H NMR data are consistent with literature.28 
 
3.5.3 Basic hydrolysis of esters 
2-(o-Tolyl)cyclopropane-1-carboxylic acid (61b) 
 
Sodium hydroxide solution (1 M, 9.5 mL, 9.5 mmol, 2 equiv) was added to a solution of 
60b (1.00 g, 4.91 mmol, 1 equiv) in ethanol (18 mL). After the solution was left stirring 
overnight at room temperature, hydrochloric acid solution (2 M, 7.10 mL, 14.2 mmol, 3 
equiv) and water (5 mL) were added at 0 °C. The solution was extracted with ethyl acetate 
(50 mL + 2 × 30 mL) and washed with brine solution (2 × 30 mL). After drying the 
solution with magnesium sulfate, the solution was concentrated under reduced pressure 
to give the title compound as a white solid (816 mg, 4.63 mmol) in 94% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.18 – 7.12 (m, 3H, CHAr), 7.01 (d, J = 7 Hz, 1H, CHAr), 2.63 – 
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2.59 (m, 1H, CH-Ar), 2.41 (s, 3H, CH3), 1.81 – 1.77 (m, 1H, CH-COOH), 1.65 (ddd, J = 
9.1, 4.5, 5.0 Hz, 1H, CH2), 1.43 – 1.39 (m, 1H, CH2) ppm. 13C NMR (125 MHz, CDCl3): 
δ 180.4 (C=O), 138.1 (CAr), 137.3 (CAr), 130.0 (CHAr), 127.0 (CHAr), 126.0 (CHAr), 126.0 
(CHAr), 25.6 (CH-Ar), 22.3 (CH-COOH), 19.6 (Ar-CH3), 16.0 (CH2) ppm. IR (Neat): 
2926, 1685 cm-1. HRMS (ASAP) m/z: [M + H]+ Calcd for C11H13O2 177.0916; Found 
177.0944. Melting point: 67.3 – 69.7 °C. 
 
2-(m-Methoxyphenyl)cyclopropane-1-carboxylic acid (61c) 
 
Sodium hydroxide solution (1 M, 7.35 mL, 7.35 mmol, 2 equiv) was added to a solution 
of 60c (808 mg, 3.67 mmol, 1 equiv) in ethanol (14 mL). After the solution was left 
stirring overnight at room temperature, hydrochloric acid solution (2 M, 5.5 mL, 11 
mmol, 3 equiv) and water (8.5 mL) were added to the reaction solution at 0 °C. The 
solution was extracted with ethyl acetate (55 mL + 2 × 30 mL) and washed with brine 
solution (2 × 30 mL). After drying the solution with magnesium sulfate, the solution was 
concentrated under reduced pressure to give the title compound as a white solid (690 mg, 
3.59 mmol) in 98% yield. 1H NMR (500 MHz, CDCl3): δ 7.20 (t, J = 8 Hz, 1H, CHAr), 
6.76 (d, J = 8 Hz, 1H, CHAr), 6.69 (d, J = 7.5 Hz, 1H, CHAr), 6.65 (s, 1H, CHAr), 3.79 (s, 
3H, OCH3), 2.60 – 2.56 (m, 1H, CH-Ar), 1.90 (ddd, J = 8.4, 4.5, 4.5 Hz, 1H, CH-COOH), 
1.65 (ddd, J = 9.5, 4.5, 5.0 Hz, 1H, CH2), 1.41 – 1.37 (m, 1H, CH2) ppm. 13C NMR (125 
MHz, CDCl3): δ 179.7 (C=O), 159.8 (CAr), 141.2 (CAr), 129.6 (CHAr), 118.6 (CHAr), 
112.3 (CHAr), 112.0 (CHAr), 56.2 (OCH3), 27.1 (CH-Ar), 24.0 (CH-COOH), 17.5 (CH2) 
159 
ppm. IR (Neat): 2934, 1684 cm-1. HRMS (ESI) m/z: [M - H]- Calcd for C11H11O3 
191.0708; Found 191.0699. Melting point: 94.3 – 95.1 °C. 
 
2-(m-Fluorophenyl)cyclopropane-1-carboxylic acid (61d) 
 
Sodium hydroxide solution (1 M, 5.1 mL, 5.1 mmol, 2 equiv) was added to a solution of 
60d (529 mg, 2.54 mmol, 1 equiv) in ethanol (45 mL). After the solution was left stirring 
overnight at room temperature, hydrochloric acid solution (2 M, 3.8 mL, 7.6 mmol, 3 
equiv) and water (5 mL) were added to the reaction solution at 0 °C. The solution was 
extracted with ethyl acetate (80 mL + 2 × 20 mL) and washed with brine solution (2 × 40 
mL). After drying the solution with magnesium sulfate, the solution was concentrated 
under reduced pressure to give the title compound as a white solid (367 mg, 2.04 mmol) 
in 80% yield. 1H NMR (500 MHz, CDCl3): δ 7.24 (d, J = 6.5 Hz, 1H, CHAr), 6.92 – 6.89 
(m, 2H, CHAr), 6.79 (d, J = 10 Hz, 1H, CHAr), 2.61 – 2.57 (m, 1H, CH-Ar), 1.90 (ddd, J 
= 8.4, 4.5, 4.5 Hz, 1H, CH-COOH), 1.67 (ddd, J = 9.6, 4.8, 5.0 Hz, 1H, CH2), 1.40 – 1.36 
(m, 1H, CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 179.5 (C=O), 163.0 (d, J = 244 Hz, 
CAr), 142.2 (d, J = 7.5 Hz, CAr), 130.0 (d, J = 7.5 Hz, CHAr), 122.1 (d, J = 3.8 Hz, CHAr), 
113.7 (d, J = 21.3 Hz, CHAr), 113.2 (d, J = 22.5 Hz, CHAr), 26.6 (d, J = 2.5 Hz, CH-Ar), 
24.1 (CH-COOH), 17.5 (CH2) ppm. IR (Neat): 1685 cm-1. HRMS (ESI) m/z: [M - H]- 
Calcd for C10H8FO2 179.05083; Found 179.05068. Melting point: 78.9 – 79.9 °C. 
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2-(p-Tolyl)cyclopropane-1-carboxylic acid (61e) 
 
Sodium hydroxide solution (1 M, 4.7 mL, 4.7 mmol, 2 equiv) was added to a solution of 
60e (477 mg, 2.33 mmol) in ethanol (43 mL). After the solution was left stirring overnight 
at room temperature, hydrochloric acid solution (2 M, 3.6 mL, 7.2 mmol) and water (21 
mL) were added to the reaction solution at 0 °C. The solution was extracted with ethyl 
acetate (80 mL + 2 × 40 mL) and washed with brine solution (30 mL). After drying the 
solution with magnesium sulfate, the solution was concentrated under reduced pressure 
to give the title compound as a white solid (344 mg, 1.95 mmol) in 84% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.10 (d, J = 7.5 Hz, 2H, CHAr), 7.01 (d, J = 8 Hz, 2H, CHAr), 2.59 
– 2.55 (m, 1H, CH-Ar), 2.32 (s, 3H, CH3), 1.87 (ddd, J = 8.4, 4.5, 4.5 Hz, 1H, CH-
COOH), 1.63 (ddd, J = 9.3, 4.8, 5 Hz, 1H, CH2), 1.39 – 1.35 (m, 1H, CH2) ppm. Melting 
point: 113.0 – 116.4 °C. 1H NMR data are consistent with literature.54  
 
2-(p-Methoxyphenyl)cyclopropane-1-carboxylic acid (61f) 
 
Sodium hydroxide solution (1 M, 8.5 mL, 8.5 mmol, 2 equiv) was added to a solution of 
60f (918 mg, 4.17 mmol, 1 equiv) in ethanol (15 mL). After the solution was left stirring 
overnight at room temperature, hydrochloric acid solution (2 M, 6.40 mL, 12.8 mmol, 3 
quiv) and water (9 mL) were added at 0 °C. The solution was extracted with ethyl acetate 
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(50 mL + 2 × 30 mL) and washed with brine solution (2 × 30 mL). After drying the 
solution with magnesium sulfate, the solution was concentrated under reduced pressure 
to give the title compound as a white solid (791 mg, 4.12 mmol) in 99% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.05 (d, J = 8.5 Hz, 2H, CHAr), 6.83 (d, J = 9 Hz, 2H, CHAr), 3.79 
(s, 3H, OCH3), 2.59 – 2.55 (m, 1H, CH-Ar), 1.83 (ddd, J = 8.4, 4.5, 4.5 Hz, 1H, CH-
COOH), 1.62 (ddd, J = 9.5, 4.8, 4.5 Hz, 1H, CH2), 1.37 – 1.34 (m, 1H, CH2) ppm. Melting 
point: 109.9 – 113.3 °C. 1H NMR data are consistent with literature.54  
 
2-(p-Bromophenyl)cyclopropane-1-carboxylic acid (61g)55 
 
Sodium hydroxide solution (1 M, 6.9 mL, 6.9 mmol, 2 equiv) was added to a solution of 
60g (922 mg, 3.43 mmol, 1 equiv) in ethanol (12 mL). After the solution was left stirring 
overnight at room temperature, hydrochloric acid solution (2 M, 5.20 mL, 10.4 mmol, 3 
equiv) and water (5 mL) were added to the reaction solution at 0 °C. The solution was 
extracted with ethyl acetate (3 × 30 mL) and washed with brine solution (2 × 30 mL). 
After drying the solution with magnesium sulfate, the solution was concentrated under 
reduced pressure to give the title compound as a white solid (823.1 mg, 3.41 mmol) in 
100% yield. 1H NMR (500 MHz, CDCl3): δ 7.41 (d, J = 8.5 Hz, 2H, CHAr), 6.98 (d, J = 
8 Hz, 2H, CHAr), 2.57 – 2.53 (m, 1H, CH-Ar), 1.88 (ddd, J = 8.2, 4.2, 4.0 Hz, 1H, CH-
COOH), 1.66 (ddd, J = 9.2, 4.8, 5.0 Hz, 1H, CH2), 1.39 – 1.35 (m, 1H, CH2) ppm. 13C 
NMR (75 MHz, CDCl3): δ 179.3 (C=O), 138.8 (CAr), 131.7 (CHAr), 128.2 (CHAr), 120.5 
(CAr), 26.5 (CH-Ar), 24.2 (CH-COOH), 17.5 (CH2) ppm. IR (Neat): 2923, 1681 cm-1. 
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HRMS (ASAP) m/z: [M + H]+ Calcd for C10H10O2Br 240.9864; Found 240.9865. 
Melting point: 118.5 – 122.4 °C. 
 
3.5.4 Curtius rearrangement of carboxylic acids with t-BuOH + Deprotection of Boc-
group 
2-(o-Tolyl)cyclopropylamine hydrochloride (62b) 
 
Diphenyl phosphoryl azide (1.10 mL, 1.38 g, 5.02 mmol, 1.2 equiv), triethylamine (0.950 
mL, 0.692 g, 6.84 mmol, 1.6 equiv) and tert-butanol (8.80 mL, 6.76 g, 91.2 mmol, 21 
equiv) were added to a solution of 61b (749 mg, 4.25 mmol, 1 equiv) in dry toluene (25 
mL). After the reaction was heated at 82 °C for 24 h, di-tert-butyl dicarbonate (1.15 g, 
5.29 mmol, 1.2 equiv) was added and the reaction solution was allowed to stir for another 
1.5 h before concentrating it under reduced pressure. The crude mixture was subjected to 
column chromatography (15% ethyl acetate/hexane) to give the intermediate tert-butyl 
(2-(o-tolyl)cyclopropyl)carbamate as a yellowish white solid (502 mg, 2.03 mmol). 1H 
NMR (300 MHz, CDCl3): δ 7.12 – 7.05 (m, 4H), 4.82 (bs, 1H), 2.78 (bs, 1H), 2.41 (s, 
3H), 2.02 – 1.97 (m, 1H), 1.47 (s, 9H), 1.15 – 1.11 (m, 2H) ppm. Trifluoroacetic acid (5 
mL) was added to a solution of tert-butyl (2-(o-tolyl)cyclopropyl)carbamate (495 mg, 
2.00 mmol) in dichloromethane (1 mL). After the solution was stirred for 30 mins, solvent 
was removed under reduced pressure and ethereal HCl (1 M, 7 mL, 7 mmol, 3.5 equiv) 
was added to precipitate the product. Solvent was carefully removed using a glass pasteur 
pipette and the precipitate was washed with diethyl ether (3 × 10 mL). The title compound 
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was collected as a yellow solid (344 mg, 1.87 mmol) in 45% yield after two consecutive 
steps. 1H NMR (500 MHz, DMSO): δ 8.72 (br s, 3H, NH3+), 7.16 (bs, 1H, CHAr), 7.12 – 
7.09 (m, 2H, CHAr), 6.98 (d, J = 6 Hz, 1H, CHAr), 2.68 (bs, 1H, CH-NH3+), 2.46 (m, 1H, 
CH-Ar), 2.38 (s, 3H, CH3), 1.39 – 1.35 (m, 1H, CH2), 1.20 – 1.16 (m, 1H, CH2) ppm. 13C 
NMR (125 MHz, DMSO): δ 137.2 (CAr), 136.9 (CAr), 129.6 (CHAr), 126.5 (CHAr), 125.9 
(CHAr), 125.6 (CHAr), 29.6 (CH-NH3+), 19.5 (CH3), 18.9 (CH-Ar), 11.4 (CH2) ppm. IR 
(Neat): 2898 cm-1. HRMS (ESI) m/z: [M + H]+ Calcd for C10H14N 148.1126; Found 
148.1130. Melting point: 173.7 – 175.4 °C. 
 
2-(m-Methoxyphenyl)cyclopropylamine hydrochloride (62c)56 
 
Diphenyl phosphoryl azide (0.850 mL, 1.09 g, 3.95 mmol, 1.2 equiv), triethylamine 
(0.750 mL, 0.545 g, 5.38 mmol, 1.7 equiv) and tert-butanol (7.00 mL, 5.43 g, 73.2 mmol, 
22 equiv) were added to a solution of 61c (627 mg, 3.26 mmol, 1 equiv) in dry toluene 
(20 mL). After the reaction was heated at 82 °C for 24 h, di-tert-butyl dicarbonate (1.06 
g, 4.88 mmol, 1.5 equiv) was added and the reaction solution was allowed to stir for 
another 2 h before concentrating it under reduced pressure. The crude mixture was 
subjected to rapid column chromatography (20% ethyl acetate/hexane) to give the 
intermediate tert-butyl (2-(m-methoxyphenyl)cyclopropyl)carbamate as a white solid 
(459 mg, 1.74 mmol). 1H NMR (500 MHz, CDCl3): δ 7.17 (t, J = 8 Hz, 1H), 6.72 (d, J = 
8 Hz, 2H), 6.65 (bs, 1H), 4.82 (bs, 1H), 3.78 (s, 3H), 2.74 (bs, 1H), 2.03 – 1.99 (m, 1H), 
1.45 (s, 9H), 1.17 – 1.15 (m, 2H) ppm. Trifluoroacetic acid (3 mL) was added to a solution 
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of tert-butyl (2-(m-methoxyphenyl)cyclopropyl)carbamate (458 mg, 1.74 mmol, 1 equiv) 
in dichloromethane (2 mL). After the solution was stirred for 50 mins, solvent was 
removed under reduced pressure and ethereal HCl (1 M, 6 mL, 6 mmol, 3.4 equiv) was 
added to precipitate the product. Solvent was carefully removed using a glass pasteur 
pipette and the precipitate was washed with diethyl ether (4 × 10 mL). The title compound 
was collected as a sandy brown solid (330 mg, 1.65 mmol) in 50% yield after two 
consecutive steps. 1H NMR (300 MHz, DMSO): δ 8.68 (br s, 3H, NH3+), 7.19 (t, J = 7.8 
Hz, 1H, CHAr), 6.77 – 6.70 (m, 3H, CHAr), 3.73 (s, 3H, OCH3), 2.77 (bs, 1H, CH-NH3+), 
2.35 (bs, 1H, CH-Ar), 1.45 – 1.39 (m, 1H, CH2), 1.22 – 1.15 (m, 1H, CH2) ppm. 13C 
NMR (75 MHz, DMSO): δ 159.4 (CAr), 140.9 (CAr), 129.4 (CHAr), 118.5 (CHAr), 111.9 
(CHAr), 111.8 (CHAr), 55.0 (OCH3), 30.5 (CH-NH3+), 20.8 (CH-Ar), 13.2 (CH2) ppm. IR 
(Neat): 3065, 2958, 2870 cm-1. HRMS (ESI) m/z: [M + H]+ Calcd for C10H14ON 
164.1075; Found 164.1076. Melting point: 146.5 – 147.8 °C. 
 
2-(m-Fluorophenyl)cyclopropylamine hydrochloride (62d) 
 
Diphenyl phosphoryl azide (0.500 mL, 613 mg, 2.23 mmol, 1.2 equiv), triethylamine 
(0.420 mL, 308 mg, 3.04 mmol, 1.6 equiv) and tert-butanol (3.90 mL, 3.00 g, 40.5 mmol, 
22 equiv) were added to a solution of 61d (339 mg, 1.88 mmol, 1 equiv) in dry toluene 
(11 mL). After the reaction was heated at 82 °C for 22 h, di-tert-butyl dicarbonate (670 
mg, 3.07 mmol, 1.6 equiv) was added and the reaction solution was allowed to stir for 
another 2 h before concentrating it under reduced pressure. The crude mixture was 
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subjected to column chromatography (15% ethyl acetate/hexane) to give the intermediate 
tert-butyl (2-(m-fluorophenyl)cyclopropyl)carbamate as a white solid (203 mg, 0.809 
mmol). 1H NMR (500 MHz, CDCl3): δ 7.21 (q, J = 6.5 Hz, 1H), 6.92 (d, J = 7.5 Hz, 1H), 
6.87 – 6.80 (m, 2H), 4.84 (bs, 1H), 2.71 (bs, 1H), 2.05 – 2.02 (m, 1H), 1.45 (s, 9H), 1.16 
(t, J = 7.5 Hz, 2H) ppm. Trifluoroacetic acid (2 mL) was added to a solution of tert-butyl 
(2-(m-fluorophenyl)cyclopropyl)carbamate (203 mg, 0.809 mmol, 1 equiv) in 
dichloromethane (3 mL). After the solution was stirred for 30 mins, solvent was removed 
under reduced pressure and ethereal HCl (1 M, 4 mL, 4 mmol, 4.9 equiv) was added to 
precipitate the product. Solvent was carefully removed using a glass pasteur pipette and 
the precipitate was washed with diethyl ether (3 × 10 mL). The title compound was 
collected as a white solid (146 mg, 0.776 mmol) in 41% yield after two consecutive steps. 
1H NMR (300 MHz, DMSO): δ 8.72 (br s, 3H, NH3+), 7.32 (q, J = 6 Hz, 1H, CHAr), 7.02 
(t, J = 6.9 Hz, 3H, CHAr), 2.84 – 2.79 (m, 1H, CH-NH3+), 2.45 – 2.38 (m, 1H, CH-Ar), 
1.50 – 1.43 (m, 1H, CH2), 1.23 (m, 1H, CH2) ppm. 13C NMR (125 MHz, DMSO): δ 162.3 
(d, J = 241.3 Hz, CAr), 142.5 (d, J = 7.5 Hz, CAr), 130.2 (d, J = 8.8 Hz, CHAr), 122.7 (d, J 
= 2.5 Hz, CHAr), 113.0 (d, J = 17.5 Hz, CHAr), 112.9 (d, J = 18.8 Hz, CHAr), 30.7 (CH-
NH3+), 20.5 (d, J = 2.5 Hz, CH-Ar), 13.5 (CH2) ppm. IR (Neat): 2990, 2945, 2863, cm-1. 
HRMS (ASAP) m/z: [M + H]+ Calcd for C9H11NF 152.0876; Found 152.0906. Melting 
point: 173.8 – 175.4 °C 
 
2-(p-Tolyl)cyclopropylamine hydrochloride (62e) 
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Diphenyl phosphoryl azide (0.500 mL, 0.640 g, 2.33 mmol, 1.2 equiv), triethylamine 
(0.410 mL, 298 mg, 2.94 mmol, 1.6 equiv) and tert-butanol (3.80 mL, 2.95 g, 39.7 mmol, 
21 equiv) were added to a solution of 61e (331 mg, 1.88 mmol, 1 equiv) in dry toluene 
(11 mL). After the reaction was heated at 82 °C for 24 h, di-tert-butyl dicarbonate (647 
mg, 2.96 mmol, 1.6 equiv) was added and the reaction solution was allowed to stir for 
another 2 h before concentrating it under reduced pressure. The crude mixture was 
subjected to column chromatography (15% ethyl acetate/hexane) to give the intermediate 
tert-butyl (2-(p-tolyl)cyclopropyl)carbamate as a white solid (228 mg, 0.921 mmol). 1H 
NMR (500 MHz, CDCl3): δ 7.07 (d, J = 8 Hz, 2H), 7.02 (d, J = 7.5 Hz, 2H), 4.84 (bs, 
1H), 2.69 (bs, 1H), 2.30 (s, 3H), 2.02 – 1.98 (m, 1H), 1.45 (s, 9H), 1.14 – 1.12 (m, 2H) 
ppm. Trifluoroacetic acid (2 mL) was added to a solution of tert-butyl (2-(p-
tolyl)cyclopropyl)carbamate (216 mg, 0.872 mmol, 1 equiv) in dichloromethane (2 mL). 
After the solution was stirred for 30 mins, solvent was removed under reduced pressure 
and ethereal HCl (1 M, 4 mL, 4 mmol, 4.6 equiv) was added to precipitate the product. 
Solvent was carefully removed using a glass pasteur pipette and the precipitate was 
washed with diethyl ether (2 × 10 mL). The title compound was collected as a yellow 
solid (124 mg, 0.675 mmol) in 38% yield after two consecutive steps. 1H NMR (500 
MHz, DMSO): δ 8.67 (br s, 3H, NH3+), 7.09 (d, J = 7.5 Hz, 2H, CHAr), 7.03 (d, J = 8 Hz, 
2H, CHAr), 2.70 (bs, 1H, CH-NH3+), 2.34 (bs, 1H, CH-Ar), 2.25 (s, 3H, CH3), 1.41 – 1.37 
(m, 1H, CH2), 1.14 – 1.11 (m, 1H, CH2) ppm. 13C NMR (125 MHz, DMSO): δ 136.2 
(CAr), 135.3 (CAr), 128.9 (CHAr), 126.1 (CHAr), 30.4 (CH-NH3+), 20.6 (CH3), 20.4 (CH-
Ar), 13.0 (CH2) ppm. IR (Neat): 2903 cm-1. HRMS (ESI) m/z: [M + H]+ Calcd for 
C10H14N 148.11262; Found 148.11215. Melting point: 150.2 – 155.5 °C. 
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2-(p-Methoxyphenyl)cyclopropylamine hydrochloride (62f) 
 
Diphenyl phosphoryl azide (0.970 mL, 1.24 g, 4.51 mmol, 1.2 equiv), triethylamine 
(0.850 mL, 0.620 g, 6.13 mmol, 1.6 equiv) and tert-butanol (7.80 mL, 6.06 g, 81.8 mmol, 
21 equiv) were added to a solution of 61f (746 mg, 3.88 mmol, 1 equiv) in dry toluene 
(24 mL). After the reaction was heated at 82 °C for 24 h, di-tert-butyl dicarbonate (991 
mg, 4.54 mmol, 1.2 equiv) was added and the reaction solution was allowed to stir for 
another 2 h before concentrating it under reduced pressure. The crude mixture was 
subjected to column chromatography (20% ethyl acetate/hexane) to give the intermediate 
tert-butyl (2-(p-methoxyphenyl)cyclopropyl)carbamate as a white solid (608 mg, 2.31 
mmol). 1H NMR (500 MHz, CDCl3): δ 7.08 (d, J = 8 Hz, 2H), 6.81 (d, J = 8 Hz, 2H), 
4.81 (bs, 1H), 3.77 (s, 3H), 2.65 (bs, 1H), 2.00 (bs, 1H), 1.46 (s, 9H), 1.11 – 1.08 (m, 2H) 
ppm. Trifluoroacetic acid (2 mL) was added to a solution of trans-tert-Butyl-2-(p-
methoxyphenyl)cyclopropylcarbamate (0.371 g, 1.41 mmol) in dichloromethane (2 mL). 
After the solution was stirred for 30 mins, solvent was removed under reduced pressure 
and ethereal HCl (1 M, 4 mL, 4 mmol, 2.9 equiv) was added to precipitate the product. 
Solvent was carefully removed using a glass pasteur pipette and the precipitate was 
washed with diethyl ether (5 × 10 mL). The title compound was collected as pale-yellow 
powder (225 mg, 1.13 mmol) in 41% yield after two consecutive steps. 1H NMR (500 
MHz, CD3OD): δ 7.10 (d, J = 8 Hz, 2H, CHAr), 6.86 (d, J = 8 Hz, 2H, CHAr), 3.76 (s, 3H, 
OCH3), 2.76 – 2.75 (m, 1H, CH-NH3+), 2.35 (bs, 1H, CH-Ar), 1.39 – 1.36 (m, 1H, CH2), 
1.25 (q, J = 7 Hz, 1H, CH2) ppm. 13C NMR (125 MHz, CD3OD): δ 160.1 (CAr), 131.6 
(CAr), 128.6 (CHAr), 115.1 (CHAr), 55.7 (OCH3), 31.8 (CH-NH3+), 21.9 (CH-Ar), 13.4 
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(CH2) ppm. IR (Neat): 3128, 3037, 2884 cm-1. Melting point: 176.4 – 179.4 °C. 1H NMR 
data are consistent with literature.50  
 
2-(p-Bromophenyl)cyclopropylamine hydrochloride (62g) 
 
Diphenyl phosphoryl azide (0.800 mL, 1.02 g, 3.72 mmol, 1.5 equiv), triethylamine 
(0.700 mL, 508 mg, 5.02 mmol, 2 equiv) and tert-butanol (6.40 mL, 4.96 g, 66.9 mmol, 
26 equiv) were added to a solution of 61g (612 mg, 2.54 mmol, 1 equiv) in dry toluene 
(20 mL). After the reaction was heated at 82 °C for 24 h, di-tert-butyl dicarbonate (841 
mg, 3.85 mmol, 1.5 equiv) was added and the reaction solution was allowed to stir for 
another 1 h before concentrating it under reduced pressure. The crude mixture was 
subjected to column chromatography (15% ethyl acetate/hexane) to give the intermediate 
tert-butyl (2-(p-bromophenyl)cyclopropyl)carbamate as a white solid (372 mg, 1.19 
mmol). 1H NMR (500 MHz, CDCl3): δ 7.37 (d, J = 7.5 Hz, 2H), 7.02 (d, J = 7.5 Hz, 2H), 
4.81 (bs, 1H), 2.67 (bs, 1H), 2.00 (bs, 1H), 1.45 (s, 9H), 1.15 – 1.12 (bs, 2H) ppm. 
Trifluoroacetic acid (4 mL) was added to a solution of tert-butyl (2-(p-
bromophenyl)cyclopropyl)carbamate (372 mg, 1.19 mmol, 1 equiv) in dichloromethane 
(3 mL). After the solution was stirred for 30 mins, solvent was removed under reduced 
pressure and ethereal HCl (1 M, 5 mL, 5 mmol, 4.2 equiv) was added to precipitate the 
product. Solvent was carefully removed using a glass pasteur pipette and the precipitate 
was washed with diethyl ether (2 × 10 mL). The title compound was collected as an off 
white solid (287 mg, 1.16 mmol) in 46% yield after two consecutive steps. 1H NMR (500 
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MHz, CD3OD): δ 7.45 (d, J = 8 Hz, 2H, CHAr), 7.11 (d, J = 8 Hz, 2H, CHAr), 2.85 (ddd, 
J =7.6, 4, 4 Hz, 1H, CH-NH3+), 2.38 – 2.34 (m, 1H, CH-Ar), 1.46 – 1.42 (m, 1H, CH2), 
1.33 (q, J = 7 Hz, 1H, CH2) ppm. 13C NMR (125 MHz, CD3OD): δ 139.1 (CAr), 132.7 
(CHAr), 129.4 (CHAr), 121.5(CAr), 32.0 (CH-NH3+), 22.1 (CH-Ar), 13.9 (CH2) ppm. IR 
(Neat): 3013, 2884 cm-1. Melting point: 191.0 – 194.7 °C. 1H NMR data are consistent 
with literature.50  
 
3.5.5 Oxidative ring-opening of ferrocenylmethylcyclopropylamines 
N-(Ferrocenylmethyl)-3-hydroxy-3-phenylpropanamide (65a) 
 
Triethylamine (0.130 mL, 94.4 mg, 0.933 mmol, 1.9 equiv) was added to a suspension of 
trans-2-phenylcyclopropylamine hydrochloride (82.2 mg, 0.485 mmol, 1 equiv) and 
magnesium sulfate (219 mg, 1.82 mmol, 3.8 equiv) in dry dichloromethane (4 mL). This 
mixture was stirred for 10 minutes before ferrocenecarboxaldehyde (123 mg, 0.575 
mmol, 1.2 equiv) was added. After 3 hours of stirring, another portion of 
ferrocenecarboxaldehyde (20.0 mg, 93.4 μmol, 0.2 equiv) and one spatula of magnesium 
sulfate were added. The mixture was allowed to stir overnight after which another portion 
of ferrocenecarboxaldehyde (14.4 mg, 67.3 μmol, 0.1 equiv) and a spatula of magnesium 
sulfate were added. After 2 hours of stirring, dry toluene (8 mL) was added to precipitate 
triethylamine hydrochloride and the mixture was filtered. After removal of solvents under 
reduced pressure, more triethylamine hydrochloride precipitated out, therefore dry 
toluene (10 mL) was added and the mixture was filtered again. After removal of solvents, 
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sodium borohydride (45.2 mg, 1.19 mmol, 2.5 equiv) was added to the solution of crude 
imine mixture (213 mg) in dry methanol (5 mL) at −10 °C. After stirring for 15 minutes 
at −10 °C, the reaction was left stirring at room temperature. Another portion of sodium 
borohydride (17.1 mg, 0.452 mmol, 0.9 equiv) was added after 45 mins at −10 °C. After 
stirring for 15 minutes at −10 °C, the reaction solution was left stirring overnight at room 
temperature. The reaction was quenched with water (5 mL) and methanol was evaporated 
under reduced pressure. After the aqueous layer was extracted with ethyl acetate (3 × 10 
mL), the combined organic extracts were washed with brine (10 mL) and dried over 
magnesium sulfate. This crude mixture was subjected to column chromatography (40-
80% ethyl acetate/hexane) which yielded the title compound as a yellow-orange solid 
(77.8 mg, 0.214 mmol) in a 44% overall yield. 1H NMR (500 MHz, CDCl3): δ 7.36 – 
7.25 (m, 5H, CHAr), 6.08 (s, 1H, NH), 5.09 (dd, J = 8.75, 3.5 Hz, 1H, CH-OH), 4.14 – 
4.12 (m, 11H, CH2-NH and CHCp), 2.59 – 2.50 (m, 2H, CH2-CHOH) ppm. 13C NMR 
(125 MHz, CDCl3): δ 171.1 (C=O), 143.1 (CAr), 128.5 (CHAr), 127.7 (CHAr), 125.6 
(CHAr), 84.4 (CCp), 70.9 (CH-OH), 68.6 (CHCp), 68.2 (CHCp), 68.1 (CHCp), 44.7 (CH2-
CHOH), 38.8 (CH2-NH) ppm. IR (Neat): 3300, 1646 cm-1. HRMS (ASAP) m/z: [M]+ 




Triethylamine (0.150 mL, 109 mg, 1.08 mmol, 2 equiv) was added to a suspension of 62b 
(101 mg, 0.550 mmol, 1 equiv) and magnesium sulfate (235 mg) in dry dichloromethane 
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(4 mL). This mixture was stirred for 10 minutes before ferrocenecarboxaldehyde (139 
mg, 0.651 mmol, 1.2 equiv) was added. After 3 hours of stirring, another portion of 
ferrocenecarboxaldehyde (25.8 mg, 0.121 mmol, 0.2 equiv) and one spatula of 
magnesium sulfate were added. The mixture was allowed to stir overnight after which 
another portion of ferrocenecarboxaldehyde (12.1 mg, 56.5 μmol, 0.1 equiv) and a spatula 
of magnesium sulfate were added. After 2 hours of stirring, dry toluene (8 mL) was added 
to precipitate triethylamine hydrochloride and the mixture was filtered. After removal of 
solvents under reduced pressure, more triethylamine hydrochloride precipitated out, 
therefore dry toluene (10 mL) was added and the mixture was filtered again. After 
removal of solvents, sodium borohydride (50.1 mg, 1.32 mmol, 2.4 equiv) was added to 
the solution of crude imine mixture (252 mg) in dry methanol (7 mL) at −10 °C. After 
stirring for 15 minutes at −10 °C, the reaction was left stirring at room temperature. 
Another portion of sodium borohydride (20.9 mg, 0.552 mmol, 1.7 equiv) was added after 
4 h 30 mins at −10 °C. After stirring for 15 minutes at −10 °C, the reaction solution was 
left stirring overnight at room temperature. The reaction was quenched with water (4 mL) 
and methanol was evaporated under reduced pressure. After the aqueous layer was 
extracted with ethyl acetate (3 × 10 mL), the combined organic extracts were washed with 
brine (10 mL) and dried over magnesium sulfate. This crude mixture was subjected to 
column chromatography (40-80% ethyl acetate/hexane) which yielded the title compound 
as a brown-orange solid (46.1 mg, 0.122 mmol) in a 22% overall yield. 1H NMR (500 
MHz, CDCl3): δ 7.47 (d, J = 7.5 Hz, 1H, CHAr), 7.21 – 7.14 (m, 2H, CHAr), 7.10 – 7.09 
(m, 1H, CHAr), 6.29 (bs, 1H, NH), 5.27 (d, J = 9 Hz, 1H, CH-OH), 4.14 – 4.12 (m, 11H, 
CH2-NH and CHCp), 2.50 – 2.40 (m, 2H, CH2-CHOH), 2.29 (s, 3H, CH3) ppm. 13C NMR 
(125 MHz, CDCl3): δ 171.3 (C=O), 141.1 (CAr), 134.1 (CAr), 130.5 (CHAr), 127.5 (CHAr), 
126.5 (CHAr), 125.3 (CHAr), 84.5 (CCp), 68.7 (CHCp), 68.3 (CHCp), 68.3 (CHCp), 67.5 (CH-
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OH), 43.4 (CH2-CHOH), 38.9 (CH2-NH), 19.1 (CH3) ppm. IR (Neat): 3305, 1636 cm-1. 
HRMS (ESI) m/z: [M]+ Calcd for C21H23FeNO2 377.10782; Found 377.10726. Melting 




Magnesium sulfate (231 mg, 1.92mmol, 3.8 equiv) was added to a solution of 62c (101 
mg, 0.506 mmol, 1 equiv) and triethylamine (0.210 ml, 1.51 mmol, 3 equiv) in dry 
dichloromethane (5 mL). This mixture was stirred for 15 mins before 
ferrocenecarboxaldehyde (0.130 g, 0.608 mmol, 1.2 equiv) was added. After 4 h of 
stirring, another portion of ferrocenecarboxaldehyde (19.7 mg, 0.0920 mmol, 0.2 equiv) 
and magnesium sulfate (103 mg, 0.859 mmol, 1.7 equiv) were added. The mixture was 
allowed to stir overnight after which another portion of ferrocenecarboxaldehyde (14.3 
mg, 0.0668 mmol, 0.1 equiv) and a spatula of 4 Å molecular sieves were added. After 2 
h of stirring, dry toluene (10 mL) was added to precipitate triethylamine hydrochloride 
and the mixture was filtered. After removal of solvents under reduced pressure, more 
triethylamine hydrochloride precipitated out, therefore dry toluene (4 mL) was added and 
the mixture was filtered again. After removal of solvents, sodium borohydride (41.1 mg, 
1.09 mmol, 2.2 equiv) was added to the solution of crude imine mixture (240 mg) in dry 
methanol (3 mL) at −10 °C. After stirring for 15 mins at −10 °C, the reaction solution was 
left stirring overnight at room temperature. The reaction was quenched with water (5 mL) 
and methanol was evaporated by purging nitrogen gas through the flask. After the 
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aqueous layer was extracted with ethyl acetate (3 × 15 mL), the combined organic extracts 
were washed with brine (5 mL) and dried over magnesium sulfate. This crude mixture 
was subjected to column chromatography (40-80% ethyl acetate/hexane) which yielded 
the title compound as a brownish orange solid (112 mg, 0.284 mmol) in a 56% overall 
yield. 1H NMR (500 MHz, CDCl3): δ 7.26 – 7.23 (m, 1H, CHAr), 6.94 – 6.91 (m, 2H, 
CHAr), 6.81 (d, J = 8 Hz, 1H, CHAr), 6.05 (bs, 1H, NH), 5.08 – 5.07 (m, 1H, CH-OH), 
4.15 – 4.13 (m, 11H, CH2-NH and CHCp), 3.80 (s, 3H, OCH3), 2.56-2.54 (m, 2H, CH2-
CHOH) ppm. 13C NMR (125 MHz, CDCl3): δ 171.2 (C=O), 160.0 (CAr), 145.0 (CAr), 
129.8 (CHAr), 118.0 (CHAr), 113.5 (CHAr), 111.3 (CHAr), 84.6 (CCp), 71.1 (CH-OH), 68.8 
(CHCp), 68.4 (CHCp), 68.4 (CHCp), 68.4 (CHCp), 55.5 (OCH3), 44.9 (CH2-CHOH), 39.0 
(CH2-NH) ppm. IR (Neat): 3310, 1647 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 




Magnesium sulfate (134 mg, 1.11 mmol, 5.8 equiv) was added to a solution of 62d (35.4 
mg, 0.189 mmol, 1 equiv) and triethylamine (0.0800 mL, 0.574 mmol, 3 equiv) in dry 
dichloromethane (2.0 mL). This mixture was stirred for 15 mins before 
ferrocenecarboxaldehyde (43.7 mg, 0.204 mmol, 1.1 equiv) was added. After 4 h of 
stirring, another portion of ferrocenecarboxaldehyde (4.50 mg, 0.0210 mmol, 0.1 equiv) 
and magnesium sulfate (100.6 mg, 0.836 mmol, 4.4 equiv) were added. The mixture was 
allowed to stir overnight after which another portion of ferrocenecarboxaldehyde (2.80 
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mg, 0.0131 mmol, 0.1 equiv) and a spatula of 4Å molecular sieves were added. After 2 h 
of stirring, dry toluene (5.0 mL) was added to precipitate triethylamine hydrochloride and 
the mixture was filtered. After removal of solvents under reduced pressure, more 
triethylamine hydrochloride salt precipitated out, so dry toluene (2.0 mL) was added and 
the mixture filtered again. After removal of solvents, sodium borohydride (11.6 mg, 0.306 
mmol, 1.6 equiv) was added to the solution of crude imine mixture in dry methanol (1.0 
mL) at −10 °C. After stirring for 15 mins at −10 °C, the reaction solution was left stirring 
overnight at room temperature. The reaction was quenched with water (5 mL) and 
methanol was evaporated by purging nitrogen gas through the flask. After the aqueous 
layer was extracted with ethyl acetate (3 × 10 mL), the combined organic extracts were 
washed with brine (3 mL) and dried over magnesium sulfate. This crude mixture was 
subjected to column chromatography (40-70% ethyl acetate/hexane) which yielded the 
title compound as a brown solid (35.2 mg, 0.0923 mmol) in a 49% overall yield. 1H NMR 
(300 MHz, CDCl3): δ 7.33 – 7.26 (m, 1H, CHAr), 7.13 – 7.10 (m, 2H, CHAr), 6.99 – 6.93 
(m, 1H, CHAr), 5.93 (bs, 1H, NH), 5.11 (t, J = 6.3 Hz, 1H, CH-OH), 4.15 – 4.14 (m, 11H, 
CH2-NH and CHCp), 2.53 (d, J = 6 Hz, 2H, CH2-CHOH) ppm. 13C NMR (125 MHz, 
CDCl3): δ 171.0 (C=O), 163.0 (d, J = 245 Hz, CAr), 145.9 (d, J = 7.5 Hz, CAr), 130.1 (d, 
J = 8.75 Hz, CHAr), 121.2 (d, J = 3.75 Hz, CHAr), 114.5 (d, J = 21.25 Hz, CHAr), 112.7 
(d, J = 22.5 Hz, CHAr), 84.3 (CCp), 70.3 (CH-OH), 68.7 (CHCp), 68.3 (CHCp), 68.3 (CHCp), 
68.3 (CHCp), 44.5 (CH2-CHOH), 38.9 (CH2-NH) ppm. IR (Neat): 3238, 1650 cm-1. 
HRMS (ESI) m/z: [M + Na]+ Calcd for C20H20NO2FFeNa 404.0725; Found 404.0710. 





Magnesium sulfate (252 mg, 2.09 mmol, 3.8 equiv) was added to a solution of 62e (101 
mg, 0.550 mmol, 1 equiv) and triethylamine (0.230 ml, 1.65 mmol, 3 equiv) in dry 
dichloromethane (5 mL). This mixture was stirred for 15 mins before 
ferrocenecarboxaldehyde (139 mg, 0.650 mmol, 1.2 equiv) was added. After stirring 
overnight, another portion of ferrocenecarboxaldehyde (23.1 mg, 0.108 mmol, 0.2 equiv) 
and magnesium sulfate (136 mg, 1.13 mmol, 2 equiv) were added. The mixture was 
allowed to stir for 2 more hours after which another portion of ferrocenecarboxaldehyde 
(11.7 mg, 0.0547 mmol, 0.1 equiv) and a spatula of 4Å molecular sieves were added. 
After stirring overnight, dry toluene (10 mL) was added to precipitate triethylamine 
hydrochloride and the mixture was filtered. After removal of solvents under reduced 
pressure, more triethylamine hydrochloride precipitated out, so dry toluene (4.0 mL) was 
added and the mixture was filtered again. After removal of solvent, sodium borohydride 
(62.4 mg, 1.65 mmol, 3 equiv) was added to the solution of crude imine mixture (251 mg) 
in dry methanol (3 mL) at −10 °C. After stirring for 15 mins at −10 °C, the reaction 
solution was left stirring overnight at room temperature. The reaction was quenched with 
water (5 mL) and methanol was evaporated by purging nitrogen gas through the flask. 
After the aqueous layer was extracted with ethyl acetate (3 × 15 mL), the combined 
organic extracts were washed with brine (5 mL) and dried over sodium sulfate. This crude 
mixture was subjected to column chromatography (40-80% ethyl acetate/hexane) which 
yielded the title compound as a yellow oil (119 mg, 0.315 mmol) in 58% overall yield. 
1H NMR (500 MHz, CDCl3): δ 7.25 (d, J = 7.5 Hz, 2H, CHAr), 7.15 (d, J = 8 Hz, 2H, 
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CHAr), 5.99 (bs, 1H, NH), 5.08 (d, J = 8.5 Hz, 1H, CH-OH), 4.15 – 4.13 (m, 11H, CH2-
NH and CHCp), 3.92 (bs, 1H, OH), 2.61 – 2.50 (m, 2H, CH2-CHOH), 2.34 (s, 3H, CH3) 
ppm. 13C NMR (125 MHz, CDCl3): δ 171.1 (C=O), 140.1 (CAr), 137.4 (CAr), 129.2 
(CHAr), 125.5 (CHAr), 84.4 (CCp), 70.9 (CH-OH), 68.6 (CHCp), 68.2 (CHCp), 68.2 (CHCp), 
44.8 (CH2-CHOH), 38.8 (CH2-NH), 21.1 (CH3) ppm. IR (Neat): 3299, 1636 cm-1. HRMS 




Sodium sulfate (283 mg, 1.99 mmol, 3.7 equiv) was added to a solution of 62f (107.4 mg, 
0.538 mmol, 1 equiv) and triethylamine (0.230 mL, 1.65 mmol, 3 equiv) in dry 
dichloromethane (5.0 mL). The mixture was stirred for 15 mins before 
ferrocenecarboxaldehyde (138 mg, 0.647 mmol, 1.2 equiv) was added. After stirring 
overnight, another portion of ferrocenecarboxaldehyde (23.0 mg, 0.107 mmol, 0.2 equiv) 
and sodium sulfate (0.150 g, 1.06 mmol) were added. The mixture was stirred for 3 h after 
which another portion of ferrocenecarboxaldehyde (11.4 mg, 0.0533 mmol, 0.1 equiv) 
and a spatula of 4Å molecular sieves were added. After 2 h of stirring, dry toluene (10 
mL) was added to precipitate triethylamine hydrochloride and the mixture was filtered. 
After removal of solvents under reduced pressure, more triethylamine hydrochloride 
precipitated out, therefore dry toluene (5.0 mL) was added and the mixture was filtered 
again. After removal of solvents, sodium borohydride (32.7 mg, 0.864 mmol, 1.6 equiv) 
was added to a solution of the crude imine mixture (240 mg) in dry methanol (3 mL) at 
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−10 °C. After stirring for 15 mins at −10 °C, the mixture was stirred overnight at room 
temperature. The reaction was quenched with water (5 mL) and methanol was evaporated 
by purging nitrogen gas through the flask. After the aqueous layer was extracted with 
ethyl acetate (3 × 15 mL), the combined organic extracts were washed with brine (5 mL) 
and dried over sodium sulfate. The crude mixture was subjected to column 
chromatography (40-80% ethyl acetate/hexanes) which yielded a 65.0 mg mixture of the 
title compound and an unknown impurity that was not removable by column 
chromatography (using either 50% ethyl acetate/hexanes or 5% 
methanol/dichloromethane), therefore preparative TLC was used to obtain the title 
compound (52.0 mg, 0.132 mmol) as a yellowish orange solid in 25% yield. 1H NMR 
(300 MHz, CDCl3): δ 7.27 (d, J = 8.1 Hz, 2H, CHAr), 6.86 (d, J = 8.4 Hz, 2H, CHAr), 6.13 
(bs, 1H, NH), 5.04 (d, J = 8.4 Hz, 1H, CH-OH), 4.15 – 4.14 (m, 11H, CH2-NH and CHCp), 
3.79 (s, 3H, OCH3), 2.61 – 2.46 (m, 2H, CH2-CHOH) ppm. 13C NMR (75 MHz, CDCl3): 
δ 171.3 (C=O), 159.2 (CAr), 135.4 (CAr), 127.0 (CHAr), 114.0 (CHAr), 84.5 (CCp), 70.7 
(CH-OH), 68.8 (CHCp), 68.7 (CHCp), 68.3 (CHCp), 55.4 (OCH3), 44.9 (CH2-CHOH), 38.9 
(CH2-NH) ppm. IR (Neat): 3301, 1636 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 




Triethylamine (0.110 mL, 79.9 mg, 0.789 mmol, 1.9 equiv) was added to a suspension of 
62g (106 mg, 0.426 mmol, 1 equiv) and magnesium sulfate (197 mg, 1.63 mmol, 3.8 
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equiv) in dry dichloromethane (4 mL). This mixture was stirred for 10 minutes before 
ferrocenecarboxaldehyde (104 mg, 0.487 mmol, 1.1 equiv) was added. After 3 hours of 
stirring, another portion of ferrocenecarboxaldehyde (18.0 mg, 0.0841 mmol, 0.2 equiv) 
and one spatula of magnesium sulfate were added. The mixture was allowed to stir 
overnight after which another portion of ferrocenecarboxaldehyde (9.60 mg, 0.0449 
mmol, 0.1 equiv) and a spatula of magnesium sulfate were added. After 2 hours of stirring, 
dry toluene (8 mL) was added to precipitate triethylamine hydrochloride and the mixture 
was filtered. After removal of solvents under reduced pressure, more triethylamine 
hydrochloride precipitated out, therefore dry toluene (5 mL) was added and the mixture 
was filtered again. After removal of solvents, sodium borohydride (65.4 mg, 1.73 mmol, 
4 equiv) was added to the solution of crude imine mixture (233 mg) in dry methanol (5 
mL) at −10 °C. After stirring for 15 minutes at −10 °C, the reaction was left stirring at 
room temperature. Another portion of sodium borohydride (28.7 mg, 0.759 mmol, 1.8 
equiv) was added after 45 mins at −10 °C. After stirring for 15 minutes at −10 °C, the 
reaction solution was left stirring overnight at room temperature. The reaction was 
quenched with water (3 mL) and methanol was evaporated under reduced pressure. After 
the aqueous layer was extracted with ethyl acetate (3 × 10 mL), the combined organic 
extracts were washed with brine (10 mL) and dried over magnesium sulfate. This crude 
mixture was subjected to column chromatography (40-80% ethyl acetate/hexane) which 
yielded the title compound as a yellowish orange (82.5 mg, 0.187 mmol) in a 44% overall 
yield. 1H NMR (500 MHz, CDCl3): δ 7.44 (d, J = 8 Hz, 2H, CHAr), 7.20 (d, J = 8.5 Hz, 
2H, CHAr), 6.13 (bs, 1H, NH), 5.03 – 5.00 (m, 1H, CH-OH), 4.14 – 4.09 (m, 11H, CH2-
NH and CHCp), 2.48 – 2.47 (m, 2H, CH2-CHOH) ppm. 13C NMR (125 MHz, CDCl3): δ 
170.9 (C=O), 142.2 (CAr), 131.7 (CHAr), 127.4 (CHAr), 121.5 (CAr), 84.2 (CCp), 70.3 (CH-
OH), 68.7 (CHCp), 68.4 (CHCp), 68.3 (CHCp), 68.3 (CHCp), 44.5 (CH2-CHOH), 38.9 (CH2-
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NH) ppm. IR (Neat): 3302, 1636 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 
C20H20BrFeNO2Na 463.9925; Found 463.9934. Melting point: 113.6 – 115.1 °C. 
 
3.5.6 Preparation of N-(ferrocenylmethyl)-cyclopropylamine 73 
N-(Ferrocenylmethyl)-cyclopropylamine (73) 
 
A suspension of ferrocenecarboxaldehyde (445 mg, 2.08 mmol, 1 equiv), magnesium 
sulfate (639 mg, 5.30 mmol, 1.7 equiv), and cyclopropylamine (0.120 mL, 98.9 mg, 1.73 
mmol, 0.8 equiv) in dichloromethane (15 mL) was stirred for 5.5 h at room temperature 
before another portion of cyclopropylamine (0.100 mL, 82.4 mg, 1.44 mmol, 0.7 equiv) 
and magnesium sulfate (1 spatula) was added. After stirring overnight at room 
temperature, the reaction was filtered through a small plug of silica gel, using 
dichloromethane first to elute unreacted ferrocenecarboxaldehyde then ethyl acetate to 
elute a mixture of unreacted ferrocenecarboxaldehyde and imine intermediate 72.  
The ethyl acetate eluent was concentrated under reduced pressure then dissolved in 
anhydrous methanol with 4Å molecular sieves (6 spatula) added. The suspension was 
cooled to −10 °C before sodium borohydride (72.0 mg, 1.90 mmol, 0.9 equiv) was added. 
The suspension was stirred at −10 °C for another 5 mins then room temperature overnight. 
The reaction was quenched with water (10 mL), filtered then extracted with 
dichloromethane (3 × 20 mL). The combined organic extracts were dried over magnesium 
sulfate and concentrated under reduced pressure. After the crude mixture was purified by 
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column chromatography (1:1 ethyl acetate/hexane), the title compound was collected as 
a brown oil in 11% (60.5 mg, 0.237 mmol) yield. 1H NMR (500 MHz, CDCl3): δ 4.17 (s, 
2H, CHCp), 4.12 (s, 5H, CHCp), 4.10 (s, 2H, CHCp), 3.57 (s, 2H, CH2-NH), 2.18 – 2.17 
(m, 1H, CH-NH), 0.44 – 0.43 (m, 2H, CH2-CH-NH), 0.362 – 0.358 (m, 2H, CH2-CH-
NH) ppm. 13C NMR (125 MHz, CDCl3): δ 86.9 (CCp), 68.5 (CHCp), 68.4 (CHCp), 67.8 
(CHCp), 48.6 (CH2-NH), 30.1 (CH-NH), 6.4 (CH2-CH-NH) ppm. IR (Neat): 3086 cm-1. 
HRMS (ASAP) m/z: [M]+ Calcd for C14H17FeN 255.0710; Found 255.0707. 
 
3.5.7 Preparation of ruthenocene derivatives 
Ruthenocenecarboxaldehyde (75) 
 
Ruthenocene (0.200 g, 0.864 mmol, 1 equiv) was added portion-wise to a mixture of 
phosphorus(V) oxychloride (0.160 mL, 265 mg, 1.73 mmol, 2 equiv) and N-
methylformanilide (0.320 mL, 351 mg, 2.60 mmol, 3 equiv) over 30 mins. After stirring 
the mixture at room temperature for 1 h 30 mins, it was heated at 65 °C for 2 h and never 
exceeding 70 °C. After cooling the mixture to 0 °C, sodium acetate (672 mg) in water (16 
mL) was slowly added and the mixture was stirred overnight at room temperature. The 
reaction mixture was extracted with diethyl ether (3 × 16 mL), then the combined organic 
extracts was washed with 1 M HCl (10 mL), brine (10 mL), saturated sodium carbonate 
solution (10 mL) and brine (10 mL). The combined organic extracts were dried over 
magnesium sulfate and concentrated under reduced pressure. After column 
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chromatography (40% hexane in diethyl ether), the title compound was collected as a 
yellow solid (135 mg, 0.522 mmol) in 60% yield. 1H NMR (400 MHz, CDCl3): δ 9.73 
(s, 1H, -CHO), 5.09 (t, J = 1.6 Hz, 2H, Cp), 4.86 (t, J = 2.0 Hz, 2H, Cp), 4.65 (s, 5H, Cp) 
ppm. 13C NMR (100 MHz, CDCl3): δ 190.1 (-CHO), 84.5 (CCp), 74.2 (CHCp), 72.0 
(CHCp), 70.9 (CHCp) ppm. IR (Neat): 3094, 1669, 1654, 1457, 1373, 1246, 1102, 1033 
cm-1. HRMS (ESI) m/z: [M + H]+ Calcd for C11H11ORu 260.9853; Found 260.9850. 





A mixture of trans-2-phenylcyclopropylamine hydrochloride (25.6 mg, 0.151 mmol, 1 
equiv), magnesium sulfate (141 mg, 1.17 mmol, 7.7 equiv), triethylamine (0.100 mL, 
0.721 mmol) in dichloromethane (2 mL) was stirred at room temperature for 10 mins 
before the addition of ruthenocenecarboxaldehyde 75 (38.6 mg, 0.149 mmol, 1 equiv). 
After stirring the mixture at room temperature overnight, another portion of magnesium 
sulfate (72.0 mg, 0.598 mmol, 4 equiv) was added and the mixture was further stirred for 
an additional 4 h. The reaction was mixture was diluted with toluene and filtered. The 
filtrate was concentrated under reduced pressure and used in further reaction without 
purification due to instability of the imine. 
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A solution of the imine in methanol (4 mL) was cooled to −10 °C before the addition of 
sodium borohydride (43.9 mg, 1.16 mmol, 7.7 equiv). The solution was stirred at −10 °C 
for 15 mins then room temperature overnight. The reaction solution was slowly quenched 
with water (1 ml), extracted with ethyl acetate (3 × 10 mL) and dried over magnesium 
sulfate. After column chromatography (30% ethyl acetate/hexane), the title compound 
was obtained as a yellow oil (23.2 mg, 61.6 µmol) in 41% yield. 1H NMR (500 MHz, 
CDCl3): δ 7.25 (t, J = 5 Hz, 2H, CHAr), 7.14 (t, J = 7.5 Hz, 1H, CHAr), 7.04 (d, J = 8 Hz, 
2H, CHAr), 4.60 (s, 1H, CHCp), 4.58 (s, 1H, CHCp), 4.52 (s, 5H, CHCp), 4.47 (s, 2H, CHCp), 
3.42 (s, 2H, CH2-NH), 2.44 (bs, 1H, CH-NH), 1.91 (bs, 1H, CH-Ar), 1.11 – 1.07 (m, 1H, 
CH2-CHNH), 0.97 (q, J = 5.5 Hz, 1H, CH2-CHNH) ppm. 13C NMR (100 MHz, CDCl3): 
δ 142.4 (CAr), 128.2 (CHAr), 125.8 (CHAr), 125.4 (CHAr), 91.3 (CCp), 70.9 (CHCp), 70.9 
(CHCp), 70.4 (CHCp), 69.9 (CHCp), 47.9 (CH2-NH), 41.3 (CH-NH), 25.2 (CH-Ar), 17.3 
(CH2-CH-Ar) ppm. IR (Neat): 3086, 3027, 2924, 1603, 1581, 1542, 1497, 1319, 1230, 
1099 cm-1. HRMS (ESI) m/z: [M + H]+ Calcd for C20H22NRu 378.0796; Found 378.0798. 
 
3.5.8 X-ray crystallography 
Crystals of 65d were obtained from recrystallisation in ethyl acetate/hexanes. 
CCDC reference number 1434659. Data for 65d were collected at −173 °C on crystals 
mounted on a Hampton Scientific cryoloop at the MX1 beamline of the Australian 
Synchrotron.58 The structures were solved by direct methods with SHELXS-97, refined 
using full-matrix least-squares routines against F2 with SHELXL-97,59 and visualised 
using X-SEED.60 All non-hydrogen atoms were refined anisotropically. All protons were 
clearly visible in difference maps during the refinement, including the amide N-H and 
alcohol O-H, but all were later placed in calculated positions and refined using a riding 
model with fixed C–H distances of 0.95 Å (sp2CH), 1.00 Å (sp3CH), 0.99 Å (CH2), 0.98 
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Å (CH3), N–H distances of 0.88 Å and O–H distances of 0.84 Å The thermal parameters 
of all hydrogen atoms were estimated as Uiso(H) = 1.2Ueq(C) except for CH3 where 
Uiso(H) = 1.5Ueq(C). A summary of crystallographic data is stated below. 
 Crystal data for 65d: C20H20FFeNO2, M = 381.22, monoclinic, a = 10.5080(11), 
b = 35.761(4), c = 9.5150(16) Å, E = 107.758(6) °, U = 3405.2(8) Å3, T = 100 K, space 
group P21/n (no. 14), Z = 8, 31981 reflections measured, 7745 unique (Rint = 0.0460), 
6200 > 4s(F), R = 0.0624 (observed), Rw = 0.1474 (all data).  
Data for the structure of complex 65d were obtained on the MX1 beamline at the 
Australian Synchrotron, Victoria, Australia. 
 
3.5.9 In vitro assay of ruthenocenyl-2-PCPA 76 
 LSD1 inhibitory activity of 76 was assessed using an LSD1 fluorometric drug 
discovery kit (BML-AK544-0001, Enzo), while MAO inhibition was determined using 
MAO-Glo assay system (V1401, Promega). 
 
3.6 References 
(1) de Meijere, A. Chem. Rev. 2003, 103, 931. 
(2) Cao, B.; Xiao, D.; Joullié, M. M. Org. Lett. 1999, 1, 1799. 
(3) Denolf, B.; Mangelinckx, S.; Törnroos, K. W.; De Kimpe, N. Org. Lett. 2007, 9, 
187. 
(4) Khan, M. N. A.; Suzuki, T.; Miyata, N. Med. Res. Rev. 2013, 33, 873. 
(5) Cerny, M. A.; Hanzlik, R. P. J. Am. Chem. Soc. 2006, 128, 3346. 
(6) Sun, Q.; Zhu, R.; Foss, F. W.; Macdonald, T. L. Chem. Res. Toxicol. 2008, 21, 
711. 
(7) Nguyen, T. H.; Maity, S.; Zheng, N. Beilstein J. Org. Chem. 2014, 10, 975. 
(8) Wimalasena, K.; Wickman, Heang B.; Mahindaratne, Mathew P. D. Eur. J. Org. 
Chem. 2001, 2001, 3811. 
(9) Blackburn, A.; Bowles, D. M.; Curran, T. T.; Kim, H. Synth. Commun. 2011, 42, 
1855. 
184 
(10) Madelaine, C.; Buriez, O.; Crousse, B.; Florent, I.; Grellier, P.; Retailleau, P.; Six, 
Y. Org. Biomol. Chem. 2010, 8, 5591. 
(11) Madelaine, C.; Six, Y.; Buriez, O. Angew. Chem. Int. Ed. 2007, 46, 8046. 
(12) Itoh, T.; Kaneda, K.; Teranishi, S. Tetrahedron Lett. 1975, 16, 2801. 
(13) Maity, S.; Zhu, M.; Shinabery, R. S.; Zheng, N. Angew. Chem. Int. Ed. 2012, 51, 
222. 
(14) Nguyen, T. H.; Morris, S. A.; Zheng, N. Adv. Synth. Catal. 2014, 356, 2831. 
(15) Hartinger, C. G.; Dyson, P. J. Chem. Soc. Rev. 2009, 38, 391. 
(16) Schluga, P.; Hartinger, C. G.; Egger, A.; Reisner, E.; Galanski, M.; Jakupec, M. 
A.; Keppler, B. K. Dalton Trans. 2006, 1796. 
(17) Liu, Z.; Sadler, P. J. Acc. Chem. Res. 2014, 47, 1174. 
(18) Spencer, J.; Mendham, A. P.; Kotha, A. K.; Richardson, S. C. W.; Hillard, E. A.; 
Jaouen, G.; Male, L.; Hursthouse, M. B. Dalton Trans. 2009, 918. 
(19) Spencer, J.; Amin, J.; Wang, M.; Packham, G.; Alwi, S. S. S.; Tizzard, G. J.; 
Coles, S. J.; Paranal, R. M.; Bradner, J. E.; Heightman, T. D. ACS Med. Chem. 
Lett. 2011, 2, 358. 
(20) Biot, C.; Nosten, F.; Fraisse, L.; Ter-Minassian, D.; Khalife, J.; Dive, D. Parasite 
(Paris, France) 2011, 18, 207. 
(21) Gasser, G.; Ott, I.; Metzler-Nolte, N. J. Med. Chem. 2011, 54, 3. 
(22) Top, S.; Vessières, A.; Leclercq, G.; Quivy, J.; Tang, J.; Vaissermann, J.; Huché, 
M.; Jaouen, G. Chem. - Eur. J. 2003, 9, 5223. 
(23) Hillard, E.; Vessières, A.; Thouin, L.; Jaouen, G.; Amatore, C. Angew. Chem. Int. 
Ed. 2006, 45, 285. 
(24) Pigeon, P.; Top, S.; Vessières, A.; Huché, M.; Hillard, E. A.; Salomon, E.; Jaouen, 
G. J. Med. Chem. 2005, 48, 2814. 
(25) Gee, Y. S. BSc (Hons) Thesis, University of Wollongong, 2013. 
(26) Pi, C.; Li, Y.; Cui, X.; Zhang, H.; Han, Y.; Wu, Y. Chem. Sci. 2013, 4, 2675. 
(27) Chen, Y.; Zhang, X. P. J. Org. Chem. 2007, 72, 5931. 
(28) Davi, M.; Lebel, H. Chem. Commun. 2008, 4974. 
(29) Cho, S. J.; Jensen, N. H.; Kurome, T.; Kadari, S.; Manzano, M. L.; Malberg, J. E.; 
Caldarone, B.; Roth, B. L.; Kozikowski, A. P. J. Med. Chem. 2009, 52, 1885. 
(30) Feldman, K. S.; Simpson, R. E. Tetrahedron Lett. 1989, 30, 6985. 
(31) Iwama, T.; Matsumoto, H.; Ito, T.; Shimizu, H.; Kataoka, T. Chem. Pharm. Bull. 
1998, 46, 913. 
(32) Zagorski, M. G.; Salomon, R. G. J. Am. Chem. Soc. 1980, 102, 2501. 
(33) Maity, S.; Zheng, N. Angew. Chem. Int. Ed. 2012, 51, 9562. 
(34) Yang, M.; Culhane, J. C.; Szewczuk, L. M.; Jalili, P.; Ball, H. L.; Machius, M.; 
Cole, P. A.; Yu, H. Biochemistry 2007, 46, 8058. 
(35) Mimasu, S.; Sengoku, T.; Fukuzawa, S.; Umehara, T.; Yokoyama, S. Biochem. 
Biophys. Res. Commun. 2008, 366, 15. 
(36) Binda, C.; Valente, S.; Romanenghi, M.; Pilotto, S.; Cirilli, R.; Karytinos, A.; 
Ciossani, G.; Botrugno, O. A.; Forneris, F.; Tardugno, M.; Edmondson, D. E.; 
Minucci, S.; Mattevi, A.; Mai, A. J. Am. Chem. Soc. 2010, 132, 6827. 
(37) Ogasawara, D.; Itoh, Y.; Tsumoto, H.; Kakizawa, T.; Mino, K.; Fukuhara, K.; 
Nakagawa, H.; Hasegawa, M.; Sasaki, R.; Mizukami, T.; Miyata, N.; Suzuki, T. 
Angew. Chem. Int. Ed. 2013, 52, 8620. 
(38) Ortega Munoz, A.; Fyfe, M. C. T.; Martinell Pedemonte, M.; Estiarte Martinez, 
M. d. l. A.; Valls Vidal, N.; Kurz, G.; Castro Palomino Laria, J. C. 
WO2013057322A1, 2013. 
185 
(39) Maes, T.; Tirapu, I.; Mascaró, C.; Ortega, A.; Estiarte, A.; Valls, N.; Castro-
Palomino, J.; Arjol, C. B.; Kurz, G. J. Clin. Oncol. 2013, 31, e13543. 
(40) Johnson, N. W.; Kasparec, J.; Miller, W. H.; Rouse, M. B.; Suarez, D.; Tian, X. 
WO2012135113A2, 2012. 
(41) Sanders, R.; Mueller-Westerhoff, U. T. J. Organomet. Chem. 1996, 512, 219. 
(42) Malachowski, M. R.; Grau, M. F.; Thomas, J. M.; Rheingold, A. L.; Moore, C. E. 
Inorg. Chim. Acta 2010, 364, 132. 
(43) Alkan, A.; Gleede, T.; Wurm, F. R. Organometallics 2017, 36, 3023. 
(44) Kunze, B.; Steinmetz, H.; Höfle, G.; Huss, M.; Wieczorek, H.; Reichenbach, H. 
J. Antibiot. 2006, 59, 664. 
(45) Cozzi, R.; Attanasio, R. Expert Rev. Clin. Pharmacol. 2012, 5, 125. 
(46) Ueda, R.; Suzuki, T.; Mino, K.; Tsumoto, H.; Nakagawa, H.; Hasegawa, M.; 
Sasaki, R.; Mizukami, T.; Miyata, N. J. Am. Chem. Soc. 2009, 131, 17536. 
(47) Chen, Y.; Huang, L.; Ranade, M. A.; Zhang, X. P. J. Org. Chem. 2003, 68, 3714. 
(48) Masllorens, J.; Moreno-Manas, M.; Pla-Quintana, A.; Roglans, A. Org. Lett. 
2003, 5, 1559. 
(49) Taber, D. F.; Nelson, C. G. J. Org. Chem. 2006, 71, 8973. 
(50) Benelkebir, H.; Hodgkinson, C.; Duriez, P. J.; Hayden, A. L.; Bulleid, R. A.; 
Crabb, S. J.; Packham, G.; Ganesan, A. Biorg. Med. Chem. 2011, 19, 3709. 
(51) Shimojuh, N.; Imura, Y.; Moriyama, K.; Togo, H. Tetrahedron 2011, 67, 951. 
(52) Concellón, J. M.; Concellón, C.; Méjica, C. J. Org. Chem. 2005, 70, 6111. 
(53) Lebel, H.; Davi, M. Adv. Synth. Catal. 2008, 350, 2352. 
(54) Concellón, J. M.; Rodríguez-Solla, H.; Simal, C. Org. Lett. 2007, 9, 2685. 
(55) Andreotti, D.; Arista, L.; Cardullo, F.; Spada, S.; Thewlis, K. M.; Ward, S. E. 
WO2006087169A1, 2006. 
(56) Arvidsson, L. E.; Johansson, A. M.; Hacksell, U.; Nilsson, J. L. G.; Svensson, K.; 
Hjorth, S.; Magnusson, T.; Carlsson, A.; Lindberg, P.; Andersson, B.; Sanchez, 
D.; Wikström, H.; Sundell, S. J. Med. Chem. 1988, 31, 92. 
(57) Joubert, C. C. Master of Science Thesis, University of the Free State, 2011. 
(58) McPhillips, T. M.; McPhillips, S. E.; Chiu, H.-J.; Cohen, A. E.; Deacon, A. M.; 
Ellis, P. J.; Garman, E.; Gonzalez, A.; Sauter, N. K.; Phizackerley, R. P.; Soltis, 
S. M.; Kuhn, P. J. Synchrotron Radiat. 2002, 9, 401. 
(59) Sheldrick, G. M. SHELX97, Programs for Crystal Structure Analysis; Universität 
Göttingen: Germany, 1998. 





Palladium-catalysed dearomative [3 + 2] cycloaddition of 3-nitroindoles with 
vinylcyclopropane dicarboxylates 
4.1 Introduction 
4.1.1 Activation of vinylcyclopropanes by Pd catalysts in cycloadditions 
 Donor‐acceptor (DA) three-membered rings, such as vinylcyclopropanes (VCPs) 
and vinylaziridines, are useful scaffolds in synthetic methodologies.1-4 These DA three-
membered rings are readily prepared and are generally stable to store and handle. Upon 
activation, they can be unmasked and reveal a reactive 1,3-dipole intermediates, which 
can participate in reactions such as cycloadditions and nucleophilic additions. 
 Apart from the strain energy present in the ring, the reactivity of DA three-
membered rings can also be attributed to the functional groups present on the ring. One 
terminal on the ring would have a “donor” group to stabilise the cation formed upon 
activation, while the adjacent terminal would have an “acceptor” group to stabilise the 
anion. VCP dicarboxylate (Figure 27, boxed) is an example of DA three-membered ring. 
Upon activation to form 1,3-dipole, the vinyl group is the cation-stabilising donor group, 
while the adjacent diesters-carrying carbon stabilises the anion. Apart from esters, other 
electron withdrawing groups such as ketones and nitriles can also be used to stabilise the 
anion formed in 1,3-dipole.  
 Several methods have been reported to activate these three-membered rings 
(Figure 27). It has been reported that arylcyclopropanes, aziridines and less commonly 
VCPs can unleash a 1,3-dipole simply by thermal activation to cleave the C-C bond.5-7 
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Alternatively, Lewis acids can chelate with the acceptor group therefore polarising the 
bond between the donor and acceptor groups. The resulting dipole in each case can 
undergo reaction with a dipolarophile 78 to yield five-membered carbo- and 
heterocycles.8  
 For VCPs, metal catalysis is the more common approach for activation. Low 
valent metals such as Pd(0),9 Ni(0),10,11 Fe(0)12 and Ir(0)13 have been reported to interact 
with the vinyl group to stabilise the cation formed in 1,3-dipole as a metal-allyl complex. 
This review will focus on studies that employ Pd-catalysis to create all-carbon 
zwitterionic 1,3-dipoles from VCP dicarboxylates. 
Figure 27: Methods to reveal 1,3-dipole from donor-acceptor three-membered ring. 
 The vinyl group in a vinylcyclopropane dicarboxylate provides a handle to 
interact with Pd(0), and hence prompting the ring-opening of cyclopropane via oxidative 
addition and the formation of a Pd-stabilised 1,3-dipole (Figure 27). This zwitterionic 
intermediate is composed of a cationic Pd-π-allyl complex and a dicarboxylate stabilised 
anion. As a result, this reactive intermediate can participate in [3 + 2] cycloaddition with 
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electron deficient olefins and other dipolarophiles. The resulting five-membered ring 
product has established two new C−C bonds and could have up to four stereocenters, 
therefore providing scope for asymmetric synthesis. Furthermore, preparation of a five-
membered ring through this method provides high atom economy as all atoms in the 
substrates are preserved in the resulting product. For these reasons, the [3 + 2] 
cycloaddition of VCP dicarboxylates with dipolarophiles have been widely studied in the 
last few decades as a key method for preparing 5-membered carbocycles. 
 Prior to the discovery of VCP as 1,3-dipole in [3 + 2] cycloaddition, Trost et al. 
reported the use of trimethylenemethane (TMM) as 1,3-dipole to react with α,β-
unsaturated ester and ketone (Scheme 31a).14 This method provided the five-membered 
ring product but with trimethylsilyl acetate as the by-product during the generation of 
TMM in situ. Later, Tsuji and colleagues introduced the use of VCP dicarboxylates in [3 
+ 2] cycloadditions with α,β-unsaturated esters and ketones (Scheme 31b).15 This method 
provided the cyclopentane product in good yield and it had superior atom economy 





Scheme 31: Construction of five-membered ring from the Pd-catalysed [3 + 2] 
cycloaddition of electron-poor olefin with: (a) trimethylenemethane (TMM); (b) 
vinylcyclopropane dicarboxylate. 
 As seen from Trost and Tsuji’s work, α,β-unsaturated carbonyls and electron 
deficient olefins are attractive dipolarophiles for 1,3-dipoles as they are good Michael 
acceptors to yield the five-membered carbocycles. Given the success of asymmetric 
processes involving Pd-allyl complexes and the importance of enantiomerically pure 
structures in target synthesis, much effort has been paid to developing asymmetric 
variants of the process shown in Scheme 31b. 
 Shi et al. developed novel chiral imidazoline−phosphines with a 1,1′-
binaphthalene framework as N,P-ligands 79 and applied them to the Pd-catalysed 
cycloaddition of VCP dicarboxylate and VCP dinitrile with β,γ-unsaturated α-keto esters 
80 (Scheme 32).16 The resulting five-membered carbocycles were obtained in excellent 
yield, enantioselectivity and diastereoselectivity. In terms of substrate scope, this method 
favoured dipolarophiles with electron-rich aromatic rings or heterocycles at the γ position 
where good yields and excellent diastereoselectivities were obtained. No product was 




Scheme 32: Asymmetric synthesis of functionalised cyclopentane through Pd-catalysed 
[3 + 2] cycloaddition of VCP with β,γ-unsaturated α‑keto esters. 
 Apart from α,β-unsaturated carbonyls, nitroolefins are also excellent 
dipolarophiles for 1,3-dipoles, but have received scant attention to date. It’s important to 
note that the use of nitroolefins as substrates provides a convenient avenue to ultimately 
install nitrogen-containing functional groups, such as amines and amides. For example, 
as part of a strategy to prepare the polycyclic Melodinus alkaloids, Goldberg et al. 
subjected β,2-dinitrostyrene and VCP dicarboxylate to a Pd-catalysed [3 + 2] 
cycloaddition (Scheme 33a).17 The resulting nitrocyclopentane product was obtained as 
a mixture of inseparable diastereomers in 60% yield. The obtained cycloadducts were 
then subjected to zinc reduction of nitro groups to amines followed by in situ 
lactamisation to yield dihydroquinolinone products (Scheme 33a). 
Later, Liu et al. reported the enantioselective Pd-catalysed cycloadditions of 
dicyano VCP with β-nitrostyrenes to yield nitrocyclopentanes (Scheme 33b).18 The 
reaction generally tolerated electron donating and electron withdrawing substituents at 
different positions on the ring to give good yields with moderate to good 
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enantioselectivities. Interestingly, this method could not generate the product when a 
strongly electron withdrawing nitro group is at the ortho position on the phenyl ring, 
which Goldberg et al. had employed in the previous study with VCP dicarboxylate.17 
Even though the reaction gave poor diastereoselectivities of 1:0.9 to 1:1.6, the authors 
stated that the diastereomers could be separated by chromatography, therefore providing 
practicality to access both enantioenriched diastereomers individually. 
 VCPs can also be used to construct five-membered carbocycles with higher 
complexity, such as spirocycles. Spirocyclopentanes containing 1,3-indanedione moieties 
are common cores of many biologically active molecules, such as Fredericamycin A 
(antibiotics)19 and indacrinone (MK-196) (uricosuric diuretics)20. In order to access this 
class of spirocycles, Liu and co-workers conducted a Pd-catalysed cycloaddition study 
using nitroolefins with a spirocyclic VCP containing 1,3-indanedione (Scheme 33c).21 A 
series of ligands were screened and it was discovered that N,N-ligands provided the best 
enantioselectivity, P,P-ligand provided moderate enantioselectivity, while N,P-ligands 
generated a racemic mixture. The reaction was compatible with heterocycles and aromatic 
rings with electron donating or electron withdrawing group, where desired products were 
obtained in good yield with moderate diastereoselectivity and excellent 
enantioselectivity. A sharp reduction in diastereoselectivity was observed when the 
substituent on the olefin was an unsaturated cycloalkane, while the excellent 
enantioselectivity remained unchanged. 
 As the nitroolefin substrates and palladium catalyst depicted in Scheme 33 are 
essentially identical, the differences in the obtained diastereoselectivity could be 
attributed to the delicate balance in reaction parameters such as VCP substrates and/or 
ligands. 
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Scheme 33: Pd-catalysed [3 + 2] cycloaddition of VCPs with nitroolefins. 
 Spiroindolenines are another class of spirocycles that can be commonly found in 
biologically active compounds and commercial drugs.22-24 Similarly to spiro[4.5]deca-
6,9-diene-8-ones, rapid approaches to access spiroindolenines are limited, thus Liu et al. 
reported the preparation of these spirocycles from the Pd-catalysed cycloaddition of VCP 
dicarboxylates and α,β-unsaturated imines, which were generated in situ from aryl 
sulfonyl indoles 83 (Scheme 34).25 In general, spiroindolenines were prepared in good 
yield with excellent enantioselectivity and diastereoselectivity. The newly formed 
cyclopentane moiety had four stereocenters which two of them were quaternary carbons. 
The electronic nature of substituents had no significant effects on the reaction, however 
steric hindrance around the sulfonyl moiety did impact yields and enantioselectivities. A 
slight reduction in the enantioselectivities and a drastic drop in yields were observed when 
ortho substituted phenyl ring was around the sulfonyl moiety. Besides, substitution on the 
indole ring also slightly reduced the enantioselectivities of the products. The VCP played 
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two roles in this reaction: firstly, the malonate anion of the 1,3-dipole deprotonated the 
indole which caused the formation of α,β-unsaturated imine and the liberation of 
benzenesulfinate anion. Once the malonate anion on the 1,3-dipole is protonated, the 
benzenesulfinate anion then attacked the Pd-allyl complex to form by-product 84. On the 
other hand, another 1,3-dipole attacked the in situ generated α,β-unsaturated imine to 
form the desired cycloadduct in a [3 + 2] cycloaddition manner. Due to the consumption 
of 1,3-dipole for the initial indole deprotonation, excess VCP was required for this [3 + 
2] cycloaddition. 
 
Scheme 34: Pd-catalysed cycloaddition of VCPs with in situ generated unsaturated 
imines. 
 Instead of using chiral ligands, Jørgensen and colleagues conducted the 
stereoselective Pd-catalysed [3 + 2] cycloaddition of dicyano VCPs with α,β-unsaturated 
aldehydes in the presence of a chiral organocatalyst 85 (Scheme 35).26 The role of the 
amine organocatalyst was to activate the aldehyde substrate as a reactive iminium ion 
intermediate and controls the sense of attack by the 1,3-dipole generated from the VCP 
by the achiral Pd-catalyst. Electron-donating and electron-withdrawing substituents can 
be accommodated at various positions on the β-phenyl ring of the aldehydes, although 
longer reaction time was required for substrates with ortho substituted phenyl rings, 
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potentially due to steric hindrance. β-Heteroaryl and β-alkyl aldehyde substrates provided 
similar good yields but with slightly lower diastereoselectivity. Furthermore, VCPs with 
two different germinal electron-withdrawing groups were screened to yield the 
cyclopentane derivatives with four stereocenters. More importantly, the use of these 
VCPs created a quaternary stereocenter in the cycloadduct, which is a long-standing 
challenge in organic synthesis.27-29 The cycloaddition of these VCPs provided the 
cycloadducts in high yields, excellent enantioselectivity and good diastereoselectivity. In 
a separate study, Jørgensen et al. demonstrated that a similar Pd/organo dual catalysis 
method can be extended to vinylaziridines with α,β-unsaturated aldehydes, where good 
yields, high enantioselectivity and moderate diastereoselectivity were obtained.30 
 
Scheme 35: Asymmetric [3 + 2] cycloaddition of VCPs and α,β-unsaturated aldehydes 
by synergistic palladium and organocatalysis. 
Yao and colleagues also reported the utilisation of organo/palladium dual catalysis 
to construct spiro[4.5]deca-6,9-diene-8-ones 88 from the cycloaddition of VCP 
dicarboxylates and para-quinone methides 86 (Scheme 36).31 A series of phosphine-
thiourea organocatalyst were examined at the start of the study. Changing the electronic 
nature of the thiourea-phenyl ring fine-tuned the acidity of thiourea, while the 
diastereoselectivity was not affected, the yield varied from 56 to 93%. As such, 87 bearing 
a p-methoxy group on the thiourea-phenyl ring was identified to provide the optimal yield 
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and diastereoselectivity. Even though moderate to good yields were obtained when 
standard monodentate and bidentate phosphine ligands were employed, the 
diastereoselectivity dropped significantly. These results highlight the need of bifunctional 
organo/metal catalysis to achieve diastereoselectivity. It was proposed that while the 
phosphine moiety of the organocatalyst activated the VCP into 1,3-dipole, the thiourea-
NH moieties of the organocatalyst chelated to the oxygen of para-quinone methide 86 
through hydrogen bonding. This method was applied to a range of VCP dicarboxylate 
and para-quinone methide substrates and it showed great functional group compatibility. 
Despite a chiral ligand 87 being employed, the reaction was not enantioselective and the 
authors aimed to investigate the enantioselective variant in a future study. Interestingly, 
when vinylaziridine was used instead of VCP, the diastereoselectivity declined drastically 
(76:24 dr when using vinylaziridine compared to 96:4 dr when using VCP). 
Scheme 36: [3 + 2] cycloaddition of para-quinone methides with VCPs through 
metal/organo synergistic catalysis. 
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Scheme 37: Pd-catalysed cycloaddition of substituted VCPs with Meldrum’s acid 
alkylidenes and azlactone alkylidenes. 
 Recently, Trost et al. investigated the stereoselective Pd-catalysed cycloaddition 
of substituted VCPs with Meldrum’s acid alkylidenes 89 (Scheme 37a) and azlactone 
alkylidenes 90 (Scheme 37b).32 Pd-π-allyl species are known to isomerise between η3 and 
η1 haptomers – a process called π-σ-π interconversion (Figure 28a). When the η3 
haptomer isomerises to the η1 haptomer, the latter can undergo a σ-bond rotation then 
isomerise to a η3 isomer, which has the opposite configuration to the starting η3 haptomer. 
This interconversion allows the stereoconvergence of both VCP enantiomers to 
enantioenriched products, thus Trost and co-workers employed the chiral ligands that they 
previously developed to create a chiral environment around the Pd centre, which can 
influence the π-σ-π interconversion and hence the stereoselectivity of the cycloaddition 
(Figure 28b). By having a chiral ligand as the mould for the Pd allyl complex, the 
sterically unfavoured η3 haptomer is prompted to undergo π-σ-π interconversion to the 
sterically favoured η3 haptomer. Promotion of π-σ-π interconversion is said to achieve 
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Curtin–Hammett conditions, where the interconversion between the diastereomeric 
complexes is more rapid than the irreversible ring closing step, therefore the 
interconversion is the crucial factor to control stereoselectivity. Curtin–Hammett 
principle stated that on the basis that the rates of conformational interconversion are faster 
than the rates of reaction, the relative amount of products formed from two critical 
conformations are entirely relied on the difference in transition states free energy, and not 
the relative populations of the conformations.33  
 This concept was applied to two sets of substrates, Meldrum’s acid derivatives of 
VCP with alkylidenes 89 and VCP dicarboxylate with azlactone alkylidenes 90 (Scheme 
37). As a result, the obtained cycloadducts were highly substituted and stereoselective. 
Using the Meldrum’s acid derivatives of VCP as example (as depicted in Figure 28a), 
conformers A and F are diastereomers with different free energies due to the steric 
interference between the substrate and ligand in F. Regardless of the relative population 
of these two conformers, conformer F rapidly converts to conformer A by undergoing π-
σ-π interconversion. As this π-σ-π interconversion is faster than the reaction, the reaction 
achieves Curtin–Hammett conditions and selectively provides the major enantiomer and 






Figure 28: (a) Isomerisation of Pd-π-allyl complex through π-σ-π interconversion; (b) 
Stereoconvergent of Pd-π-allyl intermediates directed by Trost ligand through π-σ-π 
interconversion. (Figure was adapted from literature32) 
 With variation in the dipolarophile, VCPs can access not only cyclopentane 
derivatives but also five-membered heterocycles. Tsuji et al. reported the [3 + 2] 
cycloaddition of VCP dicarboxylates with aryl isocyanates to prepare pyrrolidine 
derivatives in good yield (Scheme 38a).34 VCP with mono- and disubstituted olefins, 
phenyl isocyanates with electron donating and electron withdrawing groups, were 
screened and they all provided good yield. However, no cyclisation product was obtained 
when alkyl isocyanates were attempted. 
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 Johnson and co-workers have reported the diastereoselective preparation of 
tetrahydrofuran derivatives from the cycloaddition of VCP dicarboxylate with aldehydes 
(Scheme 38b).35 Various ligands were screened in order to gain stereocontrol over the 
product and the diamine ligand bathophenanthroline (BPhen) was found to be the optimal 
ligand in their method to give the cis isomer as the major diastereomer. They reported 
high yields and short reaction times for electron-poor aldehydes. On the other hand, 
electron-rich aldehydes provided poor yields even though total consumption of VCP was 
observed. It was proposed that electron-rich aldehydes have lower electrophilicity, 
therefore disfavouring the nucleophilic attack of 1,3-dipole. 
Scheme 38: Construction of five-membered heterocycles from Pd-catalysed 
cycloaddition of VCPs with: (a) aryl isocynates; (b) aldehydes. 
 
4.1.2 Vinylcyclopropanes in nucleophilic additions catalysed by Pd(0) 
As seen above, Pd-π-allyl complexes derived from VCPs have been widely 
employed in [3 + 2] cycloaddition, however nucleophilic addition to π-allyl complexes 
forming acyclic products is less reported. Nucleophilic attack to π-allyl complexes gives 
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rise to acyclic products, which can be either linear or branched, therefore this provides 
the scope to study the regioselectivity. Jiang and colleagues utilised oxindoles 93 as the 
nucleophiles to attack Pd-π-allyl complexes derived from VCP dicarboxylates and found 
the reaction was highly regioselective towards the linear product (Scheme 39).36 Various 
substituents could be accommodated at the oxindole aromatic ring and C3 position, 
products were obtained in good to excellent yields with > 20:1 linear/branched ratio. 
Similar yields and linear/branched ratios were observed when cyano and phenyl sulfonyl 
were used as the acceptor groups in VCPs. 
Scheme 39: Pd-catalysed allylation of oxindoles with VCPs. 
 Werz et al. reported the Pd/Cu-catalysed three-component coupling of terminal 
alkynes, arynes and VCP dicarboxylate (Figure 29).37 The aryne was generated in situ by 
treating 2-(trimethylsilyl)phenyl trifluoromethanesulfonate 94 with a fluoride source. 
Meanwhile, Cu(I) activated the terminal alkyne to form the copper acetylide nucleophile 
95, which then coupled to the aryne and formed a highly nucleophilic organocopper 
intermediate 96. Eventually the nucleophilic intermediate 96 attacked the Pd-π-allyl 
complex to form the product and allowed the regeneration of Pd(0) and Cu(I). Aromatic, 
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heterocyclic and alkyl groups on terminal alkynes were found to give moderate to good 
yields with only the linear product obtained. However, when an ester group was installed 
on the terminal alkyne, no product was formed. It was proposed that this lack of reactivity 
was due to the electron-withdrawing group reducing the nucleophilicity of the acetylide. 
Notably, the regioselectivity could not be maintained when unsymmetrical arynes were 
used because the copper acetylide could attack either one of the two aryne carbons 
without any regio-control. 
 
Figure 29: Pd-catalysed three-component coupling of terminal alkynes, arynes and VCP 
dicarboxylates. 
 Recently, the Hyland group has reported the Pd-catalysed addition of boronic 
acids to Pd-π-allyl complexes (Figure 30).38 The reaction was conducted under mild 
conditions using neat water as the solvent, without the need of a ligand or additive. 
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Furthermore, the reactions regioselectivity depended on the 1,3-dipole source, being 
linear-selective for VCP dicarboxylates and branched-selective for styrenylcyclopropane 
dicarboxylates. It was proposed that Pd(0) nanoparticles (PdNPs) were formed in the 
presence of aryl boronic acids and these nanoparticles activated the VCPs into Pd-π-allyl 
complexes. Aryl boronic acids then underwent transmetallation with the Pd-π-allyl 
complexes, follow by reductive elimination to yield the products and regeneration of the 
Pd(0) catalyst. The regioselectivity was established during the reductive elimination 
based on the VCP substrates. When vinylcyclopropanes (R = H) were employed, linear 
products 97 were favoured as the terminal alkenes were more thermodynamically stable 
than internal alkene. Moreover, orientating the Pd-Ar complex towards terminal carbon 
minimises the steric repulsion against the VCP fragment during reductive elimination. On 
the other hand, the use of styrenylcyclopropane (R = Ar) provided branched products 98 
selectively as these products had more stable conjugated systems. 
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Figure 30: Pd-catalysed ring-opening of VCP dicarboxylates by boronic acids. 
 While the use of VCPs to generate 1,3-dipoles under Pd-catalysis have 
demonstrated great utility in the syntheses of five-membered rings and spirocycles via [3 
+ 2] cycloadditions to isolated π-systems, it has yet to be applied to prepare fused 
polycycles such as indoline-derived heterocycles. These fused systems would require the 
addition of 1,3-dipole to aromatic systems – a method that has not been well developed. 
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4.1.3 Indoline-derived heterocycles 
 Indoline-derived heterocycles are prevalent in a host of important biologically 
active molecules, therefore new methods for their preparation is a major area of 
investigation for synthetic chemists. The 2,3-fused pyrrolo derivatives (pyrroloindolines) 
feature a tricyclic skeleton with two N-heterocycles (Figure 31) and the preparation of 
these derivatives has been widely explored.39 Notably, the construction of 3a-amino-
pyrroloindolines is a particular interest due to their potent antibacterial properties.40 
Furthermore, these cores play a key role as intermediates for the preparation of 
heterodimeric C3a-C3a′ linked cyclotryptamine-based alkaloids.41 
 
Figure 31: Representative examples of pyrroloindoline and cyclopenta[b]indoline cores. 
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 An important class of 2,3-fused cyclopentannulated indolines core 
(cyclopenta[b]indolines) are found in bioactive molecules such as diazepinoindoline 
(treatment and prevention of central nervous system disorders)42 and polyveoline 
(antitrypanosomal alkaloid)43 (Figure 31). Despite being featured in various biologically 
active compounds, the construction of this indoline core has not been deeply investigated 
compared to the related pyrroloindolines. 
 Traditionally, cyclopenta[b]indolines were prepared in multiple steps by 
photochemical cyclization or heterocyclization of alkenylarylamines.44-47 Recently, 
Gilbertson and colleagues prepared cyclopenta[b]indoline in a step-efficient manner via 
a Pd-N-heterocyclic carbene-catalysed cyclopentannulation of diazabicyclic olefins 99 
with ortho-functionalised aryl halides 100 (Scheme 40).48 Although this method 
proceeded with high diastereoselectivity, it could not provide access to 
cyclopenta[b]indoline derivatives with electron-withdrawing groups or a halogen at C7, 
nor a substituent at C8b.  
 
Scheme 40: Pd-NHC catalysed cycloaddition of diazabicyclic olefins 99 with ortho-
functionalised aryl halides 100. 
206 
 Indole derivatives are readily available flat skeleton that can be converted into a 
three-dimensional structure through cycloaddition. Hence, the [3 + 2] dearomative 
cycloaddition of 1,3-dipoles to the indole skeleton could be the most atom-efficient 
method to prepare cyclopenta[b]indolines.49 Alkynyl Fischer carbene complexes 101 
have been used by Barluenga for the asymmetric [3 + 2] cyclopentannulation of indoles 
(Scheme 41a).50 Lian and Davies reported a Rh-catalysed version of this reaction with 
vinyldiazoacetates 102 (Scheme 41b),51 while Doyle and co-workers developed an 
asymmetric Rh-catalysed variant with enoldiazoacetamides 103 (Scheme 41c).52 The 
cycloadditions of indoles with metal carbenoids gave excellent yields, however further 
functionalisation at C1 and C8b is limited. 
 
Scheme 41: Construction of cyclopenta[b]indoline through the [3 + 2] dearomative 
cycloaddition of metal carbenoids to indole core. 
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 As demonstrated from the examples shown in Section 4.1.1 above, DA 
cyclopropanes are versatile and useful building blocks that generate 1,3-dipole to 
construct five-membered rings. Therefore, subjecting DA cyclopropanes to the [3 + 2] 
dearomative indole cycloaddition can be an atom efficient method to prepare 
cyclopenta[b]indolines. Kerr and colleagues reported the Yb(OTf)3-catalysed formal [3 + 
2] annulation of 3-alkylindoles with 1,1-cyclopropanediesters as formal 1,3-dipoles to 
provide cyclopenta[b]indolines in high yield and diastereoselectivity (Scheme 42a).53,54 
Besides, an enantioselective cycloaddition of electron-rich indoles with 1,1-
cyclopropanediesters using a BOX/Cu(II)-catalyst was also reported (Scheme 42b).55 
Although these reported methods are highly efficient for the construction of 
cyclopenta[b]indoline core, subsequent functionalisation at C1 is limited as it is occupied 
by alkyl or aryl groups. 
 While electron-rich indoles were employed in the several examples illustrated 
above, the reversal of polarity using electron-poor indoles as the cycloaddition partners 
is investigated to a lesser extent. Trost made an important contribution in this area with 
the [3 + 2] cycloaddition reactions of Pd-TMM to electron-deficient aromatics, including 
3-nitro-1-phenylsulfonyl indoles to give cyclopenta[b]indolines (Scheme 42c).56 By 
installing a nitro group on the C3 position and an electron-withdrawing group on the 
nitrogen, the typically nucleophilic indole was converted into an electrophilic Michael 
acceptor for the 1,3-dipole derived from TMM. Although this innovative method 
efficiently provides access to cyclopenta[b]indolines, further functionalisation at C1 is 
still restricted, similar to previous examples. 
While TMM had been employed in [3 + 2] cycloaddition with aromatic systems 
such as nitroindoles, the versatile VCPs have not been used as partners with aromatic 
systems. The use of VCP dicarboxylates in [3 + 2] cycloaddition with aromatic systems 
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can provide functional groups as handles for further derivatisation, such as vinyl and ester 
groups. This strategy can be employed to overcome the limitation from reported studies 
where further derivatisation was restricted due to lack of manipulable functional groups.  
 
Scheme 42: Construction of cyclopenta[b]indoline through the [3 + 2] dearomative 
cycloaddition of indoles with 1,3-dipoles derived from: (a & b): DA cyclopropanes; (c) 
TMM. 
4.2 Aim and research plan 
 Even though the preparation of cyclopenta[b]indoline core is less reported than 
the pyrroloindoline counterpart, existing methods provide access to this core in high yield 
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and excellent atom economy. However, the cycloadducts obtained from most of these 
studies have limited capacity to undergo further transformation due to lack of manipulable 
functional groups around the cyclopentane ring. Biologically active molecules that 
feature the cyclopenta[b]indoline core usually have higher complexity in their structures, 
hence there is a need to develop methods that can construct densely functionalised 
derivatives of this core in a step- and atom-economic manner. Furthermore, 
cyclopenta[b]indoline with amine group at C8b is analogous to 3a-amino-pyrroloindoline 
(Figure 31) which possessed antibacterial property. However, there is only one reported 
method that can provide access to cyclopenta[b]indolines with amine functionality at 
C8b.56 
 Given this gap in the synthetic methodology, we aimed to construct densely 
functionalised cyclopenta[b]indolines from the cycloaddition of 3-nitroindoles with 1,3-
dipoles generated from VCP dicarboxylates under Pd(0) catalysis (Scheme 43). The 
presence of a nitro group at C3 position serves two purposes: (1) to convert the indole 
into an electrophilic system such that the zwitterionic 1,3-dipole can act as the nucleophile 
towards C2 in a Michael addition fashion, and; (2) to install a handle for further reaction.  
Scheme 43: Proposed reaction: Pd-catalysed [3 + 2] cycloaddition of 3-nitroindoles with 
VCP dicarboxylates. 
 The densely functionalised cycloadduct features a vinyl group at C1, geminal 
diesters at C3 and nitro group at C8b. Each of these functional groups has the potential to 
undergo further chemical transformation. For instance, the nitro group at C8b can be 
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reduced to an amine or removed entirely using radical nitration,57 therefore the use of 3-
nitroindole as substrate provides flexibility in further structural modification compared to 
3-alkylindoles. The vinyl group can also undergo a Heck reaction,58,59 olefin metathesis60 
or cyclopropanation. As for the geminal diesters, they can undergo transesterification or 
basic hydrolysis as well as mono-decarboxylation. The presence of these functional 
groups provides the handle for further derivatisation, therefore this creates a path to access 
complex analogues of cyclopenta[b]indolines. 
 As mentioned earlier, cycloadditions utilising VCPs achieve excellent atom 
efficiency compared to TMM which have trimethylsilyl acetate as side product. 
Furthermore, the variation in olefin terminal and electron-withdrawing groups (carbonyls 
or nitriles) provides substrate scope for investigation. 
 This chapter will discuss the optimisation process to develop a diastereoselective 
[3 + 2] cycloaddition method for VCPs and 3-nitroindoles and investigation of the 
substrate scope. Subsequently, the obtained cyclopenta[b]indolines will be subjected to 
various chemical transformations to demonstrate their potential for further derivatisation. 
 It is of note that as this study was conducted, a parallel study using vinylaziridine 
and 3-nitroindole to construct pyrroloindolines was performed at our lab.61 Partial results 
from that study, in particular the chemical transformation of pyrroloindoline, will be 
reported in this chapter. Also as this study was being concluded, Vitale and co-workers 
reported similar investigation with opposite stereochemical outcome,62 which will be 
discussed in the following section. 
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4.3 Results and discussion 
4.3.1 Optimisation of reaction conditions 
 The study was initiated with 3-nitro-1-tosylindole 106a and diethyl 2-
vinylcyclopropane-1,1,-dicarboxylate 104 as reaction partners to investigate the proposed 
dearomative cycloaddition. Vinylcyclopropane 104 was prepared from commercially 
available diethyl malonate and trans-1,4-dibromo-2-butene under basic conditions in 
good yield – in both cases the spectra data obtained matched that reported in the literature 
(Scheme 44a). The 1H NMR data of 104 was consistent with literature.63 
On the other hand, the electrophilic 3-nitroindole 106a was prepared by the N-
tosylation of indole, follow by a selective nitration at C3 position using in situ generated 
acetyl nitrate at −70 °C (Scheme 44b). The lone pair of electrons on indole nitrogen 
inductively accumulates electron density at C3 position and hence making it nucleophilic 
towards acetyl nitrate. However, it has been reported that nitration at C6 position can 
occur substantially at temperature higher than −50 °C (5% and 25% of C6 nitration at −50 
°C and −10 °C respectively).64 Similarly, this nitration method was employed instead of 
classical arene nitration method as the latter is not chemoselective and may nitrate the 
indole phenyl ring. The 1H NMR data of 106a was consistent with literature.65 
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Scheme 44: Preparation of starting materials for dearomatisation reaction. 
 In a parallel study conducted in our lab using vinylaziridine in cycloaddition with 
3-nitroindoles 106a, the combination of BPhen and Pd2(dba)3·CHCl3 was identified as a 
suitable catalyst system for the reaction.61 Therefore, this catalyst and ligand combination 
was initially deployed in the proposed reaction. Gratifyingly, the reaction proceeded in 
good yield, providing the desired cyclopenta[b]indoline 107a/107a', but as a mixture of 
cis (favoured) and trans diastereoisomers in low dr (Table 4, entry 1). Due to the 
dearomatisation of the indole ring, the methine carbon adjacent to N-tosyl group was 
converted from sp2 to sp3 hybridisation and hence the corresponding singlets shifted up-
field from 8.57 ppm (106a) to 6.36 (107a') and 6.31 (107a) ppm in the 1H NMR spectrum. 
Also, as a result of the reaction, the allylic methine proton experiences a deshielding effect 
due to the presence of nitro group in close proximity. In the 1H NMR spectrum of 
107a/107a', the corresponding signal was shifted down-field from 2.57 ppm (104) to 3.41 
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(107a') and 3.30 ppm (107a). In the 13C NMR spectrum of the mixture, the C-NO2 signal 
shifted up-field from 133.2 ppm (106a) to 102.7 and 101.3 ppm (107a/107a'). More 
importantly, the signal of the methine carbon adjacent to N-tosyl group shifted up-field 
significantly from 127.8 ppm (106a) to 73.7 and 73.3 ppm (107a/107a') as a result of the 
indole dearomatisation. The determination of their relative stereochemistry will be 
discussed later in the dearomatised cycloadducts 108a and 108a'. 
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Table 4: Optimisation of dearomative cycloaddition between vinylcyclopropane-1,1-





Solvent dr (trans:cis)b Yieldc 
1 CH3  MeCN 1:1.3 62 
2 CF3  MeCN 1.3:1 95 
3 CF3  THF 1.7:1 95 
4d CF3 I (0.3) THF 3.1:1 95 
5d CF3 Br (0.3) THF 2.8:1 97 
6d CF3 Cl (0.3) THF 2.6:1 92 
7 CF3 I (1.0) THF 3.7:1 74 
8d CF3 I (0.5) THF 4.3:1 (80) 
9d CF3 LiI (0.5) THF N/A Trace 
10d CF3 ClO4 (0.5) THF 2.0:1 75 
a Reactions carried out at 0.1 M, rt with 5 mol% Pd2(dba)3∙CHCl3 and 10 mol% BPhen with 1.0 eq. of VCP 
104/105 and 1.3 eq. of indole 106a. 107a/108a refers to the trans diastereoisomer and 107a'/108a' to the 
cis diastereoisomer. b Determined from the 1H NMR of the crude reaction mixture. c Yield was calculated 
from 1H NMR of the reaction mixture using mesitylene as an internal standard, with isolated yield in 
brackets where applicable. d 1:1 molar ratio of indole:VCP utilised. 
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It was postulated that the reversibility of the addition of the VCP-derived 
zwitterionic dipole to the 3-nitroindole could play a role in determining the ultimate 
diastereoselectivity of the reaction. As such the di(trifluoroethyl) ester analogue 105 was 
investigated as this would afford a more stable dipole and potentially facilitate this 
reversible addition.32 Interestingly, deploying 105 in the reaction reversed the sense of 
selectivity, favouring trans cyclopenta[b]indoline 108a in MeCN, while switching the 
solvent to THF increased the dr moderately (Table 4, entries 2 and 3). In the 1H NMR 
analysis of the crude mixture (Figure 32), the ratio of diastereoisomers was determined 
by measuring the integration ratio of the singlets at 6.32 (108a') and 6.24 (108a) ppm, 
which were assigned as the methine protons adjacent to the NTs group (TsN-CH). 
Chromatographic purification and crystallisation of the mixture allowed the isolation of 
pure 108a, which was later determined as the trans diastereoisomer by X-ray 




Figure 32: Determination of diastereoselectivity using 1H NMR spectrum of the reaction 
crude for 108a/108a': The singlets at 6.32 (108a') and 6.24 (108a) ppm correspond to 
the methine proton adjacent to NTs group (HC-NTs), and the integration ratio of these 
two singlets reflect the diastereoselectivity of the reaction. Crude 1H NMR spectrum in 
this figure was obtained from entry 3 (Table 4), which provided a dr of 1.7:1 (108a: 
108a'). After chromatographic purification and serial recrystallisation, a crystalline 
solid was obtained and its 1H NMR spectrum only displayed the singlet at 6.24 ppm. 
Subsequent X-ray crystallography analysis revealed that the crystalline solid was the 
trans diastereomer 108a (Figure 33), and hence the singlet at 6.24 ppm was assigned to 
the HC-NTs from 108a. 
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Figure 33: Thermal Ellipsoid Plot for the crystal structure of 108a. Thermal ellipsoids 
are shown at the 50% probability level. All methyl and aromatic-ring hydrogen atoms 
are omitted for clarity. 
It was postulated that π-σ-π interconversion between the two diastereomeric 
zwitterionic π-allylpalladium complexes derived from the vinylcyclopropane adding to 
the 3-nitroindole could be an important control factor in determining the dr of the 
reaction.66 Given that halide additives are known to increase the rate of π-σ-π 
interconversion,66 these were then investigated in the reaction (Figure 34). In line with 
this, it was found that the use of halide additives had a positive effect on the dr of the 
reaction (Table 4, entries 4-8), with 0.5 equiv of nBu4NI proving optimal (Table 4, entry 
8).  
The NBu4I additive can play a role during the Michael addition and the subsequent 
intermediate Pd-π-allyl complex. During the Michael addition, NBu4I stabilised the 1,3-
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dipole derived from 105 (Figure 34), hence increasing the reversibility of Michael 
addition with indole 106a. After the Michael addition and during the transition state, the 
tetrabutylammonium cation stabilised the anion, therefore decreasing the rate of 
nucleophilic attack (decreasing k2 and k2'). Meanwhile, the iodide allowed the 
interconversion between the η3 and η1 intermediates, therefore accelerating the π-σ-π 
interconversion between TS1 and TS2 (increasing k1). Curtin–Hammett condition was 
achieved when k1 > k2 and k2', therefore the diastereoselectivity of the reaction relied 
solely on the free energy of TS1 and TS2, where TS1 was presumed to have a lower 
energy as 108a was observed as the major diastereomer.  
The individual effect of the tetrabutylammonium cation and iodide was then 
investigated. When LiI was introduced as the iodide source in the absence of 
tetrabutylammonium cation, only trace amount of product was detected (Table 4, entry 
9). The low yield could be due to catalyst poisoning via palladate formation stabilised by 
Li+.67 On the other hand, the introduction of tetrabutylammonium perchlorate as a source 
of NBu4+ without a halide only resulted in a slight increase in dr compared to that of when 
no additive was added (Table 4, entry 10). Therefore, both ionic species in NBu4I were 
crucial to provide diastereoselective control. 
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Figure 34: Addition of tetrabutylammonium iodide increases the rate of π-σ-π 
interconversion by stabilising TS1 and TS2. 
 Lowering of the temperature (Table 5, entry 11) had no effect on the dr, but 
resulted in a slight decrease in yield while increasing the temperature to 40 °C (Table 5, 
entry 12) moderately reduced the dr. A screen of other solvents (Table 5, entries 13-16) 
resulted in lower yields and diastereoselectivity, indicating that THF was optimal.  
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Table 5: Optimisation of dearomative cycloaddition between vinylcyclopropane-1,1-
dicarboxylates and 3-nitro-1-tosylindole: Temperature and solvent screening.a 
 
Entry Solvent Temperature dr (trans:cis)b Yieldc 
11 THF 0 °C 4.2:1 77 
12 THF 40 °C 3.4:1 80 
13 DCM rt 1.7:1 74 
14 Dioxane rt 2.4:1 74 
15 MeCN rt 1.8:1 75 
16 PhMe rt 4.0:1 64 
a Reactions carried out at 0.1 M, rt with 5 mol% Pd2(dba)3∙CHCl3 and 10 mol% BPhen with 1.0 eq. of VCP 
105 and 1.3 eq. of indole 106a. 108a refers to the trans diastereoisomer and 108a' to the cis diastereoisomer. 
b Determined from the 1H NMR of the crude reaction mixture. c Yield was calculated from 1H NMR of the 
reaction mixture using mesitylene as an internal standard. d 1:1 molar ratio of indole:VCP utilised. 
 
Using THF as the solvent a selection of other ligands (Figure 35) were trialled in 
the reaction (Table 6, entries 17-27), including diphosphine, diamine and chiral Trost 
ligands, but while some resulted in an increased yield the dr was significantly lower than 
BPhen for all cases. Recent literature suggested that Pd(0) with electron-rich dba 
analogues displayed enhanced reactivity due to the destabilisation of back-bonding 
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therefore increasing dba ligand dissociation.68 However in this study, the use of Pd2(4,4'-
OMe-dba)3∙CHCl3 provided similar yield and dr to that of Pd2(dba)3∙CHCl3. As such, the 
reaction scope was investigated with the optimum conditions in entry 8 (Table 4). The 
catalyst/ligand loading can be lowered to 2.5 mol%/5 mol% respectively, however a 
noticeable drop in dr was observed (Table 6, entry 29). 
Figure 35: Candidates for ligand screening. 
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Table 6: Optimisation of dearomative cycloaddition between vinylcyclopropane-1,1-
dicarboxylates and 3-nitro-1-tosylindole: Ligand and catalyst screening.a 
 
a Reactions carried out at 0.1 M, rt with 5 mol% Pd catalyst and 10 mol% ligand with 1.0 eq. of VCP 105 
and 1.3 eq. of indole 106a. 108a refers to the trans diastereoisomer and 108a' to the cis diastereoisomer. b 
Determined from the 1H NMR of the crude reaction mixture. c Yield was calculated from 1H NMR of the 
Entry Catalyst Ligand dr 
(trans:cis)b 
Yieldc 
17d Pd2(dba)3∙CHCl3 dppe 2.2:1 76 
18d Pd2(dba)3∙CHCl3 (R)-BINAP 1.1:1 66 
29d Pd2(dba)3∙CHCl3 Bipy 1.9:1 92 
20d Pd2(dba)3∙CHCl3 Phen 2.7:1 97 
21d Pd2(dba)3∙CHCl3 neocuproine 2.0:1 84 
22d Pd2(dba)3∙CHCl3 phen-dione 1.9:1 25 
23d Pd2(dba)3∙CHCl3 hydroxy phen 1.8:1 96 
24d Pd2(dba)3∙CHCl3 (S,S)-DACH-Ph Trost 
ligand 
1.6:1 67 
25d Pd2(dba)3∙CHCl3 (R,R)-DACH-Pyridyl 
Trost ligand 
1.5:1 100 
26d Pd2(dba)3∙CHCl3 (R,R)-ANDEN-Ph Trost 
ligand 
1.2:1 71 
27d Pd2(dba)3∙CHCl3 (S,S)-ANDEN-Ph Trost 
ligand 
1.2:1 83 
28 Pd2(4,4'-OMe-dba)3∙CHCl3 BPhen 4.2:1 81 
29d Pd2(dba)3∙CHCl3e BPhene 3.1:1 82 
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reaction mixture using mesitylene as an internal standard. d 1:1 molar ratio of indole:VCP utilised. e 
Pd2(dba)3∙CHCl3 (2.5 mol%), BPhen (5 mol%) (Halving catalyst & ligand loadings). 
 
4.3.2 Reaction scope 
4.3.2.1 Preparation of indole and VCP substrates 
 Derivatives of 3-nitroindoles and VCPs were prepared in order to explore the 
substrate scope of the dearomatisation reaction. Firstly, ten analogues of N-tosylated 3-
nitroindoles were prepared (Scheme 45) using the same method as shown in Section 4.3.1. 
 
R = 5-Cl 87%  106b, 15% 
R = 5-Br 90%  106c, 79% 
R = 5- CO2Me 68%  106d, 62% 
R = 5-CN 51%  106e, 59% 
R = 5-NO2 88%  106f, 60% 
R = 5-Me 90%  106g, 19% 
R = 5-OMe 90%  106h, 20% 
R = 6-Cl 72%  106i, 43% 
R = 7-Cl 82%  106j, 64% 
R = 4-CO2Me 71%  106k, 33% 
 
Scheme 45: Two-step preparation of N-tosylated 3-nitroindoles 106b-k, provided by D. 
Rivinoja (University of Wollongong). 
 Other indoles with different N-protecting groups and electron-withdrawing group 
on C3 were also prepared to investigate the tuning of the electron-withdrawing groups 
(Scheme 46). Nitro indole 109a was prepared firstly by indole nitration at C3, followed 
by triflation on the indole nitrogen. In the 1H NMR spectrum of nitro indole 109a, the 
absence of doublet at 6.52 ppm suggested that the nitration of C3 was successful, while 
224 
the absence of broad singlet at 12.65 ppm indicated that the installation of triflate group 
on indole nitrogen was successful. Similarly in the 1H NMR spectrum of indole 109d, the 
absence of a doublet at 6.52 ppm and broad singlet at 12.70 ppm indicated that the 
installation of -C(O)CF3 at C3 and tosyl group on indole nitrogen were successful. 
 
Scheme 46: Preparation of indole substrates with varied N-protecting groups and 
electron-withdrawing group on C3. Conditions: (a) NBS, AgNO3, MeCN, 16%. (b) 
DMAP, Et3N, CH2Cl2, trifluoromethanesulfonic anhydride, 65%. (c) BzCl, NaOH, n-
Bu4NHSO4, CH2Cl2, 33%. (d) HNO3, Ac2O, −70 °C, 11%. (e) HNO3, Ac2O, −70 °C, 28%. 
(f) TFAA, DMF, 80%. (g) TsCl, NaOH, n-Bu4NHSO4, CH2Cl2, 7%. Indole substrates 109b 
and 109c were provided by D. Rivinoja (University of Wollongong). 
 As observed from Section 4.3.1, the change from VCP 104 to 105 significantly 
enhanced the diastereoselectivity due to increasing electron-withdrawing capability in 
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alkyl terminal and hence stabilisation of 1,3-dipole. In order to study the influence of 
substitution on the terminal vinyl position, a VCP analogue 110 was prepared from the 
Grubbs metathesis of 105 with styrene in a good yield of 79% (Scheme 47). In the 1H 
NMR spectrum of 110, the aromatic proton signals (7.30, 7.26 – 7.23 ppm) and olefin 
proton signals (doublet at 6.69 ppm for Ph-CH=CH and doublet of doublets at 5.83 ppm 
for Ph-CH=CH) suggested that the Grubbs metathesis was successful. The coupling 
constant for the olefin proton signals was 15.5 – 16.0 Hz, indicating that the (E) olefin 
isomer was obtained as the sole product. 
Besides, a VCP analogue 111 with dibenzyl esters was also synthesised in a good 
yield of 84% using similar preparation method of VCPs 104 and 105 (Scheme 47). In the 
1H NMR spectrum of 111, the characteristic cyclopropane signals were observed at 2.63, 
1.76, and 1.60 ppm. 
 
Scheme 47: Preparation of VCP derivatives 110 and 111. 
 
4.3.2.2 Scope of reaction 
Using the optimised experimental conditions (entry 8, Table 4), various 
substituted N-tosyl-3-nitroindoles 106a-k were subjected to the dearomatisation reaction 
with VCP 105 (Table 7). In most cases, the reaction proceeded in high yield (73 – 88%) 
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and good diastereoselectivity (3:1 to 4.3:1). Halogen substituents were tolerated by the 
Pd(0)-catalyst, providing products 108b, 108c, 108i and 108j. It is important that these 
halides were not affected by our catalyst system so that they can be amenable to further 
coupling reactions. Strongly electron-withdrawing groups (products 108d, 108e and 
108f) and an inductively donating methyl group (108g) also afforded the desired products. 
However, a 5-methoxy substituted 3-nitro-indole proved unreactive – presumably due to 













a Diastereoselectivity (trans:cis) was determined from the 1H NMR of the crude reaction mixture. All yields 
are for isolated products after chromatographic purification.  
  
Curiously, when a methyl ester substituent was present at the 4-position of the 
starting indole 106k, an inseparable mixture of unidentified products resulting from 
multiple VCP additions to the indole was obtained using the standard optimised 
conditions. This was suggested based on the 1H NMR spectrum of the mixture, where a 
higher integration number was observed for CH2CF3 at approximately 4.50 ppm (Figure 
36). Furthermore, all the olefin signals appeared as multiplets at around 5.00 – 5.50 ppm, 
which suggests internal alkene was present instead of terminal alkene. Besides, in the 13C 
NMR spectrum, five carbonyl signals were observed (165.4 – 168.0 ppm) while the 
proposed desired cycloadduct has only three carbonyls (Figure 36). 
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Figure 36: 1H and 13C NMR spectra of the product derived from the cycloaddition of 
VCP 105 and 3-nitroindole 106k with methyl ester at C4. 
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 However, when the NBu4I additive was absent, the reaction proceeded smoothly 
but providing the cis diastereoisomer 108k' with almost complete selectivity (Scheme 
48). Unlike other substituents at C5, C6 or C7 of indole substrates, the methyl ester 
substituent at the C4 position of indole is in close proximity to the vinyl group or Pd-π-
allyl complex during the reaction, and hence it may create steric hindrance which dictates 
the cis diastereoselectivity of the reaction – this is discussed in more detail below. The 
relative stereochemistry of product 108k' was determined by X-ray crystallographic 
analysis of its ester hydrolysis product 120 (later in Section 4.3.3, Scheme 52b). A similar 
reversal in diastereoselectivity was observed with the analogous vinylaziridine substrate 
in another study conducted parallel to this study.61 
Scheme 48: Absence of NBu4I additive reversed the diastereoselectivity of the reaction. 
Diastereoselectivity (cis:trans) was determined from the 1H NMR of the crude reaction 
mixture. 
 Variation of the VCP was next investigated and interestingly, when a styryl-
cyclopropane 110 was used, product 112 was obtained but a significant decrease in 
diastereoselectivity was observed (Scheme 49). Use of dibenzyl 2-vinylcyclopropane-
1,1-dicarboxylate 111 gave the product 113 with slightly lowered dr and as expected, 
when the NBu4I additive was absent, the dr dropped to 1:1.3 where the cis isomer is the 
major diastereomer. These two experiments provide additional evidence for our theory of 
reversible Michael attack and a π-σ-π interconversion being important for the selectivity. 
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Scheme 49: Variation of the vinylcyclopropane. Diastereoselectivity (trans:cis) was 
determined from the 1H NMR of the crude reaction mixture. All yields are for isolated 
products after chromatographic purification. 
 The focus was then switched to the electron-withdrawing groups on the indole 
substrate, as they are likely crucial to the reactivity of the indole starting material to the 
dearomatisation process (Scheme 50). The reaction proceeds, but the diastereoselectivity 
decreases when the indole nitrogen is protected with a trifluoromethanesulfonate group 
(product 114a, Scheme 50). Having an N-benzoyl-protected indole nitrogen gives similar 
diastereoselectivity to that of the tosyl counterpart but with a significantly poorer yield 
(product 114b, Scheme 50). Furthermore, in the case of the N-Bz cycloadduct, the 
conditions reported here provide an improved diastereoselectivity compared to the 
reported diastereoselectivity of 1:1 where dppe ligand and acetonitrile were used in the 
absence of tetrabutylammonium halide.62 As a control experiment, no reaction occurred 
when the indole bears an N-methyl group, which increases the electron density of the 
indole substrate and hence reduces its electrophilicity for the Michael addition of 1,3-
dipole (product 114c, Scheme 50). Lastly, no conversion was observed when the nitro 
group at C3 was replaced with a trifluoroketone, suggesting that the nitro group at C3 




Scheme 50: Variation of the N-protecting groups and electron-withdrawing groups at C3 
on the indole substrates. Diastereoselectivity (trans:cis) was determined from the 1H 
NMR of the crude reaction mixture. All yields are for isolated products after 
chromatographic purification. 
 
4.3.3 Chemical transformation of cyclopenta[b]indolines and pyrroloindoline 
 To demonstrate the synthetic utility of the densely cyclopenta[b]indolines and 
pyrroloindoline functionalised cycloadducts, the reduction of nitro group to an amine was 
first investigated. The reduction of the nitro group is of interest since pyrroloindolines 
with an amine group at C3a feature in natural bioactive compounds, such as 
psychotrimine (antibacterial).40 Moreover, the installation of an amine group may allow 
diazotisation, which can allow replacement of the amine group with a halide for later 
substitution or coupling reactions.69 The investigation was initiated using the trans 
diastereomer of pyrroloindoline 115 with a nitro group at C3a, which was obtained from 
a parallel study in our laboratory (Scheme 51a).61 Upon treatment of zinc powder under 
acidic condition, it was discovered that the nitro reduction was required to be performed 
233 
at low temperature (0 °C) or epimerisation of amine 116 could occur at room temperature 
or higher temperature. The degree of epimerisation is proportional to the temperature of 
the reaction. The zinc-mediated reduction of nitro group under acidic condition proceeds 
via a radical mechanism, where zinc powder acts as a reducing agent for the nitro group 
and subsequent intermediates through SET, while TMSCl in MeOH provides the proton 
source for the reaction intermediates and final product.  
The same reduction conditions were then applied to 108a and 108k' which 
provided the corresponding amines 117a and 117k' in high yield and with the same dr as 
the starting cyclopent[b]indoline (Scheme 51b). In the 1H NMR spectrum of 117a, the 
signals for HC-NTs and CH-CH=CH2 shifted up-field compared to the substrate 108a 
due to the loss of two electronegative oxygens during reduction of nitro group (HC-NTs: 
shifted from 6.24 to 5.61 ppm; CH-CH=CH2: shifted from 3.30 to 2.85 ppm). Similarly, 
in the 13C NMR spectrum of 117a, the signal for C-NH2 was detected at 79.7 ppm, which 
was shifted up-field from 100.8 ppm for C-NO2 in substrate 108a. Importantly, the 
presence of the newly formed amine group was indicated in the 1H NMR (2H broad 
singlet at 4.08 ppm) and IR (3510 and 3263 cm-1) spectra. 
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Scheme 51: Chemical transformation of nitro group in pyrroloindoline and 
cyclopenta[b]indolines: (a) Zinc-mediated reduction of nitro group in pyrroloindoline 
115 under acidic condition. (b) Zinc-mediated reduction of nitro group in 
cyclopenta[b]indolines 108a and 108k' under acidic condition. (c) Radical denitration of 
pyrroloindoline 115. Diastereoselectivity (trans:cis) was determined from the 1H NMR of 
the crude reaction mixture. 
Apart from reducing the nitro group to an amine, the nitro group can also be 
completely removed through radical denitration. Pyrroloindoline 115 was treated with 
Bu3SnH and AIBN to yield the denitrated cycloadduct 118 in a moderate yield of 62% 
(Scheme 51c). The denitration also proceeds through a radical pathway where the •SnBu3 
radical (initiated by AIBN) adds on to one of the oxygen in nitro group, follow by 
fragmentation to eliminate the nitro-SnBu3 chain, and eventually a hydrogen abstraction 
by Bu3SnH to furnish the product 118.70 The formation of denitrated 118 was evidenced 
by its 1H NMR spectrum, where signals for protons in close proximity to the substrate’s 
nitro group were shifted up-field (NTs-CH-NTs: shifted from 7.07 to 6.44 ppm; CH-
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CH=CH2: shifted from 3.62 – 3.56 to 3.07 – 3.00 ppm). Notably, as the nitro group was 
replaced with a hydrogen sourced from Bu3SnH, the relevant proton displayed a triplet at 
3.68 ppm, which split the NTs-CH-NTs signal into a doublet in the spectrum at 6.44 ppm. 
Also due to the substitution of nitro group with hydride, the corresponding carbon shifted 
up-field significantly from 101.6 ppm to 49.7 ppm. 
The use of diethyl ester VCP 104 in dearomatisation yielded cycloadducts 
107a/107a' in poor diastereoselectivity (Section 4.3.1). And hence cyclopent[b]indoline 
108a was subjected to transesterification in ethanol to access cycloadduct 107a in 
diastereo-enriched form, where the dr remained the same as the substrate 108a (Scheme 
52a). The obtained cyclopent[b]indoline 107a was then subjected to Krapcho 
decarboxylation conditions. However instead of undergoing decarboxylation, a 
rearomative denitration occurred to give rise to cyclopent[b]indole 119 (Scheme 52 a). In 
the 1H NMR spectrum of 119, no singlet was observed at 6.30 – 6.40 ppm, suggesting 
that the proton in Ts-N-CH was absent following rearomatisation. Besides, the proton 
integration values for OCH2CH3 remained the same as the substrate, indicating that 
decarboxylation did not take place. In the 13C NMR spectrum of 119, a total of six 
quaternary aromatic carbon signals were detected, while no signal was detected around 
100.0 and 73.0 ppm, suggesting that the signals for C-NO2 and Ts-N-CH shifted down-
field to the aromatic region due to rearomative denitration. The proposal of rearomative 
denitration to yield cyclopent[b]indole 119 was also supported by HRMS analysis where 
the sodiated adduct was detected with good accuracy. This cyclopent[b]indole features as 
the core unit of many alkaloids that display broad spectrum of pharmacological 
properties, such as paspaline (Maxi-K channel antagonist, potential treatment for 
Alzheimer’s disease)71 and yuehchukene (antifertility agent)72.  
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Scheme 52: Chemical transformation of densely functionalised cyclopenta[b]indolines: 
(a) Transesterification of 108a to yield 107a, follow by rearomative denitration to form 
cyclopent[b]indole 119. (b) Face-selective hydrolysis of 108k' to yield carboxylic acid 
120. 
 In order to demonstrate the utility of the geminal diesters, cyclopenta[b]indoline 
108k' was treated with ammonia in methanol to undergo basic hydrolysis (Scheme 52b). 
Interestingly, basic hydrolysis selectively occurred at the ester on the convex face (same 
face as the nitro and vinyl groups), while the ester on the opposite concave face underwent 
transesterification with the methanol solvent (Figure 37). It was hypothesised that both 
geminal diesters in the substrate 108k' underwent transesterification with the methanol 
solvent in the first place, but subsequently the basic hydrolysis only occurred at the least 
hindered convex face to yield 120. This result not only showcased the utility of the 
geminal diesters, but also the selective facial differentiation of these ester groups. 
Moreover, the resulting carboxylic acid 120 was also crystalline, which allowed the 
determination of the cis-relationship between the vinyl and nitro groups by X-ray 
crystallography (Figure 37). This thereby verifies the switch of diastereoselectivity when 
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indole substrate 106k underwent dearomative cycloaddition with VCP 105 (Section 
4.3.2.2).  
 
Figure 37: Crystal structure of 120 obtained from the face-selective hydrolysis of 108k'. 
As the nitro and vinyl groups are on the same face in 120, this supports that 108k' is has 
cis relative stereochemistry. 
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4.3.4 Proposed reaction mechanism 
 
Figure 38: Proposed mechanism. 
The reaction is likely initiated by Pd(0)-activation of the VCP by oxidative 
addition to form 1,3-dipole A, follow by a Michael addition with the electron-deficient 
indole 106 to form intermediates TS1 or TS2 (Figure 38). Subsequently, an irreversible 
ring-closure of TS1 or TS2 furnishes the cyclopenta[b]indoline products 108/108'. The 
final ring-closure step was revealed as irreversible based on the observation of control 
experiments. The diastereomeric ratio remained the same after a mixture of 108a/108a' 
(1.7:1 dr) was subjected to standard dearomatisation condition (Scheme 53a). Meanwhile, 
after subjecting 113 and 105 into standard dearomatisation condition, 113 was fully 
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recovered with no sign of 108a detected (Scheme 53b), indicating that no incorporation 
of 105 and hence verifying that the ring-closure step is irreversible. 
 
Scheme 53: Control experiments demonstrating irreversibility of the final ring-closure 
step. 
The stereochemical outcome in this study attracts scope for discussion, especially 
as it is opposite to the concurrent report from Vitale and co-workers,62 where the cis 
diastereomer was the major product. Due to planar chirality, the Pd-stabilised zwitterionic 
1,3-dipole A can either attack the si or re face of indole substrate 106, therefore forming 
intermediates TS1 or TS2. After Michael addition and prior to ring-closure, these 
intermediates can undergo π-σ-π facial interconversion. Although the current process 
provides a racemic mixture of products, both enantiomers of the dipole (A and enant. A) 
and their resultant Michael adducts, need to be acknowledged as they allow products of 
the same absolute configuration to emerge from opposite enantiomers of the dipole. 
Besides, an equilibrium between A and enant. A is also likely to be present due to π-σ-π 
interconversion. These factors are also crucial for the development of the future 
enantioselective variant of this study. 
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The trans diastereomer 108 is the major product for almost all cases in this study, 
suggesting that the irreversible ring-closure via TS1 and enant. TS1 is the favourable 
pathway, which is tentatively attributed to the stabilisation of TS1 by a cation-π-
interaction between the electron-rich indole backbone and the cationic π–allyl Pd 
complex.73 Based on the results obtained during reaction optimisation, the trans 
diastereoselectivity is also attributed to the reversibility of the Michael addition (control 
via stabilisation of 1,3-dipole) and the facile π-σ-π interconversion between TS1 and TS2 
with their enantiomers (mediated using NBu4I additive). For instance, the formation of 
113 is trans diastereoselective in the presence of halide additive but reverts back to a 
poorly diastereoselective reaction when the additive is absent. As proposed by Trost,66 
the halide additive results in a Curtin–Hammett scenario, where swift interconversion of 
the intermediate Pd-allyl complexes occurs, and hence funnelling the reaction to proceed 
via TS1 selectively, which should be lower in energy than TS2. 
 Comparing the use of VCPs 104 and 105 in the absence of halide additives (entries 
1 and 2, Table 4), a switch of diastereoselectivity is observed. This indicates that 
increasing stability of the malonyl-anion A (derived from 105) allows for some 
interconversion between TS1 and TS2 outside of the π-σ-π pathway through reversible 
addition of the dipole. 
For indole substrate 106k where a methyl ester substituent is present at C4, the 
diastereoselectivity completely switches to the cis cycloadduct. This complete switch of 
diastereoselectiviy is likely caused by a disfavoured steric interaction between the C4 
ester and the Pd-allyl unit in TS1 over-riding the π-stacking interaction, thereby 
promoting the reaction to proceed via TS2 instead. 
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Vitale and co-workers postulated TS3 (Figure 38, box) during the cycloaddition 
of dicyano VCP to 3-nitroindole in order to place the Pd-allyl moiety in a pseudo-
equatorial position, therefore minimising diaxial interaction.62 However, this proposed 
transition state is probably unfavourable in our study due to steric reasons. One of the 
cyano group in TS3 is in pseudo-axial position adjacent to the indole backbone, which is 
an unfavourable arrangement for the larger ester groups of the 1,1-diester-derived VCPs. 
4.4 Conclusion and future work 
 In summary, the Pd-catalysed dearomative [3 + 2] cycloaddition of 3-nitroindoles 
with 2-vinylcyclopropane-1,1-dicarboxylates was achieved in high yields and moderate-
good diastereoselectivity (up to 88% yield and 4.3:1 dr). Critically, this 
diastereoselectivity was complementary to the concurrent report on vinylcyclopropane 
addition to electron-deficient indoles, which is proposed to be due to the presence of a 
halide additive allowing for Curtin–Hammett control of the reaction. Furthermore, the 
densely functionalised cyclopenta[b]indoline products demonstrate potential to undergo 
further chemical transformation and provide access to other core structures. Of particular 
note is the facial differentiation of the geminal diester group, highlighting the versatility 
of 1,1-diester-derived vinylcyclopropanes, which can also be prepared in a single step 
from commercial materials and are easily handled and stored.  
In a related study in our research group, pyrroloindolines were constructed from 
the dearomative cycloaddition of vinylaziridine and 3-nitroindole in excellent dr (up to 
98:2 for trans diastereomer), under similar reaction conditions to this study without the 
halide additive.61 In this study, even with the addition of halide additive, the magnitude 
of diastereoselectivity was lower than the parallel study. And hence computational studies 
can be conducted to understand the dr discrepancies in the use of vinylaziridine and VCP 
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as 1,3-dipole sources, in particular the free energy of each transition state between 
Michael addition and ring-closure. Moreover, computational studies can also provide 
insight into the contribution of nitro group in the reaction. It was hypothesised that the 
nitro group reverses the polarity of the indole core and tunes it into an electrophile. Due 
to the proximity between the nitro group and the Pd-π-allyl complex, it is possible that 
the nitro group can also have influence to the stereochemistry, either by steric or 
electronic effect. Thus the interaction between the nitro group and Pd-π-allyl complex 
should be modelled computationally to provide clearer insight to the reaction. 
Furthermore, developing enantioselective variants of the reaction is also an 
important next phase of the study. Despite the poor diastereoselectiviy obtained in the 
preliminary optimisation using chiral phosphorus ligand and Trost ligands (entries 18, 24 
– 27, Table 6), there is still scope for other chiral ligands to develop an enantioselective 
and diastereoselective method for the preparation of cyclopenta[b]indolines. In a 
preliminary study from our group, instead of using BPhen as the ligand, diamine chiral 
ligand (S)-t-BuPyOx74 was used in the synthesis of pyrroloindolines from vinylaziridines 
and 3-nitroindoles under Pd-catalysed dearomative cycloaddition (Scheme 54).75 The 
bulky t-butyl group on the chiral carbon was hypothesised to provide facial selectivity in 
the transition state therefore establishing the enantioselectivity of the reaction. Although 
slight erosion was observed in diastereoselectivity compared to the BPhen counterpart, a 
promising initial ee of 46% was observed in the preliminary screening. This result is 
encouraging and the chiral ligand should be applied to the reaction described in this 
chapter. Since enantioselectivity is attributed to the bulky t-butyl group, other bulky group 
such as aryl group can be attempted in the condition screening. 
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Scheme 54: Enantioselective preparation of pyrroloindoline through Pd-catalysed 
cycloaddition of 3-nitroindoles with vinylaziridines using diamine chiral ligand (S)-t-
BuPyOx.  
 The ring-strain present in three-membered rings granted these scaffolds the 
reactivity to participate in various reactions, especially in cycloaddition with 
dipolarophiles. While cyclobutane has a strain energy value of 26.7 kcal/mol, 
interestingly this value is fairly close to that of cyclopropane, which has a strain energy 
value of 27.5 kcal/mol.76 Although the cycloaddition reactions of donor-acceptor 
cyclobutanes is less explored compared to the three-membered counterparts, existing 
literature mostly focusses on the use of Lewis acid catalysis to activate this four-
membered ring.77-82 To the best of our knowledge, Pd-catalysed cycloaddition of 
vinylcyclobutane with dipolarophiles has not been reported, therefore we were intrigued 
to investigate if vinylcyclobutane dicarboxylate 121 can be synthesised and subjected to 
the cycloaddition with 3-nitroindole 106a to yield cycloadduct 122a (Scheme 55a). 
Hexahydrocarbazole 122a is featured in many bioactive alkaloids,83 for instances 
strychnine84 (toxin) and vindoline85 (precursors for oncolytic agent vinblastine). 
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 The preparation of vinylcyclobutane 121 was found to be challenging during a 
preliminary study conducted as part this investigation (Scheme 55b). Firstly, substrate 
dimerisation occurred during the olefin metathesis of 123 with allyl acetate or allyl methyl 
carbonate, and the undesired dimers were inseparable from their respective products 124 
or 125. Furthermore, conversion was not observed during the cyclisation step for both 
precursors 124 and 125. In the future, optimisation of olefin metathesis should be carried 
out to minimise dimerisation and hence pure cyclisation precursors can be obtained. 
Besides, screening of alternative cyclisation method is also required to access 
vinylcyclobutane 121. Due to time constraint, no further investigation was carried out to 
optimise these reaction conditions. 
Scheme 55: (a) Proposed [4 + 2] cycloaddition of vinylcyclobutane dicarboxylate 121 




Majority of the organic syntheses and molecule characterisation were performed 
by Y. S. Gee, with the exception of a few substrates which are stated as follow. 
Preliminary optimisation of reaction condition (entries 1 – 3, Table 4) was conducted by 
Dr S. Wales (University of Wollongong). VCP 104, several indole substrates (106b-k, 
109b-c) and cycloadduct 107a/107a' were provided by D. J. Rivinoja (University of 
Wollongong) in a collaborative project which was conducted concurrently with this study. 
X-ray crystallography was performed by Dr M. Gardiner (University of Tasmania). 
General experimental details for organic syntheses and molecule characterisation 
are stated in Chapter 2 Section 2.5.1. 
 
4.5.1 Preparation of 2-vinylcyclopropane-1,1-dicarboxylates  
Diethyl 2-vinylcyclopropane-1,1-dicarboxylate (104) 
 
The title compound was prepared from reported method86 as a colourless oil (1.71 g, 8.07 
mmol) in 82% yield. 1H NMR (500 MHz, CDCl3): δ 5.48 – 5.40 (m, 1H, CH=CH2), 5.30 
(d, J = 15.0 Hz, 1H, CH=CH2), 5.13 (d, J = 10.0 Hz, 1H, CH=CH2), 4.27 – 4.13 (m, 4H), 
2.57 (q, J = 10.0 Hz, 1H), 1.69 (dd, J = 7.5, 5.0 Hz, 1H, CH2), 1.55 (dd, J = 5.0, 4.0 Hz, 





A suspension of malonic acid (2.00 g, 19.3 mmol, 1 equiv), magnesium sulfate (2.06 g, 
17.1 mmol, 0.9 equiv), 2,2,2-trifluoroethanol (8.00 mL, 0.110 mol, 5.7 equiv) and sulfuric 
acid (0.450 mL) in benzene (10 mL) were heated to reflux for 48 h. The reaction 
suspension was cooled to room temperature and filtered, then the filtrate was diluted with 
benzene (20 mL) and washed with 10% sodium carbonate solution (3 × 20 mL), water 
(20 mL) and brine (20 mL). The solution was dried over sodium sulfate and concentrated 
under reduced pressure to yield the title product as a colourless oil (3.17 g, 11.8 mmol) 
in 61% yield. 1H NMR (500 MHz, CDCl3): δ 4.55 (q, J = 16.5 Hz, 4H, OCH2), 3.61 (s, 
2H, O=C-CH2-C=O) ppm. 13C NMR (125 MHz, CDCl3): δ 164.0 (C=O), 122.5 (q, J = 
276.2 Hz, CF3), 61.2 (q, J = 36.3 Hz, OCH2), 40.2 (O=C-CH2-C=O) ppm. NMR data 
consistent with literature.87  
 
Bis(2,2,2-trifluoroethyl) 2-vinylcyclopropane-1,1-dicarboxylate (105) 
 
A suspension of bis(2,2,2-trifluoroethyl) malonate (503 mg, 1.87 mmol, 1 equiv), trans-
1,4-dibromo-2-butene (407 mg, 1.90 mmol, 1 equiv) and caesium carbonate (1.52 g, 4.66 
mmol) in THF (38 mL) was heated at 60 °C for 24 h. The reaction suspension was cooled 
to room temperature and filtered, then the filtrate was diluted with ether (80 mL) and 
washed with saturated sodium bicarbonate solution (30 mL), water (30 mL) and brine (30 
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mL). After the solution was dried over sodium sulfate and concentrated under reduced 
pressure, column chromatography (50% dichloromethane in hexane) was performed to 
yield the title compound as a colourless oil (353 mg, 1.10 mmol) in 59% yield. 1H NMR 
(500 MHz, CDCl3): δ 5.50 – 5.43 (m, 1H, CH=CH2), 5.35 (d, J = 17 Hz, 1H, CH=CH2), 
5.23 (d, J = 10.5 Hz, 1H, CH=CH2), 4.61 – 4.45 (m, 4H, CH2CF3), 2.74 (q, J = 8.5 Hz, 
1H, CH-CH=CH2), 1.90 (dd, J = 7.5, 5.5 Hz, 1H, CH2-CH-CH=CH2), 1.74 (dd, J = 9.0, 
5.5 Hz, 1H, CH2-CH-CH=CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 167.5 (C=O), 165.2 
(C=O), 131.3 (CH=CH2), 122.6 (q, J = 275 Hz, CF3), 120.3 (CH=CH2), 61.3 (q, J = 37.5 
Hz, OCH2), 61.2 (q, J = 37.5 Hz, OCH2), 35.0 (C-(COOCF3)2), 32.9 (CH-CH=CH2), 21.5 
(CH2-CH-CH=CH2) ppm. NMR data consistent with literature.32 
 
Bis(2,2,2-trifluoroethyl) (E)-2-styrylcyclopropane-1,1-dicarboxylate (110) 
 
A solution of 105 (158 mg, 0.495 mmol, 1 equiv), Grubbs Catalyst 2nd Generation (10.2 
mg, 12.0 µmol, 2.4 mol%) and styrene (1.10 mL, 997 mg, 9.57 mmol, 19.3 equiv) in 
dichloromethane (4 mL) was heated at 40 °C for 1 h then concentrated under reduced 
pressure. After column chromatography (5 – 20% ethyl acetate in hexane), the title 
compound was obtained as a colourless oil (155 mg, 0.392 mmol) in 79% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.30 (d, J = 4.5 Hz, 4H, CHAr) , 7.26 – 7.23 (m, 1H, CHAr), 6.69 (d, 
J = 15.5 Hz, 1H, Ph-CH=CH), 5.83 (dd, J = 16.0, 8.5 Hz, 1H, Ph-CH=CH), 4.63 – 4.44 
(m, 4H, OCH2), 2.91 (q, J = 8.5 Hz, 1H, Ph-CH=CH-CH), 2.05 – 2.02 (m, 1H, CH2-
C(CO2CH2CF3)2), 1.85 (dd, J = 9.0, 5.0 Hz, 1H, CH2-C(CO2CH2CF3)2) ppm. 13C NMR 
(125 MHz, CDCl3): δ 167.4 (C=O), 165.4 (C=O), 136.1 (CAr), 135.4 (Ph-CH=CH), 128.6 
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(CHAr), 128.0 (CHAr), 126.2 (CHAr), 122.4 (Ph-CH=CH), 61.3 (q, J = 37.5 Hz, OCH2), 
61.2 (q, J = 36.3 Hz, OCH2), 35.3 (C(CO2CH2CF3)2), 33.4 (Ph-CH=CH-CH), 22.3 (CH2-
C(CO2CH2CF3)2) ppm. IR (Neat): 3033, 1743, 1412, 1273, 1159, 1113 cm-1. HRMS 
(ESI) m/z: [M + Na]+ Calcd for C17H14F6O4Na 419.0694; Found 419.0686. 
 
Dibenzyl 2-vinylcyclopropane-1,1-dicarboxylate (111) 
 
A suspension of dibenzyl malonate (0.440 mL, 0.500 g, 1.76 mmol, 1 equiv), trans-1,4-
dibromo-2-butene (373 mg, 1.74 mmol, 1 equiv ) and caesium carbonate (1.44 g, 4.42 
mmol, 2.5 equiv) in THF (35 mL) was heated at 60 °C for 24 h. The suspension was 
cooled to room temperature and filtered. The filtrate was diluted with diethyl ether (70 
mL) and washed with saturated sodium bicarbonate solution (50 mL), water (50 mL) then 
brine (50 mL). After the solution was dried over sodium sulfate and concentrated under 
reduced pressure, column chromatography (50% dichloromethane in hexane) was 
performed to yield the title compound as a colourless oil (495 mg, 1.47 mmol) in 84% 
yield. 1H NMR (500 MHz, CDCl3): δ 7.32 – 7.26 (m, 10H, CHAr), 5.44 – 5.37 (m, 1H, 
CH=CH2), 5.28 (d, J = 17.0 Hz, 1H, CH=CH2), 5.08-5.20 (m, 5H, CH=CH2 and 2 × 
OCH2), 2.63 (q, J = 8.5 Hz, 1H, CH-CH=CH2), 1.76 (dd, J = 7.5, 5.0 Hz, 1H, CH2-
C(CO2Bn)2), 1.60 (dd, J = 9.0, 4.5 Hz, 1H, CH2-C(CO2Bn)2) ppm. 13C NMR (100 MHz, 
CDCl3): δ 169.4 (C=O), 167.2 (C=O), 135.5 (CAr), 135.4 (CAr), 132.8 (CH=CH2), 128.5 
(CHAr), 128.4 (CHAr), 128.3 (CHAr), 128.23 (CHAr), 128.21 (CHAr), 128.0 (CHAr), 118.8 
(CH=CH2), 67.4 (OCH2), 67.3 (OCH2), 35.9 (C-(CO2Bn)2), 31.7 (CH-CH=CH2), 20.8 
(CH2-C-(CO2Bn)2) ppm. IR (Neat): 3034, 1722, 1498, 1455, 1379, 1317, 1266, 1189, 
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1123 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C21H20O4Na 359.1259; Found 
359.1273. 
 
4.5.2 Preparation of indole substrates 




Ground sodium hydroxide pearls (1.56 g, 39.0 mmol, 4.6 equiv) was added to a solution 
of indole (996 mg, 8.50 mmol, 1 equiv) and tetrabutylammonium bisulfate (293 mg, 0.862 
mmol, 0.1 equiv) in dichloromethane (85 mL). The solution was stirred for 10 mins before 
the addition of tosyl chloride (2.43 g, 12.8 mmol, 1.5 equiv). The reaction was left stirring 
for overnight before the addition of saturated ammonium chloride solution (50 mL). After 
stirring the mixture for 30 mins, the organic fraction was isolated while the aqueous 
fraction was extracted with dichloromethane (2 × 30 mL). The combined organic 
fractions were dried over magnesium sulfate and concentrated under reduced pressure. 
The title compound was collected as an off white solid (2.03 g, 7.49 mmol) in 88% yield 
after column chromatography (20% ethyl acetate in hexane). 1H NMR (500 MHz, 
CDCl3): δ 7.99 (d, J = 8.5 Hz, 1H, CHAr), 7.75 (d, J = 8 Hz, 2H, CHAr Tosyl), 7.55 (d, J = 
3.5 Hz, 1H, TsN-CH=CH), 7.51 (d, J = 8 Hz, 1H, CHAr), 7.30 (t, J = 8 Hz, 1H, CHAr), 
7.22 – 7.18 (m, 3H, CHAr and 2 × CHAr Tosyl), 6.64 (d, J = 3.5 Hz, 1H, TsN-CH=CH), 2.31 
(s, 3H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 144.9 (CAr), 135.4 (CAr), 134.9 (CAr), 
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130.8 (CAr), 129.8 (CHAr Tosyl), 126.8 (CHAr Tosyl), 126.3 (TsN-CH=CH), 124.5 (CHAr), 
123.2 (CHAr), 121.3 (CHAr), 113.5 (CHAr), 109.0 (TsN-CH=CH), 21.5 (CH3) ppm. NMR 




After the slow addition of acetic anhydride (1.00 mL, 1.08 g, 10.6 mmol) to 70% nitric 
acid (0.200 mL, 211 mg, 3.36 mmol, 3 equiv) at 0 °C, the solution was stirred at room 
temperature for 20 mins and then added to a solution of 1-tosyl-1H-indole (304 mg, 1.12 
mmol, 1 equiv) in acetic anhydride (2 mL) at −78 °C for 2 h. The reaction was quenched 
with ice cold water (20 mL) at −78 °C, slowly warmed to rt and then extracted with ethyl 
acetate (3 × 20 mL). The organic extractions were concentrated under reduced pressure 
and the residue was dissolved in ethyl acetate (30 mL), washed with saturated sodium 
bicarbonate solution (5 × 20 mL) and dried over magnesium sulfate. After removal of 
solvent under reduced pressure, the crude solid was recrystallised in methanol to give the 
title compound as a beige solid (242 mg, 0.764 mmol) in 68% yield. 1H NMR (500 MHz, 
CDCl3): δ 8.57 (s, 1H, CH=C-NO2), 8.24 (d, J = 7.5 Hz, 1H, CHAr), 8.00 (d, J = 7 Hz, 
1H, CHAr), 7.88 (d, J = 7.5 Hz, 2H, CHAr Tosyl), 7.47 – 7.45 (m, 2H, CHAr), 7.33 (d, J = 8 
Hz, 2H, CHAr Tosyl), 2.40 (s, 3H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 146.8 (CAr), 
133.9 (CAr), 133.6 (CAr), 133.2 (C-NO2), 130.5 (CHAr Tosyl), 127.8 (HC=CNO2), 127.5 
(CHAr Tosyl), 126.8 (CHAr), 125.9 (CHAr), 121.8 (CAr), 121.2 (CHAr), 113.6 (CHAr), 21.7 





A solution of N-bromosuccinimide (1.60 g, 8.97 mmol, 1.05 equiv) in acetonitrile was 
heated at 82 °C for 10 mins prior to the addition of silver(I) nitrate (1.53 g, 8.99 mmol, 
1.05 equiv) and indole (1.00 g, 8.54 mmol, 1 equiv). The reaction was heated to 102 °C 
for 2 h then filtered to remove silver bromide. The filtrate was concentrated under reduced 
pressure then dissolved in dichloromethane (90 mL) and washed with 4% sodium 
bicarbonate solution (2 × 45 mL). Insolubles were filtered, organic fraction was isolated 
and dried over magnesium sulfate. After column chromatography (40% ethyl acetate in 
hexane), the title compound was collected as a yellow solid (0.220 g, 1.35 mmol) in 16% 
yield. 1H NMR (400 MHz, DMSO): δ 12.65 (bs, 1H, NH), 8.65 (d, J = 3.2 Hz, 1H, CH-
C-NO2), 8.11 – 8.07 (m, 1H, CHAr), 7.59 – 7.55 (m, 1H, CHAr), 7.39 – 7.32 (m, 2H, CHAr) 
ppm. 13C NMR (100 MHz, DMSO): δ 135.5 (CAr), 131.0 (CH=C-NO2), 128.9 (CAr), 
124.6 (CHAr), 124.2 (CHAr), 120.3 (CAr), 119.9 (CHAr), 113.8 (CHAr) ppm. NMR data 





A solution of 3-nitro-1H-indole (101 mg, 0.622 mmol, 1 equiv), DMAP (81.9 mg, 0.670 
mmol, 1.1 equiv) and triethylamine (0.350 mL, 254 mg, 2.51 mmol, 4 equiv) in 
dichloromethane (6 mL) was cooled to 0 °C prior to the addition of 
trifluoromethanesulfonic anhydride (0.350 mL, 587  mg, 2.08 mmol, 3.3 equiv). After the 
addition, the solution was allowed to warm to room temperature and stirred overnight. 
Reaction was quenched with ice-cold water (5 mL). Organic layer was isolated and the 
aqueous layer was extracted with ethyl acetate (3 × 20 mL). After the combined organic 
extracts were dried over sodium sulfate and concentrated under reduced pressure, column 
chromatography (20 – 40% ethyl acetate in hexane) was performed to yield the title 
compound as a yellow solid (118 mg, 0.401 mmol) in 65% yield. 1H NMR (500 MHz, 
CDCl3): δ 8.37 – 8.34 (m, 2H, CHAr and HC=C-NO2), 7.96 (d, J = 6.8 Hz, 1H, CHAr), 
7.62 – 7.58 (m, 2H, CHAr) ppm. 13C NMR (100 MHz, CDCl3): δ 135.8 (CAr), 134.7 (CAr), 
128.2 (CHAr), 127.7 (HC=C-NO2), 127.3 (CHAr), 121.81 (CAr), 121.77 (CHAr), 119.3 (q, 
J = 320 Hz, CF3), 113.9 (CHAr) ppm. 19F NMR (470 Hz, CDCl3): δ −74.64 (s, CF3) ppm. 
IR (Neat): 3170, 1591, 1560, 1513, 1478, 1443, 1416, 1355, 1316, 1267, 1215, 1142, 
1124, 1101, 1067 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C9H5F3N2O4SNa 




The title compound was prepared from reported method61 as a colourless oil (141 mg, 
0.636 mmol) in 33% yield. 1H NMR (500 MHz, CDCl3): δ 8.40 (d, J = 8.3 Hz, 1H, CHAr), 
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7.73 - 7.71 (m, 2H, CHAr), 7.59 (t, J = 7.3 Hz, 2H, CHAr), 7.51 (t, J = 7.5 Hz, 2H, CHAr), 
7.39 - 7.36 (m, 1H, CHAr), 7.32 - 7.28 (m, 2H, overlapping CHAr & CH=CH-N), 6.60 (d, 




The title compound was prepared from (1H-indol-1-yl)(phenyl)methanone based on a 
reported method.61 Recrystallization from hot methanol gave the title compound as a 
white solid (132 mg, 0.496 mmol) in 11% yield. 1H NMR (500 MHz, CDCl3): δ 8.38-
8.36 (m, 1H, CHAr), 8.32-8.31 (m, 1H, CHAr), 8.28 (s, 1H, NO2C=CH-N), 7.79-7.77 (m, 
2H, CHAr), 7.74-7.71 (m, 1H, CHAr), 7.61 (t, J = 7.7 Hz, 2H, CHAr), 7.55-7.51 (m, 2H, 
CHAr) ppm. 13C NMR (125 MHz, CDCl3): δ 168.3 (C=O), 135.3 CAr), 133.7 (CHAr), 
133.3 (NO2C=CH-N), 132.3 (CAr), 129.8 (CHAr), 129.4 (CHAr), 129.2 (NO2C=CH-N), 
127.3 (CHAr), 126.5 (CHAr), 121.9 (CAr), 120.9 (CHAr), 116.5 (CHAr) ppm. IR (Neat): 
3141, 1708, 1545, 1479, 1450, 1387, 1370, 1317, 1299, 1213, 1145, 1120 cm-1. NMR 





The title compound was prepared as an off-white solid (727 mg, 3.41 mmol) in 80% yield 
based on reported method.92 1H NMR (400 MHz, DMSO): δ 12.70 (bs, 1H, NH), 8.49 
(q, J = 0.5 Hz, 1H, CHAr), 8.22 – 8.16 (m, 1H, CHAr), 7.62 – 7.57 (m, 1H, CHAr), 7.37 – 
7.30 (m, 2H, CHAr) ppm. 13C NMR (100 MHz, DMSO): δ 173.9 (q, J = 30.0 Hz, 
C(O)CF3), 137.6 (CH=C), 136.6 (CAr), 125.7 (CAr), 124.3 (CHAr), 123.4 (CHAr), 121.1 
(CHAr), 116.9 (q, J = 290.0 Hz, CF3), 113.0 (CHAr), 108.8 (CAr) ppm. NMR data 




Ground sodium hydroxide pearls (206 mg, 5.15 mmol, 5.5 equiv) was added to a solution 
of 2,2,2-trifluoro-1-(1H-indol-3-yl)ethan-1-one (199 mg, 0.935 mmol, 1 equiv) and 
tetrabutylammonium bisulfate (32.8 mg, 0.0966 mmol, 0.1 equiv) in dichloromethane (10 
mL). The solution was stirred for 10 mins before the addition of tosyl chloride (0.270 g, 
1.42 mmol, 1.5 equiv). The reaction was left stirring overnight at room temperature. 
Tetrabutylammonium bisulfate (33.2 mg, 0.0978 mmol, 0.1 equiv) and ground sodium 
hydroxide pearls (0.180 g, 4.50 mmol, 4.8 equiv) were added to the suspension. The 
reaction was left stirring overnight at 55 °C before the addition of saturated ammonium 
chloride solution (20 mL). The solution was stirred for 2 h then the organic fraction was 
isolated and the aqueous fraction was extracted with dichloromethane (2 × 10 mL). The 
combined organic extracts were dried over magnesium sulfate and concentrated under 
reduced pressure. After column chromatography (20% ethyl acetate in hexane), the title 
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compound was collected as an oily white solid (22.6 mg, 0.0615 mmol) in 7% yield. NMR 
data consistent with literature.92  
 
4.5.3 Typical procedure for Pd-catalyzed dearomative [3 + 2] cycloaddition of 3-
nitroindoles with 2-vinylcyclopropane-1,1-dicarboxylates 
An oven-dried 3 mL reaction vial equipped with a magnetic stir bar was charged with the 
2-vinylcyclopropane-1,1-dicarboxylate derivative (0.0500 mmol, 1.0 equiv), the indole 
derivative (0.0500 mmol, 1 equiv), Pd2(dba)3·CHCl3 (2.60 mg, 0.00251 mmol, 5 mol %), 
BPhen (1.70 mg, 0.00500 mmol, 10 mol %) and NBu4I (10.1 mg, 0.0273 mmol, 0.5 
equiv). The vial was fitted with a septum cap and purged with N2. Anhydrous THF (0.820 
mL) was added and the reaction was stirred till the consumption of both substrates as 
indicated from TLC. The solvent was removed under reduced pressure and the crude 





Based on the typical procedure, the title compound was obtained as a pale yellow oil (53.7 
mg, 102 mmol) in 99% yield after column chromatography (20 % ethyl acetate in 
hexane). 1H NMR (500 MHz, CDCl3): δ 7.73 (t, J = 8.5 Hz, 2H, CHAr), 7.52 - 7.51 (m, 
3H, CHAr), 7.47 - 7.43 (m, 2H, CHAr), 7.41 (d, J = 8.5 Hz, 2H, CHAr), 7.37 (d, J = 8.0 Hz, 
256 
1H, CHAr), 7.22 (t, J = 7.5 Hz, 1H, CHAr), 7.15 (t, J = 7.5 Hz, 1H, CHAr), 7.10 (dd, J = 
13.5, 8.0 Hz, 3H, CHAr), 6.36 (s, 1H, Ts-N-CH Major), 6.31 (s, 1H, Ts-N-CH Minor), 5.78 
(ddd, J = 17.4, 10.0, 7.5 Hz, 1H, CH=CH2 Major), 5.53 (dt, J = 17.0, 9.5 Hz, 1H, CH=CH2 
Minor), 5.28 - 5.11 (m, 4H, CH=CH2), 4.48 - 4.16 (m, 8H, OCH2CH3), 3.41 (app q, J = 7.0 
Hz, 1H, CH-CH=CH2 Major), 3.30 (dt, J = 14.0, 6.5 Hz, 1H, CH-CH=CH2 Minor), 2.59 (dd, 
J = 13.5, 6.5 Hz, 1H, CHCH2 Major), 2.40 (dd, J = 13.5, 56.5 Hz, 1H, CHCH2 Minor), 2.31 - 
2.28 (m, 7H, CH3 and CHCH2), 2.21 (app t, J = 14.0 Hz, 1H, CHCH2 Major), 1.40-1.31 (m, 
12H, OCH2CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 169.8 (2 × overlapping C=O), 
167.9 (C=O), 166.7 (C=O), 145.1 (CAr), 145.0 (CAr), 144.5 (CAr), 142.6 (CAr), 133.0 (CAr), 
132.8 (CH=CH2), 132.4 (CH=CH2), 132.1 (CHAr), 132.0 (CHAr), 129.80 (CHAr Tosyl), 
129.79 (CHAr Tosyl), 128.9 (CHAr), 128.6 (CAr), 127.8 (CHAr Tosyl), 127.7 (CHAr Tosyl), 126.5 
(CHAr), 126.0 (CHAr), 125.3 (CHAr), 124.7 (CAr), 121.1 (CH=CH2), 120.7 (CH=CH2), 
118.3 (CHAr), 117.8 (CHAr), 102.7 (C-NO2), 101.3 (C-NO2), 73.7 (Ts-N-CH), 73.3 (Ts-
N-CH), 64.9 (C-(CO2Et)2), 64.1 (C-(CO2Et)2), 62.85 (OCH2CH3), 62.80 (OCH2CH3), 
62.65 (OCH2CH3), 62.61 (OCH2CH3), 53.8 (CH-CH=CH2), 50.5 (CH-CH=CH2), 39.6 
(CHCH2), 37.5 (CHCH2), 21.71 (CH3), 21.70 (CH3), 14.18 (CO2CH2CH3), 14.14 
(CO2CH2CH3), 14.10 (CO2CH2CH3), 14.08 (CO2CH2CH3) ppm. IR (Neat): 2987, 1730, 
1551, 1368, 1265, 1172, 1091, 734, 664 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 






Based on the typical procedure, the title compound was obtained as a white solid (28.3 
mg, 0.0445 mmol) in 80% yield after column chromatography (25 – 50% diethyl ether in 
hexane). The major isomer was isolated by recrystallization in methanol and 
dichloromethane. 1H NMR (500 MHz, CDCl3): δ 7.75 (d, J = 8.5 Hz, 1H, CHAr), 7.49 (t, 
J = 8.0 Hz, 1H, CHAr), 7.43 (d, J = 8.5 Hz, 2H, CHAr Tosyl), 7.38 (d, J = 7.5 Hz, 1H, CHAr), 
7.18 (t, J = 7.5 Hz, 1H, CHAr), 7.13 (d, J = 8.0 Hz, 2H, CHAr Tosyl), 6.24 (s, 1H, CH-NTs), 
5.75 (ddd, J = 17.4, 10.5, 7.5 Hz, 1H, CH=CH2), 5.31 (d, J = 10.5 Hz, 1H, CH=CH2), 
5.17 (d, J = 17.0 Hz, 1H, CH=CH2), 5.02 – 4.95 (m, 1H, OCH2CF3), 4.84 – 4.77 (m, 1H, 
OCH2CF3), 4.57 – 4.50 (m, 1H, OCH2CF3), 4.47 – 4.40 (m, 1H, OCH2CF3), 3.30 (dt, J = 
14.0, 6.5 Hz, 1H, CH-CH=CH2), 2.47 (dd, J = 13.5, 5.5 Hz, 1H, CH2-CH-CH=CH2), 2.34 
(s, 3H, CH3), 2.28 (app t, J = 14.0 Hz, 1H, CH2-CH-CH=CH2) ppm. 13C NMR (125 MHz, 
CDCl3): δ 167.7 (C=O), 164.5 (C=O), 145.5 (CAr), 144.0 (CAr), 132.3 (CHAr), 132.1 (CAr), 
131.6 (CH=CH2), 129.8 (CHAr Tosyl), 128.6 (CHAr). 127.7 (CHAr Tosyl), 125.3 (CHAr), 123.9 
(CAr), 122.5 (q, J = 275 Hz, CF3), 122.4 (q, J = 270 Hz, CF3), 121.2 (CH=CH2), 117.9 
(CHAr), 100.8 (C-NO2), 73.6 (CH-NTs), 63.7 (C(CO2CH2CF3)2), 62.1 (q, J = 37.5 Hz, 
OCH2CF3), 61.9 (q, J = 37.5 Hz, OCH2CF3), 50.2 (CH-CH=CH2), 37.4 (CH2-CH-
CH=CH2), 21.6 (CH3) ppm. 19F NMR (470 Hz, CDCl3): δ −73.61 (t, J = 8.0 Hz, CF3), 
−73.75 (t, J = 8.9 Hz, CF3) ppm. IR (Neat): 1751, 1551, 1461, 1420, 1370, 1285, 1241, 
1157, 1072 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C26H22F6N2O8SNa 659.0899; 






Based on the typical procedure, the title compound was obtained as a colourless film (31.1 
mg, 0.0464 mmol) in 88% yield after column chromatography (10 – 20% ethyl acetate in 
hexane). 1H NMR (400 MHz, CDCl3): δ 7.69 – 7.65 (m, 2H, CHAr Major and CHAr Minor), 
7.52 – 7.41 (m, 7H, 3 × CHAr Major and 4 × CHAr Minor), 7.34 (d, J = 2.0 Hz, 1H, CHAr Major), 
7.18 – 7.16 (m, 4H, 2 × CHAr Major and 2 × CHAr Minor), 6.28 (s, 1H, Ts-N-CH Minor), 6.24 
(d, J = 0.8 Hz, 1H, Ts-N-CH Major), 5.74 (ddd, J = 17.3, 10.2, 7.6 Hz, 1H, CH=CH2 Major), 
5.51 – 5.44 (m, 1H, CH=CH2 Minor), 5.38 (d, J = 10.4 Hz, 1H, CH=CH2 Major), 5.31 – 5.25 
(m, 2H, CH=CH2 Minor), 5.19 (d, J = 17.2 Hz, 1H, CH=CH2 Major), 5.01 – 4.92 (m, 1H, 
OCH2CF3 Major), 4.88 – 4.70 (m, 1H of OCH2CF3 Major and 2H of OCH2CF3 Minor), 4.59 – 
4.50 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 4.47 – 4.37 (m, 2H, OCH2CF3 Major and 
OCH2CF3 Minor), 3.42 (app q, J = 6.8 Hz, 1H, CH-CH=CH2 Minor), 3.29 (dt, J = 14.4, 6.4 
Hz, 1H, CH-CH=CH2 Major), 2.66 (dd, J = 14.0, 6.4 Hz, 1H, CH-CH2 Minor), 2.50 (dd, J = 
14.0, 4.4 Hz, 1H, CH-CH2 Major), 2.40 (dd, J = 12.6, 5.6 Hz, 1H, CH-CH2 Minor), 2.36 (s, 
3H, CH3 Tosyl Major), 2.35 (s, 3H, CH3 Tosyl Minor), 2.28 (app t, J = 14.4 Hz, 1H, CH-CH2 Major) 
ppm. 13C NMR (100 MHz, CDCl3): δ 167.6 (C=O Major), 167.4 (C=O Minor), 165.9 (C=O 
Minor), 164.4 (C=O Major), 145.8 (CAr Major), 145.7 (CAr Minor), 142.7 (CAr Major), 140.9 (CAr 
Minor), 132.6 (CHAr Major), 132.4 (CHAr Minor), 132.0 (CAr Minor), 131.9 (CAr Major), 131.6 (CAr 
Minor), 131.3 (CH=CH2 Minor), 130.94 (CH=CH2 Major), 130.87 (CAr Major), 130.1 (CHAr Tosyl 
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Major), 130.0 (CHAr Tosyl Minor), 129.3 (CAr Minor), 129.0 (CHAr Minor), 128.6 (CHAr Major), 
127.64 (CHAr Tosyl Major), 127.58 (CHAr Tosyl Minor), 125.5 (CAr Major), 122.5 (q, J = 275 Hz, 
CF3 Major and CF3 Minor), 122.4 (q, J = 276 Hz, CF3 Major and CF3 Minor), 122.2 (CH=CH2 
Minor), 121.9 (CH=CH2 Major), 118.8 (CHAr Major), 118.7 (CHAr Minor), 101.7 (C-NO2 Minor), 
100.4 (C-NO2 Major), 73.9 (Ts-N-CH Major and Ts-N-CH Minor), 64.6 (C-(CO2CH2CF3)2 
Minor), 63.8 (C-(CO2CH2CF3)2 Major), 62.7 – 61.4 (m, CH2CF3 Major and CH2CF3 Minor), 53.8 
(CH-CH=CH2 Minor), 50.2 (CH-CH=CH2 Major), 39.6 (CH-CH2 Minor), 37.4 (CH-CH2 Major), 
21.6 (CH3 Major and CH3 Minor) ppm. 19F NMR (470 Hz, CDCl3): δ −73.51 (t, J = 8.0 Hz, 
CF3 Minor), −73.61 (t, J = 7.5 Hz, CF3 Major), −73.70 (t, J = 8.5 Hz, CF3 Minor), −73.75 (t, J 
= 8.5 Hz, CF3 Major) ppm. IR (Neat): 1751, 1553, 1472, 1419, 1373, 1285, 1241, 1158, 
1105, 1091, 1068 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C26H21ClF6N2O8SNa 





Based on the typical procedure, the title compound was obtained as an off-white solid 
(34.6 mg, 0.0484 mmol) in 87% yield after column chromatography (15 – 40% ethyl 
acetate in hexane). 1H NMR (500 MHz, CDCl3): δ 7.63 – 7.59 (m, 5H, 2 × CHAr Major and 
3 × CHAr Minor), 7.52 (d, J = 8.0 Hz, 2H, CHAr Minor), 7.48 (d, J = 1.5 Hz, 1H, CHAr Major), 
7.44 (d, J = 8.0 Hz, 2H, CHAr Major), 7.17 (d, J = 7.5 Hz, 4H, 2 × CHAr Major and 2 × CHAr 
Minor), 6.27 (s, 1H, Ts-N-CH Minor), 6.23 (s, 1H, Ts-N-CH Major), 5.74 (ddd, J = 17.3, 10.3, 
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7.5 Hz, 1H, CH=CH2 Major), 5.50 – 5.43 (m, 1H, CH=CH2 Minor), 5.38 (d, J = 10.5 Hz, 1H, 
CH=CH2 Major), 5.31 – 5.25 (m, 2H, CH=CH2 Minor), 5.19 (d, J = 17.0 Hz, 1H, CH=CH2 
Major), 5.00 – 4.93 (m, 1H, OCH2CF3 Major), 4.87 – 4.71 (m, 1H of OCH2CF3 Major and 2H 
of OCH2CF3 Minor), 4.58 – 4.50 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 4.46 – 4.38 
(m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 3.42 (app q, J = 8.5 Hz, 1H, CH-CH=CH2 
Minor), 3.28 (dt, J = 14.0, 6.5 Hz, 1H, CH-CH=CH2 Major), 2.66 (dd, J = 14.0, 6.5 Hz, 1H, 
CH-CH2 Minor), 2.49 (dd, J = 14.0, 4.5 Hz, 1H, CH-CH2 Major), 2.42 – 2.39 (m, 1H, CH-
CH2 Minor), 2.37 (s, 3H, CH3 Tosyl Major), 2.36 (s, 3H, CH3 Tosyl Minor), 2.28 (app t, J = 14.0 
Hz, 1H, CHCH2 Major) ppm. 13C NMR (125 MHz, CDCl3): δ 167.5 (C=O Major), 165.8 
(C=O Minor), 164.4 (C=O Major), 145.8 (CAr Major), 145.7 (CAr Minor), 143.2 (CAr Major), 141.4 
(CAr Minor), 135.4 (CHAr Major), 135.3 (CHAr Minor), 132.0 (CAr Minor), 131.9 (CAr Major), 131.5 
(CHAr Major), 131.2 (CH=CH2 Minor), 130.9 (CH=CH2 Major), 130.1 (CHAr Tosyl Major), 130.0 
(CHAr Tosyl Minor), 129.6 (CAr Minor), 129.4 (CHAr Minor), 127.63 (CHAr Tosyl Major), 127.57 
(CHAr Tosyl Minor), 125.7 (CAr Major), 122.5 (q, J = 276 Hz, CF3 Major and CF3 Minor), 122.4 (q, 
J = 276 Hz, CF3 Major and CF3 Minor), 122.2 (CH=CH2 Minor), 121.9 (CH=CH2 Major), 119.2 
(CHAr Major), 119.0 (CHAr Minor), 118.9 (CAr Minor), 118.2 (CAr Major), 101.7 (C-NO2 Minor), 
100.3 (C-NO2 Major), 73.8 (Ts-N-CH Major and Ts-N-CH Minor), 64.6 (C-(CO2CH2CF3)2 
Minor), 63.7 (C-(CO2CH2CF3)2 Major), 62.6 – 61.5 (m, CH2CF3 Major and CH2CF3 Minor), 53.8 
(CH-CH=CH2 Minor), 50.2 (CH-CH=CH2 Major), 39.6 (CH-CH2 Minor), 37.4 (CH-CH2 Major), 
21.7 (CH3 Major and CH3 Minor) ppm. 19F NMR (470 Hz, CDCl3): δ −73.51 (t, J = 8.0 Hz, 
CF3 Minor), −73.61 (t, J = 8.0 Hz, CF3 Major), −73.69 (t, J = 8.5 Hz, CF3 Minor), −73.74 (t, J 
= 8.5 Hz, CF3 Major) ppm. IR (Neat): 1751, 1559, 1555, 1472, 1419, 1370, 1283, 1250, 
1161, 1103, 1068 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C26H21BrF6N2O8SNa 






Based on the typical procedure, the title compound was obtained as a colourless film (30.5 
mg, 0.0439 mmol) in 84% yield after column chromatography (20 – 30% ethyl acetate in 
hexane). 1H NMR (400 MHz, CDCl3): δ 8.21 – 8.15 (m, 3H, CHAr Major and 2 × CHAr 
Minor), 8.02 (d, J = 1.2 Hz, 1H, CHAr Major), 7.79 (d, J = 8.8 Hz, 1H, CHAr Major), 7.75 (d, J 
= 8.8 Hz, 1H, CHAr Minor), 7.56 (d, J = 8.0 Hz, 2H, CHAr Tosyl Minor), 7.48 (d, J = 8.4 Hz, 
2H, CHAr Tosyl Major), 7.18 – 7.15 (m, 4H, 2 × CHAr Tosyl Major and 2 × CHAr Tosyl Minor), 6.39 
(s, 1H, Ts-N-CH Minor), 6.29 (d, J = 0.8 Hz, 1H, Ts-N-CH Major), 5.80 (ddd, J = 17.3, 10.2, 
7.2 Hz, 1H, CH=CH2 Major), 5.57 – 5.49 (m, 1H, CH=CH2 Minor), 5.39 (d, J = 10.4 Hz, 1H, 
CH=CH2 Major), 5.31 (d, J = 16.8 Hz, 1H, CH=CH2 Minor), 5.27 (d, J = 10.0 Hz, 1H, 
CH=CH2 Minor), 5.20 (d, J = 17.2 Hz, 1H, CH=CH2 Major), 5.01 – 4.91 (m, 1H, OCH2CF3 
Major), 4.87 – 4.73 (m, 1H of OCH2CF3 Major and 2H of OCH2CF3 Minor), 4.60 – 4.50 (m, 
2H, OCH2CF3 Major and OCH2CF3 Minor), 4.48 – 4.39 (m, 2H, OCH2CF3 Major and OCH2CF3 
Minor), 3.92 (s, 3H, OCH3 Minor), 3.91 (s, 3H, OCH3 Major), 3.49 (app q, J = 7.2 Hz, 1H, CH-
CH=CH2 Minor), 3.35 (dt, J = 14.4, 6.4 Hz, 1H, CH-CH=CH2 Major), 2.71 – 2.64 (m, 1H, 
CH-CH2 Minor), 2.52 (ddd, J = 13.8, 5.4, 0.8 Hz, 1H, CH-CH2 Major), 2.45 (dd, J = 14.0, 7.6 
Hz, 1H, CH-CH2 Minor), 2.34 (s, 3H, CH3 Tosyl Major), 2.33 (s, 3H, CH3 Tosyl Minor), 2.28 – 2.25 
(m, 1H, CH-CH2 Major) ppm. 13C NMR (100 MHz, CDCl3): δ 167.6 (C=O Major), 167.5 
(C=O Minor), 165.8 (C=O Minor), 165.6 (C=O Major), 164.4 (C=O Major), 147.7 (CAr Major), 
145.9 (CAr Major), 145.81 (CAr Minor), 145.77 (CAr Minor), 134.0 (CHAr Major), 133.9 (CHAr 
Minor), 132.4 (CAr Minor), 132.1 (CAr Major), 131.4 (CH=CH2 Minor), 131.1 (CH=CH2 Major), 
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130.2 (CHAr Major), 130.1 (CHAr Tosyl Major and CHAr Tosyl Minor), 128.2 (CHAr Minor), 128.1 
(CAr Minor), 127.8 (CAr Minor), 127.6 (CHAr Tosyl Major), 127.5 (CHAr Tosyl Minor), 127.4 (CAr 
Major), 124.2 (CAr Major), 122.5 (q, J = 280 Hz, CF3 Major and CF3 Minor), 122.4 (q, J = 280 
Hz, CF3 Major and CF3 Minor), 122.1 (CH=CH2 Minor), 121.7 (CH=CH2 Major), 117.0 (CHAr 
Major), 116.7 (CHAr Minor), 101.8 (C-NO2 Minor), 100.2 (C-NO2 Major), 74.2 (Ts-N-CH Major), 
73.9 (Ts-N-CH Minor), 64.6 (C-(CO2CH2CF3)2 Minor), 63.7 (C-(CO2CH2CF3)2 Major), 62.6 – 
61.5 (m, CH2CF3 Major and CH2CF3 Minor), 53.4 (CH-CH=CH2 Minor), 52.5 (OCH3 Major and 
OCH3 Minor), 49.9 (CH-CH=CH2 Major), 39.7 (CH-CH2 Minor), 37.5 (CH-CH2 Major), 21.64 
(CH3 Major), 21.61 (CH3 Minor) ppm. 19F NMR (470 Hz, CDCl3): δ −73.54 (t, J = 8.5 Hz, 
CF3 Minor), −73.62 (t, J = 8.0 Hz, CF3 Major), −73.68 (t, J = 8.0 Hz, CF3 Minor), −73.74 (t, J 
= 8.0 Hz, CF3 Major) ppm. IR (Neat): 1754, 1722, 1555, 1374, 1287, 1243, 1165, 1111, 






Based on the typical procedure, the title compound was obtained as a colourless film (31.0 
mg, 0.0469 mmol) in 82% yield after column chromatography (20 – 30% ethyl acetate in 
hexane). 1H NMR (400 MHz, CDCl3): δ 7.85 – 7.82 (m, 3H, CHAr Major and 2 × CHAr 
Minor), 7.77 – 7.74 (m, 2H, CHAr Major and CHAr Minor), 7.68 (d, J = 4.0 Hz, 1H, CHAr Major), 
7.55 (d, J = 8.0 Hz, 2H, CHAr Minor), 7.47 (d, J = 8.0 Hz, 2H, CHAr Major), 7.22 – 7.19 (m, 
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4H, 2 × CHAr Major and 2 × CHAr Minor), 6.30 (d, J = 1.6 Hz, 2H, Ts-N-CH Major and Ts-N-
CH Minor), 5.74 (ddd, J = 17.3, 10.4, 7.2 Hz, 1H, CH=CH2 Major), 5.51 – 5.42 (m, 1H, 
CH=CH2 Minor), 5.43 (d, J = 10.4 Hz, 1H, CH=CH2 Major) 5.35 – 5.30 (m, 2H, CH=CH2 
Minor), 5.23 (d, J = 17.2 Hz, 1H, CH=CH2 Major), 4.99 – 4.89 (m, 1H, OCH2CF3 Major), 4.87 
– 4.76 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 4.74 – 4.67 (m, 1H, OCH2CF3 Minor), 
4.61 – 4.52 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 4.49 – 4.38 (m, 2H, OCH2CF3 
Major and OCH2CF3 Minor), 3.43 (app q, J = 8.0 Hz, 1H, CH-CH=CH2 Minor), 3.33 (dt, J = 
16.0, 8.0 Hz, 1H, CH-CH=CH2 Major), 2.68 (dd, J = 16.0, 8.0 Hz, 1H, CH-CH2 Minor), 2.57 
(ddd, J = 14.0, 5.6, 1.2 Hz, 1H, CH-CH2 Major), 2.44 (dd, J = 13.8, 9.6 Hz, 1H, CH-CH2 
Minor), 2.37 (s, 3H, CH3 Tosyl Major), 2.36 (s, 3H, CH3 Tosyl Minor), 2.26 (app t, J = 14.8 Hz, 1H, 
CH-CH2 Major) ppm. 13C NMR (100 MHz, CDCl3): δ 167.3 (C=O Major), 167.2 (C=O Minor), 
165.9 (C=O Minor), 164.3 (C=O Major), 147.5 (CAr Major), 146.3 (CAr Major), 146.2 (CAr Minor), 
145.6 (CAr Minor), 136.2 (CHAr Major), 136.0 (CHAr Minor), 132.8 (CHAr Major), 132.0 (CAr Minor), 
131.9 (CAr Major), 130.85 (CH=CH2 Minor), 130.80 (CHAr Minor), 130.6 (CH=CH2 Major), 130.2 
(CHAr Tosyl Major and CHAr Tosyl Minor), 128.5 (CAr Minor), 127.5 (CHAr Tosyl Major), 127.4 (CHAr 
Tosyl Minor), 124.8 (CAr Major), 122.8 (CH=CH2 Minor), 122.48 (CH=CH2 Major), 122.45 (q, J = 
275 Hz, CF3 Major and CF3 Minor), 122.39 (q, J = 276 Hz, CF3 Major and CF3 Minor), 118.0 
(CHAr Major), 117.72 (CAr Major), 117.69 (CHAr Minor), 109.6 (C≡N Minor), 109.0 (C≡N Major), 
101.3 (C-NO2 Minor), 99.9 (C-NO2 Major), 74.1 (Ts-N-CH Minor), 74.0 (Ts-N-CH Major), 64.5 
(C-(CO2CH2CF3)2 Minor), 63.7 (C-(CO2CH2CF3)2 Major), 62.8 – 61.6 (m, CH2CF3 Major and 
CH2CF3 Minor), 54.0 (CH-CH=CH2 Minor), 50.0 (CH-CH=CH2 Major), 40.0 (CH-CH2 Minor), 
37.5 (CH-CH2 Major), 21.7 (CH3 Major and CH3 Minor) ppm. 19F NMR (470 Hz, CDCl3): δ 
−73.50 (t, J = 8.5 Hz, CF3 Minor), −73.60 (t, J = 8.0 Hz, CF3 Major), −73.69 (t, J = 8.0 Hz, 
CF3 Minor), −73.72 (t, J = 7.5 Hz, CF3 Major) ppm. IR (Neat): 2232, 1754, 1555, 1373, 1287, 
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1241, 1169, 1089, 1066 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C27H21F6N3O8SNa 





Based on the typical procedure, the title compound was obtained as a colourless oil film 
(29.6 mg, 0.0434 mmol) in 73% yield after column chromatography (20% ethyl acetate 
in hexane). 1H NMR (400 MHz, CDCl3): δ 8.38 (dd, J = 9.0, 2.0 Hz, 3H, 1 × CHAr Major 
and 2 × CHAr Minor), 8.24 (d, J = 2.0 Hz, 1H, CHAr Major), 7.88 – 7.84 (m, 2H, CHAr Major 
and CHAr Minor), 7.58 (d, J = 4.2 Hz, 2H, CHAr Minor), 7.51 (d, J = 8.4 Hz, 2H, CHAr Major), 
7.21 (d, J = 8.0 Hz, 4H, 2 × CHAr Major and 2 × CHAr Minor), 6.37 (s, 1H, Ts-N-CH Minor), 
6.35 (s, 1H, Ts-N-CH Major), 5.81 (ddd, J = 17.3, 10.2, 7.2 Hz, 1H, CH=CH2 Major), 5.55 – 
5.45 (m, 2H, CH=CH2 Minor and CH=CH2 Major), 5.38 – 5.33 (m, 2H, CH=CH2 Minor), 5.24 
(d, J = 17.2 Hz, 1H, CH=CH2 Major), 4.99 – 4.90 (m, 1H, OCH2CF3 Major), 4.88 – 4.68 (m, 
1H of OCH2CF3 Major and 2H of OCH2CF3 Minor), 4.62 – 4.51 (m, 2H, OCH2CF3 Major and 
OCH2CF3 Minor), 4.49 – 4.39 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 3.49 (app q, J = 
6.8 Hz, 1H, CH-CH=CH2 Minor), 3.37 (dt, J = 14.4, 6.4 Hz, 1H, CH-CH=CH2 Major), 2.71 
(dd, J = 14.0, 6.4 Hz, 1H, CH-CH2 Minor), 2.59 (dd, J = 18.0, 4.8 Hz, 1H, CH-CH2 Major), 
2.48 (dd, J = 14.0, 8.8 Hz, 1H, CH-CH2 Minor), 2.37 (s, 6H, CH3 Tosyl Major and CH3 Tosyl 
Minor), 2.29 (app t, J = 14.0 Hz, 1H, CH-CH2 Major) ppm. 13C NMR (100MHz, CDCl3): δ 
167.3 (C=O Major), 167.2 (C=O Minor), 165.8 (C=O Minor), 164.3 (C=O Major), 149.0 (CAr 
265 
Major), 147.1 (CAr Minor), 146.4 (CAr Major), 146.3 (CAr Minor), 144.8 (CAr Major), 132.0 (CAr 
Minor), 131.9 (CAr Major), 130.7 (CH=CH2 Minor), 130.4 (CH=CH2 Major), 130.3 (CHAr Tosyl Major 
and CHAr Tosyl Minor), 128.4 (CAr Minor), 128.2 (CHAr Major), 128.0 (CHAr Minor), 127.5 (CHAr 
Tosyl Major), 127.4 (CHAr Tosyl Minor), 124.8 (CAr Major), 124.7 (CHAr Major), 122.9 (CH=CH2 
Minor), 122.8 (CHAr Minor), 122.6 (CH=CH2 Major), 122.44 (q, J = 275 Hz, CF3 Major and CF3 
Minor), 122.37 (q, J = 276 Hz, CF3 Major and CF3 Minor), 117.1 (CHAr Major), 116.9 (CHAr Minor), 
101.1 (C-NO2 Minor), 99.6 (C-NO2 Major), 74.6 (Ts-N-CH Major and Ts-N-CH Minor), 64.5 (C-
(CO2CH2CF3)2 Minor), 63.7 (C-(CO2CH2CF3)2 Major), 62.8 – 61.6 (m, CH2CF3 Major and 
CH2CF3 Minor), 53.7 (CH-CH=CH2 Minor), 49.8 (CH-CH=CH2 Major), 39.9 (CH-CH2 Minor), 
37.5 (CH-CH2 Major), 21.7 (CH3 Major and CH3 Minor) ppm. 19F NMR (470 Hz, CDCl3): δ 
−73.50 (t, J = 8.5 Hz, CF3 Minor), −73.59 (t, J = 8.0 Hz, CF3 Major), −73.67 (t, J = 8.5 Hz, 
CF3 Minor), −73.71 (t, J = 8.9 Hz, CF3 Major) ppm. IR (Neat): 1753, 1558, 1529, 1375, 1344, 
1287, 1248, 1165, 1085 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C26H21F6N3O10SNa 





Based on the typical procedure, the title compound was obtained as an off-white solid 
(30.3 mg, 0.0466 mmol) in 78% yield after column chromatography (20 – 30% ethyl 
acetate in hexane). The major isomer was isolated by recrystallization in methanol. 1H 
NMR (400 MHz, CDCl3): δ 7.62 (d, J = 8.0 Hz, 1H, CHAr), 7.43 (d, J = 8.0 Hz, 2H, 
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CHAr), 7.30 – 7.27 (m, 1H, CHAr), 7.13 (d, J = 8.0 Hz, 3H, CHAr), 6.21 (d, J = 1.2 Hz, 
1H, Ts-N-CH), 5.76 (ddd, J = 17.4, 10.2, 7.6 Hz, 1H, CH=CH2), 5.31 (d, J = 10.4 Hz, 
1H, CH=CH2), 5.17 (d, J = 17.2 Hz, 1H, CH=CH2), 5.02 – 4.93 (m, 1H, OCH2CF3), 4.85 
– 4.76 (m, 1H, OCH2CF3), 4.57 – 4.48 (m, 1H, OCH2CF3), 4.47 – 4.38 (m, 1H, 
OCH2CF3), 3.28 (dt, J = 16.0, 5.6 Hz, 1H, CH-CH=CH2), 2.45 (ddd, J = 13.6, 5.6, 1.2 
Hz, 1H, CH-CH2), 2.34 (s, 6H, CH3), 2.28 (app t, J = 14.0 Hz, 1H, CH-CH2) ppm. 13C 
NMR (100 MHz, CDCl3): δ 167.8 (C=O), 164.5 (C=O), 145.3 (CAr), 141.8 (CAr), 135.4 
(CAr), 133.2 (CHAr), 132.2 (CAr), 131.7 (CH=CH2), 129.8 (CHAr Tosyl), 128.7 (CHAr), 127.7 
(CHAr Tosyl), 124.0 (CAr), 121.1 (CH=CH2), 117.6 (CHAr), 100.9 (C-NO2), 73.7 (Ts-N-
CH), 63.7 (C-(CO2CH2CF3)2), 62.1 (q, J = 38.0 Hz, CH2CF3), 61.9 (q, J = 37.0 Hz, 
CH2CF3), 50.3 (CH-CH=CH2), 37.4 (CH-CH2), 21.6 (CH3), 21.2 (CH3) ppm. 19F NMR 
(470 Hz, CDCl3): δ −73.62 (t, J = 8.0 Hz, CF3), −73.75 (t, J = 8.5 Hz, CF3) ppm. IR 
(Neat): 1751, 1550, 1486, 1419, 1370, 1285, 1244, 1158, 1092, 1071 cm-1. HRMS (ESI) 
m/z: [M + Na]+ Calcd for C27H24F6N2O8SNa 673.1055; Found 673.1056. Melting point: 





Based on the typical procedure, the title compound was obtained as a colourless oil (34.1 
mg, 0.0508 mmol) in 88% yield after column chromatography (30% diethyl ether in 
hexane). 1H NMR (500 MHz, CDCl3): δ 7.76 (d, J = 1.5 Hz, 1H, CHAr Major), 7.73 (s, 1H, 
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CHAr Minor), 7.55 (d, J = 8.0 Hz, 2H, CHAr Minor), 7.47 (d, J = 8.0 Hz, 2H, CHAr Major), 7.30 
(d, J = 8.0 Hz, 2H, CHAr Major and CHAr Minor), 7.19 – 7.14 (m, 6H, 3 × CHAr Major and 3 × 
CHAr Minor), 6.29 (s, 1H, Ts-N-CH Minor), 6.24 (s, 1H, Ts-N-CH Major), 5.73 (ddd, J = 17.3, 
10.3, 7.5 Hz, 1H, CH=CH2 Major), 5.50 – 5.43 (m, 1H, CH=CH2 Minor), 5.33 (d, J = 10.5 
Hz, 1H, CH=CH2 Major), 5.29 – 5.24 (m, 2H, CH=CH2 Minor), 5.18 (d, J = 17.0 Hz, 1H, 
CH=CH2 Major), 5.01 – 4.94 (m, 1H, OCH2CF3 Major), 4.88 – 4.74 (m, 1H of OCH2CF3 Major 
and 2H of OCH2CF3 Minor), 4.58 – 4.50 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 4.46 
– 4.39 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 3.42 (app q, J = 7.0 Hz, 1H, CH-
CH=CH2 Minor), 3.29 (dt, J = 14.0, 6.5 Hz, 1H, CH-CH=CH2 Major), 2.67 (dd, J = 13.5, 6.5 
Hz, 1H, CH-CH2 Minor), 2.50 (dd, J = 13.8, 5.0 Hz, 1H, CH-CH2 Major), 2.43 – 2.40 (m, 
1H, CH-CH2 Minor), 2.36 (s, 6H, CH3 Tosyl Major and CH3 Tosyl Minor), 2.29 (app t, J = 14.0 Hz, 
1H, CH-CH2 Major) ppm. 13C NMR (125 MHz, CDCl3): δ 167.6 (C=O), 164.4 (C=O), 
145.8 (CAr), 145.2 (CAr), 138.7 (CAr), 131.9 (CAr), 131.2 (CH=CH2), 130.1 (CHAr Tosyl), 
129.3 (CHAr), 127.7 (CHAr Tosyl), 125.7 (CHAr), 122.5 (q, J = 276.3 Hz, CF3), 122.4 (q, J 
= 276.3 Hz, CF3), 122.3 (CAr), 121.6 (CH=CH2), 118.0 (CHAr), 100.3 (C-NO2), 74.0 (Ts-
N-CH), 63.7 (C-(CO2CH2CF3)2), 62.1 (q, J = 36.3 Hz, CH2CF3), 62.0(q, J = 36.3 Hz, 
CH2CF3), 50.1 (CH-CH=CH2), 37.4 (CH-CH2), 21.7 (CH3) ppm. 19F NMR (470 Hz, 
CDCl3): δ −73.54 (t, J = 8.5 Hz, CF3 Minor), −73.62 (t, J = 8.9 Hz, CF3 Major), −73.69 (t, J 
= 8.5 Hz, CF3 Minor), −73.74 (t, J = 7.5 Hz, CF3 Major) ppm. IR (Neat): 1757, 1751, 1551, 
1417, 1373, 1288, 1238, 1173, 1153 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 






Based on the typical procedure, the title compound was obtained as beige solid (32.7 mg, 
0.0487 mmol) in 88% yield after column chromatography (20 – 40% ethyl acetate in 
hexane). 1H NMR (500 MHz, CDCl3): δ 7.56 – 7.17 (m, 14H, CHAr Major and CHAr Minor), 
6.40 (s, 1H, Ts-N-CH Minor), 6.38 (s, 1H, Ts-N-CH Major), 5.62 (ddd, J = 17.4, 10.3, 7.5 
Hz, 1H, CH=CH2 Major), 5.50 – 5.42 (m, 1H, CH=CH2 Minor), 5.30 (d, J = 10.0 Hz, 1H, 
CH=CH2 Major), 5.24 – 5.21 (m, 2H, CH=CH2 Minor), 5.10 (d, J = 15.0 Hz, 1H, CH=CH2 
Major), 5.01 – 4.94 (m, 1H, OCH2CF3 Major), 4.84 – 4.73 (m, 3H, OCH2CF3 Major and 
OCH2CF3 Minor), 4.57 – 4.42 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 4.25 – 4.11 (m, 
2H, OCH2CF3 Major and OCH2CF3 Minor), 3.36 – 3.24 (m, 2H, CH-CH=CH2 Major and CH-
CH=CH2 Minor), 2.49 (dd, J = 13.8, 7.0 Hz, 1H, CH-CH2 Minor), 2.40 (s, 6H, CH3 Tosyl Major 
and CH3 Tosyl Minor), 2.34 (dd, J = 14.0, 5.5 Hz, 1H, CH-CH2 Major), 2.26 (dd, J = 14.0, 8.5 
Hz, 1H, CH-CH2 Minor), 2.06 (app t, J = 14.0 Hz, 1H, CH-CH2 Major) ppm. 13C NMR (100 
MHz, CDCl3): δ 167.6 (C=O Major), 167.4 (C=O Minor), 165.7 (C=O Minor), 164.3 (C=O 
Major), 146.0 (CAr Major), 145.7 (CAr Minor), 141.6 (CAr Major), 139.8 (CAr Minor), 134.1 (CAr 
Minor), 133.9 (CHAr Major), 133.5 (CHAr Minor), 132.3 (CAr Minor), 132.1 (CAr Major), 131.5 
(CH=CH2 Minor), 130.9 (CH=CH2 Major), 130.0 (CHAr Tosyl Major), 129.8 (CHAr Tosyl Minor), 
128.9 (CHAr Minor), 128.6 (CAr Major), 128.5 (CHAr Tosyl Minor), 128.4 (CHAr Tosyl Major), 127.64 
(CHAr Major), 127.61 (CHAr Major), 127.1 (CAr Major), 126.9 (CAr Minor), 125.0 (CHAr Minor), 
122.4 (q, J = 276 Hz, CF3 Major and CF3 Minor), 122.3 (q, J = 276 Hz, CF3 Major and CF3 
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Minor), 122.0 (CH=CH2 Minor), 121.7 (CH=CH2 Major), 101.2 (C-NO2 Minor), 100.7 (C-NO2 
Major), 74.4 (Ts-N-CH Minor), 74.0 (Ts-N-CH Major), 64.3 (C-(CO2CH2CF3)2 Minor), 63.7 (C-
(CO2CH2CF3)2 Major), 62.7 – 61.5 (m, CH2CF3 Major and CH2CF3 Minor), 54.7 (CH-CH=CH2 
Minor), 51.7 (CH-CH=CH2 Major), 38.4 (CH-CH2 Minor), 36.8 (CH-CH2 Major), 21.7 (CH3 Major 
and CH3 Minor) ppm. 19F NMR (470 Hz, CDCl3): δ −73.63 - −73.78 (m, CF3 Major and CF3 
Minor) ppm. IR (Neat): 1757, 1559, 1465, 1457, 1378, 1288, 1241, 1172 cm-1. HRMS 





Based on the typical procedure with the exclusion of tetrabutylammonium iodide, the title 
compound was obtained as a colourless oil (34.0 mg, 0.0490 mmol) in 88% yield after 
column chromatography (20 – 30% ethyl acetate in hexane). 1H NMR (400 MHz, 
CDCl3): δ 7.96 (dd, J = 8.4, 0.8 Hz, 1H, CHAr), 7.73 (dd, J = 7.6, 0.8 Hz, 1H, CHAr), 7.55 
(t, J = 8.0 Hz, 1H, CHAr), 7.49 (d, J = 8.4 Hz, 2H, CHAr Tosyl), 7.17 (d, J = 8.0 Hz, 2H, 
CHAr Tosyl), 6.03 (s, 1H, Ts-N-CH), 6.00 – 5.91 (m, 1H, CH=CH2), 5.09 (d, J = 10.4 Hz, 
1H, CH=CH2), 5.08 (d, J = 16.8 Hz, 1H, CH=CH2), 4.87 – 4.74 (m, 2H, OCH2CF3), 4.57 
– 4.47 (m, 1H, OCH2CF3), 4.46 – 4.37 (m, 1H, OCH2CF3), 3.81 (app q, J = 7.2 Hz, 1H, 
CH-CH=CH2), 3.75 (s, 3H, OCH3), 2.65 (dd, J = 14.0, 8.0 Hz, 1H, CH-CH2), 2.54 (dd, J 
= 16.0, 8.0 Hz, 1H, CH-CH2), 2.35 (s, 3H, CH3 Tosyl) ppm. 13C NMR (100 MHz, CDCl3): 
δ 167.7 (C=O), 165.9 (C=O), 165.7 (C=O), 145.7 (CAr), 143.9 (CAr), 133.9 (CH=CH2), 
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132.1 (CAr), 132.0 (CHAr), 130.0 (CHAr Tosyl), 129.4 (CAr), 128.2 (CHAr), 127.71 (CHAr 
Tosyl), 127.66 (CAr), 122.5 (q, J = 280 Hz, CF3), 122.4 (q, J = 280 Hz, CF3), 121.4 (CHAr), 
119.0 (CH=CH2), 102.2 (C-NO2), 76.7 (Ts-N-CH), 64.1 (C-(CO2CH2CF3)2), 62.6 – 61.1 
(m, CH2CF3), 53.3 (CH-CH=CH2), 52.5 (OCH3), 40.7 (CH-CH2), 21.6 (CH3 Tosyl) ppm. 
19F NMR (470 Hz, CDCl3): δ −73.79 - −73.84 (m, CF3) ppm. IR (Neat): 1753, 1733, 
1731, 1557, 1371, 1286, 1242, 1169, 1089 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 





Based on the typical procedure, the title compound was obtained as a colourless film (29.2 
mg, 0.0410 mmol) in 73% yield after column chromatography (20% ethyl acetate in 
hexane). 1H NMR (500 MHz, CDCl3): δ 7.78 – 7.12 (m, 26H, CHAr Major and CHAr Minor), 
6.57 (d, J = 15.0 Hz, 1H, CH=CH-Ph Minor), 6.46 (d, J = 15.0 Hz, 1H, CH=CH-Ph Major), 
6.35 (s, 1H, Ts-N-CH Minor), 6.27 (s, 1H, Ts-N-CH Major), 6.01 (dd, J = 15.0, 10.0 Hz, 1H, 
CH=CH-Ph Major), 5.78 (dd, J = 15.0, 10.0 Hz, 1H, CH=CH-Ph Minor), 5.03 – 4.96 (m, 1H, 
OCH2CF3 Major), 4.86 – 4.73 (m, 1H of OCH2CF3 Major and 2H of OCH2CF3 Minor), 4.60 – 
4.52 (m, 2H, OCH2CF3 Major and OCH2CF3 Minor), 4.50 – 4.42 (m, 2H, OCH2CF3 Major and 
OCH2CF3 Minor), 3.62 (app q, J = 10.0 Hz, 1H, CH-CH=CH2 Minor), 3.48 (dt, J = 15.0, 10.0 
Hz, 1H, CH-CH=CH2 Major), 2.73 (dd, J = 12.5, 5.0 Hz, 1H, CH-CH2 Minor), 2.56 (dd, J = 
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15.0, 5.0 Hz, 1H, CH-CH2 Major), 2.48 (dd, J = 12.5, 5.0 Hz, 1H, CH-CH2 Minor), 2.38 (app 
t, J = 15.0 Hz, 1H, CH-CH2 Major), 2.33 (s, 3H, CH3 Major), 2.32 (s, 3H, CH3 Minor) ppm. 13C 
NMR (125 MHz, CDCl3): δ 167.74 (C=O Major), 167.66 (C=O Minor), 166.0 (C=O Minor), 
164.5 (C=O Major), 145.5 (CAr Major), 145.4 (CAr Minor), 144.2 (CAr Major), 142.2 (CAr Minor), 
136.6 (CH=CH-Ph Minor), 135.8 (CAr Major), 135.6 (CAr Minor), 135.5 (CH=CH-Ph Major), 
132.3 (CHAr Major), 132.1 (CAr Major and CHAr Minor), 129.9 (CHAr Tosyl Major and CHAr Tosyl 
Minor), 128.8 (CHAr Major), 128.7 (CHAr Minor), 128.6 (CHAr Minor), 128.5 (2 × CHAr Major), 
128.0 (CAr Minor), 127.7 (CHAr Tosyl Major), 127.6 (CHAr Tosyl Minor), 126.7 (CHAr Minor), 126.5 
(CHAr Major), 126.4 (CHAr Minor), 126.2 (CHAr Minor), 125.4 (CHAr Major), 124.1 (CAr Major), 
122.6 (q, J = 275 Hz, CF3 Major and CF3 Minor), 122.5 (q, J = 275 Hz, CF3 Major and CF3 
Minor), 122.5 (CH=CH-Ph Major), 122.3 (CH=CH-Ph Minor), 118.0 (CHAr Major), 117.6 (CHAr 
Minor), 102.3 (C-NO2 Minor), 101.3 (C-NO2 Major), 73.6 (Ts-N-CH Major and Ts-N-CH Minor), 
64.8 (C-(CO2CH2CF3)2 Minor), 63.9 (C-(CO2CH2CF3)2 Major), 62.6 – 61.5 (m, CH2CF3 Major 
and CH2CF3 Minor), 53.6 (CH-CH=Ph Minor), 49.9 (CH-CH=Ph Major), 40.3 (CH-CH2 Minor), 
38.0 (CH-CH2 Major), 21.6 (CH3 Major and CH3 Minor) ppm. 19F NMR (470 Hz, CDCl3): δ 
−73.48 (t, J = 8.0 Hz, CF3 Minor), −73.59 (t, J = 8.0 Hz, CF3 Major), −73.67 - −73.73 (m, CF3 
Major and CF3 Minor) ppm. IR (Neat): 1752, 1549, 1464, 1417, 1370, 1286, 1246, 1170, 







Based on the typical procedure, the title compound was obtained as a colourless film (18.0 
mg, 0.0276 mmol) in 48% yield after column chromatography (20 – 50% ethyl acetate in 
hexane). 1H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 8.4 Hz, 1H, CHAr Major), 7.64 (d, J = 
8.0 Hz, 1H, CHAr Minor), 7.51 – 7.06 (m, 34H, CHAr Major and CHAr Minor), 6.40 (s, 1H, Ts-
N-CH Minor), 6.33 (s, 1H, Ts-N-CH Major), 5.74 (ddd, J = 17.4, 10.2, 7.6 Hz, 1H, CH=CH2 
Major), 5.48 – 5.39 (m, 1H of CH=CH2 Major and 1H of CH=CH2 Minor), 5.30 – 5.06 (m, 11H, 
1 × CH=CH2 Major, 2 × OCH2 Major, 1 × CH=CH2 Minor and 2 × OCH2 Minor), 3.40 (app q, J 
= 8.0 Hz, 1H, CH-CH=CH2 Minor), 3.24 (dt, J = 14.4, 6.4 Hz, 1H, CH-CH=CH2 Major), 2.59 
(dd, J = 13.6, 6.8 Hz, 1H, CH-CH2 Minor), 2.43 (dd, J = 13.6, 5.2 Hz, 1H, CH-CH2 Major), 
2.37 – 2.29 (m, 7H, CH3 Major, CH3 Minor and CH-CH2 Minor), 2.22 (app t, J = 14.0 Hz, 1H, 
CH-CH2 Major) ppm. 13C NMR (100 MHz, CDCl3): δ 169.40 (C=O Major), 169.37 (C=O 
Minor), 167.5 (C=O Minor), 166.3 (C=O Major), 145.0 (CAr Major), 144.9 (CAr Minor), 144.4 (CAr 
Major), 142.5 (CAr Minor), 135.2 (CAr Major), 135.0 (CAr Minor), 134.9 (CAr Minor), 134.7 (CAr 
Major), 132.8 (CAr Minor), 132.6 (CAr Major), 132.5 (CH=CH2 Minor), 132.2 (CH=CH2 Major), 
132.0 (CHAr Major), 131.9 (CHAr Minor), 129.7 (CHAr Major and CHAr Minor), 128.58 (CHAr 
Major), 128.56 (CHAr Major), 128.55 (CHAr Major), 128.50 (CHAr Minor), 128.48 (CHAr Minor), 
128.4 (CHAr Major), 128.3 (CAr Minor), 128.2 (CHAr Minor), 127.7 (CHAr Major), 127.6 (CHAr 
Minor), 126.3 (CHAr Minor), 125.9 (CHAr Minor), 125.1 (CHAr Major), 124.4 (CAr Major), 121.0 
(CH=CH2 Minor), 120.6 (CH=CH2 Major), 118.1 (CHAr Major), 117.7 (CHAr Minor), 102.6 (C-
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NO2 Minor), 101.1 (C-NO2 Major), 73.7 (Ts-N-CH Major), 73.3 (Ts-N-CH Minor), 68.6 (OCH2 
Major), 68.4 (OCH2 Major), 68.3 (OCH2 Minor), 68.2 (OCH2 Minor), 65.0 (C-(CO2Bn)2 Minor), 
64.2 (C-(CO2Bn)2 Major), 53.6 (CH-CH=CH2 Minor), 50.4 (CH-CH=CH2 Major), 39.6 (CH-
CH2 Minor), 37.6 (CH-CH2 Major), 21.6 (CH3 Major and CH3 Minor) ppm. IR (Neat): 1730, 1550, 
1456, 1368, 1269, 1241, 1170, 1089, 1068 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for 





Based on the typical procedure, the title compound was obtained as a white solid (18.3 
mg, 0.0298 mmol) in 61% yield after column chromatography (20% ethyl acetate in 
hexane). 1H NMR (400 MHz, CDCl3): δ 7.73 (d, J = 8.0 Hz, 1H, CHAr), 7.64 (d, J = 8.0 
Hz, 1H, CHAr), 7.58 – 7.49 (m, 4H, CHAr), 7.40 – 7.31 (m, 2H, CHAr), 6.56 (s, 1H, Tf-N-
CH), 6.49 (s, 1H, Tf-N-CH), 5.90 (ddd, J = 17.3, 10.2, 7.2 Hz, 1H, CH=CH2), 5.64 (ddd, 
J = 17.6, 9.2, 8.4 Hz, 1H, CH=CH2), 5.43 – 5.36 (m, 3H, CH=CH2), 5.30 (d, J = 20.0 Hz, 
1H, CH=CH2), 4.89 – 4.49 (m, 6H, OCH2CF3), 4.40 – 4.28 (m, 2H, OCH2CF3), 3.54 – 
3.44 (m, 2H, CH-CH=CH2), 2.75 (dd, J = 13.6, 6.4 Hz, 1H, CH-CH2), 2.59 (ddd, J = 14.0, 
5.6, 1.2 Hz, 1H, CH-CH2), 2.53 (dd, J = 13.6, 9.2 Hz, 1H, CH-CH2), 2.33 (app t, J = 14.0 
Hz, 1H, CH-CH2) ppm. 13C NMR (125 MHz, CDCl3): δ 167.0 (C=O), 166.8 (C=O), 
165.3(C=O), 164.5 (C=O), 141.4 (CAr), 139.6 (CAr), 133.0 (CHAr), 132.7 (CHAr), 131.3 
(CH=CH2), 131.0 (CH=CH2), 129.1 (CHAr), 127.2 (CHAr), 127.1 (CHAr), 127.0 (CAr), 
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126.5 (CHAr), 123.1 (CAr), 122.5 (CH=CH2), 122.33 (q, J = 275 Hz, CF3), 122.31 (q, J = 
275 Hz, CF3), 122.2 (q, J = 275 Hz, CF3), 122.1 (q, J = 275 Hz, CF3), 121.9 (CH=CH2), 
115.9 (CHAr), 115.5 (CHAr), 101.6 (C-NO2), 100.5 (C-NO2), 74.7 (Tf-N-CH), 74.3 (Tf-
N-CH), 64.0 (C-(CO2CH2CF3)2), 63.5 (C-(CO2CH2CF3)2), 62.7 – 61.3 (m, CH2CF3), 53.4 
(CH-CH=CH2), 50.0 (CH-CH=CH2), 40.0 (CH-CH2), 37.9 (CH-CH2) ppm. 19F NMR 
(470 Hz, CDCl3): δ −71.39 (s, N-SO2-CF3 Major), −72.11 (s, N-SO2-CF3 Minor), −73.52 (t, J 
= 8.0 Hz, CH2CF3 Minor), −73.61 (t, J = 8.5 Hz, CH2CF3 Major), −73.74 - −73.80 (m, CH2CF3 
Major and CH2CF3 Minor) ppm. IR (Neat): 1756, 1559, 1465, 1412, 1350, 1286, 1222, 1168, 






Based on the typical procedure, the title compound was obtained as a colourless oil (7.00 
mg, 0.0119 mmol) in 21% yield. NMR data consistent with literature.62 IR (Neat): 1751, 
1749, 1658, 1550, 1480, 1379, 1349, 1281, 1158 cm-1 (IR provided as not previously 
reported in the literature). 
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Zinc powder (92.7 mg, 1.42 mmol, 21.5 equiv) was slowly added to a solution of 11561 
(35.6 mg, 0.0660 mmol, 1 equiv) and trimethylsilyl chloride (0.170 mL, 1.34 mmol, 20.3 
equiv) in methanol at 0 °C. After stirring the reaction suspension at 0 °C for 1 h, the 
suspension was filtered and washed with methanol (2 × 2.5 mL) then dichloromethane (2 
× 2.5 mL). After the filtrate was washed with saturated sodium bicarbonate solution (15 
mL), organic fraction was isolated while aqueous fraction was extracted with 
dichloromethane (3 × 15 mL). The combined organic fractions were dried over sodium 
sulfate and concentrated under reduced pressure. Column chromatography was performed 
to yield the title compound as a white solid (24.6 mg, 0.0483 mmol, 73% yield). 1H NMR 
(500 MHz, CDCl3): δ 7.99 (d, J = 8.5 Hz, 2H, CHAr Tosyl), 7.69 (d, J = 8.5 Hz, 2H, CHAr 
Tosyl), 7.60 (d, J = 8.5 Hz, 1H, CHAr), 7.34 – 7.29 (m, 3H, CHAr Tosyl & CHAr), 7.18 (d, J 
= 8 Hz, 2H CHAr Tosyl), 7.08 (d, J = 7 Hz, 1H CHAr), 7.03 (t, J = 7 Hz, 1H CHAr), 6.46 (s, 
1H, TsN-CH-NTs), 5.43 – 5.36 (m, 1H, CH=CH2), 5.17 (d, J = 10 Hz, 1H, CH=CH2), 
5.11 (d, J = 17 Hz, 1H, CH=CH2), 4.47 (d, J = 22 Hz, 2H, NH2), 3.79 (dd, J = 11.8, 6.5 
Hz, 1H, CH2-NTs), 3.10 (m, 1H, CH-CH=CH2), 2.77 (t, J = 12 Hz, 1H, CH2-NTs), 2.43 
(s, 3H, CH3), 2.34 (s, 3H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 144.4 (CAr), 143.7 
(CAr), 143.3 (CAr), 137.2 (CAr), 134.4 (CAr), 132.8 (CH=CH2), 130.3 (CHAr), 129.6 (CHAr 
Tosyl), 129.5 (CHAr Tosyl), 127.9 (CHAr Tosyl), 127.6 (CHAr Tosyl), 126.7 (CHAr), 126.6(CAr), 
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124.0(CHAr), 119.6 (CH=CH2), 116.2 (CHAr), 82.0 (TsN-CH-NTs), 80.5 (C-NH2), 50.6 
(CH2-NTs), 49.2 (CH-CH=CH2), 21.61 (CH3), 21.57 (CH3) ppm. IR (Neat): 3510, 3504, 
1363, 1340, 1172 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C26H27N3O4S2Na 





A solution of 108a (30.1 mg, 47.3 µmol, 1 equiv) and trimethylsilyl chloride (0.150 mL, 
128 mg, 1.18 mmol, 25 equiv) in methanol was cooled to 0 °C prior to the slow addition 
of zinc powder (62.4 mg, 0.954 mmol, 20 equiv). After the reaction was stirred at 0 °C 
for 2 h 20 mins, another portion of trimethylsilyl chloride (0.0500 mL, 42.8 mg, 0.394 
mmol, 8 equiv) was added and the reaction was stirred at room temperature for 2 h then 
70 °C for 30 mins. The reaction was cooled to room temperature and filtered. The 
insoluble solid was washed with methanol (1 mL) and dichloromethane (3 × 1 mL). The 
filtrate and the combined washings were treated with saturated sodium bicarbonate 
solution (10 mL) and diluted with dichloromethane (10 mL). The organic fraction was 
isolated and the aqueous fraction was extracted with dichloromethane (2 × 10 mL). The 
combined organic fractions were dried over sodium sulfate then concentrated under 
reduced pressure. 1H NMR analysis of the crude residue revealed that approximately 66% 
conversion was completed. In order to maximise the conversion, a solution of the crude 
residue and trimethylsilyl chloride (0.100 mL, 85.6 mg, 0.788 mmol, 17 equiv) in 
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methanol (1 mL) was cooled to 0 °C prior to the slow addition of zinc powder (33.5 mg, 
0.512 mmol, 11 equiv). The reaction was stirred for 35 mins at 0 °C then filtered. Washing 
and extraction were carried out as previous. After column chromatography (40% ethyl 
acetate in hexane), the title compound was obtained as a colourless oil film (22.0 mg, 36.3 
µmol) in 77% yield. 1H NMR (400 MHz, CDCl3): δ 7.71 (d, J = 8.0 Hz, 1H, CHAr), 7.55 
(d, J = 8.0 Hz, 2H, CHAr), 7.38 – 7.34 (m, 1H, CHAr), 7.16 (d, J = 8.0 Hz, 2H, CHAr), 7.09 
– 7.03 (m, 2H, CHAr), 5.72 (ddd, J = 17.4, 10.0, 7.2 Hz, 1H, CH=CH2), 5.61 (s, 1H, Ts-
N-CH), 5.19 (d, J = 8.0 Hz, 1H, CH=CH2), 5.08 (d, J = 16.0 Hz, 1H, CH=CH2), 5.01 – 
4.91 (m, 1H, OCH2CF3), 4.81 – 4.72 (m, 1H, OCH2CF3), 4.53 – 4.37 (m, 2H, OCH2CF3), 
4.08 (bs, 2H, NH2), 2.85 (dt, J = 16.0, 4.0 Hz, 1H, CH-CH=CH2), 2.35 – 2.30 (m, 4H, 
CH3 and CH-CH2), 2.19 (app t, J = 16.0 Hz, 1H, CH-CH2) ppm. 13C NMR (100 MHz, 
CDCl3): δ 168.6 (C=O), 165.6 (C=O), 144.7 (CAr), 143.7 (CAr), 134.7 (CH=CH2), 133.3 
(CAr), 130.6 (CHAr), 129.5 (CHAr Tosyl), 128.7 (CAr), 127.7 (CHAr Tosyl), 126.7 (CHAr), 
124.8 (CHAr), 122.7 (q, J = 280 Hz, CF3), 122.6 (q, J = 280 Hz, CF3), 118.5 (CH=CH2), 
117.6 (CHAr), 79.7 (C-NH2), 70.5 (Ts-N-CH), 63.4 (C-(CO2CH2CF3)2), 61.7 (q, J = 40.0 
Hz, CH2CF3), 61.6 (q, J = 40.0 Hz, CH2CF3), 45.1 (CH-CH=CH2), 36.3 (CH-CH2), 21.5 
(CH3) ppm. 19F NMR (470 Hz, CDCl3): δ −73.62 (t, J = 8.0 Hz, CF3), −73.71 (t, J = 8.5 
Hz, CF3) ppm. IR (Neat): 3510, 3263, 1751, 1598, 1459, 1412, 1363, 1286, 1164, 1092, 







Zinc powder (76.7 mg, 1.17 mmol, 23 equiv) was slowly added to a solution of 108k' 
(36.0 mg, 51.8 µmol, 1 equiv), trimethylsilyl chloride (0.140 mL, 0.120 g, 1.10 mmol, 21 
equiv) in methanol (0.6 mL) at 0 °C. After stirring the reaction suspension at 0 °C for 30 
mins, the suspension was filtered and the solids were washed with dichloromethane (3 × 
1 mL). The filtrate was diluted with dichloromethane (10 mL) and treated with saturated 
sodium bicarbonate solution (5 mL). Organic fraction was isolated and aqueous fraction 
was extracted with dichloromethane (2 × 10 mL). The combined organic fractions were 
dried over magnesium sulfate and concentrated under reduced pressure. After column 
chromatography (40% ethyl acetate in hexane), the title compound was collected as a 
colourless oil (31.1 mg, 46.8 µmol) in 90% yield. 1H NMR (400 MHz, CDCl3): δ 7.98 
(dd, J = 8.2, 0.8 Hz, 1H, CHAr), 7.70 – 7.66 (m, 3H, CHAr), 7.40 (t, J = 8.0 Hz, 1H, CHAr), 
7.19 (d, J = 8.0 Hz, CHAr), 5.76 – 5.66 (m, 1H, CH=CH2), 5.56 (s, 1H, Ts-N-CH), 5.09 – 
5.05 (m, 2H, CH=CH2), 4.92 – 4.75 (m, 2H, OCH2CF3), 4.49 – 4.34 (m, 2H, OCH2CF3), 
3.83 (s, 3H, OCH3), 3.20 – 3.14 (m, 1H, CH-CH=CH2), 2.52 (dd, J = 13.6, 7.2 Hz, 1H, 
CH-CH2), 2.36 – 2.32 (m, 4H, CH-CH2 and CH3 Tosyl) ppm. 13C NMR (100 MHz, CDCl3): 
δ 168.9 (C=O), 167.3 (C=O), 166.5 (C=O), 144.7 (CAr), 144.1 (CAr), 134.4 (CH=CH2), 
133.9 (CAr), 133.8 (CAr), 129.9 (CHAr), 129.6 (CHAr Tosyl), 128.1 (CHAr Tosyl), 127.62 (CAr), 
127.59 (CHAr), 122.7 (q, J = 275.0 Hz, CF3), 120.6 (CHAr), 118.1 (CH=CH2), 80.2 (C-
NH2), 74.6 (Ts-N-CH), 64.8 (C-(CO2CH2CF3)2), 61.7 (q, J = 40.0 Hz, OCH2CF3), 61.5 
(q, J = 40.0 Hz, OCH2CF3), 52.9 (CH-CH=CH2), 52.6 (OCH3), 40.8 (CH-CH2), 21.6 (CH3 
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Tosyl) ppm. 19F NMR (470 Hz, CDCl3): δ −73.57 (t, J = 7.0 Hz, CF3), −73.58 (t, J = 7.5 
Hz, CF3) ppm. IR (Neat): 1751, 1715, 1445, 1363, 1279, 1162, 1090 cm-1. HRMS (ESI) 




0.2 M AIBN (0.440 mL, 0.0880 mmol, 1.2 equiv) was added to a solution of 11561 (40.9 
mg, 75.8 µmol, 1 equiv) and tributyltin hydride (40.0 µL, 43.3 mg, 149 µmol, 2 equiv) in 
toluene (1 mL). After the reaction was heated at 80 °C for 48 h, the reaction was cooled 
to room temperature then CCl4 (0.150 mL) was added and left stirring for 40 mins. The 
reaction was poured into saturated potassium fluoride solution (15 mL) and extracted with 
ethyl acetate. After drying the organic fraction with sodium sulfate, the solution was 
concentrated under reduced pressure. NMR analysis indicated that no conversion had 
occurred therefore the reaction crude was resubjected to the same reaction condition for 
a longer time of 96 h. Column chromatography (35% ethyl acetate in hexane) was 
performed to yield the title compound as a white solid (23.4 mg, 47.3 µmol) in 62% yield. 
 1H NMR (500 MHz, CDCl3): δ 7.96 (d, J = 8.0 Hz, 2H, CHAr Tosyl), 7.59 (d, J = 8.0 Hz, 
2H, CHAr Tosyl), 7.52 (d, J = 8.5 Hz, 1H, CHAr), 7.32 (d, J = 8.0 Hz, 2H, CHAr Tosyl), 7.22 
– 7.16 (m, 3H, CHAr Tosyl & CHAr), 7.03 (d, J = 7.5 Hz, 1H, CHAr), 6.98 (t, J = 7.5 Hz, 1H, 
CHAr), 6.44 (d, J = 7.0 Hz, 1H, N-CH-N), 5.50 (dt, J = 16.5, 9.5 Hz, 1H, CH=CH2), 5.16 
– 5.11 (m, 2H, CH=CH2), 3.73 (dd, J = 11.3, 7.0 Hz, 1H, CH2-NTs), 3.68 (t, J = 8.0 Hz, 
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1H, CH-CH-CH=CH2), 3.07 – 3.00 (m, 1H, CH-CH=CH2), 2.69 (t, J = 11.5 Hz, 1H, CH2-
NTs), 2.44 (s, 3H, CH3), 2.35 (s, 3H, CH3) ppm. 13C NMR (125 MHz, CDCl3): δ 144.2 
(CAr), 143.5 (CAr), 142.2 (CAr), 137.4 (CAr), 134.5 (CAr), 133.7 (CH=CH2), 129.6 (CHAr), 
129.5 (CHAr), 128.6 (CHAr), 128.3 (CAr), 127.7 (CHAr), 127.4 (CHAr), 126.7 (CHAr), 124.1 
(CHAr), 118.8 (CH=CH2), 116.5 (CHAr), 81.1 (N-CH-N), 50.4 (N-CH2), 49.7 (CH-CH-
CH=CH2), 47.6 (CH-CH=CH2), 21.60 (CH3), 21.56 (CH3) ppm. IR (Neat): 1355, 1345, 
1168, 1161, 1091, 1003 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C26H26N2O4S2Na 





A suspension of 108a/108a' (mixture of diastereomers, 28.3 mg, 44.5 µmol, 1 equiv) and 
potassium carbonate (14.1 mg, 102 µmol, 2.3 equiv) in ethanol (3 mL) was stirred 
overnight at room temperature. The reaction was diluted with water (5 mL). Organic 
fraction was isolated and aqueous fraction was extracted with diethyl ether (3 × 10 mL). 
Combined organic fractions were washed with brine (5 mL) and dried over sodium 
sulfate. After column chromatography (20% ethyl acetate in hexane), the title compound 
was collected as a white oil film (18.8 mg, 35.6 µmol) in 80% yield. The data collected 
for this compound matches that obtained for the direct cycloaddition. 
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Diethyl 4-tosyl-1-vinyl-1,4-dihydrocyclopenta[b]indole-3,3(2H)-dicarboxylate (119) 
 
A suspension of 107a (19.8 mg, 37.5 µmol, 1 equiv), sodium chloride (4.80 mg, 82.0 
µmol, 2.2 equiv) and water (1 drop) in DMSO (0.500 mL) was heated in a microwave 
reactor at 170 °C for 5 mins. The reaction was diluted with water (4 mL) then extracted 
with ethyl acetate (3 × 10 mL). The combined organic extracts were dried over sodium 
sulfate and concentrated under reduced pressure. After column chromatography (20% 
ethyl acetate in hexane), the title compound was obtained as an off-white oil film (9.00 
mg, 18.7 µmol) in 50% yield. 1H NMR (400 MHz, CDCl3): δ 7.89 (d, J = 8.4 Hz, 2H, 
CHAr), 7.60 (dd, J = 7.0, 1.6 Hz, 1H, CHAr), 7.43 – 7.40 (m, 1H, CHAr), 7.23 (d, J = 8.0 
Hz, 2H, CHAr), 7.20 – 7.13 (m, 2H, CHAr), 5.91 (ddd, J = 17.3, 9.4, 8.0 Hz, 1H, CH=CH2), 
5.22 (d, J = 17.2 Hz, 1H, CH=CH2), 5.11 (d, J = 10.0 Hz, 1H, CH=CH2), 4.31 – 4.17 (m, 
4H, OCH2CH3), 3.88 (app q, J = 6.0 Hz, 1H, CH-CH=CH2), 3.46 (dd, J = 13.2, 7.6 Hz, 
1H, CH-CH2), 2.93 (dd, J = 12.8, 5.6 Hz, 1H, CH-CH2), 2.34 (s, 3H, CH3 Tosyl), 1.29 (t, J 
= 7.2 Hz, 6H, OCH2CH3) ppm. 13C NMR (100 MHz, CDCl3): δ 170.2 (C=O), 169.5 
(C=O), 144.6 (CAr), 140.0 (CAr), 139.1 (CAr), 138.8 (CH=CH2), 136.1 (CAr), 130.8 (CAr), 
129.6 (CHAr Tosyl), 127.7 (CHAr Tosyl), 125.4 (CAr), 124.5 (CHAr), 123.0 (CHAr), 119.8 
(CHAr), 116.0 (CH=CH2), 114.3 (CHAr), 62.5 (C-(CO2Et)2), 62.1 (OCH2CH3), 48.3 (CH-
CH2), 40.9 (CH-CH=CH2), 21.6 (CH3 Tosyl), 14.0 (OCH2CH3) ppm. IR (Neat): 1727, 
1446, 1366, 1252, 1173 cm-1. HRMS (ESI) m/z: [M + Na]+ Calcd for C26H27NO6SNa 




hexahydrocyclopenta[b]indole-3-carboxylic acid (120) 
 
Ammonia solution (7 N in methanol, 2 mL) was added to 108k' (33.5 mg, 48.2 mmol) at 
5 °C. The reaction solution was stirred at 5 °C for 1 h then concentrated under reduced 
pressure. After column chromatography (5% methanol in dichloromethane), the title 
compound was obtained as a white solid (16.3 mg, 29.9 mmol) in 62% yield. 1H NMR 
(500 MHz, CDCl3): δ 7.98 (d, J = 5.0 Hz, 1H, CHAr), 7.72 (d, J = 10.0 Hz, 1H, CHAr), 
7.54 (t, J = 10.0 Hz, 1H, CHAr), 7.47 (d, J = 10.0 Hz, 2H, CHAr Tosyl), 7.17 (d, J = 5.0 Hz, 
2H, CHAr Tosyl), 6.05 (ddd, J = 17.3, 9.8, 8.0 Hz, 1H, CH=CH2), 5.90 (s, 1H, Ts-N-CH), 
5.80 (bs, 1H, CO2H), 5.08 (t, J = 15.0 Hz, 2H, CH=CH2), 3.83 – 3.78 (m, 1H, CH-
CH=CH2), 3.74 (s, 3H, OCH3), 3.57 (s, 3H, OCH3), 2.78 (dd, J = 15.0, 10.0 Hz, 1H, CH-
CH2), 2.49 (dd, J = 15.0, 10.0 Hz, 1H, CH-CH2), 2.35 (s, 3H, CH3 Tosyl) ppm. 13C NMR 
(100 MHz, CDCl3): δ 171.4 (C=O), 170.2 (C=O), 165.8 (C=O), 145.7 (CAr), 143.9 (CAr), 
135.2 (CH=CH2), 132.3 (CAr), 131.6 (CHAr), 130.0 (CHAr), 129.7 (CAr), 128.7 (CAr), 
128.0 (CHAr), 127.5 (CHAr), 120.7 (CHAr), 118.1 (CH=CH2), 103.0 (C-NO2), 78.2 (Ts-N-
CH), 64.0 (C-CO2H), 52.82 (CH-CH=CH2 or OCH3), 52.77 (CH-CH=CH2 or OCH3), 
52.6 (OCH3), 41.2 (CH-CH2), 21.7 (CH3 Tosyl) ppm. IR (Neat): 3438, 3196, 2954, 1730, 
1688, 1685, 1553, 1436, 1374, 1294, 1238, 1173 cm-1. LRMS (ESI) = 567, (M+Na)+. 
Melting point: 194.3 – 196.4 °C. 
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4.5.5 X-ray crystallographic information 
Crystals of 108a and 120 were recrystallised from dichloromethane/methanol and 
dichloromethane, respectively. Data for 108a and 120 were collected at 100 K on crystals 
mounted on a Hampton Scientific cryoloop on Bruker QUEST. The structures were 
solved by intrinsic phasing methods with SHELXT, refined using full-matrix least-
squares routines against F2 with SHELXL-2014,93 and visualised using OLEX2.94 All 
non-hydrogen atoms were refined anisotropically. All hydrogen atoms were placed in 
calculated positions and refined using a riding model with fixed C–H distances of 0.95 Å 
(sp2CH), 1.00 Å (CH), 0.99 Å (CH2), 0.98 Å (CH3). The thermal parameters of all 
hydrogen atoms were estimated as Uiso(H) = 1.2Ueq(C) except for CH3 where Uiso(H) = 
1.5Ueq(C). A summary of crystallographic data given below. 
Crystal data for 108a: C26H22N2O8F6S (M = 636.53 g/mol): monoclinic, space 
group P21/n (no. 14), a = 10.893(2) Å, b = 19.835(4) Å, c = 12.801(3) Å, β = 96.80(3)°, 
V = 2746.3(10) Å3, Z = 4, T = 100 K, μ(Cu Kα) = 1.907 mm-1, Dcalc = 1.5393 g/cm3, 25858 
reflections measured (8.26° ≤ 2Θ ≤ 132.76°), 4761 unique (Rint = 0.0448, Rsigma = 0.0303) 
which were used in all calculations. The final R1 was 0.0351 (I>=2V(I)) and wR2 was 
0.0870 (all data). 
Crystal data for 120: C25H24NO11S (M = 544.54 g/mol): triclinic, space group P-
1 (no. 2), a = 8.5498(19) Å, b = 9.5122(13) Å, c = 16.619(2) Å, α = 95.944(10)°, β = 
100.270(12)°, γ = 107.515(14)°, V = 1250.3(4) Å3, Z = 2, T = 100(2) K, μ(Cu Kα) = 1.699 
mm-1, Dcalc = 1.4463 g/cm3, 41132 reflections measured (5.48° ≤ 2Θ ≤ 145.62°), 4913 
unique (Rint = 0.0364, Rsigma = 0.0197) which were used in all calculations. The final R1 
was 0.0571 (I>=2V(I)) and wR2 was 0.1637 (all data). 
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Figure A1: U87 cells show no response to Q-PAC constituent molecules. U87 cultures 
were treated with the components of Q-PAC (2-PCPA, CPA and PBE) and the phenyl-
free control compound QAC, with their confluence (A), viability (B) and migration (C) 
assessed after 24 h (n=4 per concentration). (D-E) Co-treatment with 2-PCPA and PBE 
did not affect confluence (D) or viability (E) of U87 cultures over a 48 h period (n=3 
per concentration). Data represent mean ± SEM, * P<0.05, ** P<0.01, ***P<0.001, 
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NMR spectra for Chapter 3 
Synthesis and biological evaluation of metallocene derivatives of cyclopropylamines 
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NMR spectra for Chapter 4 
Palladium-catalysed dearomative [3 + 2] cycloaddition of 3-nitroindoles with 
vinylcyclopropane dicarboxylates
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1H & 13C NMR of Diethyl (3aS,8bR)-8b-nitro-4-tosyl-1-vinyl-1,3a,4,8b-










1H & 13C NMR of (1R,3S,3aS,8bR)-3,8-Bis(methoxycarbonyl)-8b-nitro-4-tosyl-1-vinyl-




Figure A2: Thermal Ellipsoid Plot for the crystal structure of 108a. Thermal ellipsoids 
are shown at the 50% probability level. All methyl and aromatic-ring hydrogen atoms 




Figure A3: Thermal Ellipsoid Plot for the crystal structure of 120. Thermal ellipsoids 
are shown at the 50% probability level. All methyl and aromatic-ring hydrogen atoms 
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Yi Sing Gee,‡a Neils J. M. Goertz,‡a Michael G. Gardinerb and
Christopher J. T. Hyland*a
The in situ reduction of ferrocenyl cyclopropylimines to the corresponding amines triggers a facile oxi-
dative ring-opening to yield the formal four-electron oxidation products: N-ferrocenylmethyl β-hydro-
xyamides. This process is believed to proceed via generation of a ferrocinium ion in the presence of air,
leading to facile formation of a distonic radical cation that is ultimately trapped by oxygen.
Introduction
Cyclopropylamines 1 are found in a broad variety of biologi-
cally active compounds, such as the antibiotics Ciprofloxacin,
Moxifloxacin, Trovafloxacin and the antidepressant
2-phenylcyclopropylamine (2-PCPA).1,2 Therefore, much atten-
tion has been paid to understanding the reactivity of these
important structures.3,4 Cyclopropylamines 1 can undergo
characteristic, irreversible ring-opening reactions via a single-
electron transfer mechanism to yield a distonic radical cation
2 (Scheme 1). This process is particularly important in biologi-
cal systems; for example, 2-PCPA inhibits monoamine oxidase
by flavin adenine dinucleotide (FAD) oxidation of the cyclo-
propylamine nitrogen and subsequent ring-opening to a
distonic radical cation similar to 2.5 The ability of cyclopropyl-
amines to undergo this ring-opening process has also seen
them used as tools for studying biological amine-oxidation.6,7
Given this widespread importance, several groups have studied
the ring-opening of cyclopropylamines initiated by single elec-
tron oxidation and subsequent reaction with oxygen
(Scheme 1). Endoperoxides 3 derived from aminocyclopro-
panes 1 have been prepared by aerobic electrochemical oxi-
dation8 as well as autocatalytic radical ring-opening under
aerobic conditions using an oxidising agent [(phen)3Fe(PF6)3]
or hydrogen-abstracting agents ((RO)2/UV) (Scheme 1).9 In the
latter case, excess peroxide can convert the endoperoxide into
a simple β-hydroxyamide 4. Epoxy-ketones can also be formed
by CuCl2-catalysed oxygenation of 1-pyrrolidino[n,1,0]-bicy-
cloalkanes.10 It has also been shown that N-cyclopropylanilines
can undergo slow air oxidation under ambient conditions to
yield simple β-hydroxyamides 4.11 However, to date we are
unaware of any studies into the reactivity of organometallic
derivatives of cyclopropylamines.
Ferrocene (Fc) can undergo reversible oxidation and this
has rendered it important in bioorganometallic drugs, such as
Scheme 1 Previous work on ring-opening of cyclopropylamines 1
initiated by oxidation of amine nitrogen and subsequent reaction with
oxygen. Current study on the internal oxidation of ferrocenyl-amino-
cyclopropanes. Fc = ferrocene.
†Electronic supplementary information (ESI) available. CCDC 1434659. For ESI
and crystallographic data in CIF or other electronic format see DOI: 10.1039/
c5ob02577j
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ferroquine12 and ferrocifens.13 In ferrocifens it is likely that
the active quinone methide form of the drug is only formed
following oxidation of the ferrocene to the ferrocinium ion. As
such, we postulated that cyclopropylamine-ferrocene conju-
gates could harness the redox ability of ferrocene to initiate
oxidative ring-opening processes in the presence of air.
Given the importance of both the ferrocene moiety and
cyclopropylamines in biological systems, understanding of
these ring-opening processes could provide important infor-
mation for the utilisation of organometallic derivatives of
cyclopropylamines in biological applications. Herein, we
describe the NaBH4 initiated oxidative ring-opening of ferroce-
nyl cyclopropylimines 5 to N-ferrocenylmethyl β-hydroxy-
amides 7 (Scheme 1). This is the first process where ferrocene
initiates an oxidative cyclopropane ring-opening, allowing syn-
thesis of a series of novel organometallic β-hydroxyamides.
Results and discussion
Work commenced with commercially available 2-PCPA, which
was transformed to imine 5a by condensation with ferrocene-
carboxyaldehyde. Upon reduction of this imine with stoichio-
metric sodium borohydride none of the amine 8a was
observed – instead the ring-opened and oxidised N-ferrocenyl-
methyl β-hydroxyamide product 7a was observed to form
rapidly (Scheme 2). The same product was formed when
Bu3SnH on silica gel was used as the reducing agent.
It is of note that unlike the previously reported electroche-
mical and autocatalytic ring-opening reactions no dioxolane
products were observed under these present conditions.
Following this intriguing result, a series of 2-PCPA ana-
logues were prepared (Scheme 3). The procedure originated
with cinnamic esters 9b–g, which were subjected to Corey–
Chaykovsky cyclopropanation to yield cyclopropanes 10b–g.
After basic hydrolysis, the carboxylic acids were converted to
2-PCPA analogues 11b–g by a Curtius rearrangement and de-
protection. These 2-PCPA analogues 11b–g were then subjected
to condensation with ferrocenecarboxaldehyde to yield imines
5b–g (Scheme 4). In all cases, treatment of these cyclopropyl-
amines with sodium borohydride, gave the ring-opened N-fer-
rocenylmethyl β-hydroxyamides 7b–g (22–58% yield over two
steps from the amine salt). A range of differently substituted
aromatic groups, including ortho, meta and para substituents
could be tolerated. The structure of 7d was confirmed un-
ambiguously by X-ray crystallography (Scheme 4).
Scheme 2 Oxidative ring-opening of 5a initiated by treatment with
NaBH4.
Scheme 3 Syntheses of 2-PCPA derivatives.
Scheme 4 Reductive amination of ferrocenecarboxaldehyde and
2-PCPA analogues 11a–g to yield N-ferrocenylmethyl β-hydroxyamides
7a–g. Molecular structure of 7d. Thermal ellipsoids are shown at the
50% probability level. All methine, methylene and aromatic-ring hydro-
gen atoms are omitted for clarity. Intra-/intermolecular H-bonding is
also not shown for clarity. The asymmetric unit contains another similar
molecule of 7d, featuring a 120° rotation of the C(methylene)–
C(methine) bond to allow intramolecular H-bonding to the carbonyl
carbon (CvO⋯H–O).
Organic & Biomolecular Chemistry Paper















































Mechanistically, it is proposed that the ferrocene moiety
plays a key role in the reaction, especially as the corresponding
benzyl-derivatives have been reported to be air stable.14 Air-
generated ferrocinium ions have been recently utilised as the
terminal oxidant in asymmetric dehydrogenative Heck reac-
tions.15 Therefore, it is proposed the ferrocinium ion 12, gen-
erated in situ by air that acts as an internal oxidant to generate
aminium radical 6 from cyclopropylamines 8, which are the
initial NaBH4 reduction products (Fig. 1). Cyclopropane ring-
opening of 6 then occurs exclusively by cleavage of the C1–C2
bond as this pathway gives the more stable benzylic carbon-
centred radical. This is consistent with Wimalasena et al. who
suggest the carbon-centered radical is a discrete intermediate
in radical ring-opening of cyclopropylamines and therefore,
ring-opening and molecular oxygen insertion are not con-
certed.9 The resulting distonic radical cation 13 is able to be
trapped with dioxygen to give adduct 14 which can undergo
5-exo-trig cyclisation to radical cation 15. The catalytic cycle is
propagated by abstraction of an electron from 8 by radical
cation 15, which yields dioxolane 16 as an intermediate.
Dioxolane 16 is not observed for the current reaction, as it
is likely isomerisation with concomitant O–O bond cleavage to
yield N-ferrocenylmethyl β-hydroxyamides 7 is a facile process
under basic conditions. This isomerisation step to the hydro-
xyamide could occur via several pathways. While it has been
reported that 1,2-dioxolanes can undergo conversion to
β-ketoalcohols in the presence of silica gel,16 in our case this is
unlikely as signals corresponding to the hydroxyamide were
observed in the 1H NMR of the crude reaction material prior to
contact with silica gel. Therefore, it is more likely that the iso-
merisation occurs via base-mediated17 or radical abstraction9
of H. Of these two possibilities the base-mediated mechanism
would appear more likely as no clear mechanism for gen-
eration of RO• is apparent and our conditions are intrinsically
basic due to the presence of NaBH4.
The analogue 18 of 2-PCPA, where the phenyl ring is
replaced with ferrocene, also displays a strong propensity to
undergo these ferrocene-mediated ring-opening processes
(Scheme 5). When carboxylic acid 17 was subjected to a
Curtius rearrangement, enal 21 was observed instead of cyclo-
propylamine 18. The analogous cinnamaldehyde product has
been reported to be obtained from the oxidation of 2-PCPA by
horseradish peroxidase.18 Similarly to the 2-PCPA analogues 8,
it is thought that amine 18 is intrinsically unstable in the pres-
ence of air and likely undergoes a similar oxidation/ring-
opening sequence. Interestingly, the distonic radical cation 19
does not appear to be trapped by molecular oxygen, prefering
to undergo a second oxidation, then elimination and hydro-
lysis to the enal. The preference for oxidation to an α-ferroce-
nylcarbenium ion 20, rather than trapping with molecular
oxygen, may be related to the well-established stabilisation of
Fig. 1 Proposed mechanism of NaBH4-initiated ring-opening-oxidation of cyclopropylimines 5.
Scheme 5 Attempted Curtius rearrangement of 17 to yield enal 21.
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α-carbocations by ferrocene. Such systems show fulvene
character and direct iron–α-carbon bonding.19
Conclusion
In conclusion, we have unveiled a novel ring-opening process
of cyclopropylamine facilitated by the redox ability of ferrocene
in air. This process yields novel N-ferrocenylmethyl β-hydroxy-
amides and provides information about the reactivity of organo-
metallic cyclopropylamine derivatives. The increased reactivity
of the ferrocenyl derivatives of 2-PCPA towards oxidation with
molecular oxygen and ring-opening suggests the possibility of
modulating aminocyclopropane reactivity with less-readily oxi-
dised metallocene fragments. It may also be possible to employ
ferrocene as a catalytic additive to enhance the oxidative ring-
opening of aminocyclopropanes. It is worth noting that distonic
radical cations can participate in useful reactions like [3 + 2]
cycloadditions with olefins.20 As such, the current method of
generating such species under environmentally friendly con-
ditions could lead to reaction with species other than molecular
oxygen to obtain more complex organometallic compounds.
It is also the first report of a very facile conversion to the
hydroxyamide skeleton by internal redox. As β-hydroxyamide
products feature in bioactive compounds, such as Cruentaren
A (antifungal)21 and Octreotide (growth hormone inhibitor),22
organometallic derivatives of this moiety are of potential inter-
est to medicinal chemists.23
Experimental
General information
Unless stated specifically, all chemicals were purchased from
commercial suppliers and used without purification. All reac-
tions were conducted in oven-dried glassware under nitrogen
atmosphere. Reaction solvents were dried by passing through
a column of activated alumina and then stored over 4 Å mole-
cular sieves. Progress of reactions was tracked by TLC and was
performed on aluminium backed silica gel sheets (Grace
Davison, UV254). TLC plates were visualised under UV lamp at
254 nm and/or by treatment with one of the following TLC
stains: Phosphomolybdic acid (PMA) stain: PMA (10 g), absol-
ute EtOH (100 mL); Potassium permanganate stain: KMnO4
(1.5 g), 10% NaOH (1.25 mL), water (200 mL); Vanillin stain:
Vanillin (15 g), concentrated H2SO4 (2.5 mL), EtOH (250 mL).
Preparative TLC was carried out on glass backed TLC plates
with silica matrix. Column chromatography was performed
using silica gel (40–75 μm) as the solid phase. For NMR spec-
troscopy analytes were dissolved in deuterated chloroform or
stated otherwise. NMR spectra for each compound were col-
lected from one of the following instrument: Mercury 2000
spectrometer operates at 500 and 125 MHz for 1H and 13C
NMR respectively, or Varian spectrometer operates at 300 and
75 MHz for 1H and 13C NMR respectively. NMR data are
expressed in parts per million (ppm) and referenced to the
solvent (7.26 ppm for 1H NMR and 77.16 ppm for 13C NMR).
The following abbreviations are used to assign the multiplicity
of the 1H NMR signal: s = singlet; bs = broad singlet; d =
doublet; t = triplet; q = quartet; quin = quintet; dd = doublet of
doublets; m = multiplet. For mass spectroscopy analytes were
dissolved in HPLC grade methanol. Spectra of low-resolution
mass spectrometry were obtained from a Shimadzu
LC-2010 mass spectrometer (ESI) or a Shimadzu QP5050 mass
spectrometer (EI). High-resolution mass spectra were collected
from a Waters Xevo G1 QTOF mass spectrophotometer (ESI or
ASAP) or Thermo Scientific LTQ Orbitrap XL (ESI). Infrared
spectra were obtained from a Shimadzu IRAffinity-1 Fourier
transform infrared spectrophotometer with ATR attachment.
Melting point measurements were taken on a Buchi M-560.
The 2-PCPA derivatives (11a–g) were prepared according to lit-
erature procedures; their syntheses and characterisation are
provided in the ESI.†
Typical procedure for the synthesis of N-ferrocenylmethyl
β-hydroxyamides
Triethylamine (0.93 mmol, 1.9 equiv.) was added to a suspen-
sion of 2-PCPA derivative hydrochloride salt (0.48 mmol, 1
equiv.) and magnesium sulphate (1.82 mmol, 3.8 equiv.) in dry
dichloromethane (4 mL). This mixture was stirred for
10 minutes before ferrocenecarboxaldehyde (0.58 mmol, 1.2
equiv.) was added. After 3 hours of stirring, another portion of
ferrocenecarboxaldehyde (93.4 μmol, 0.2 equiv.) and one
spatula of magnesium sulphate were added. The mixture was
allowed to stir overnight, after which another portion of ferro-
cenecarboxaldehyde (67.3 μmol, 0.1 equiv.) and a spatula of
magnesium sulphate were added. After 2 hours of stirring, dry
toluene (8 mL) was added to precipitate triethylamine hydro-
chloride and the mixture was filtered. After removal of solvents
under reduced pressure, more triethylamine hydrochloride
precipitated out, therefore dry toluene (10 mL) was added and
the mixture was filtered again. After removal of solvents,
sodium borohydride (2.07 mmol, 4.3 equiv.) was added to the
solution of crude imine mixture in dry methanol (5 mL) at
−10 °C. After stirring for 15 minutes at −10 °C, the reaction
was left stirring at room temperature. Another portion of
sodium borohydride (0.78 mmol, 1.6 equiv.) was added after
45 min at −10 °C. After stirring for 15 minutes at −10 °C, the
reaction solution was left stirring overnight at room tempera-
ture. The reaction was quenched with water (5 mL) and metha-
nol was evaporated under reduced pressure. After the aqueous
layer was extracted with ethyl acetate (3 × 10 mL), the com-
bined organic extracts were washed with brine (10 mL) and
dried over magnesium sulphate. This crude mixture was sub-
jected to column chromatography (typically 40–80% ethyl
acetate in hexane), which yielded the N-ferrocenylmethyl
β-hydroxyamides.
N-(Ferrocenylmethyl)-3-hydroxy-3-phenylpropanamide (7a).
Obtained as a yellowish orange solid (77.8 mg, 0.21 mmol) in a
44% overall yield. 1H NMR (500 MHz, CDCl3): δ 7.36–7.25 (m,
5H), 6.08 (s, 1H), 5.09 (dd, J = 8.75, 3.5 Hz, 1H), 4.14–4.12 (m,
11H), 2.59–2.50 (m, 2H) ppm. 13C NMR (125 MHz, CDCl3):
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δ 171.1, 143.1, 128.5, 127.7, 125.6, 84.4, 70.9, 68.6, 68.2, 68.1,
44.7, 38.8 ppm. IR (Neat): 3300, 1646 cm−1. HRMS (ASAP)
Found: M, 363.0914. C20H21FeNO2 requires M, 363.0922.
Melting point: 114.7–116.9 °C.
N-(Ferrocenylmethyl)-3-hydroxy-3-(o-methylphenyl) propana-
mide (7b). Obtained as brownish orange solid (46.1 mg,
0.12 mmol) in a 22% overall yield. 1H NMR (500 MHz, CDCl3):
δ 7.47 (d, J = 7.5 Hz, 1H), 7.21–7.14 (m, 2H), 7.10–7.09 (m, 1H),
6.29 (bs, 1H), 5.27 (d, J = 9 Hz, 1H), 4.14–4.12 (m, 11H),
2.50–2.40 (m, 2H), 2.29 (s, 3H) ppm. 13C NMR (125 MHz,
CDCl3): δ 171.3, 141.1, 134.1, 130.5, 127.5, 126.5, 125.3, 84.5,
68.7, 68.3, 68.3, 67.5, 43.4, 38.9, 19.1 ppm. IR (Neat): 3305,
1636 cm−1. HRMS (ESI) Found: M+, 377.10726. C21H23FeNO2
requires M+, 317.10782. Melting point: 103.2–107.3 °C.
N-(Ferrocenylmethyl)-3-hydroxy-3-(m-methoxyphenyl) propa-
namide (7c). Obtained as a brownish orange solid (111.5 mg,
0.28 mmol) in a 56% overall yield. 1H NMR (500 MHz, CDCl3):
δ 7.26–7.23 (m, 1H), 6.94–6.91 (m, 2H), 6.81 (d, J = 8 Hz, 1H),
6.05 (bs, 1H), 5.08–5.07 (m, 1H), 4.15–4.13 (m, 11H), 3.80 (s,
3H), 2.56–2.54 (m, 2H) ppm. 13C NMR (125 MHz, CDCl3): δ
171.2, 160.0, 145.0, 129.8, 118.0, 113.5, 111.3, 84.6, 71.1, 68.8,
68.4, 68.4, 68.4, 55.5, 44.9, 39.0 ppm. IR (Neat): 3310,
1647 cm−1. HRMS (ESI) Found: (M + Na)+, 416.0918.
C21H23NO3Fe requires (M + Na)+, 416.0925. Melting point:
83.2–86.8 °C.
N-(Ferrocenylmethyl)-3-hydroxy-3-(m-fluorophenyl) propana-
mide (7d). Obtained as a brown solid (35.2 mg, 0.09 mmol) in
a 49% overall yield. 1H NMR (300 MHz, CDCl3): δ 7.33–7.26
(m, 1H), 7.13–7.10 (m, 2H), 6.99–6.93 (m, 1H), 5.93 (bs, 1H),
5.11 (t, J = 6.3 Hz, 1H), 4.15–4.14 (m, 11H), 2.53 (d, J = 6 Hz,
2H) ppm. 13C NMR (125 MHz, CDCl3): δ 171.0, 163.0 (d, J = 245
Hz), 145.9 (d, J = 7.5 Hz), 130.1 (d, J = 8.75 Hz), 121.2 (d, J =
3.75 Hz), 114.5 (d, J = 21.25 Hz), 112.7 (d, J = 22.5 Hz), 84.3,
70.3, 68.7, 68.3, 68.3, 68.3, 44.5, 38.9 ppm. IR (Neat): 3238,
1650 cm−1. HRMS (ESI) Found: (M + Na)+, 404.0710.
C20H20NO2FFe requires (M + Na)+, 404.0725. Melting point:
112.3–116.3 °C.
N-(Ferrocenylmethyl)-3-hydroxy-3-(p-methylphenyl) propana-
mide (7e). Obtained as a yellow oil (118.8 mg, 0.32 mmol) in
58% overall yield. 1H NMR (500 MHz, CDCl3): δ 7.25 (d, J = 7.5
Hz, 2H), 7.15 (d, J = 8 Hz, 2H), 5.99 (bs, 1H), 5.08 (d, J = 8.5 Hz,
1H), 4.15–4.13 (m, 11H), 3.92 (bs, 1H), 2.61–2.50 (m, 2H), 2.34
(s, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 171.1, 140.1, 137.4,
129.2, 125.5, 84.4, 70.9, 68.6, 68.2, 68.2, 44.8, 38.8, 21.1 ppm.
IR (Neat): 3299, 1636 cm−1. HRMS (ESI) Found: (M + Na)+,
400.0979. C21H23NO2Fe requires (M + Na)+, 400.0976.
N-(Ferrocenylmethyl)-3-hydroxy-3-(p-methoxyphenyl) propa-
namide (7f). Obtained as a yellowish orange solid in 25%
yield. 1H NMR (300 MHz, CDCl3): δ 7.27 (d, J = 8.1 Hz, 2H),
6.86 (d, J = 8.4 Hz, 2H), 6.13 (bs, 1H), 5.04 (d, J = 8.4 Hz, 1H),
4.15–4.14 (m, 11H), 3.79 (s, 3H), 2.61–2.46 (m, 2H) ppm. 13C
NMR (75 MHz, CDCl3): δ 171.3, 159.2, 135.4, 127.0, 114.0, 84.5,
70.7, 68.8, 68.7, 68.3, 55.4, 44.9, 38.9 ppm. IR (Neat): 3301,
1636 cm−1. HRMS (ESI) Found: (M + Na)+, 416.0937.
C21H23FeNO3 requires (M + Na)+, 416.0925. Melting point:
80.5–83.8 °C.
N-(Ferrocenylmethyl)-3-hydroxy-3-(p-bromophenyl) propana-
mide (7g). Obtained as a yellowish orange solid (82.5 mg,
0.19 mmol) in a 44% overall yield. 1H NMR (500 MHz, CDCl3):
δ 7.44 (d, J = 8 Hz, 2H), 7.20 (d, J = 8.5 Hz, 2H), 6.13 (bs, 1H),
5.03–5.00 (m, 1H), 4.14–4.09 (m, 11H), 2.48–2.47 (m, 2H) ppm.
13C NMR (125 MHz, CDCl3): δ 170.9, 142.2, 131.7, 127.4, 121.5,
84.2, 70.3, 68.7, 68.4, 68.3, 68.3, 44.5, 38.9 ppm. IR (Neat):
3302, 1636 cm−1. HRMS (ESI) Found: (M + Na)+, 463.9934.
C20H20BrFeNO2 requires (M + Na)+, 463.9925. Melting point:
113.6–115.1 °C.
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